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GENERAL INTRODUCTION
Pancreas: anatomy and function
The pancreas is an elongated, tapered organ located centrally in the upper abdomen behind the 
stomach in the retroperitoneum. Traditionally, the pancreas is divided in the head, neck, body, 
and tail. The pancreatic head is the widest part of the organ and lies along the duodenum. The 
tapered left side (body and tail) extends slightly upward and ends near the spleen. Unlike other 
abdominal organs, the pancreas has no well-defined capsule with only a sheet of connective 
tissue separating the pancreatic parenchyma from surrounding peripancreatic fat. The pancreas 
has digestive and hormonal functions and is made up of exocrine and endocrine glands. The 
exocrine gland secretes digestive enzymes (trypsin, amylase, lipase), which help break down 
carbohydrates, fats, proteins, and acids in the duodenum where they are activated. The exocrine 
tissue also secretes bicarbonate to neutralize stomach acid in the duodenum. Approximately 1.5 
liter of pancreatic juice is produced per day. The endocrine gland, which consists of the islets 
of Langerhans, secretes hormones into the bloodstream. The main hormones secreted by the 
endocrine gland in the pancreas are insulin and glucagon, which regulate the level of glucose in 
the blood, somatostatin, which inhibits insulin and glucose uptake, and pancreatic polypeptide 
(PP), secreted in response to vagal stimulation and eating. PP modulates pancreatic hormone 
secretion and affects gastrointestinal secretions (1).
Acute pancreatitis: diagnosis and incidence.
The diagnosis of acute pancreatitis relies on clinical, biochemical and/or radiological criteria and 
can be made if two of the following three features are present: acute onset of severe abdominal 
pain often radiating to the back; serum lipase and/or amylase activity at least three times the 
upper limit of normal; and characteristic acute pancreatitis findings on cross-sectional imaging 
(2,3). Clinical symptoms of acute pancreatitis are an acute-onset of upper abdominal pain that 
increases rapidly in severity and persists without spontaneous relief. The intensity of the pain 
generally results in the patient seeking medical attention. Acute pancreatitis is the leading cause 
of gastrointestinal-related hospital admissions in the Western world. In the Netherlands, about 
4000 patients are admitted with the diagnosis acute pancreatitis annually (4,5). The incidence 
of acute pancreatitis varies from region to region and is estimated to be 10-50 cases per 100,000 
people per year. Worldwide, the incidence of acute pancreatitis is increasing, probably related 
to the rising incidence of gallstones, obesity, and aging of the population; all are well-known 
risk factors for acute pancreatitis (6-9).
Acute pancreatitis: causes
There are numerous known causes of acute pancreatitis, all of which precipitate the disease 
by causing acinar cell injury. Acute pancreatitis can be triggered by mechanical (gallstones, 
tumor), metabolic (alcohol, hyperlipidemia), vascular (ischemia, vasculitis), or infectious 
(mumps, ascariasis) events. Up to 10-15% of cases remain idiopathic. Worldwide, gallstone 
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disease and alcohol abuse account for greater than 80% of cases of acute pancreatitis. The 
incidence of pancreatitis in patients with these conditions is, however, low (5-10%), suggesting 
that additional co-factors are necessary to precipitate acute pancreatitis (2,3). 
Acute pancreatitis: pathophysiology
The common denominator mediating the clinical onset of acute pancreatitis is the premature 
activation of pancreatic enzymes and their extravasation into the pancreatic interstitium 
and peripancreatic tissues. It is hypothesized that intraparenchymal and extrapancreatic 
extravasation of these activated enzymes leads to autodigestion resulting in a variety of 
pathologic abnormalities ranging from mild edema and reactive inflammatory changes 
to severe tissue injury, damage to the pancreatic capillary network, hemorrhage and tissue 
necrosis. The extravasation of pancreatic lipase results in the development of retroperitoneal 
and subperitoneal fat necrosis, which can undergo secondary infection. Furthermore, these 
activated enzymes trigger an inflammatory response mediated by cytokines: interleukins and 
tumor necrosis factor alpha, which is toxic to acinar cells. These cytokines activate and intensify 
the inflammatory cascade responsible for the development of systematic inflammatory response 
syndrome (SIRS) that may ultimately culminate in (multiple) organ failure. There are evolving 
data that the magnitude of the inflammatory response, mediated by the immune system, is 
responsible for most of the morbidity and mortality in acute pancreatitis rather than the degree 
and extent of local pancreatic damage (10-13).
Acute pancreatitis: clinical sequelae and morphologic changes
Acute pancreatitis is traditionally categorized in terms of clinical manifestations (mild, moderate 
severe, and severe dependent on the presence of systemic complications with or without 
accompanying local complications) or morphologic imaging-based findings (interstitial and 
necrotizing pancreatitis, dependent on absence or presence of tissue necrosis, respectively) 
(14,15). 
Clinical sequelae
Approximately 80% of patients with acute pancreatitis have a mild illness and recover 
promptly without significant systemic or local sequelae, whereas 20% have a more serious 
illness characterized by organ failure, pancreatic necrosis, various infections, and death (2,14). 
In patients with severe acute pancreatitis, the clinical course is arbitrarily conceptualized as 
a process evolving in two overlapping phases (early and late phase). During the early phase, 
the systemic manifestations are linked to the host response to local pancreatic injury caused 
by activation of the cytokine cascade manifested as the SIRS and/or the compensatory anti-
inflammatory syndrome (CARS). SIRS and CARS may occur concurrently in the escalating 
cascades of cytokine release. Organ failure is likely when SIRS or CARS persists, with 
dysfunctioning respiratory, renal, or cardiovascular systems. Severity in the early phase 
depends on the presence and duration of SIRS and organ failure (11,14). The late phase of 
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acute pancreatitis, occurring in those with moderate severe and severe acute pancreatitis, is 
characterized by ongoing systemic inflammation, complications, and/or organ failure beyond 
the first week. Organ failure is the main cause of death in severe acute pancreatitis, both in the 
early and late phase. Organ failure in the early phase is secondary to SIRS, whereas infection 
and sepsis are the presumed causes of organ dysfunction in the late phase (13,16). 
Morphologic changes
Similar to the variability of the clinical presentation of acute pancreatitis, the pattern of 
pancreatic and extrapancreatic manifestations on imaging in evolving pancreatitis manifests in 
many ways, including interstitial edema, necrosis of pancreatic parenchyma and peripancreatic 
tissues, sterile and infected necrosis, and extrapancreatic complications. Morphologically, two 
types of acute pancreatitis are discriminated: interstitial and necrotizing pancreatitis (14,17).
Interstitial pancreatitis is the most common type (about 80-90%) and usually resolves within a 
few days. It is characterized by local or diffuse enlargement of the pancreas due to inflammatory 
edema of the parenchyma and/or peripancreatic tissues, but without recognizable tissue 
necrosis. On contrast-enhanced computed tomography (CECT), the pancreatic parenchyma 
is perfused normally with homogeneous or occasionally heterogeneous enhancement (due to 
edema). The peripancreatic fat may show some inflammatory changes such as haziness or mild 
stranding (figure 1)(18,19).
Figure 1 Acute interstitial pancreatitis. 
Normal enhancement of the pancreas with 
swelling and little peripancreatic fat stranding.
Necrotizing pancreatitis is less common (about 10-20%). The defining feature of necrotizing 
pancreatitis is the presence of necrosis within the pancreatic parenchyma or the surrounding 
tissues. Most commonly, necrosis of both the pancreatic parenchyma and peripancreatic tissues 
occurs, although either can occur alone. CECT findings of necrosis include non-enhancement 
of pancreatic parenchyma and inflammatory changes composed of various densities in 
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the surrounding tissues (figure 2). Compromise of pancreatic perfusion and CT signs of 
peripancreatic necrosis may evolve over days to weeks, respectively. Early CT within 72h after 
symptom onset may, therefore, underestimate the extent of disease (18,19).
Figure 2A and B Combined necrosis and extrapancreatic necrosis. (A) CT shows nonenhancing parts 
of pancreatic neck and body (asterisks) with surrounding acute necrotic collections (arrows). (B) CT 
depicts a normal enhancing pancreatic parenchyma surrounded by acute necrotic collections. Note, 
calcified stone in the gallbladder.
The distinction between interstitial and necrotizing pancreatitis is important to physicians 
in planning appropriate treatment and to the scientist in developing useful protocols for 
clinical research. Patients with necrotizing pancreatitis have a much higher risk of infection of 
pancreatic or peripancreatic necrosis, a more severe and prolonged clinical course often with 
periods of organ failure, and a higher mortality rate than patients with interstitial pancreatitis 
(16).
Interrelation between clinical sequelae and morphologic changes
In general, the clinical and morphologic changes are interrelated closely; patients with mild 
acute pancreatitis often have interstitial disease, whereas those with severe acute pancreatitis 
tend to have necrotizing pancreatitis. Clinical and morphologic severity, however, do not 
necessarily overlap; thus, patients with clinically mild acute pancreatitis may show severe 
morphologic manifestations on CT. Conversely, patients may sustain severe disease clinically 
(i.e. persistent organ failure) whereas CT only shows minimal inflammatory changes. In these 
patients, clinical severity is often mainly driven by the presence of significant co-morbid disease 
(20,21). 
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Acute pancreatitis: imaging
Historically, the pancreas was a difficult organ to evaluate both clinically and by antiquated 
radiographic methods, including plain radiographs and gastrointestinal contrast studies. 
These examinations were not very sensitive, were limited to the secondary changes caused by 
pancreatic complications on the adjacent bowel loops, and thus, were not able to demonstrate 
the full extent of the disease process adequately. With the development of grey-scale ultrasound 
in the early 1970s, for the first time it was possible to visualize the pancreas non-invasively, 
albeit often hindered by overlying, gas-containing bowel loops precluding adequate evaluation 
of the entire pancreas. The introduction of CT in the late 1970s enabled to visualize the 
entire pancreas and its diseases, including acute pancreatitis and associated complications, in 
a relatively fast, reproducible, objective, and non-invasive manner. When CT was first used 
in acute pancreatitis, scans were non-enhanced and non- or ill-perfused areas of pancreatic 
necrosis were not demonstrable. Based on the observations by Kivisaari and colleagues in 
1983, slow infusion of intravenous contrast medium improved the differentiation of pancreatic 
parenchymal swelling from peripancreatic edema, albeit necrosis of pancreatic parenchyma 
was still not identifiable (22). Author groups from Germany and Finland were among the 
first to combine rapid intravenous contrast bolus with dynamic CT, thereby enabling the 
identification of areas of reduced pancreatic perfusion corresponding to pancreatic necrosis 
(23,24). In the last 3 decades, the rapid technological advances of CT and magnetic resonance 
imaging (MRI) have paralleled the understanding of the pathophysiology and increasing 
knowledge of the natural clinical course of acute pancreatitis. Particularly, the introduction 
of contrast-enhanced multidetector high resolution CT imaging has altered the approach to 
diagnose and evaluate patients suspected of having acute pancreatitis substantially (17,25). 
Besides complete assessment of acute pancreatitis and its complications, imaging techniques 
also serve as a platform for innovative minimally invasive interventional therapies.
Acute pancreatitis: role of imaging modalities 
In patients with acute pancreatitis, imaging tests are performed to confirm or exclude the 
clinical diagnosis, establish the cause of pancreatitis, assess severity, detect complications, and 
provide guidance for patient management (25).
Imaging modalities used commonly include abdominal ultrasound and CT, and occasionally 
MRI. To elucidate the etiology of acute pancreatitis, abdominal ultrasound is used in the 
early phase for assessment of biliary stones and biliary obstruction (figure 3). At a later 
stage, abdominal ultrasound is also helpful for characterization of pancreatic collections, 
by differentiating fluid from non-liquid material, and for guiding diagnostic or therapeutic 
interventions. CT is the imaging modality of choice for overall assessment of acute pancreatitis 
because of its high accuracy, fast acquisition, and wide availability. In the initial phase, CT 
can provide the diagnosis when in doubt or come up with an alternative diagnosis, help 
triage patients with different grades of severity, and identify early local complications, such as 
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pancreatic parenchymal necrosis. In the late phase, CT is essential for assessment of evolution 
of local complications, for guidance of when and how to employ invasive treatment, and for 
monitoring response to treatment (17,19). MRI is as sensitive as CT for diagnosis and severity 
assessment, but superior to CT in the characterization of pancreatic collections by identifying 
accurately non-liquefied material (necrotic tissue or debris) within collections (figure 4) 
(26,27). MRI also allows for assessment of pancreatic duct integrity. However, availability, 
longer scanning time leading to motion artefacts, and the need for specialized MRI-compatible 
monitoring equipment in critically ill patients, and high costs hamper the widespread use 
of MRI in acute pancreatitis. Therefore, at present, MRI has a complementary role in acute 
pancreatitis.
Figure 3A and B Ultrasound of cholelithiasis and biliary pancreatitis. (A) Ultrasound depicts multiple 
tiny stones in a non-distended gallbladder as cause of biliary pancreatitis. (B) Ultrasound showing a 
slightly swollen pancreas with surrounding hypoechoic fluid.
Figure 4A and B CT versus MRI of walled-off necrosis. (A) CT shows walled-off necrosis replacing 
a large part of the pancreatic parenchyma. (B) Corresponding T2-weighted MRI accurately depicts 
necrotic material (arrowheads) within the collection.
A B
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Acute pancreatitis: imaging findings 
Irrespective of the etiology, morphologic findings of acute pancreatitis can be described in terms 
of alterations of the pancreatic parenchyma (interstitial edema and necrosis), peripancreatic 
tissues (fat stranding and collections), and extrapancreatic abnormalities (involvement of 
parenchymal organs, biliary system, vascular structures, and gastro-intestinal tract). The 
spectrum of morphologic abnormalities is dictated by the severity of acute pancreatitis. In 
about 10-20% of all cases, CECT will show normal or near normal findings and the diagnosis of 
acute pancreatitis hinges on upper abdominal pain and elevated pancreatic enzymes (17,18,28). 
Typical findings of morphologically mild acute pancreatitis includes focal or diffuse enlargement 
of the pancreas, parenchymal inhomogeneity due to edema, irregular gland margins with 
increased attenuation of peripancreatic fat or fat stranding, and/or small fluid collections. In 
around 20% of cases the inflammation is a focal process, often involving only the head or tail 
(17,18,28). With increasing severity of the attack, more pronounced abnormalities are observed 
with development of pancreatic collections and pancreatic necrosis. CT diagnosis of pancreatic 
necrosis is defined as non-enhancing pancreatic parenchyma. In general, visual comparison 
between the degree of pancreatic and splenic parenchymal enhancement is deemed adequate 
for detection of pancreatic necrosis (29). Pancreatic necrosis may be focal or multifocal, limited 
or extensive, confined to the periphery or full thickness. Pancreatic necrosis develops early in 
the course of acute pancreatitis (within 24-48h) and is complete within 72-96h after symptom 
onset (18,28,30). Cross-sectional imaging is performed best after this time period, since early 
CT may miss or underestimate the presence of pancreatic necrosis (figure 5). When pancreatic 
necrosis has been established on CECT, the extent of necrosis tends to remain stable during the 
following disease course as opposed to pancreatic collections. Pancreatic necrosis represents 
the most severe form of acute pancreatitis and the mediator for most of the systemic and local 
complications. The presence, and possibly the extent, of pancreatic and peripancreatic necrosis, 
increases the probability of infection. In turn, when pancreatic necrosis becomes infected, it is 
associated with a two-to-threefold increase in mortality: about 20-30% for infected necrosis 
compared with 9-12% for sterile necrosis (6,16).
Acute pancreatitis: classification & prediction
Clinical outcome of patients with mild or severe acute pancreatitis differs considerably. 
Consequently, classifying and predicting disease severity accurately is crucial, and has resulted 
in ample attention in the medical literature over the past five decades. 
Prediction of disease severity at the onset of the disease is, however, distinctly different from 
assessing the actual disease severity. Prediction of severity is about identifying factors or 
parameters that correlate accurately with mild or severe disease, before it actually develops. 
Assessment of actual disease severity is a method used to grade the severity of acute pancreatitis 
and, thus, is about classification of severity. In the following sections, this will be discussed in 
more depth.
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Figure 5A and B False-negative pancreatic necrosis on early CT. (A) CT performed on the day of 
admission shows a normal enhancing pancreatic parenchyma with little surrounding peripancreatic 
fluid. (B) Follow-up CT on day 3 reveals nonenhancement of pancreatic body and tail, indicating 
pancreatic necrosis.
Classification
Since the first clinical description of acute pancreatitis by Fitz in 1889, several classification 
systems of pancreatitis have been proposed (31). Terms used initially to describe and classify 
pancreatitis included ‘pancreatic hemorrhage’, ‘hemorrhagic suppurative, gangrenous 
pancreatitis’, and ‘disseminated fat necrosis’. With increasing knowledge and understanding of 
pancreatitis, modifications to existing classification systems were deemed necessary. Between 
1963 and 1992, five interdisciplinary symposia on pancreatitis were convened with the aim to 
define and classify the spectrum of (acute and chronic) pancreatitis. 
In 1963, the first international symposium on pancreatitis was held in Marseille, France. 
Staging was based on clinical grounds and categorized in acute, relapsing acute, chronic, 
and relapsing chronic pancreatitis. The spectrum of infectious complications (pancreatic 
infections), however, was not addressed (32).
In 1983, the second international meeting on classification of pancreatitis was held in Cambridge. 
At that meeting it was agreed that acute and chronic pancreatitis are essentially distinct entities. 
For the first time, the 1983 Cambridge Classification acknowledged the varying severity of 
acute pancreatitis by distinguishing mild and severe disease. Also, infectious complications of 
acute pancreatitis were addressed and several definitions were proposed: pancreatic phlegmon 
(inflammatory mass in or around the pancreas) and pancreatic abscess (pus in or around the 
pancreas) (33).
In 1984, a second Marseille symposium clarified the earlier works and emphasized certain 
pathologic (calculi, focal necrosis, fibrosis) and physiologic (diabetes, steatorrhea) complications 
A B
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of pancreatitis (34). Both the 1983 Cambridge and 1984 Marseilles Classification acknowledged 
the variable clinical course of acute pancreatitis and identified various local complications; 
necrosis, hemorrhage, and pseudocysts. 
In 1988, further modifications were added to the 1984 Marseilles Classification at a meeting 
in Rome, Italy (35,36). These related mainly to clinicopathologic criteria of local pancreatic 
complications. The 1988 Marseilles-Rome Classification still lacked specific definitions for 
discriminating the various local complications of acute pancreatitis and nomenclature was 
often ambiguous. For example, the secondary infections associated with acute pancreatitis 
were classified as ‘pancreatic abscess’, ‘infected pancreatic necrosis’, ‘infected pseudocyst’, or 
‘phlegmon’. In research, these entities were used often interchangeable and inappropriate 
rendering reliable comparison of scientific data impossible (37,38). 
In 1992, the final international symposium in the 20th century was held in Atlanta, Georgia, 
USA (Table 1) (39). This meeting was unique in the sense that it was the first symposium that 
focused on acute pancreatitis only resulting in a universally applied and accepted classification 
system depending on both clinical and pathological criteria. The 1992 Atlanta Classification 
abandoned the terms ‘infected pseudocyst’, ‘phlegmon’, ‘hemorrhagic pancreatitis’, and 
‘persistent acute pancreatitis’. Definitions were proposed for ‘acute pancreatitis’, ‘mild and 
severe acute pancreatitis’, ‘acute fluid collection’, ‘pancreatic necrosis’, ‘pseudocyst’, and 
‘pancreatic abscess’.
The 1992 Atlanta Classification initially provided a suitable framework for categorizing 
and grading acute pancreatitis and proved useful over the following two decades. Over the 
subsequent years, it became apparent that this classification system became outdated and 
needed an update, by and large based on studies put forth by the Dutch Pancreatitis Study 
Group, which forms the basis for this thesis. 
Prediction
The early recognition of acute pancreatitis severity enables clinicians to modify their medical 
management and transfer patients to the appropriate levels of care. The identification of 
patients most likely to develop organ failure and necrotizing pancreatitis will also facilitate the 
selection of the most seriously ill group of patients for inclusion in randomized clinical trials 
(40). Prediction of disease severity can be done using thorough clinical evaluation including 
detailed assessment of established risk factors. Risk factors of severity are patient-related factors 
or clinical features present at baseline that contribute to a poor outcome. Among these are older 
age (55 or more years), alcohol, obesity (body mass index: BMI greater than 30 kg/m2), first 
or second episode of disease, and presence of co-morbid disease. Based on clinical evaluation 
alone at the day of admission, however, clinicians fail to predict those with severe acute 
pancreatitis in up to 30-50% of cases. Other means of determination of the severity include the 
use of single prognostic indicators (e.g. serum blood urea nitrogen, creatinine, hematocrit, levels 
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of C-reactive protein, procalcitonin) and the utilization of multiple clinical scoring systems. These 
predictors of severity can be measured at admission and at various stages thereafter in order to 
assess response to therapy. Multiple scoring systems incorporate physiologic, laboratory, and 
TABLE 1. Summary of the 1992 Atlanta Classification
Definition
Acute pancreatitis An acute inflammatory process of the pancreas with variable involvement of 
other regional tissues or remote organ systems
Associated with raised pancreatic enzyme levels in blood and/or urine
Severity
Mild acute pancreatitis Associated with minimal organ dysfunction and an uneventful recovery; 
lacks the features of severe acute pancreatitis. Usually normal enhancement 
of pancreatic parenchyma on contrast-enhanced computed tomography
Severe acute pancreatitis Associated with organ failure and/or local complications such as necrosis, 
abscess or pseudocyst
Predicted severity Ranson score ≥ 3 or APACHE II score ≥ 8
Organ failure and systemic complications
Shock Systolic blood pressure < 90 mmHg
Pulmonary insufficiency PaO2 ≤ 60 mmHg
Renal failure Creatinine ≥ 177 µmol/l or ≤ 2 mg/dl after rehydration
Gastrointestinal bleeding 500 ml in 24 h
Disseminated intravascular 
coagulation 
Platelets ≤ 100,000/mm3, fibrinogen < 1·0 g/l and fibrin-split products > 80 
µg/l
Severe metabolic disturbances Calcium ≤ 1·87 mmol/l or ≤ 7·5mg/dl
Local complications
Acute fluid collections Occur early in the course of acute pancreatitis, are located in or near the 
pancreas and always lack a wall of granulation of fibrous tissue. In about half 
of patients, spontaneous regression occurs. In the other half, an acute fluid 
collection develops into a pancreatic abscess or pseudocyst
Pancreatic necrosis Diffuse or focal area(s) of non-viable pancreatic parenchyma, typically 
associated with peripancreatic fat necrosis
Non-enhanced pancreatic parenchyma > 3 cm or involving more than 30% of 
the area of the pancreas
Acute pseudocyst Collection of pancreatic juice enclosed by a wall of fibrous or granulation 
tissue, which arises as a result of acute pancreatitis, pancreatic trauma or 
chronic pancreatitis, occurring at least 4 weeks after onset of symptoms, is 
round or ovoid and most often sterile; when pus is present, lesion is termed a 
‘pancreatic abscess’
Pancreatic abscess Circumscribed, intra-abdominal collection of pus, usually in proximity to 
the pancreas, containing little or no pancreatic necrosis, which arises as a 
consequence of acute pancreatitis or pancreatic trauma
Often 4 weeks or more after onset
Pancreatic abscess and infected pancreatic necrosis differ in clinical 
expression and extent of associated necrosis
APACHE, Acute Physiology And Chronic Health Evaluation; PaO2, arterial partial pressure of oxygen.
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occasionally CT parameters obtained during the first 48h of hospitalization. For all scoring 
systems, continuous variables are acquired with incremental increase of scores correlating with 
clinical outcome parameters, such as organ failure, need for intensive care or intervention, and 
mortality. Subsequently, these continuous variables are converted into binary values as for each 
scoring system cutoff scores are derived (e.g. after receiver operating characteristic (ROC)-
curve analysis) to differentiate most accurately high-risk from low-risk patients. Among 
the most studied are the Ranson score, Glasgow score, Imrie score, Systemic Inflammatory 
Response Syndrome (SIRS), Bedside Index of Severity in Acute Pancreatitis (BISAP), and 
Acute Physiology and Chronic Health Evaluation (APACHE)-II score (40-43). Finally, since 
the introduction of CT for diagnosis and assessment of acute pancreatitis some four decades 
ago, several imaging-based scoring systems have been proposed to predict the severity of acute 
pancreatitis. Determinants of most CT-based scoring systems include pancreatic changes, 
peripancreatic, and extrapancreatic features. 
• Pancreatic changes include the subjective or objective enlargement of the pancreatic gland 
and presence and extent of parenchymal necrosis. 
• Peripancreatic features include fat stranding or edema, (fluid) collection(s) (presence, 
number, and volume), perirenal edema, mesenteric inflammation and retroperitoneal 
extension. 
• Extrapancreatic features include the presence of ascites, pleural effusion, vascular, 
gastrointestinal, and/or extrapancreatic parenchymal organ complications. 
Over the past four decades, at least 10 different radiographic scoring systems have been developed 
using incremental numerical scores or grades with higher scores or grades correlating with 
increasing morbidity and mortality (Table 2) (44-53). Two of these evaluate the presence and 
extent of parenchymal necrosis (i.e. CT Severity Index (CTSI) and Modified CT Severity Index 
(MCTSI)) for which the use of intravenous contrast material is indispensable. The remainder 
of scoring systems can be assessed on unenhanced CT scans. 
Among all imaging-based scoring systems available, the CTSI is the most commonly used and 
studied. The CTSI combines the Balthazar grade (0-4 points) with the extent of pancreatic 
necrosis (0-6 points) on a 10-point severity scale (Table 3) (47). The calculated CTSI can be 
subdivided in three categories; CTSI 0-3, 4-6, and 7-10, corresponding to predicted mild, 
moderate, and severe disease, respectively, with corresponding increase in morbidity and 
mortality. Main advantage of the CTSI is its intuitive design as it accurately depicts the order 
of increasing morphologic severity of acute pancreatitis. Interstitial pancreatitis is reflected 
by CTSI of 0 (normal pancreas), 1 (swelling of the pancreatic gland), and 2 (peripancreatic 
fat stranding). Extrapancreatic necrosis is potentially reflected by a CTSI of 3 and 4 (1 or 
more pancreatic collections, respectively). In general, CTSI greater than 4 (5-10) denotes the 
presence of pancreatic collections and parenchymal necrosis with more points accredited with 
increasing extent of necrosis (figure 6).
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TABLE 3. Balthazar Grade and CT Severity Index
Characteristics Balthazar Grade CTSI
Pancreatic inflammation
Normal pancreas
Focal or diffuse enlargement of the pancreas
Peripancreatic inflammation / fat stranding
Single acute fluid collection
Two or more acute fluid collections 
A
B
C
D
E
0
1
2
3
4
Pancreatic parenchymal necrosis
None
Less than 30%
Between 30 and 50%
More than 50%
0
2
4
6
Figure 6A-D CT severity index. (A) CTSI of 2: swollen but normal enhancing pancreas (asterisks) with 
little peripancreatic fat stranding (arrowheads). (B) CTSI of 4: normal enhancing pancreatic parenchyma 
(asterisks) with more than 2 collections (arrows). (C) CTSI of 6: less than 30% nonenhancing pancreatic 
parenchyma at the level of pancreatic body (arrowheads) with associated necrotic collections (arrows); 
A: ascites in the left paragolic gutter. (D) CTSI of 10: extensive necrosis of more than 50% of pancreatic 
parenchyma with associated necrotic collections. Note, calcified stones in the gallbladder.
A B
C D
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THESIS OUTLINE
The focus of this thesis is on the classification and severity prediction of acute pancreatitis. 
Two main topics are addressed:
• Part I: Classification of acute pancreatitis: definitions and terminology.
• Part II: Severity prediction of acute pancreatitis: clinical- versus imaging-based scoring 
systems and morphologic severity of acute pancreatitis.
Part I – Classification of acute pancreatitis
Severity classification of acute pancreatitis is essential for patient triage and transfer, comparing 
different methods of therapy, allocation of patients for clinical trials and reporting of scientific 
data. Regarding the classification of acute pancreatitis, this thesis aimed to explore the validity 
of the 1992 Atlanta Classification, to offer means of improvement of classifying local pancreatic 
complications, to present the newly Revised Atlanta Classification, and to investigate the 
interobserver agreement of the interpretation of CT-based criteria for pancreatic morphologic 
changes, using the Revised Atlanta Classification.
Although, the 1992 Atlanta Classification represented a clinical classification system, some 
of the Atlanta definitions are used by radiologists to classify morphologic findings of acute 
pancreatitis on cross-sectional imaging, primarily CT. Hitherto, the interobserver agreement 
between radiologists using the 1992 Atlanta definitions for describing findings on CT was 
unknown. Therefore, in Chapter 2 we performed an interobserver agreement study on 
categorizing pancreatic collections between five abdominal radiologists using the 1992 Atlanta 
definitions. 
Despite the passage of nearly two decades since the publication of the original 1992 Atlanta 
Classification, no attempts directed toward objective validation of the Atlanta definitions have 
been performed. Chapter 3 provides an overview on the use of the Atlanta definitions in 
the literature and aimed to assess to what extent the 1992 Atlanta Classification is accepted, 
including the variation in interpretation of the 1992 Atlanta definitions. In Chapter 4, we 
explored whether the terms abandoned by the 1992 Atlanta Classification (including ‘infected 
pseudocyst’ and ‘phlegmon’) were discarded effectively in the literature and we searched for 
new terms that emerged after the publication of the 1992 Atlanta Classification to describe 
manifestations in acute pancreatitis that might not have been addressed adequately.
Based on the results of the interobserver agreement study on the Atlanta definitions (chapter 
2) and the two literature reviews (chapters 3 and 4), several deficiencies in the 1992 Atlanta 
definitions pertaining to complex pancreatic collections were noted. Instead of using subjective 
interpretative terms (such as the Atlanta definitions), we proposed to use objective descriptive 
terms to describe morphologic findings of acute pancreatitis on cross-sectional imaging 
General Introduction & Outline of this Thesis | 27
with the aim to improve inter-rater agreement among readers of various specialties. In 
Chapter 5, results of an interobserver agreement study are presented among 17 surgeons, 
gastroenterologists, and radiologists using a new set of descriptive terms for describing features 
of acute pancreatitis on CT.
Over the last decade, a number of inconsistencies and ambiguities of the 1992 Atlanta 
Classification have been identified. This, combined with advances in knowledge of the natural 
history of acute pancreatitis, improved diagnostic imaging, and the development of minimally 
invasive treatment options for complicated pancreatitis, necessitated an update of disease 
severity classification and nomenclature of pancreatic collections. Chapter 6 presents the 2012 
Revised Atlanta Classification which were formulated after an iterative web-based worldwide 
consultation of specialists involving different disciplines. 
The 2012 Revised Atlanta Classification have proposed a new set of terms to classify pancreatic 
collections depicted by cross-sectional imaging based on their composition and morphology 
with the aim to facilitate accurate communication between clinicians and radiologists by 
using a common and unified terminology. Chapter 7 describes the interobserver agreement 
regarding CT morphology of acute pancreatitis among abdominal radiologists using the 2012 
Revised Atlanta definitions. 
Part II – Severity prediction of acute pancreatitis
Given the wide spectrum of clinical manifestations of acute pancreatitis, early identification of 
those at risk for severe disease, systemic and local complications, and mortality is imperative. 
Currently, there are a plethora of predictive systems, including single prognostic markers (e.g. 
serum creatinine, hematocrit, blood urea nitrogen, among others), clinical scoring systems 
(among them are APACHE-II, BISAP, Glasgow score, and Imrie score), and imaging-based 
scoring systems.
Pertaining to the actual and predicted severity of acute pancreatitis, this thesis aimed to 
investigate and compare the accuracy of clinical and imaging-based scoring systems for 
predicting the ultimate severity of acute pancreatitis, to find out the best means of diagnosing 
the most severe and lethal local complication of acute pancreatitis (i.e. infected necrosis), and 
to assess the clinical outcome of the different morphologic types of acute pancreatitis in two 
different cohort of patients.
Among all imaging-based scores, the CTSI, constructed by Balthazar and colleagues, is the most 
studied (47). Patients with higher CTSI scores have increased morbidity and mortality. In 2004, 
a modified CTSI has been proposed, the MCTSI, which adds extrapancreatic findings (pleural 
effusion, ascites, extrapancreatic complications), reduces the categorization of pancreatic 
necrosis to none, <30%, and >30%, and simplifies the scoring of peripancreatic changes. In a 
relatively small study (n=66), the MCTSI compared with CTSI was found to better correlate 
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with patient outcome (54). In Chapter 8, we performed a comparative evaluation of the 
MCTSI and CTSI with the aim to investigate which scoring system performed best in assessing 
the severity of acute pancreatitis in a large cohort of patients (n=196) using updated definitions 
for severity. 
The challenge for clinicians is to determine quickly and accurately, preferably at admission, 
those who will progress to organ failure and develop severe acute pancreatitis. Few studies 
compared the predictive accuracies of imaging-based and clinical scoring systems early in 
the course of acute pancreatitis. To this end, we compared the accuracy of seven CT scoring 
systems and two clinical scoring systems for predicting the severity of acute pancreatitis at 
admission in Chapter 9. 
In Chapter 10, an overview of the role of imaging-based scoring systems in predicting the 
severity and clinical outcome in patients with acute pancreatitis is addressed, including a review 
of clinically relevant prognostic CT findings with direct impact on patient management.
Infected necrosis is the most common, most severe, and most lethal of the infectious 
complications of acute pancreatitis. Diagnosis of infected necrosis can be challenging in 
patients with severe acute pancreatitis as the disease itself may present with a septic profile 
(signs of SIRS; fever, leukocytosis, tachycardia, and tachypnea), which may be indistinguishable 
from infectious extrapancreatic complications or sepsis syndrome. Chapter 11 addresses this 
issue and evaluates the role of clinical presentation, cross-sectional imaging, and fine needle 
aspiration in diagnosing infected necrosis.
Interstitial pancreatitis has been recognized as a distinct clinicopathologic form of acute 
pancreatitis for almost nine decades. While nearly 85% of patients hospitalized for acute 
pancreatitis have interstitial pancreatitis, most clinical studies over the past 3 decades have 
evaluated severity of necrotizing pancreatitis and only a few have focused on the clinical 
outcome of those with interstitial disease. In Chapter 12, we analyzed the severity of interstitial 
pancreatitis among a cohort of non-transferred consecutive patients and also compared the 
severity between patients with interstitial pancreatitis and those with extrapancreatic necrosis.
According to the 2012 Revised Atlanta Classification, necrotizing pancreatitis is defined as 
necrosis of pancreatic parenchyma only, extrapancreatic tissue (EXPN) only, or combined 
necrosis, which is the most common. Many have reported on clinical outcome of patients with 
combined necrosis, however, little is known about patients with EXPN alone. In Chapter 13, 
the clinical outcome of patients with EXPN alone was compared with those with combined 
necrosis in a large multicenter cohort of patients with necrotizing pancreatitis.
It is indisputable that the presence of parenchymal necrosis is associated with increased rates 
of morbidity and mortality. The relationship between extent of parenchymal necrosis and 
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clinical outcome, however, is contentious. Some have found a clear correlation between extent 
of parenchymal necrosis versus clinical outcome, whereas others have not. Many studies have 
reported on the presence and extent of parenchymal necrosis, but few studies have addressed 
the site of parenchymal necrosis as determining factor for clinical outcome. In Chapter 14, we 
evaluated the clinical significance of the specific location of parenchymal necrosis in a large 
cohort of patients with necrotizing pancreatitis. 
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ABSTRACT
Objectives: The 1992 Atlanta Classification is a clinically based classification system that 
defines the severity and complications of acute pancreatitis. A study was undertaken to 
assess the interobserver agreement of categorizing peripancreatic collections on computed 
tomography (CT) using the Atlanta Classification.
Methods: Preoperative contrast-enhanced CTs from 70 consecutive patients (49 men; median 
age, 59 years; range, 29-79 years) operated for acute necrotizing pancreatitis (2000-2003) 
in 11 hospitals were reviewed. Five abdominal radiologists independently categorized the 
peripancreatic collections according to the Atlanta Classification. Radiologists were aware of 
the timing of the CT and the clinical condition of the patient. Interobserver agreement was 
determined.
Results: Interobserver agreement among the radiologists was poor (κ,0.144; SD, 0.095). In 3 
(4%) of 70 cases, the same Atlanta definition was chosen. In 13 (19%) of 70 cases, 4 radiologists 
agreed, and in 42 (60%) of 70 cases, 3 radiologists agreed on the definition. In 21 cases (30%), 
1 or more of the radiologists classified a collection as 'pancreatic abscess' whereas 1 or more 
radiologist used another Atlanta definition.
Conclusion: The interobserver agreement of the Atlanta Classification for categorizing 
peripancreatic collections in acute pancreatitis on CT is poor. The Atlanta Classification should 
not be used to describe complications of acute pancreatitis on CT.
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INTRODUCTION
Treatment of acute necrotizing pancreatitis (ANP) is a challenge, and consultation with or 
referral to specialized institutions is advised on several occasions;1-3 therefore, adequate 
communication regarding both the severity and complications of ANP is of utmost importance. 
In 1992, an international symposium on acute pancreatitis was held in Atlanta to resolve 
lingering disputes regarding the definitions of various complications in acute pancreatitis. 
Agreement was reached on a clinically based classification system to define the disease and its 
complications: the so-called Atlanta Classification.4
Contrast-enhanced computed tomography (CECT) is the primary radiological diagnostic 
modality to assess the various complications of acute pancreatitis.1-3 The CT severity index 
(CTSI)5 was specifically designed to assess the severity of acute pancreatitis. Recently, a 
'modified CT severity index' was presented.6 However, the CTSI and modified CTSI are not 
designed to characterize peripancreatic collections, and consequently, the Atlanta Classification 
is frequently used to describe (peri-)pancreatic collections on CT.
To our knowledge, no study has determined the interobserver agreement when using the 
Atlanta Classification for this purpose. In the current study, to determine the interobserver 
agreement, 5 abdominal radiologists reevaluated preoperative CECTs from 70 consecutive 
patients operated for ANP.
MATERIALS AND METHODS
Patient Identification
In 11 hospitals of the Dutch Acute Pancreatitis Study Group, including all 8 Dutch university 
medical centers, 106 consecutive patients (age, >18 years) who underwent surgical intervention 
for proven or suspected infection of (peri-)pancreatic necrosis between October 1, 2000, and 
October 1, 2003, were identified by a hospital computer database search. Surgical outcome of 
these patients has been described elsewhere.7 Patients were included in the present study if a 
preoperative CECT had been performed and was available for analysis.
Data Collection
Date of hospital admission, date of CT, the original CT reports, and the preoperative CTs 
were retrieved from the participating and referring centers. In the CT reports, the use of the 
exact terms “pancreatic necrosis,” “pseudocyst,” and “pancreatic abscess” was scored. Terms 
such as “nonenhancement” or “fluid collection” were not scored, because they are not used in 
the Atlanta Classification. All preoperative CTs were digitalized by high resolution scanning 
(Diagnostic Pro; Vidar Systems Corporation, Herndon, Va).
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Study Protocol
From the (last) preoperative CT scan, 2 to 3 slices at different anatomic levels were selected; 
including the slice depicting the maximum diameter of the fluid-containing collection in or 
around the pancreas. These images were inserted in a computer slide presentation. The individual 
slides were coded, and the dates of the following events were added: hospital admission, 
preoperative CT, and surgical intervention. Five experienced abdominal radiologists from 5 
different hospitals (TLB, MSVL, JSL, EJVDJ, and SPS) independently reviewed the selected 
images or the entire CT. The radiologists were aware of the fact that all patients were operated 
upon for severe acute pancreatitis. The radiologists were, however, blinded for the results 
of the original report and were blinded for the reports of the other radiologists. If required 
by a radiologist, the complete digitalized CT was presented. The radiologists were asked to 
characterize the (peri-)pancreatic collections as acute fluid collection, pseudocyst, pancreatic 
abscess, or pancreatic necrosis according to the Atlanta Classification, (Table 1). A fifth option 
'mixture' was added for cases in which the radiologist felt the morphological changes depicted 
by CT had features of several definitions and thus did not fit within the confines of the Atlanta 
Classification. The option 'no collection' was added as it was anticipated that in some cases, no 
peripancreatic collection was apparent on the CT scan. The radiologists were familiar with the 
Atlanta Classification, and all read the appropriate definitions before review. The definitions 
remained available during the entire review process.
TABLE 1. Complications of Acute Pancreatitis as Described by the 1992 Atlanta Classification6
Acute fluid collection Occurs early in the course of acute pancreatitis, are located in or near the pancreas, 
and always lack a wall of granulation or fibrous tissue.
Acute pseudocyst A collection of pancreatic juice enclosed by a wall of fibrous or granulation tissue 
that arises as a consequence of acute pancreatitis or pancreatic trauma or chronic 
pancreatitis. Formation of a pseudocyst requires 4 or more weeks from the onset of 
acute pancreatitis.
Pancreatic abscess A circumscribed intra-abdominal collection of pus, usually in proximity to the 
pancreas, containing little or no pancreatic necrosis that arises as a consequence of 
acute pancreatitis or pancreatic trauma.
Pancreatic necrosis A diffuse or focal area(s) of nonviable pancreatic parenchyma that is typically 
associated with peripancreatic fat necrosis.
Statistical Analysis
The interobserver agreement was calculated using κ statistics. A κ level of less than 0.00 
represents no agreement; 0.00-0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0,61-0.80, 
substantial; 0.81-1.00, almost perfect agreement.8 Mean κ with SD was calculated for all 10 
radiologist pairs within the 5 radiologists. Categorical data were compared using Fisher exact 
test. Results of continuous data were expressed as median [range]. Comparison of continuous 
variables was performed using Mann-Whitney U test or Kruskal-Wallis test for multiple 
groups. A 2-tailed P < 0.05 was considered statistically significant.
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RESULTS
Patients
Of 80 scans available, 10 were non-contrast enhanced and were excluded. Therefore, 
preoperative CECTs were available for 70 (75%) of 106 patients. The patient baseline 
characteristics are shown in Table 2. Indications for surgical intervention were persistent 
sepsis despite maximal conservative therapy (61%), positive fine needle aspiration culture 
(23%), (peri-)pancreatic air on CT scan (10%), or suspected perforation of the gastrointestinal 
tract (6%). The diagnosis of infected pancreatic necrosis was confirmed in 63 patients (79%) by 
means of a positive culture from a peroperative aspirate.
TABLE 2. Patient Characteristics
Male 49 (70)
Age (y) 59 [29-79]
Preoperative intensive care unit admission (d) 38 (54)
Preoperative intensive care unit stay* (d) 7 [1-55]
Preoperative hospital stay 24 [1-140]
Mortality 24 (34)
Values are given as n (%) or median [range]. *Of patients admitted to the intensive care unit.
Original CT Reports
Sixty-four original CT reports (91%) were retrieved. In 48 reports  (75%),  one of the following 
terms was used “pancreatic necrosis” (n = 28), “pseudocyst” (n = 6), or “pancreatic abscess” (n 
= 14).
Interobserver Agreement
Among the 5 abdominal radiologists, there was slight interobserver agreement for categorizing 
collections according to the Atlanta Classification (κ, 0.144; SD, 0.095; Table 3). In 3 (4%) of 
70 cases, the radiologists chose the same definition (mixture, n = 2; pancreatic necrosis, n = 1). 
Four of 5 radiologists agreed in 15 cases (19%), and 3 of 5 agreed in 49 cases (61%). In 24 cases 
(30%), 1 or more of the radiologists classified a collection as 'pancreatic abscess' whereas 1 or 
more of the other radiologists classified the collection as 'acute fluid collection,' 'pseudocyst,' or 
'pancreatic necrosis.' See Figure 1 for examples.
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TABLE 3. Atlanta Classification Used for Defining (Peri-)Pancreatic Collections in 70 Necrotizing 
Pancreatitis Patients
Radiologist
Acute Fluid 
Collection
Pancreatic 
Abscess Pseudocyst
Pancreatic 
Necrosis Mixture
No 
Collection Total
1 10 (14) 22 (31) 0 (0) 4 (6) 32 (46) 2 (3) 70 (100)
2 1 (1) 1 (1) 0 (0) 14 (20) 53 (76) 1 (1) 70 (100)
3 8 (11) 4 (6) 0 (0) 7 (10) 51 (73) 0 (0) 70 (100)
4 14 (20) 16 (23) 2 (3) 24 (34) 14 (20) 0 (0) 70 (100)
5 15 (21) 21 (30) 20 (29) 6 (9) 3 (4) 5 (7) 70 (100)
Mean 10 (14) 13 (18) 4 (6) 11 (16) 31 (44) 2 (2) 70 (100)
Values are given as n (%).
FIGURE 1. The use of the Atlanta Classification on CT in necrotizing pancreatitis. A, Computed 
tomography scan 12 days after onset of disease. The definitions chosen for this collection were 
‘‘pseudocyst’’ (n = 1), ‘‘pancreatic abscess’’ (n = 1), ‘‘pancreatic necrosis’’ (n = 1), and ‘‘mixture’’ (n = 2). 
B, Computed tomography scan 27 days after onset of disease. The definitions chosen for this collection 
were ‘‘pancreatic abscess’’ (n = 3) and ‘‘mixture’’ (n = 2). C, Computed tomography scan 31 days after 
onset of disease. The definitions chosen were ‘‘pancreatic necrosis’’ (n = 1), ‘‘pancreatic abscess’’ (n = 1), 
‘‘pseudocyst’’ (n = 1), and ‘‘mixture’’ (n = 2).
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DISCUSSION
This study shows that the interobserver agreement for using the Atlanta Classification to 
categorize (peri-)pancreatic collections on CT is very poor, even when experienced abdominal 
radiologists are asked to judge CECTs.
Surgeons and gastroenterologists tend to rely heavily on the radiologist’s CT report of a patient 
with ANP to decide upon further treatment. The impact of a report describing a “pseudocyst” is 
completely different from that of “infected pancreatic necrosis” or a “pancreatic abscess.”1-3 As 
shown by the original CT reports in this study, radiologists often use the terms of the Atlanta 
Classification, although it is known that the Atlanta Classification was not designed originally 
for this specific purpose.
The major finding in this study was that the interobserver agreement for describing (peri-)
pancreatic collections on CT scan is very poor even when abdominal radiologists were supplied 
with the most relevant clinical data in these patients in whom the decision to operate had been 
made. These findings may be explained partially by the fact that the Atlanta Classification does 
not describe all manifestations of the disease with respect to (peri-)pancreatic collections.9 For 
example, a collection containing both necrosis and fluid does not fit with any of the definitions 
in the Atlanta Classification (see Table 1). Collections containing both impacted air and 
necrosis are often called 'pancreatic abscess,' when according to the Atlanta Classification, they 
are not. This may force the radiologist to decide between 2 definitions, feeling uncomfortable 
with both. This is a relevant problem as illustrated by the fact that the added option 'mixture' 
was used by the radiologists in up to 3 quarters of cases. Furthermore, it has been noted 
that CT is often not capable of detecting solid debris in pancreatic collections, especially 
when a significant fluid component is present.10 This leads to problems in the diagnosis of a 
'pseudocyst.' It is an extremely common error that collections containing a mixture of necrotic 
debris and fluid are termed 'pseudocyst.'9 In 9% of the original scan reports and in a mean 
of 6% of the 'expert' reports, the term 'pseudocyst' was used, although none of the patients 
had a pseudocyst, because pancreatic necrosis was detected during surgery in all cases. The 
recently revised UK guidelines on acute pancreatitis acknowledges this fact because it states 
that an ultrasound or magnetic resonance should always be performed before the diagnosis of 
pseudocyst is established. Furthermore, the guideline recommends considering all localized 
collections after necrotizing pancreatitis to be localized necrosis until proven otherwise.3
Most guidelines advice the use of the CTSI developed by Balthazar et al to quantify the extent 
of morphological changes on CT.1-3 The CTSI has been reported to have a good interobserver 
agreement.11 However, the CTSI is not concordant with the definitions of the Atlanta 
Classification.
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Interobserver agreement studies have never been reported for the Atlanta Classification, so 
the present study cannot be compared with previous studies. However, our study design is 
not likely to have introduced much observer bias, as the review was performed in a blinded 
controlled manner. One might argue that the inclusion of only CT scans of patients operated 
upon for suspected infected ANP caused selection bias. However, in daily practice, it is in these 
patients, in whom the decision for intervention is about to be taken, that the characterization 
of CT findings is most relevant. Different complications require different treatment strategies, 
ranging from conservative management to invasive percutaneous or surgical intervention. 
Interobserver variability in characterization of (peri-)pancreatic collections will potentially 
mislead the clinician in his choice for the appropriate therapy. This fact is illustrated in the 
present series by the 30% of cases in which the diagnosis of pancreatic abscess (treatment: 
percutaneous drainage) was used where other radiologists used the definitions pseudocyst 
(treatment: initially conservative), acute fluid collection (treatment: conservative), or pancreatic 
necrosis (treatment: surgery when infected).
The poor interobserver agreement of the Atlanta Classification for characterizing (peri-)
pancreatic collections on CT has several major implications. It should especially be taken 
into account in interhospital communication on acute pancreatitis patients, and it may even 
change our view of previously published clinical studies on intervention strategies in ANP. 
The Atlanta Classification should not be used to describe complications of acute pancreatitis on 
CT scan and a new descriptive radiological classification system for acute pancreatitis should 
be designed. Obviously, both interobserver and clinical studies will have to show the clinical 
relevance of such a classification. Computed tomography reports should be descriptive and 
mention the presence or absence of pancreatic necrosis, fluid collections, encapsulation, and/
or air. Finally, CT images should be reviewed by the radiologist and the clinician in unison, 
because this is likely to be the best safeguard against miscommunication and poor interpretation 
of peripancreatic collections in ANP.
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ABSTRACT
Objectives: The 1992 Atlanta Classification is a clinically based classification system that 
defines the severity and complications of acute pancreatitis. The purpose of this review was 
to assess whether the terms abandoned by the Atlanta Classification are really discarded in the 
literature. The second objective was to review what new terms have appeared in the literature 
since the Atlanta symposium.
Methods: We followed a Medline search strategy in review and guideline articles after the 
publication of the Atlanta Classification. This search included the abandoned terms: “phlegmon,” 
“infected pseudocyst,” “hemorrhagic pancreatitis,” and “persistent pancreatitis.”
Results: A total of 239 publications were reviewed, including 10 guideline articles and 42 
reviews. The abandoned terms 'hemorrhagic pancreatitis' and 'persistent pancreatitis' are 
hardly encountered. In contrast, both 'infected pseudocyst' and 'phlegmon' are frequently 
used, and several authors question their abandonment. New terminology in acute pancreatitis 
consists of 'organized pancreatic necrosis,' 'necroma,' 'extrapancreatic necrosis,' and 'central 
gland necrosis.'
Conclusions: This review demonstrates that the Atlanta Classification is still not universally 
accepted. Several abandoned terms are frequently used, and new terms have emerged that 
describe manifestations in acute pancreatitis that were not specifically addressed during the 
Atlanta symposium.
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INTRODUCTION
Between 1963 and 1992, 5 interdisciplinary symposia on pancreatitis have been convened to 
define and classify the spectrum of acute and chronic pancreatitis. The first symposium on 
pancreatitis was held in Marseille, France, in 1963.1 Staging was based on clinical grounds 
and categorized in acute, relapsing acute, chronic, and relapsing chronic pancreatitis. After the 
introduction of computed tomography (CT), this classification was revised in 1984 and 1988 
using morphological criteria to classify the spectrum of pancreatitis.2-4 This classification system 
lacked specific definitions for the complications of acute pancreatitis, and the nomenclature of 
complications was often ambiguous. Secondary infections of the pancreas associated with acute 
pancreatitis were classified as pancreatic abscess, infected pancreatic necrosis, or phlegmon. 
Often, no distinction was made between these entities, and many morphological terms were 
used interchangeably and inappropriately by radiologists and clinicians, including surgeons 
and gastroenterologists.
The last international symposium on defining acute pancreatitis and its complications was held 
in Atlanta, Georgia, in 1992.5 This international meeting was unique in the sense that it was 
the first symposium that focused on acute pancreatitis only, and this resulted in a universally 
applied classification system depending on both clinical and pathological criteria.5 The Atlanta 
symposium abandoned the terms 'infected pseudocyst,' 'phlegmon,' 'hemorrhagic pancreatitis,' 
and 'persistent acute pancreatitis.' Definitions were proposed for 'acute pancreatitis,' 'mild/severe 
acute pancreatitis,' 'acute fluid collection,' 'pancreatic necrosis,' 'pseudocyst,' and 'pancreatic 
abscess.'5 As early as 1990, Lumsden6 and Lumsden and Bradley7 stressed the importance of 
using precise terminology and definitions for the various pancreatic complications because 
each requires a distinct treatment strategy. Not only are unequivocal definitions crucial in the 
communication between physicians, they are also imperative to compare interinstitutional 
studies. Fourteen years after the Atlanta symposium, it is unknown whether the abandoned 
terms according to the Atlanta Classification are universally discarded or not. Therefore, we 
conducted a literature search to investigate the use of the abandoned terms after the publication 
of the Atlanta Classification. Furthermore, we searched for new terms that emerged in the 
literature after 1993 to describe manifestations in acute pancreatitis that were not addressed in 
the Atlanta symposium.
MATERIALS AND METHODS
The terms abandoned by the Atlanta Classification were systematically explored by a Medline 
search strategy using the following terms: “phlegmon,” “infected pseudocyst,” “hemorrhagic 
pancreatitis,” and “persistent pancreatitis.”
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To find potential new terms published after the publication of the Atlanta Classification in 
1993, we followed a predetermined strategy for a Medline search from 1993 to 2006 including 
the following terms: “acute pancreatitis; and review or guidelines.” Of 1291 hits, only articles 
addressing diagnostic and/or management strategies were included.
Bibliographic references from the guidelines and reviews were retrieved and analyzed. All types 
of publications were included (ie, original work, reviews, guidelines, case reports, editorials, 
comments). Studies published in a language other than English or German were excluded.
RESULTS
In all guidelines, published after 1993, most of the Atlanta definitions are accepted,8-17 and 
in only 1 guideline,15 we found a term that was abandoned by the Atlanta Classification: in 
the German guideline on acute pancreatitis, the term 'infected pseudocyst' is used.15 New and 
abandoned terms were used primarily in review articles, clinical studies, and case reports. First, 
the abandoned terms will be discussed, and second, the new terms on acute pancreatitis will 
be presented.
Abandoned Terms
Phlegmon
The term 'phlegmon' was abandoned by the Atlanta symposium because this condition was 
described in both edematous and necrotizing pancreatitis, either sterile or infected, resulting 
in considerable clinical confusion and treatment misadventures. However, several articles, 
published after the Atlanta symposium, still use the term 'phlegmon.'18-31 Although most authors 
accept that this term should be discarded, some openly disagree. Neff25 defines phlegmon 
as “…areas of peripancreatic infiltration with borders that are ill defined, having a mixed 
attenuation (solid and fluid), which cannot clearly be defined as fluid density. It represents 
inflammatory, edematous changes with infiltration of enzyme-rich pancreatic secretions and 
incites an inflammatory response.” He acknowledges that the term 'phlegmon' is both criticized 
and lauded because it is nonspecific. Furthermore, Neff25 states that “…the term phlegmon is 
particularly useful because it reflects prognostic uncertainty about a process that may resolve 
or progress and liquefy.” Mortele et al32-36 mention 'phlegmon' in several articles as ill-defined 
peripancreatic collections in grade Balthazar D pancreatitis. VanSonnenberg et al28 defined 
'pancreatic phlegmon' as “…inflammatory, viable pancreatic masses that are enhanced with 
intravenous contrast media during CT as opposed to pancreatic necrosis, which is defined as 
dead solid tissue.” A recent randomized controlled trial comparing early ductal decompression 
with conservative management in patients with acute biliary pancreatitis was terminated 
early when during interim analysis, a significant difference was observed in the incidence of 
complications between the experimental group and the study group.18 In 7 of 8 patients in the 
experimental group, this complication was designated as a 'pancreatic phlegmon.'  The authors 
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included pancreatic phlegmon because they felt that this local complication was not adequately 
defined by the Atlanta Classification. In their article, they provided typical clinical, imaging, and 
macroscopic (during surgical exploration) features of pancreatic phlegmon.18 Clinical features of 
a phlegmon consisted of severe and persistent epigastric pain and tenderness, nausea, vomiting, 
and protracted or episodic elevation of amylase and bilirubin levels. Radiological features of 
phlegmon consisted of normal enhancement of pancreatic parenchyma in conjunction with 
signs of peripancreatitis. Macroscopic features consisted of a pancreatic inflammatory mass, 
peripancreatic fluid, and fat necrosis.18
Infected Pseudocyst
The abandoning of the term 'infected pseudocyst' has been the least accepted. A large number 
of articles published since 1993 mention 'infected pseudocyst.'15,19,28,29,37-71 Many authors 
disagree with the proposition that ‘pancreatic abscess' is a better term for this type of collection. 
Mithofer et al50 reported that “…it has become apparent that infected pseudocyst, infected 
necrosis, and pancreatic abscess are different aspects of secondary pancreatic infection that 
vary in their associated morbidity and mortality” and “…infected pseudocysts are a different 
clinical entity, the percutaneous drainage of which is easier, safer, and more likely to be 
successful.” In an article on percutaneous drainage of pancreatic abscesses, vanSonnenberg 
et al28 excluded patients with infected pancreatic pseudocysts, and they made the following 
statement: “…although not necessarily reflecting conventional thinking, the definition of 
pancreatic abscess included infected pancreatic pseudocysts” and “…inclusion of infected 
pseudocysts might increase the success rate of pancreatic abscess drainage.” De Waele et al43 
reported that “pancreatic abscesses and infected pseudocysts arise later in the course of disease 
and should be considered as separate entities because of differences in therapy and outcome.” 
Baril et al19 reported that “…the imprecise definition of pancreatic abscess incorporates infected 
pseudocysts into this category.” Pitchumoni et al66 reported that “…an infected pseudocyst is a 
localized collection of infected fluid in the peripancreatic area that is enclosed by fibrous walls. 
Pancreatic abscesses are collections of pus that contain bacteria with little or no necrosis, in or 
around the pancreas, and are bound by adjacent tissues and organs. Pancreatic abscess differs 
from infected pseudocyst by lack of a clear membrane and the presence of an indistinct capsule 
or pseudocapsule consisting of fibrous tissue.” Baron38 reported that “…pancreatic abscess is not 
synonymous with infected pancreatic pseudocysts or infected pancreatic necrosis, they probably 
arise from limited pancreatic necrosis that subsequently liquefies and becomes infected.” Rau 
et al37 provided a new definition of infected pseudocyst: “…a localized collection of infected 
fluid in the region of the pancreas encapsulated by a wall. The presence of bacteria or fungi 
represents contamination and has no clinical significance. Furthermore, there is absence of pus 
and necrosis in infected pancreatic pseudocyst.”
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Hemorrhagic Pancreatitis
The term 'hemorrhagic pancreatitis' was only found in several case reports and a few clinical 
studies and is frequently used in cases of necrotizing pancreatitis or in combination with 
necrotizing pancreatitis (as in 'hemorrhagic-necrotizing pancreatitis’).18,65,72-80
Persistent Acute Pancreatitis
Persistent pancreatitis was only encountered in 1 review article,81 1 case report,82 and 1 clinical 
study.83 This term is used in patients with persistent abdominal pain, inability to eat, and failure 
to thrive after recovering from the acute phase of the disease. In the study by Fernandez-del 
Castillo et al,83 most of these patients had sterile necrosis (80%) and were operated on because 
of persistent unwellness.
New Terminology
Organized Pancreatic Necrosis
In 1996, Baron et al84 introduced the term 'organized pancreatic necrosis' for describing, what 
they felt, was a new type of collection. Since then, their group and others have used this term 
in several articles.38,82,85-90
Other authors referred to this collection as 'subacute pancreatic necrosis,'81 'necroma,'91 or 
'pseudocyst associated with necrosis.'92 According to Baron et al84 and Petrakis et al,81 pancreatic 
necrosis and acute fluid collections evolve and expand the initial area of pancreatic parenchyma 
necrosis, often accompanied by major pancreatic disruptions. Over a period of 2 to 3 weeks, 
these collections become encapsulated (become “organized”) and will contain variable amounts 
of both fluid and solid necrotic debris due to the liquefaction process of necrotic pancreatic 
and peripancreatic tissue.81,84 This kind of collection cannot be specifically defined to any of the 
current Atlanta definitions. Petrakis et al81 and Baron et al84 postulate that this type of collection 
represents an entity in transition from acute pancreatic necrosis to pancreatic pseudocyst. 
The same authors described in several articles the CT manifestations of 'organized/subacute 
pancreatic necrosis.' On contrast-enhanced CT (CECT), organized pancreatic necrosis is 
manifested by a collection of homogeneous or heterogeneous attenuation (fat, fluid, solid 
density, no gas bubbles), partially or completely surrounded by a wall, and expressing mass 
effect on adjacent structures. Furthermore, Baron et al,84 Petrakis et al,81 and Morgan et al89 
stated that the heterogeneous attenuation can turn into a homogeneous collection on follow-
up CECT scans because of the liquefaction process. In such a homogeneous collection, the solid 
part may then go unnoticed and may be mischaracterized as a pseudocyst. For management 
purposes, the distinction between organized pancreatic necrosis and pancreatic pseudocyst is 
deemed very important: failure of simple drainage may occur when partially liquefied necrotic 
collections are mistaken for pseudocysts.38,88 It has been demonstrated by Morgan et al89 that 
magnetic resonance imaging (MRI) is superior to CECT in identifying solid debris within 
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necrotic collections. Consequently, Morgan et al89 advocate the use of MRI before intervention 
in a subpopulation of patients (those who have symptomatic and persistent collections) for 
accurate delineation of solid debris in a collection.
Extrapancreatic Necrosis
Sakorafas et al93 first named this entity as 'extrapancreatic necrosis' or 'EXPN,' whereas other 
authors also alluded to this type of acute pancreatitis.94,95 According to Sakorafas et al,93 EXPN 
represents a necrotic process of peripancreatic fatty and connective tissue without evidence 
of necrosis of pancreatic parenchyma. The authors regarded EXPN as a subtype of acute 
necrotizing pancreatitis, rather than as a new entity. The fatty tissue necrosis is probably 
caused by the destruction of adipocytes by activated pancreatic enzymes such as lipase.93 The 
necrotic process is not only restricted to the retroperitoneal fatty tissue, but can also extend to 
pelvic viscera and bowel ligaments. Pathologically, EXPN consists of fat necrosis, extravasated 
pancreatic fluid, and inflammatory and hemorrhagic components.93 In their study, Sakorafas 
et al93 found a strong correlation between the extent and localization of EXPN and morbidity 
and mortality. This observation was confirmed in a recent study by Malangoni and Martin.49 
Despite extensive EXPN, patients can recover without substantial morbidity, especially in 
the absence of infectious complications. An important feature of EXPN on CECT is a viable, 
normally enhancing pancreas surrounded by a homogeneous or heterogeneous collection. 
The normal fatty peripancreatic tissue is replaced by homogeneous or heterogeneous density 
(fat, fluid, solid density). The aforementioned definition of EXPN resembles the definition of 
pancreatic phlegmon, which was described previously.18,96
Central Gland Necrosis/Disconnected Duct Syndrome
Central gland necrosis was initially described by Banks et al97 and regarded as a subtype of 
necrotizing pancreatitis in a study by Freeny et al.98 Central gland necrosis represents necrosis 
between the pancreatic head and tail and is nearly always associated with main pancreatic 
duct disruption.98 Because of the duct disruption in conjunction with a viable and secreting 
pancreatic tail, pancreatic enzymes continue to leak into the central cavity. Hence, organized 
pancreatic necrosis, fistulas, and pseudocysts can be anticipated when necrosis of the body of the 
gland is observed in the presence of a viable and secreting tail of the pancreas. Other potential 
complications are pancreatic ascites and pleural effusion. Fluid collections that communicate 
with the main pancreatic duct respond poorly to percutaneous drainage alone, and definitive 
treatment often requires distal pancreatectomy.98-103 Central gland necrosis is also referred to as 
'disconnected gland/duct syndrome'104-109 or 'isolated pancreatic segment.'51 If a duct disruption 
is noted during ERCP, Traverso and Kozarek110 advocate placement of transpapillary stents 
in the disrupted duct to prevent uncontrolled leakage of pancreatic juice in the pancreatic and 
peripancreatic space.
54 | Chapter 3
DISCUSSION
Acute pancreatitis is a disease with wide clinical variation, running a complicated course in 
20% of cases.17,111 In these patients, various complications may arise that warrant an accurate 
description because treatment strategies strongly depend on correct interpretation of these 
complications.10,17 Despite the definitions provided by the Atlanta symposium, problems 
exist in daily practice because imprecise terminology is used in the communication between 
physicians caring for patients with acute pancreatitis.91,112 This dispute is also found in the 
literature because abandoned terms are still frequently used in the literature. In addition, the 
first interobserver study on the radiological use of the Atlanta definitions recently demonstrated 
a poor interobserver agreement in classifying collections on CECT.113 In an editorial, Bradley114 
acknowledged the limitations of the current Atlanta definitions and stated that these definitions 
need updating and amplification. In the last decade, several authors have expressed the need for 
revision of the Atlanta Classification, and this overview of abandoned and new terminology in 
acute pancreatitis supports this statement.81,86,89,115,116
This review demonstrates that 'infected pseudocyst' and 'phlegmon' are the least accepted as 
abandoned terms. 'Hemorrhagic pancreatitis' and 'persistent pancreatitis' are hardly used in 
the literature and can be considered as effectively discarded. The most important rationale for 
the use of infected pseudocyst is the disagreement in the pathogenesis of pancreatic abscess 
and infection of a pseudocyst. Several authors are convinced that pancreatic abscess and 
infected pseudocyst are different entities with different management strategy and outcome. 
Data on results from therapy management for pancreatic abscess and infected pseudocyst exist 
in studies before the Atlanta symposium. These results are very difficult to interpret because 
of the extremely ambiguous use of pancreatic abscess in the literature before the Atlanta 
symposium.6,7,117 After 1993, no articles were found that compared differences in therapy 
management between pancreatic abscess and infected pseudocyst, and therefore, we believe, 
that there is a lack of reliable evidence that pancreatic abscess and infected pseudocyst differ in 
therapy and outcome.
Probably, the main reason for the use of the term 'phlegmon' is the fact that the Atlanta 
symposium did not address a peripancreatic collection on a CT scan that consists of mixed 
attenuation (solid, fluid, and fat density) and not primarily fluid density as is seen in acute 
fluid collections. The problem with reintroducing the term phlegmon in the literature is that 
no consensus exists on the precise definition of this term. Hence, this may propagate more 
confusion in the literature.
There are several explanations for the appearance of new terms in the literature since the 
Atlanta symposium. The proposed Atlanta definitions were the result of the knowledge 
that existed in 1992. Over time, new insights into the pathophysiology of this disease have 
been acquired. Furthermore, improved diagnostic imaging techniques and new therapeutic 
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strategies for complications of acute pancreatitis are introduced. These new treatment options 
(ie, minimally invasive surgery, endoscopic necrosectomy, percutaneous drainage) rely on 
accurate morphological description of complications in acute pancreatitis because the type of 
intervention is dependent on the contents of a collection. New insights in the pathophysiology 
of acute pancreatitis have led to the recognition of 2 additional types of acute pancreatitis, 
with possible important prognostic and management implications. Extensive retroperitoneal 
peripancreatic necrosis with no recognizable pancreatic parenchymal necrosis (EXPN) can be 
regarded as a subtype of (necrotizing) pancreatitis that has a better prognosis as compared 
with patients with gland necrosis. An impediment for introduction of this term may be the 
difficulty to reliably identify fat necrosis on a CECT because conflicting results are observed in 
the literature on identification of (peripancreatic) fat necrosis on CECT.6,95,118-121 
Central gland necrosis can be regarded as a subtype of necrotizing pancreatitis, which is 
important for the clinician and radiologist to recognize because several complications can be 
anticipated, such as the formation of organized pancreatic necrosis, pseudocysts, and fistulas. 
These patients may ultimately require distal pancreatectomy for definitive treatment of 
refractory collections or pancreatic fistulas.
The problem with the current Atlanta Classification is that it addresses the extremes of the 
spectrum of complications in acute pancreatitis. Early events in acute severe pancreatitis are the 
presence of acute fluid collections and pancreatic parenchymal necrosis. Pseudocysts (collection 
of sterile fluid) and pancreatic abscesses (collection of pus) take at least 4 weeks or more to 
evolve,5 and hence, the collections that occur in the meantime are less well defined. Many 
authors acknowledge the dynamic evolving process of acute pancreatitis and state that overlap 
of several entities may occur.50,81,86,122 'Organized pancreatic necrosis' or 'necroma' is probably 
the most important new entity that was not recognized at the Atlanta symposium. This kind 
of collection contains both fluid and necrosis and, therefore, does not fit in any of the current 
Atlanta definitions. In the current Atlanta Classification, organized pancreatic necrosis may be 
defined as either pseudocyst or pancreatic necrosis. This entity can easily be misinterpreted as 
a pseudocyst on a CT if the solid necrotic debris in the collection is not recognized. With the 
advent of more sophisticated imaging techniques, such as MRI and endoscopic ultrasonography, 
the necrotic debris can better be delineated and, hence, can direct the type of intervention that 
is deployed (simple drainage vs endoscopic/surgical necrosectomy).10
How can this review help us in designing a new Atlanta Classification? First, we feel that this 
review points out which terms may truly be abandoned. Second, the current Atlanta definitions 
should be modified to effectively discourage the use of the abandoned terms by providing strict 
clinical, pathological, and radiological criteria for every definition. Third, the term 'organized 
pancreatic necrosis,' representing a collection that contains both fluid and necrotic debris, 
seems useful for introduction. Fourth, a classification of acute pancreatitis should leave room 
for introduction of EXPN. In this regard, interstitial or edematous pancreatitis refers to a type 
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of pancreatitis that is characterized by normal pancreatic enhancement on CECT or MRI and 
absence of peripancreatic (fluid) collections. EXPN is defined as a normal enhancing pancreatic 
parenchyma on CECT or MRI surrounded by (fluid) collection(s). Necrotizing pancreatitis 
refers to non-enhancement of pancreatic parenchyma on CECT or MRI with or without 
peripancreatic (fluid) collections. Finally, central gland necrosis should be regarded as a subtype 
of necrotizing pancreatitis.
For universal application of any new classification system, we realize that acceptance is only 
achieved if international consensus is accomplished.
CONCLUSIONS
This review demonstrates that several abandoned terms are still frequently used, and new 
terms on acute pancreatitis have emerged that describe manifestations in acute pancreatitis 
that were not specifically addressed during the Atlanta symposium. Therefore, an update of the 
Atlanta Classification seems prudent, to make comparison of research data more reliable and 
improve patient management.
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ABSTRACT
Background: In a complex disease such as acute pancreatitis, correct terminology and clear 
definitions are important. The clinically based Atlanta Classification was formulated in 1992, 
but in recent years it has been increasingly criticized. No formal evaluation of the use of the 
Atlanta definitions in the literature has ever been performed.
Methods: A Medline literature search sought studies published after 1993. Guidelines, review 
articles and their cross-references were reviewed to assess whether the Atlanta or alternative 
definitions were used.
Results: A total of 447 articles was assessed, including 12 guidelines and 82 reviews. Alternative 
definitions of predicted severity of acute pancreatitis, actual severity and organ failure were 
used in more than half of the studies. There was a large variation in the interpretation of the 
Atlanta definitions of local complications, especially relating to the content of peripancreatic 
collections.
Conclusion: The Atlanta definitions for acute pancreatitis are often used inappropriately, and 
alternative definitions are frequently applied. Such lack of consensus illustrates the need for a 
revision of the Atlanta Classification.
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INTRODUCTION
Over the past five decades, several classification systems on pancreatitis have emerged from 
interdisciplinary symposia1–4. The most recent international meeting on this topic, the 1992 
Atlanta symposium, produced a clinically based classification system4,5. Definitions of acute 
pancreatitis, its severity, organ failure and the local complications ‘acute fluid collection’, 
‘pancreatic necrosis’, ‘pseudocyst’ and ‘pancreatic abscess’ were proposed. The Atlanta 
Classification attempted to introduce uniformity in the assessment of clinical severity and the 
various complications of the disease. This is the only widely accepted classification system used 
by clinicians and radiologists. With increasing knowledge of the pathophysiology of pancreatitis 
and the development of new means of intervention, several authors have pointed out 
shortcomings in the Atlanta Classification6–13. A recent review demonstrated that terminology 
abandoned by the Atlanta symposium, for instance ‘phlegmon’ and ‘infected pseudocyst’, is still 
used frequently in the literature, and that various new terms, such as ‘organized pancreatic 
necrosis’ and ‘necroma’, have been introduced since 199314. A critical evaluation of the use 
of the Atlanta Classification in the literature has never been performed. The present review 
assesses whether the definitions of the Atlanta Classification are accepted in the literature and 
evaluates the extent of variation in interpretation of these definitions.
METHODS
A Medline search of literature published between 1993 and 2006 was performed using the 
following terms: ‘acute pancreatitis and review’ and ‘acute pancreatitis and guidelines’. From 
the identified guidelines and reviews, cross-references were retrieved. The search included 
all types of publication (reviews, guidelines, original studies, case reports and editorials), 
but excluded those not in English and animal experimental studies. One author (T.L.B.) 
performed the selection and reviewed all full-text papers to assess whether the original Atlanta 
definitions (Table 1) or other definitions were used for the following five components of the 
Atlanta Classification: diagnosis (cut-off levels of pancreatic enzymes lipase and amylase); 
predicted severity (predictive scoring systems, cut-off levels of scoring systems); actual 
severity (distinction between mild and severe pancreatitis, distinction between predicted 
and actual severity); organ failure (determinants of individual failing organ systems, cut-
off levels of determinants, distinction between single-organ failure and multiorgan failure); 
local complications (pancreatic necrosis and peripancreatic necrosis, infection of necrosis, 
morphological aspects and distinction of different types of collection).
If different definitions for the components were identified, this was double checked by one of 
two other authors (H.C.v.S., M.G.B.). All disagreements were resolved by discussion among 
the authors. In addition, study results leading to new insights that might have influenced the 
interpretation of the Atlanta Classification were recorded and are discussed. As a large number 
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of references were retrieved, for each component of the Atlanta Classification that was assessed 
only the three most recent articles are cited here; the remaining references are published in 
Appendix 1 (available as supplementary material online at www.bjs.co.uk).
TABLE 1. Summary of the 1992 Atlanta Classification
Definition
Acute pancreatitis An acute inflammatory process of the pancreas with variable involvement of 
other regional tissues or remote organ systems
Associated with raised pancreatic enzyme levels in blood and/or urine
Severity
Mild acute pancreatitis Associated with minimal organ dysfunction and an uneventful recovery; 
lacks the features of severe acute pancreatitis. Usually normal enhancement 
of pancreatic parenchyma on contrast-enhanced computed tomography
Severe acute pancreatitis Associated with organ failure and/or local complications such as necrosis, 
abscess or pseudocyst
Predicted severity Ranson score ≥ 3 or APACHE II score ≥ 8
Organ failure and systemic complications
Shock Systolic blood pressure < 90 mmHg
Pulmonary insufficiency PaO2 ≤ 60 mmHg
Renal failure Creatinine ≥ 177 µmol/l or ≤ 2 mg/dl after rehydration
Gastrointestinal bleeding 500 ml in 24 h
Disseminated intravascular 
coagulation 
Platelets ≤ 100,000/mm3, fibrinogen < 1·0 g/l and fibrin-split products > 80 
µg/l
Severe metabolic disturbances Calcium ≤ 1·87 mmol/l or ≤ 7·5mg/dl
Local complications
Acute fluid collections Occur early in the course of acute pancreatitis, are located in or near the 
pancreas and always lack a wall of granulation of fibrous tissue. In about half 
of patients, spontaneous regression occurs. In the other half, an acute fluid 
collection develops into a pancreatic abscess or pseudocyst
Pancreatic necrosis Diffuse or focal area(s) of non-viable pancreatic parenchyma, typically 
associated with peripancreatic fat necrosis
Non-enhanced pancreatic parenchyma > 3 cm or involving more than 30% of 
the area of the pancreas
Acute pseudocyst Collection of pancreatic juice enclosed by a wall of fibrous or granulation 
tissue, which arises as a result of acute pancreatitis, pancreatic trauma or 
chronic pancreatitis, occurring at least 4 weeks after onset of symptoms, is 
round or ovoid and most often sterile; when pus is present, lesion is termed a 
‘pancreatic abscess’
Pancreatic abscess Circumscribed, intra-abdominal collection of pus, usually in proximity to 
the pancreas, containing little or no pancreatic necrosis, which arises as a 
consequence of acute pancreatitis or pancreatic trauma
Often 4 weeks or more after onset
Pancreatic abscess and infected pancreatic necrosis differ in clinical 
expression and extent of associated necrosis
APACHE, Acute Physiology And Chronic Health Evaluation; PaO2, arterial partial pressure of oxygen.
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RESULTS
A total of 447 articles was reviewed, including 12 guidelines and 82 reviews. These articles 
reported on studies that were not specifically designed to evaluate the Atlanta Classification; 
they merely mentioned Atlanta definitions (for example a randomized trial comparing two 
treatment strategies with the outcome ‘pseudocyst’). Therefore, an assessment of methodological 
quality was deemed inappropriate. Table 2 gives an overview of the papers according to type 
of article and impact factor of the journals in which they were published. The most important 
discrepancies for the five components of the Atlanta Classification and discrepancies in the 12 
guidelines are discussed in order.
TABLE 2. Characteristics of retrieved articles (1993–2006) specified according to impact factor of 
journal
Total no.
of studies
(n = 447)
Impact factor
High
(>5·0)
(n = 89)
Intermediate
(1·5–4·9)
(n = 273)
Low
(<1·5)
(n = 85)
Meta-analyses 3 2 1 0
Randomized 
controlled trials
34 13 18 3
Prospective series 144 28 99 17
Retrospective series 147 23 95 29
Reviews 82 10 44 28
Guidelines 12 5 5 2
Editorials 5 2 3 0
Other 20 6 8 6
Diagnosis
The Atlanta Classification provides no cut-off value for pancreatic enzyme levels. In 116 
studies, the diagnosis of acute pancreatitis was defined as a characteristic clinical history of 
abdominal pain and an increased level of pancreatic enzymes to three or more times the upper 
limit of normal. However, 31 studies used different thresholds, ranging from two or more15–17 
to more than four18–20 and more than five21–23 times the upper limit of normal.
Predicted severity
A total of 283 articles provided criteria for predicting severity in acute pancreatitis. Some 86 
reports used the severity scoring systems proposed by the Atlanta symposium16,17,23. However, 
197 studies used a different cut-off level for defining severity, or used different or additional 
scoring systems, such as computed tomography (CT) severity index, Imrie (Glasgow) score, 
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Simplified Acute Physiology score, Sequential Organ Failure Assessment or severity predictors 
(such as C-reactive protein)15,24,25. Cut-off values for severity stratification differed considerably 
between reports. For the CT severity index, the most established radiological scoring system 
developed by Balthazar and colleagues26 in 1990, the cut-off value to differentiate between 
mild and severe disease ranged from three or more to eight or more points27–29. In 32 studies, 
threshold values for Acute Physiology And Chronic Health Evaluation (APACHE) II score 
(other than eight or more) varied from five or more to 11 or more, whereas the time for 
calculating the score varied from day of admission to 24 and 48 h after admission30–32. Eleven 
studies used different threshold values for the Ranson criteria (other than three or more), 
ranging from more than three to more than five32–34.
Since the Atlanta symposium in 1992, many studies have identified new predictors of severity 
and these have been incorporated in several guidelines. Such predictors include age (over 556, 
over 7035 or over 8036 years), obesity (body mass index over 30 kg/m2)11,24,37, pleural effusion (left 
or bilateral) on chest radiograph38–40, raised haematocrit level6,41,42 and C-reactive protein level 
greater than 150 mg/dl after 48h43–45.
Actual severity
Of 297 articles providing definitions for severe acute pancreatitis, 195 defined severe disease 
according to the Atlanta Classification, although 61 merely stated that the Atlanta criteria were 
used without specification46–48. The remaining 102 articles used definitions of severe disease 
other than those of the Atlanta Classification. These definitions were based on admission to 
an intensive care unit, length of intensive care unit or hospital stay, complications requiring 
medical or operative intervention, mortality or various other, additional or non-specified 
criteria17,49,50. The authors of 45 articles used the absence and presence of pancreatic necrosis 
broadly synonymously with mild and severe acute pancreatitis respectively47,51,52. Some reports, 
however, pointed out that patients with the morphological diagnosis of interstitial pancreatitis 
may develop clinically severe disease44,53,54.
The relationship between the development of organ failure and pancreatic necrosis (the most 
important determinants of severe acute pancreatitis) is contentious. Several reports noted that 
only 51– 55 per cent of patients with pancreatic necrosis manifested organ failure55–57. In the 
study by Lankisch and colleagues53, 15 per cent of patients with acute oedematous pancreatitis 
developed organ failure. In a recent study, organ failure was the main risk factor for mortality, 
regardless of the presence or absence of pancreatic necrosis23. Conversely, other studies showed 
a good correlation between organ failure and the extent of pancreatic necrosis16,58,59 .
Finally, in 38 articles, the differentiation between ‘predicted severe’ acute pancreatitis (Ranson, 
Imrie or APACHE II score) and ‘actual severe’ disease (systemic or local complications) was not 
apparent from the published data17,28,60. The difference is important, because in recent studies 
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less than 50 per cent of patients with predicted severe disease eventually turned out to have 
actual severe disease according to the Atlanta criteria25,46. This lack of distinction may account 
for the variation in incidence of severe acute pancreatitis among institutions.
Organ failure
Criteria for organ failure were found in 149 articles. In 35 reports the exact Atlanta definitions 
for organ failure were specifically stated and used23,61,62. Seven articles restricted organ failure to 
two of the four Atlanta determinants for organ failure: respiratory and renal insufficiency63–65. 
However, 107 articles used additional criteria for organ failure and systemic complications, 
such as leucocytosis, temperature, coagulopathy, nervous system failure, hepatic failure, 
systemic inflammatory response syndrome or sepsis, or used altered thresholds or adjustments 
for the Atlanta definitions of organ failure52,66,67. The remaining articles gave no definition of 
organ failure, or simply noted that the Atlanta criteria were used, without specification.
In recent years, multiorgan failure has been acknowledged as a major determinant of mortality. 
However, no uniform definition for multiorgan failure exists: 20 reports defined it as failure 
of two or more organ systems31,46,49, and eight as failure of three or more organ systems23,68,69, 
although most studies did not define multiorgan failure.
The dynamic process of organ dysfunction is increasingly recognized, and several authors 
differentiated between transient and persistent organ failure70–72. In addition, several studies 
showed that early and progressive organ failure was associated with high mortality, but 
most patients with transient organ failure had an uncomplicated course72–74. The recent UK 
guidelines on acute pancreatitis state that organ failure in the first week resolving within 48h 
should not be considered an indicator of severe disease43.
Since 1993, several new organ failure grading systems have been developed (Goris score, 
Marshall or multiple organ dysfunction score, Bernard score, Sequential Organ Failure 
Assessment and logistic organ dysfunction syndrome score) that take into account the number 
of organ systems involved and the degree of dysfunction of each individual organ. Some 
systems also include the need for inotropic or vasopressor agents, mechanical ventilation 
and dialysis that the Atlanta symposium did not account for. Several studies have shown that 
dynamic scoring systems (such as the delta APACHE II score) or scoring systems that account 
for the physiological response to treatment (such as the delta organ failure score or cumulative 
Marshall score) are better predictors of outcome than static scoring systems31,32,71 .
Local complications
In a recent interobserver agreement study on the Atlanta definitions regarding the various local 
complications, interobserver agreement was poor: five radiologists agreed on the respective 
Atlanta definition in only three of 70 collections depicted by contrast-enhanced CT (CECT)8.
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Acute fluid collection
In 64 articles, a definition was given for an ‘acute fluid collection’. The following terms were 
used to describe acute fluid collections: ‘(peri)pancreatic fluid collections’75–77, ‘peripancreatic 
effusions’78, ‘extrapancreatic fluid collections’61,79,80, ‘immature pseudocyst’81,82 and ‘exudates’54. 
(Peri)pancreatic fluid collection was also used as an overall descriptive term for all types of 
collection related to acute pancreatitis83–85.
In most reports, the differentiation between acute fluid collection and pseudocyst was made 
after 4 weeks from onset of disease (as proposed by the Atlanta Classification). In eight reports, 
however, a different time period was used as a criterion for this distinction, varying from 3 
weeks75,86,87 to 688,89 and even 890 weeks. Moreover, they did not adequately describe whether 
acute fluid collections consisted of fluid alone or whether they may have contained necrotic 
debris85,91,92.
Authors of 17 articles regarded the occurrence of an acute fluid collection to be a local 
complication and so a sign of ‘severe disease’46,62,93. However, most others did not include acute 
fluid collection either in the definition of local complication or in that of severe disease.
Pancreatic necrosis 
Of 152 articles that gave a specific definition for ‘pancreatic necrosis’ or ‘necrotizing pancreatitis’ 
(Fig. 1), 47 used the Atlanta criterion of more than 30 per cent parenchymal necrosis to define 
necrotizing pancreatitis28,61,94. However, 85 defined necrotizing pancreatitis as any evidence of 
pancreatic parenchymal necrosis (including less than 30 per cent parenchymal necrosis)47,95,96. 
A third definition of necrotizing pancreatitis, reported in 20 papers, was the appearance of 
pancreatic necrosis or extrapancreatic necrosis, or both, on CECT (and a serum C-reactive 
protein value of more than 150 mg/dl)52,86,97.
In the Atlanta Classification, the definition of pancreatic necrosis requires pancreatic 
parenchymal non-enhancement on CECT4. However, some clinicians questioned whether 
non-enhancement on CECT meant irreversible damage and necrosis86,98,99. For instance, 
Traverso and Kozarek86 defined pancreatic necrosis as devitalized tissue found at operation. 
This was supported by Takeda and colleagues100–102, who noted that pancreatic parenchymal 
perfusion was maintained during intra-arterial angiography, while CECT showed pancreatic 
non-enhancement. In contrast, several studies demonstrated a good correlation between 
parenchymal non-enhancement on CECT and the presence of pancreatic necrosis (confirmed 
at operation)103–105.
Data on the accuracy of CECT in diagnosing extrapancreatic or peripancreatic fat necrosis are 
conflicting. Although eight groups claimed that fat necrosis could not be determined reliably 
by CECT92,106,107, several studies demonstrated a good correlation between extrapancreatic 
findings on CECT and the presence of fat necrosis at operation or autopsy104,108,109.
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FIG. 1 Contrast-enhanced computed tomography (CT) of a patient with acute pancreatitis 22 days 
after onset of symptoms, A with normal enhancement of the pancreas and B surrounded by a large 
heterogeneous and encapsulated fluid collection with gas bubbles suggesting secondary infection. Some 
would call this ‘necrotizing pancreatitis’, but others would call it ‘interstitial pancreatitis’ because there 
is no evidence of pancreatic parenchymal necrosis (only peripancreatic necrosis). A large amount of fat 
necrosis was debrided during operation. C Follow-up CT 6 months after operation reveals a normal 
enhancing pancreatic parenchyma 
The Atlanta Classification includes both infected and sterile necrosis within the definition 
of ‘pancreatic necrosis’4. Several groups claimed that pancreatic parenchymal necrosis 
without infection is not a major morbidity risk110–112 . This was supported by studies showing 
an uncomplicated course in the presence of necrosis without infection23,55,56. Beger and 
colleagues81,113 were the first to emphasize that necrosis is a potential nidus for secondary 
infection occurring in 40 – 70 per cent of patients. Recent studies confirmed this, demonstrating 
infected necrosis as the primary cause of late mortality58,114,115. However, definitions of ‘infected 
necrosis’ were also conflicting. Some authors regarded the presence of parenchymal necrosis as 
a prerequisite for the diagnosis of infected necrosis116–118, but others defined infected necrosis 
as infection that could occur in parenchymal necrosis or peripancreatic fat necrosis (in other 
words, in the absence of parenchymal necrosis), or both67,76,119.
A B
C
74 | Chapter 4
Pseudocyst
A specific definition for the term ‘pseudocyst’ was provided in 87 articles, and all were similar to 
that of the Atlanta Classification. Some controversies, however, remain. Thirty-eight articles 
included collections containing both fluid and necrotic debris under the heading of pseudocyst 
(Fig. 2)120–122. Yet Baron123 and others85,124 have stated that pseudocysts should be devoid of solid 
necrotic debris. Evidence has shown that therapeutic strategy and outcome differed between 
collections containing fluid alone and those containing necrosis and fluid84,125,126. Bradley127 
considered that mischaracterization of (peri)pancreatic fluid collections as pseudocyst 
by CECT was an extremely common error in contemporary diagnostic radiology. This 
mischaracterization has two potentially dangerous consequences: first, by instrumentation of a 
sterile collection containing both fluid and necrosis, infection may be introduced6,120,128; second, 
a delay in appropriate intervention may occur33,120,129.
The incidence, natural history and options for management differed between acute and chronic 
pseudocysts. Several authors emphasized that the results of treatment of pancreatic fluid 
collections in the literature were difficult to interpret, because often no distinction was made 
between pseudocysts and acute fluid collections, or between pseudocysts that complicated acute 
and chronic pancreatitis122,128,130. Thirty-one original articles on the treatment of pseudocysts 
were reviewed but only five dealt exclusively with pseudocysts after an episode of acute 
pancreatitis89,120,131. The remaining 26 articles reported results of the treatment of pseudocysts 
complicating acute and chronic pancreatitis121,132,133.
Pancreatic abscess
Some 68 articles provided a definition of ‘pancreatic abscess’, which was generally in line with 
the original Atlanta definition. Nine original articles after 1993 were identified that reported 
on the treatment of ‘pancreatic abscesses’, and the Atlanta definition (collection of pus and 
virtually no necrotic debris, more than 4 weeks after onset) was strictly applied in three of 
these134–136. The others included collections that contained, in addition to pus, solid necrotic 
debris137–139 or that were treated within 4 weeks of onset of disease140 or after surgery141,142. The 
diagnosis of pancreatic abscess on CECT is also controversial. In ten articles, the ‘air bubble’ 
phenomenon was considered ‘diagnostic of a pancreatic abscess’93,143,144. In 31, however, gas 
bubbles in a heterogeneous collection on CT were regarded as highly indicative of infected 
pancreatic necrosis (Fig. 3)61,67,145. Varying hypotheses exist on the aetiology of pancreatic 
abscess. Some authors considered ‘postacute pseudocysts’ and pancreatic abscesses as late 
consequences of necrotizing pancreatitis146–148. In contrast, others maintained that pancreatic 
abscesses occurred exclusively in interstitial pancreatitis with a normal enhancing pancreas on 
CECT117,149,150.
Apart from ‘infection of a pseudocyst’, several authors hypothesized that pancreatic abscesses 
evolved from progressive liquefaction of necrotic pancreatic and peripancreatic tissues, in 
time resulting in complete liquefaction76,123,151. According to the Atlanta Classification, most 
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pancreatic abscesses arise at least 4 weeks after onset of symptoms4, although others diagnose 
‘pancreatic abscesses’ after 150,152, 2153,154 or 386,146,147 weeks. Interestingly, when performing 
operative necrosectomy several months after the onset of severe acute pancreatitis, Morgan 
and colleagues10, Howard and Wagner155 and others156 observed different degrees of liquefaction 
of necrotic tissue. Several authors acknowledged this evolving process, and they postulated 
that a collection may represent a transitional entity from (infected) pancreatic necrosis to an 
(infected) pseudocyst or pancreatic abscess, as they encountered both pus and necrotic debris 
in these (infected) collections7,12,139.
Guidelines
The greatest discrepancies in the 12 guidelines6,35,36,43,148, 157–165 on acute pancreatitis related to 
the definitions of organ failure and those of predicted severe disease. These are summarized in 
Table 3.
FIG. 2. Contrast-enhanced computed 
tomography (CT) of a patient with acute 
pancreatitis 30 days after onset of symptoms. 
The fluid collection seems to be homogeneous 
and encapsulated and could be interpreted 
as a ‘pseudocyst’ according to the Atlanta 
Classification. However, at operation the 
collection was found to contain large amounts 
of necrotic debris that CT had not shown
FIG. 3. Contrast-enhanced computed 
tomography of a patient with acute 
pancreatitis 36 days after onset of symptoms. 
The body and tail of the pancreas are largely 
non-enhancing. Adjacent to the pancreatic 
bed is a large collection with predominately 
fluid-like attenuation. Because of the gas 
bubbles, some would call this a ‘pancreatic 
abscess’ but others would call it ‘infected 
pancreatic necrosis’
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TABLE 3. Overview of definitions for organ failure and predicted severe acute pancreatitis in guidelines 
for acute pancreatitis published after 1993
Guideline Definitions for organ failure Definitions for predicted severe acute pancreatitis
ACG
1997157
Refers to Atlanta Classification 1992 Ranson score ≥3 after 48h
APACHE II score >8 after 48h
UK
1998158
Refers to Atlanta Classification 1992 Ranson/Glasgow ≥3
CRP >210 mg/l (first 4 days) or >120 mg/l at 1 week
APACHE II score ≥9 (severe acute pancreatitis) or ≥6 
(includes all severe cases, but PPV of 50%)
SSAT
1998159
Not addressed Not stated
Santorini
1999160
Not addressed BMI >30 kg/m2
Pleural effusion
APACHE II score ≥6 (at 24h)
APACHE (obesity) score ≥6
CRP >150 mg/l
French
200036
Renal failure: creatinine >170 
μmol/l
Shock: systolic BP <90 mmHg 
despite fluid replacement
Pulmonary insufficiency: PaO2 ≤ 60 
mmHg on room air
Glasgow Coma Score <13
Platelets <80 g/l
At admission
Age >80 years
BMI >30 kg/m2
Chronic renal failure
Pre-existing severe illnesses
At 24–48h
Presence of organ failure by using simple measures or 
use of scoring system (e.g. SOFA)
Ranson/Imrie score >3
CECT: CT severity index ≥4 (48–72h)
CRP >150 mg/l
Note: ‘The non-specific scores (APACHE II, SAP II, etc) are not 
recommended by the Jury’
WCG
200235
SIRS
≥1 vital organ dysfunction
ARDS
Renal failure: increased serum 
creatinine >0·5 mg/dl (44 μmol/l) 
or 50% above baseline or reduction 
in calculated creatinine clearance 
>50% or need for dialysis
Hypotension: mean arterial pressure
<60 mmHg
DIC
Acute adrenal insufficiency
Acute hepatitis
Metabolic encephalopathy
Ileus
At admission
Age >70 years
Clinical assessment
BMI >30 kg/m2
Pleural effusion/infiltrates
CECT: >30% non-enhancement of the pancreas
APACHE II score ≥8
Presence of organ failure
At 24–48h
Clinical assessment
Glasgow score (no cut-off value provided)
CRP >150 mg/l
Presence of organ failure
IAP
2002161
Not addressed Not stated: surgical guideline
JSAEM
2002162
Not addressed Clinical signs
CRP (48h: no cut-off value provided)
BMI (no value provided)
CECT: necrosis
Scoring system, like JMHW, APACHE II at 24h or Ranson/
Glasgow at 24–48h: no cut-off values provided
Japanese score ≥2
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Guideline Definitions for organ failure Definitions for predicted severe acute pancreatitis
Nathens
2004148
Refers to the guidelines for 
intensive care unit admission, 
published in 1999163
Elderly (age not specified)
BMI >30 kg/m2
Patients requiring ongoing volume resuscitation
CECT: >30% non-enhancement of the pancreas
Clinical assessment
Note: ‘Disease-specific scoring systems or severity scores are useful 
adjuncts to identify patients at high risk of a complication, but 
should not replace serial clinical assessments. In addition, there 
is a recommendation against the use of markers such as CRP or 
procalcitonin to guide clinical decision making or predict clinical 
course of acute pancreatitis or to triage patients’
UK
200543
Refers to Atlanta Classification 1992 At admission
Clinical assessment
BMI >30 kg/m2
Pleural effusion
APACHE score >8
At 24–48h
Clinical assessment
Glasgow score ≥3
APACHE II score >8
Persistent organ failure for 48h (especially if multiple 
and progressive)
CRP >150 mg/l
Note: ‘Organ failure present within 1 week, which resolves within 
48h, should not be considered an indicator of a severe attack of 
acute pancreatitis’
ACG
20066
Refers to Atlanta Classification 1992
Note: ‘Criteria of organ failure will 
change in the future: gastrointestinal 
bleeding will undoubtedly be deleted’
At admission
Age >55 years
BMI >30 kg/m2
Presence of organ failure
Pleural effusion/infiltrates
24–48h
APACHE II score ≥8
Serum haematocrit ≥44%
Note: ‘Ranson signs are no longer advocated, due to a 
comprehensive evaluation of 110 studies that concluded that 
Ranson signs provided very poor predictive power of severity of 
acute pancreatitis’
JSAEM
2006164,165
Pulmonary insufficiency: dyspnoea 
Shock
Central nervous system disorders
Bleeding tendency
Negative base excess failure: rise 
of blood urea nitrogen level and 
creatinine level
Japanese score ≥2
ACG, Practice Parameters Committee of the American College of Gastroenterology; APACHE, Acute Physiology And Chronic Health 
Evaluation; UK, Working Party of the British Society of Gastroenterology, Association of Surgeons of Great Britain and Ireland, 
Pancreatic Society of Great Britain and Ireland, and Association of Upper GI Surgeons of Great Britain and Ireland; CRP, C-reactive 
protein; PPV, positive predictive value; SSAT, Society for Surgery of the Alimentary Tract; Santorini, Santorini Consensus Conference; 
BMI, body mass index; French, French Consensus Conference on Acute Pancreatitis; BP, blood pressure; PaO2, arterial partial pressure 
of oxygen; SOFA, Sequential Organ Failure Assessment; CECT, contrast-enhanced computed tomography; SAP, Simplified Acute 
Physiology; WCG, World Congress of Gastroenterology; SIRS, systemic inflammatory response syndrome; ARDS, adult respiratory 
distress syndrome; DIC, disseminated intravascular coagulation; IAP, International Association of Pancreatology; JSAEM, Japanese 
Society of Emergency Abdominal Medicine; JMHW, Japanese Ministry of Health and Welfare; Nathens, Consensus Statement 
regarding the management of the critically ill patient with severe acute pancreatitis.
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DISCUSSION
The present review has demonstrated that the Atlanta definitions of severity and local 
complications of acute pancreatitis are being used inconsistently, and that several components 
of the classification have received considerable criticism. By providing definitions, the result 
of consensus by over 40 experts based on the data available in 1992, the Atlanta symposium 
improved the management of acute pancreatitis and clinical research relating to the condition. 
However, the past 20 years have seen not only new insights in pathophysiology and therapeutic 
strategies but also improved imaging techniques. Clearly, the time has come to revise the 
classification of acute pancreatitis.
The various predictive scoring systems have not improved substantially since the Atlanta 
symposium. They are only moderately accurate in predicting severe disease in an individual 
patient. As McKay and Imrie166 have noted, predictive systems were developed initially to 
allocate patients within clinical trials and not to assess severity in an individual. Defining severity 
based on the presence or absence of organ failure also has its limitations. It is increasingly 
recognized that persistent organ failure (for more than 48h) is the most important determinant 
of morbidity and mortality, which are predominantly related to the number of organ systems 
failing, the degree of dysfunction of the organs involved and the duration of organ failure.
The definition of necrotizing pancreatitis is controversial because it incorporates both sterile 
and infected necrosis, and covers both pancreatic parenchymal necrosis and peripancreatic fat 
necrosis. Interpretations of pseudocyst and pancreatic abscess vary widely because necrotic 
debris within these collections is often not accounted for. This might be explained by the 
incapacity of CECT to detect necrotic debris in collections predominantly containing fluid, 
and its incapacity to discriminate between sterile and infected collections7,10,12,92,167. Although 
magnetic resonance imaging (MRI) and (endoscopic) ultrasonography may be of additional 
value in classifying these collections10,168,169, their applicability in severely ill patients has been 
questioned92,170.
Although the Atlanta Classification incorporates a pathological and morphological description 
of different local complications, it does not provide exact radiological criteria for each. The 
recently demonstrated poor interobserver agreement on the Atlanta Classification of local 
complications8 highlights the need for new descriptive morphological terms to describe CECT 
findings. The existing radiological grading system, the CT severity index, is a numerical scoring 
system that combines quantification of extrapancreatic changes with the extent of pancreatic 
necrosis26. Although the CT severity index has clear prognostic value with regard to morbidity 
and mortality26,171–174, it does not characterize the local complications of acute pancreatitis.
Much of the persisting controversy over the natural course of (peri)pancreatic collections is 
due to a lack of prospective data from large patient series. The authors of this review, therefore, 
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advocate a collaborative international study to clarify pathophysiology, natural course and 
optimal management of (peri)pancreatic collections. The present review has aimed to give 
an overview of the controversies regarding the Atlanta Classification in the literature. There 
are virtually no studies addressing the validation of the definitions proposed by the Atlanta 
Classification. Consequently, hardly any original data on this topic are available to analyse. 
This review, therefore, has merely categorized applications and interpretations of the Atlanta 
definitions. Correct terminology and standardized definitions are important for adequate 
communication in clinical practice and for comparing interinstitutional data for clinical 
research. The continuing failure to use standardized definitions for predicted and actual 
severe acute pancreatitis, organ failure and the local complications, and the heterogeneity of 
inclusion criteria of patients in clinical trials, have hampered the progress of evidence-based 
recommendations. This review has identified many studies that have improved insight into the 
natural course of the disease. These new insights should be used to design a new classification.
The authors propose the following recommendations for revision of the classification of acute 
pancreatitis. First, the diagnosis should incorporate two of the following three items: upper 
abdominal pain, amylase and/or lipase levels at least three times the upper limit of normal 
(as this cut-off is used most frequently in the literature), and CT or MRI findings compatible 
with acute pancreatitis. Second, persistent organ failure (for at least 48h) should have an 
important role in defining severity of acute pancreatitis. Third, it should be decided which 
predictive scoring system(s), including cut-off value, should be used to define predicted severe 
acute pancreatitis, based on a systematic review of the available data. Fourth, future studies 
should always make a clear distinction between predicted severe and actual severe disease, with 
a posteriori validation of the disease severity. Fifth, a systematic review should demonstrate 
which organ failure scoring system should be used, and definitions for organ failure should take 
into account the number of organ systems failing, the duration (less or more than 48h) of organ 
failure, and the need for specific therapy (such as inotropic or vasopressor agents, mechanical 
ventilation and dialysis). Sixth, peripancreatic fat necrosis without pancreatic parenchymal 
necrosis should be regarded either as a separate entity or as necrotizing pancreatitis. Seventh, 
infected necrosis should be regarded as a separate entity. Eighth, a term should be appointed for 
encapsulated collections containing both fluid and necrotic debris. Ninth, in order to diagnose 
a collection that contains fluid only (such as pseudocyst), MRI or (endoscopic) ultrasonography 
should be performed first to exclude necrotic debris in the collection. Tenth a new set of 
descriptive morphological terms should be designed to describe local complications on CT.
Such a new classification system should be evaluated in high-quality interobserver and 
prospective clinical studies. Adjustments should be made every few years, based on new 
data. Most importantly, clinicians and radiologists worldwide should comply with the new 
classification in clinical practice and research. Progress in the field of acute pancreatitis is 
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hampered greatly when various author groups use their own idiosyncratic definitions. When 
journal referees are requested to peer-review manuscripts, they should pay special attention to 
the correct use of definitions as defined by a new classification.
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ABSTRACT
Background/Aims: The current terminology for describing peripancreatic collections in 
acute pancreatitis (AP) derived from the Atlanta Symposium (e.g. pseudocyst, pancreatic 
abscess) has shown a very poor interobserver agreement, creating the potential for patient 
mismanagement. A study was undertaken to determine the interobserver agreement for a new 
set of morphologic terms to describe peripancreatic collections in AP.
Methods: An international, interobserver agreement study was performed: 7 gastrointestinal 
surgeons, 2 gastroenterologists and 8 radiologists in 3 US and 5 European tertiary referral 
hospitals independently evaluated 55 computed tomography (CT) scans of patients with 
predicted severe AP. The percentage agreement [median, interquartile range (IQR)] for 9 
clinically relevant morphologic terms was calculated among all reviewers, and separately 
among radiologists and clinicians. The percentage agreement was defined as poor (<0.50), 
moderate (0.51– 0.70), good (0.71–0.90), and excellent (0.91–1.00).
Results: Overall agreement was good to excellent for the terms collection (percentage 
agreement = 1; IQR 0.68–1), relation with pancreas (1; 0.68–1), content (0.88; 0.87–1), shape 
(1; 0.78–1), mass effect (0.78; 0.62–1), loculated gas bubbles (1; 1–1), and air-fluid levels (1; 
1–1). Overall agreement was moderate for extent of pancreatic nonenhancement (0.60; 0.46–
0.88) and encapsulation (0.56; 0.48–0.69). The percentage agreement was greater among 
radiologists than clinicians for extent of pancreatic nonenhancement (0.75 vs. 0.57, p = 0.008), 
encapsulation (0.67 vs. 0.46, p = 0.001), and content (1 vs. 0.78, p = 0.008).
Conclusion: Interobserver agreement for the new set of morphologic terms to describe 
peripancreatic collections in AP is good to excellent. Therefore, we recommend that current 
clinically based definitions for CT findings in AP (e.g. pancreatic abscess) should no longer be 
used.
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INTRODUCTION
Severe acute pancreatitis is associated with a wide spectrum of pathologic changes in the 
pancreatic and peripancreatic region. Changes can include pancreatic gland necrosis and/or 
various types of intra-abdominal collections containing fluid and peripancreatic fat necrosis 
[1]. Secondary infection of necrosis and these collections is often an indication for operative 
intervention and increases mortality to almost 30% [2]. Contrast-enhanced computed 
tomography (CT) is the imaging study used most widely to describe these pathologic 
changes [2–5]. Clear communication and agreement on CT findings is crucial, because 
the choice of treatment (conservative management, percutaneous catheter drainage and 
necrosectomy by laparotomy or minimally invasive approach) hinges heavily on how surgeons, 
gastroenterologists and radiologists interpret CT findings. The decision for operative or 
radiologic intervention is determined by the characteristics of the collections, such as the 
contents (fluid or solid) and microbial status (sterile or infected) [2, 3, 5, 6]. Miscommunication 
can put the patient at risk by initiating an inappropriate treatment algorithm [7].
The need for precise descriptions of the many different types of peripancreatic collections 
in acute pancreatitis was recognized in the early 1990s, resulting in the widely used Atlanta 
Classification [8]. While this work represented a very important contribution, over the 
ensuing 15 years, it has become apparent that the clinically based definitions suggested by this 
symposium, such as ‘pseudocyst’ and ‘pancreatic abscess’, lead to confusion in both daily practice 
and clinical research. This confusion frequently results in errors in diagnosis and management 
and misinterpretation of communications [2, 9–14]. Critics state that the Atlanta definitions 
do not accurately represent collections containing both liquid and solid material (i.e. pancreatic 
parenchymal necrosis and peripancreatic fat necrosis) [2, 11–15], yet these types of collections 
comprise the vast majority of collections in severe acute pancreatitis. This concern was 
substantiated in a recent interobserver study on the use of the Atlanta definitions for describing 
peripancreatic collections on CT, which demonstrated very poor agreement between 5 expert 
radiologists [13]. Currently, an international working group is consulting the members of 
several international pancreatic associations to reach consensus on a revised classification of 
acute pancreatitis. It has been formally recognized that this classification should incorporate 
objective, morphologic criteria for describing peripancreatic collections on CT [10, 14].
MATERIALS AND METHODS
An international panel of pancreatic surgeons and radiologists designed a scoring sheet with 
a set of descriptive, morphologic terms to classify peripancreatic collections on CT in severe 
acute pancreatitis (fig. 1). Definitions for the descriptive terms were not provided, because the 
aim was to test the interobserver agreement using only the objective, descriptive terminology.
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Study Population
In order to test the proposed descriptive, morphologic terms, contrast-enhanced CTs from 
patients with predicted severe acute pancreatitis were collected. One experienced radiologist 
(T.L.B.) reviewed all CTs of 248 patients with predicted severe acute pancreatitis that were 
included in a Dutch randomized controlled multicenter trial [16]. This study was approved by 
the independent ethics committees of all 15 participating hospitals and informed consent for 
participation was obtained from all patients. For each patient, a single radiologist determined 
the CT severity index (CTSI). The CTSI is an accepted prognostic score quantifying pancreatic 
and peripancreatic abnormalities [2, 5, 17]. The greater the score (range 0–10 points), the 
greater the risk of complications and death [17]. All CTs were high quality, contrast-enhanced 
and obtained during the portal venous phase. From these 248 patients, 55 CTs were included 
to cover the entire clinical spectrum of acute pancreatitis, with emphasis on severe disease 
(i.e. with pancreatic and/or peripancreatic collections). In order to rule out selection bias, CT 
selection occurred according to the following predefined and reproducible criteria: the last CT 
before percutaneous drainage or discharge in the first 30 consecutive patients that did not have 
operative therapy (5 patients with a CTSI of 1–2, 5 patients with a CTSI of 3–4, 5 patients with 
a CTSI of 5–6, and 15 patients with a CTSI of 7–10), and the last preoperative CT of the first 
25 consecutive patients who underwent operative therapy for infected necrosis (irrespective 
of CTSI). Median time [interquartile range (IQR)] between admission and CT was 18 (9–32) 
days. A total of 33/55 patients had infected necrosis as proven by bacterial culture (requiring 
operative therapy n = 25, or only percutaneous drainage n = 8). Mortality was 16% (9/55).
Participating Centers
The following 3 US and 5 European tertiary referral hospitals participated:
• Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass., USA
• Mayo Clinic, Rochester, Minn., USA
• University of Washington Medical Center, Seattle, Wash., USA
• University Medical Center Utrecht, The Netherlands
• Academical Medical Center, Amsterdam, The Netherlands
• Erasmus MC University Medical Center Rotterdam, The Netherlands
• University of Heidelberg, Heidelberg, Germany
• Royal Liverpool University Hospital, Liverpool, UK
Seven gastrointestinal surgeons, 2 gastroenterologists and 8 hepato-pancreato-biliary 
radiologists acted as blinded reviewers, 1 clinician and 1 radiologist in each centre. In 1 
center (Mayo Clinic), 2 clinicians participated. All reviewers are considered experts in acute 
pancreatitis. Four of the 17 reviewers (2 radiologists and 2 surgeons) participated in the 
generation of the scoring sheet. Conversely, 13 reviewers were naïve to the scoring sheet and 
did not receive any form of training prior to reviewing the CTs for this study.
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 • University of Washington Medical Center, Seattle, Wash., 
USA 
 • University Medical Center Utrecht, The Netherlands 
 • Academical Medical Center, Amsterdam, The Netherlands 
 • Erasmus MC University Medical Center Rotterdam, The 
Netherlands 
 • University of Heidelberg, Heidelberg, Germany 
 • Royal Liverpool University Hospital, Liverpool, UK 
 Seven gastrointestinal surgeons, 2 gastroenterologists and 8 
hepato-pancreato-biliary radiologists acted as blinded reviewers, 
1 clinician and 1 radiologist in each centre. In 1 center (Mayo 
Clinic), 2 clinicians participated. All reviewers are considered ex-
perts in acute pancreatitis. Four of the 17 reviewers (2 radiologists 
and 2 surgeons) participated in the generation of the scoring 
sheet. Conversely, 13 reviewers were naïve to the scoring sheet and 
did not receive any form of training prior to reviewing the CTs for 
this study.
 Data Collection 
 Two investigators visited each center and had separate meet-
ings with the clinicians and radiologists. In a single session, each 
reviewer evaluated individually the 55 digital CTs using DICOM 
viewer software (version 3.116, Acculite, San Francisco, Calif., 
USA) and completed the scoring sheet for each CT ( fig. 1 ). The 
investigators briefly explained the scoring sheet and software to 
the reviewers but did not coach the reviewers during the review 
process in any way. The reviewers were blinded to the clinical 
background and timing of the CT. In the case of multiple collec-
tions, the reviewer was asked to describe the most prominent col-
lection. Data from the scoring sheets were entered into a database 
by 1 investigator and 1 independent data manager, separately. 
Discrepancies were solved by a third investigator using the origi-
nal scoring sheets.
none
no
yes
yes
no
round or oval
irregular
yes
no
yes
no
intrapancreatic only
intrapancreatic and adjacent to pancreas
only adjacent to pancreas (no parenchymal perfusion defect)
separate
none
homogeneous
heterogeneous (including fat, hemorrhage, loculation and septa)
partial
complete
Relation with pancreas:
Encapsulation:
Content:
Shape:
Loculated gas bubbles:
Air-fluid level:
Mass effect (= displacement of adjacent structures: vessels, organs etc.):
Extent of PAncreatic Nonenhancement:
Is there a COllection? (= any fluid more than ‘fat stranding’)
If ‘yes’, please choose one DEscription per question:
<30%
>50%
30–50%
 Fig. 1. Scoring sheet using the descriptive 
morphologic terms for this study. (The de-
scriptor headings form the acronym PAN-
CODE: Pancreatic Nonenhancement, Col-
lection Descripition). 
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FIG. 1. Scoring sheet using the descriptive morphologic terms for this study. (The descriptor headings 
form the acronym PANCODE: Pancreatic Nonenhancement, Collection Descripition).
Data Collection
Two investigators visited each center and had separate meetings with the clinicians and 
radiologists. In a single sessio , each revi wer evaluated individually the 55 digital CTs using 
DICOM viewer software (version 3.116, Acculite, San Francisco, Calif., USA) and completed 
the scoring sheet for each CT (fig. 1). The investigators briefly explained the scoring sheet 
and software to the reviewe s but did not coach the reviewers during the review process in 
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any way. The reviewers were blinded to the clinical background and timing of the CT. In the 
case of multiple collections, the reviewer was asked to describe the most prominent collection. 
Data from the scoring sheets were entered into a database by 1 investigator and 1 independent 
data manager, separately. Discrepancies were solved by a third investigator using the original 
scoring sheets.
Data Analysis
For each item on the scoring sheet, the distribution (i.e. 20 and 80%) of options (i.e. ‘yes’ 
and ‘no’) within the 55 CTs was assessed for each of the reviewers individually. The median 
distribution of options (IQR) is shown for radiologists and clinicians separately as well as for 
all reviewers. Subsequently, the percentage agreement for each scored item was determined. 
The percentage agreement was defined as the number of reviewer combinations (e.g. reviewer 
1 vs. reviewer 2, reviewer 1 vs. reviewer 3) in agreement (i.e. choosing the same option, e.g. 
collection: ‘yes’) divided by the total number of possible reviewer combinations (n = 153) [18]. 
The percentage agreement was calculated for each of the 55 CTs individually; the median 
of the percentage agreement (IQR) is shown for clinicians and radiologists separately and 
for all reviewers. A percentage agreement of 0.91–1.00 was defined as excellent agreement, 
0.71–0.90 as good agreement, 0.51–0.70 as moderate agreement and <0.50 as poor agreement. 
When the percentage agreement was <0.71, an exploratory analysis was performed to assess 
whether combinations of options resulted in greater agreement. The percentage agreement 
was compared between clinicians and radiologists using the Wilcoxon signed-rank test. p < 
0.05 was considered statistically significant.
RESULTS
The distribution of the scored options within the 55 CTs is shown in table 1. According 
to the reviewers, the vast majority of CTs showed pancreatic nonenhancement (84%) with 
collections (median 96%) that were intrapancreatic and adjacent (78%) to the pancreas. In most 
of the CTs, the reviewers concluded that the collections were encapsulated (either partially or 
completely; 88%), heterogeneous (95%), with mass effect (80%) and were irregularly shaped 
(89%). Loculated gas bubbles were scored in 24% of CTs, while an air-fluid level was deemed 
present only in 5% of CTs. One of the CTs that was reviewed is shown in figure 2.
The percentage agreement for the descriptive terms is shown in table 2. Agreement among 
clinicians was excellent for collection, relation, shape, loculated gas bubbles, and air-fluid level; 
it was good for content and mass effect, moderate for encapsulation and poor for pancreatic 
nonenhancement. Among radiologists, agreement was excellent for collection, relation, content, 
mass effect, shape, loculated gas bubbles, and air-fluid level; it was good for extent of pancreatic 
nonenhancement and moderate for encapsulation. Agreement among all reviewers taken 
together was good to excellent for all items, except for extent of pancreatic nonenhancement 
 Describing Peripancreatic Collections in Severe Acute Pancreatitis | 99
TABLE 1. Distribution of the options of the scored descriptive terms for 55 CT scans of patients with 
predicted severe acute pancreatitis (not interobserver agreement)
Term Radiologists Clinicians All
Extent of pancreatic nonenhancement
0% 25 (16–29) 12 (7–20) 16 (13–27)
<30% 15 (14–19) 23 (15–25) 18 (14–24)
30–50% 14 (12–15) 16 (9–20) 15 (11–20)
>50% 46 (42–51) 49 (49–53) 49 (44–53)
Presence of collection
Yes 96 (95–99) 95 (91–96) 96 (95–98)
No 4 (1–5) 5 (4–9) 4 (2–5)
If ‘yes’ to presence of collection
Relation with pancreas
Intrapancreatic only 2 (2–2) 2 (2–2) 2 (2–2)
Intrapancreatic and adjacent 75 (70–80) 82 (76–89) 78 (73–84)
Only adjacent to pancreas 18 (10–24) 13 (4–15) 15 (13–20)
Separate 0 (0–0) 0 (0–2) 0 (0–0)
Encapsulation
Complete 11 (9–20) 15 (5–31) 11 (7–24)
Partial 47 (40–52) 38 (33–51) 44 (35–51)
None 35 (26–40) 35 (27–42) 35 (27–42)
Content
Homogeneous 2 (1–4) 2 (0–7) 2 (0–5)
Heterogeneous 95 (92–95) 93 (84–96) 95 (89–96)
Mass effect (on adjacent organs/structures)
Yes 83 (76–91) 75 (58–84) 80 (69–87)
No 13 (4–17) 18 (13–29) 16 (9–29)
Shape
Round/oval 9 (5–10) 4 (2–11) 9 (2–11)
Irregular 89 (85–91) 89 (84–96) 89 (84–93)
Loculated gas bubbles
Yes 24 (23–24) 22 (22–25) 24 (22–24)
No 72 (71–76) 73 (71–75) 73 (71–75)
Air-fluid level
Yes 8 (5–12) 4 (2–5) 5 (4–7)
No 87 (83–93) 91 (91–93) 91 (84–93)
Values are median percentages with the IQR percentages in parentheses. Percentages may not sum to 100% because values are medians 
and data are missing when the option ‘no collection’ was chosen.
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and encapsulation, which were only moderate. However, when in the exploratory analysis 
the extent of pancreatic nonenhancement option 1 (0%) and option 2 (<30%) were combined, 
the agreement (median percentage agreement; IQR) was good among all reviewers (0.88; 
0.52–1), good among clinicians (0.78; 0.44–1) and excellent among radiologists (1; 0.75–1). 
When encapsulation option 1 (complete) and option 2 (partial) were combined, the percentage 
agreement was good among all reviewers (0.78; 0.65–0.88) and clinicians (0.71; 0.56–1), and 
excellent among radiologists (1.0; 0.69–1). For the extent of pancreatic nonenhancement, 
encapsulation, content, and mass effect, the percentage agreement was greater among 
radiologists than among clinicians (p < 0.05; table 2).
TABLE 2. Percentage agreement among 17 reviewers for scored descriptive terms for 55 CT scans of 
patients with predicted severe acute pancreatitis (interobserver agreement)
Term Radiologists Clinicians All p value1
Extent of pancreatic nonenhancement 0.75 (0.46–1) 0.57 (0.44–0.78) 0.60 (0.46–0.88) 0.008
Presence of a collection 1 (1–1) 1 (1–1) 1 (1–1) 0.15
Relation with pancreas 1 (0.75–1) 1 (0.62–1) 1 (0.68–1) 0.55
Encapsulation 0.67 (046–0.75) 0.46 (0.36–0.61) 0.56 (0.48–0.69) 0.001
Content 1 (1–1) 0.78 (0.78–1) 0.88 (0.87–1) <0.0001
Mass effect 1 (0.71–1) 0.78 (0.50–1) 0.78 (0.62–1) 0.01
Shape 1 (0.75–1) 1 (0.78–1) 1 (0.78–1) 0.39
Loculated gas bubbles 1 (1–1) 1 (1–1) 1 (1–1) 0.24
Air-fluid level 1 (1–1) 1 (1–1) 1 (1–1) 0.06
Values are medians with the IQR in parentheses. A percentage agreement of 0.91–1.00 is excellent agreement; 0.71–0.90 good agree- 
ment; 0.51–0.70 moderate agreement, and <0.50 poor agreement. Similar outcomes [e.g. 1 (1–1)] may not lead to similar p values since 
the range represents the IQR.
1 Wilcoxon signed rank test (radiologists vs. clinicians).
FIG. 2. One of the 55 CT scans reviewed in 
this interobserver agreement study. The 
vast majority of reviewers described this CT 
as >50% pancreatic nonenhancement, with 
an intrapancreatic and adjacent collection 
which is encapsulated (either partially or 
completely), heterogeneous, with mass effect, 
an irregular shape and without loculated gas 
bubbles or an air-fluid level.
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DISCUSSION
This multidisciplinary, international interobserver study showed good to excellent 
interobserver agreement when peripancreatic collections in severe acute pancreatitis were 
described using a new set of descriptive, morphologic terms. This study was a follow-up to a 
similar interobserver study that showed very poor interobserver agreement for the widely used 
Atlanta Symposium terminology (e.g. ‘pseudocyst’, ‘pancreatic necrosis’, ‘pancreatic abscess’) 
[13]. In the prior study, 5 experienced radiologists agreed on the Atlanta definition in only 3 
of 70 contrast-enhanced CTs [13]. These inconsistent and incongruent interpretations in large 
part led to the current study, as well as the interest in developing a more accurate classification 
of acute pancreatitis [14]. The results of the present study demonstrate that, with the new set 
of terms, it was much easier to obtain objective agreement among all physicians, in contrast to 
the Atlanta definitions.
Exploratory analysis led to an even greater interobserver agreement. In this analysis, the 
combination of the first 2 options of encapsulation (complete and partial) and extent of 
pancreatic nonenhancement (0 and <30%) is acceptable, because the most important clinical 
differentiations are between (1) no encapsulation and some encapsulation, and (2) no or little 
nonenhancement (<30%) and substantial nonenhancement (>30%). Notably, in the Atlanta 
Symposium, pancreatic nonenhancement <30% was not even considered pancreatic necrosis 
[8].
Interobserver agreement on several relevant terms was significantly greater among radiologists 
than surgeons and gastroenterologists. This finding was not unexpected given the noted 
expertise of radiologists in their field of practice. In contrast, the managing clinicians are 
best at correlating the radiologic findings with the clinical condition in order to determine 
the appropriate treatment. The current data, therefore, highlight the need for a true, 
multidisciplinary team approach to severe acute pancreatitis, both in terms of clinical care and 
research publications.
Why is this study relevant? Accurate multidisciplinary communication regarding CT findings 
in severe acute pancreatitis is of considerable importance because decisions on treatment 
depend on adequate radiologic interpretation of peripancreatic collections [1–7, 19]. The 
descriptive terms used in this study each have clinical relevance regarding the type and 
timing of (operative) intervention. For example, the finding of pancreatic necrosis (extent 
of pancreatic nonenhancement) and collections with peripancreatic fat necrosis (presence of 
a collection, heterogeneous content, relation with pancreas) would both be treated initially 
without percutaneous drainage or operative intervention [1–3, 5]. When and if secondary 
infection occurs (loculated gas bubbles), some form of intervention is generally indicated 
[1–3, 5, 19]. The content of the peripancreatic collection (homogeneous, air-fluid level) can 
indicate a collection with a fluid-predominant content, such that percutaneous drainage would 
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be performed initially and, if percutaneous drainage is unsuccessful, followed by operative 
debridement [2, 3, 5, 19]. The majority of peripancreatic collections, however, tend to resolve 
without any intervention at all. These include collections referred to by the Atlanta symposium 
as ‘acute fluid collections’, i.e. homogenous peripancreatic collections occurring early on in the 
disease that have not formed any capsule whatsoever and that do not contain gas bubbles or an 
air-fluid level [8]. Whenever intervention for collections with necrosis does seem necessary, 
delaying operative intervention until demarcation (encapsulation) is documented allows easier 
and safer debridement [1, 2, 5, 20], possibly by endoscopic or minimally invasive operative 
techniques [21, 22–24]. Sterile collections causing gastric or biliary obstruction (mass effect) 
are treated usually by percutaneous or endoscopic therapy [2, 3, 5, 12, 21].
One might wonder whether the radiologic diagnoses (i.e. the descriptive terms chosen by 
the reviewers) in this study really reflect the true morphologic features of the peripancreatic 
collections, because the results of the radiologic decisions were not correlated with clinical 
findings (e.g. operative findings). We explicitly chose not to do this because the aim of this 
study was merely to determine the interobserver agreement of the descriptive terms, instead 
of their clinical relevance. The tested terminology is commonly used in daily practice, and 
it is obvious that all those caring for patients with acute pancreatitis should ‘speak the same 
language’. Although the clinical relevance of the described terms seems obvious, the exact 
magnitude of that relevance and, therefore, the impact on treatment decisions will need to be 
the subject of future large prospective studies. It should be noted, however, that the current 
terminology from the Atlanta Classification is also mostly based on expert opinion, rather than 
evidence from clinical studies, and is neither used reliably or accurately [10, 13].
A limitation of this study is that Cohen’s kappa statistic could not be used because of the 
substantial imbalance in distributions for the majority of terms (e.g. presence of collection, yes 
vs. no: 96% vs. 4%; table 1). In case of a substantial imbalance in the distribution, kappa values 
will be very low or even negative, while agreement may still, in fact, be good [25]. In such an 
event, the kappa statistic becomes meaningless [25]. To present only kappa values for the terms 
without imbalance was considered not possible because there is no generally accepted cut-off 
value for defining imbalance. Even though the percentage agreement is not a chance-adjusted 
measure, the interobserver agreement in the present study was good, given the high values of 
percentage agreement demonstrated.
Because the reviewers in the present study were from centers renowned for their experience 
in pancreatic disease, one might question how generalizable are the results to the general 
community of surgeons and radiologists. It should be noted, however, that the previous 
interobserver study using the Atlanta definitions between a similar group of expert radiologists 
showed very poor interobserver agreement [13], in contrast to the good to excellent agreement 
reported in the present study with the new descriptors. Four of the 17 reviewers in the 
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present study were involved in designing the scoring sheet, and one might argue that this 
introduced bias. However, when these 4 reviewers were excluded from the current analysis the 
interobserver agreement did not change (data not shown).
Our findings are most likely explained by the fact that the majority of the proposed morphologic, 
descriptive terms are used already in daily clinical practice by both clinicians and radiologists 
and are considered intuitive and relatively easy to use. Nevertheless, despite the strength of the 
current study it is our intent to direct our next prospective study to further validation of the 
proposed descriptive, morphologic terms and establishing how generalizable they are.
In summary, the overall interobserver agreement using the proposed morphologic terms when 
describing peripancreatic collections in severe acute pancreatitis, is good to excellent. This 
study provides another piece of important data in support of using more objective, descriptive, 
morphologic terms to describe CT findings in acute pancreatitis rather than the subjective 
Atlanta symposium terms (e.g. ‘pseudocyst’, ‘pancreatic abscess’).
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ABSTRACT
Background and objective: The Atlanta Classification of acute pancreatitis enabled 
standardised reporting of research and aided communication between clinicians. Deficiencies 
identified and improved understanding of the disease make a revision necessary.
Methods: A web-based consultation was undertaken in 2007 to ensure wide participation of 
pancreatologists. After an initial meeting, the Working Group sent a draft document to 11 
national and international pancreatic associations. This working draft was forwarded to all 
members. Revisions were made in response to comments, and the web-based consultation 
was repeated three times. The final consensus was reviewed, and only statements based on 
published evidence were retained.
Results: The revised classification of acute pancreatitis identified two phases of the disease: 
early and late. Severity is classified as mild, moderate or severe. Mild acute pancreatitis, the most 
common form, has no organ failure, local or systemic complications and usually resolves in the 
first week. Moderately severe acute pancreatitis is defined by the presence of transient organ 
failure, local complications or exacerbation of co-morbid disease. Severe acute pancreatitis 
is defined by persistent organ failure, that is, organ failure >48h. Local complications are 
peripancreatic fluid collections, pancreatic and peripancreatic necrosis (sterile or infected), 
pseudocyst and walled-off necrosis (sterile or infected). We present a standardised template for 
reporting CT images.
Conclusions: This international, web-based consensus provides clear definitions to classify 
acute pancreatitis using easily identified clinical and radiologic criteria. The wide consultation 
among pancreatologists to reach this consensus should encourage widespread adoption.
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BACKGROUND
The Atlanta Symposium in 1992 attempted to offer a global ‘consensus’ and a universally 
applicable classification system for acute pancreatitis.1 Although the Atlanta Classification 
has been useful, some of the definitions proved confusing.2 Better understanding of the 
pathophysiology of organ failure and necrotising pancreatitis and their outcomes, as well as 
improved diagnostic imaging, have made it necessary to revise the Atlanta Classification. This 
revision includes a clinical assessment of severity and provides more objective terms to describe 
the local complications of acute pancreatitis.
The goal of this report is to present the updated revision of the Atlanta Classification of acute 
pancreatitis in adults (>18 years). This revision was designed to incorporate modern concepts 
of the disease, to address areas of confusion, to improve clinical assessment of severity, to enable 
standardised reporting of data, to assist the objective evaluation of new treatments, and to 
facilitate communication among treating physicians and between institutions. This consensus 
classification defines criteria for the diagnosis of acute pancreatitis, differentiates the two 
types of acute pancreatitis (interstitial oedematous pancreatitis and necrotising pancreatitis), 
classifies the severity of acute pancreatitis into three categories, and defines the morphology 
seen on imaging of pancreatic and peripancreatic collections that arise as complications of 
acute pancreatitis. This revision is not intended to be a management guideline.
METHODS
This classification was generated by an iterative, web-based consultation process led by a 
working group and incorporating responses from the members of 11 national and international 
pancreatic societies. All responses were reviewed by the working group, and the process was 
repeated by a web-based approach until the current fourth draft, which was then finalised for 
submission. A full description of the methods is shown in online supplementary appendix 1. 
There are many substantial and important differences in the current document when compared 
to our preliminary working draft that appeared on the Pancreas Club website3 and which has 
been referred to by other authors.4–8
Revised definitions and classification of acute pancreatitis
The following definitions and classifications are proposed for use in clinical and research 
communications.
Definition of diagnosis of acute pancreatitis
The diagnosis of acute pancreatitis requires two of the following three features: (1) abdominal 
pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often 
radiating to the back); (2) serum lipase activity (or amylase activity) at least three times greater 
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than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and less commonly magnetic resonance imaging 
(MRI) or transabdominal ultrasonography.9–13
If abdominal pain suggests strongly that acute pancreatitis is present, but the serum amylase 
and/or lipase activity is less than three times the upper limit of normal, as may be the case with 
delayed presentation, imaging will be required to confirm the diagnosis.13 14 If the diagnosis of 
acute pancreatitis is established by abdominal pain and by increases in the serum pancreatic 
enzyme activities, a CECT is not usually required for diagnosis in the emergency room or on 
admission to the hospital.
Definition of onset of acute pancreatitis
The onset of acute pancreatitis is defined as the time of onset of abdominal pain (not the time 
of admission to the hospital). The time interval between onset of abdominal pain and first 
admission to the hospital should be noted. When patients with severe disease are transferred to 
a tertiary hospital, the intervals between onset of symptoms, first admission and transfer should 
be noted. Data recorded from a tertiary care hospital should be stratified to allow separate 
consideration of the outcomes of patients who were admitted directly and those admitted by 
transfer from another hospital (see online supplementary appendix 2 for suggested recording 
of data).
Definition of types of acute pancreatitis
Acute pancreatitis can be subdivided into two types: interstitial oedematous pancreatitis and 
necrotising pancreatitis.
Interstitial pancreatitis
The majority of patients with acute pancreatitis have diffuse (or occasionally localised) 
enlargement of the pancreas due to inflammatory oedema. On CECT, the pancreatic 
parenchyma shows relatively homogeneous enhancement, and the peripancreatic fat usually 
shows some inflammatory changes of haziness or mild stranding. There may also be some 
peripancreatic fluid (see below, Definition of pancreatic and peripancreatic collections) (figures 
1 and 2). The clinical symptoms of interstitial oedematous pancreatitis usually resolve within 
the first week.15
Necrotising pancreatitis
About 5–10% of patients develop necrosis of the pancreatic parenchyma, the peripancreatic 
tissue or both (see below, Definition of pancreatic and peripancreatic collections) (figures 3, 4, 
5). Necrotising pancreatitis most commonly manifests as necrosis involving both the pancreas 
and peripancreatic tissues and less commonly as necrosis of only the peripancreatic tissue, and 
rarely of the pancreatic parenchyma alone.
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FIGURE 1. A 63-year-old man with acute 
interstitial oedematous pancreatitis. There is 
peripancreatic fat stranding (arrows) without 
an acute peripancreatic fluid collection; the 
pancreas enhances completely but has a 
heterogeneous appearance due to oedema.
FIGURE 2 (A) A 38-year-old woman with acute interstitial oedematous pancreatitis and acute 
peripancreatic fluid collection (APFC) in the left anterior pararenal space (white arrows showing 
the borders of the APFC). The pancreas enhances completely, is thickened, and has a heterogeneous 
appearance due to oedema. APFC has fluid density without an encapsulating wall. (B) A few weeks 
later, a follow up CT shows complete resolution of the APFC with minimal residual peripancreatic fat 
stranding.
The impairment of pancreatic perfusion and signs of peripancreatic necrosis evolve over 
several days,16–19 which explains why an early CECT may underestimate the eventual extent 
of pancreatic and peripancreatic necrosis. In the first few days of the illness, the pattern 
of perfusion of the pancreatic parenchyma as seen on CECT may be patchy, with variable 
attenuation before the area of impaired enhancement becomes more demarcated and/or 
confluent. After the first week of the disease, a non-enhancing area of pancreatic parenchyma 
should be considered to be pancreatic parenchymal necrosis.
In peripancreatic necrosis, the pancreas enhances normally on CECT as it does with interstitial 
oedematous pancreatitis, but the peripancreatic tissues develop necrosis. Patients with 
peripancreatic necrosis alone have increased morbidity and intervention rates compared to 
patients with interstitial oedematous pancreatitis.15 17 20
A B
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FIGURE 3 (A) Acute necrotic collections (ANC) in a 44-year-old man with acute necrotising 
pancreatitis involving only the peripancreatic tissues. Note enhancement of the entire pancreatic 
parenchyma (white stars) and the heterogeneous, non-liquid peripancreatic components in the 
retroperitoneum (white arrows pointing at the borders of the ANC). (B) The ANC in the same patient 
as (A) but imaged a few weeks later demonstrate a heterogeneous collection with areas of fat (black 
arrowheads) surrounded by fluid density, and areas which have a slightly greater attenuation (black 
arrows) than seen in collections without necrosis such as shown in figure 7. This finding is typical 
for peripancreatic necrosis. White arrows denote border of ANC; white stars denote enhancement of 
pancreatic parenchyma. The ANC are not yet fully encapsulated.
The natural history of pancreatic and peripancreatic necrosis is variable, because it may remain 
solid or liquefy, remain sterile or become infected, persist, or disappear over time.
Infected pancreatic necrosis
Pancreatic and peripancreatic necrosis can remain sterile or become infected; most of the 
evidence suggests no absolute correlation between the extent of necrosis and the risk of 
infection and duration of symptoms.21–24 Infected necrosis is rare during the first week.21 25
The diagnosis of infected pancreatic necrosis is important because of the need for antibiotic 
treatment and likely active intervention.22 The presence of infection can be presumed when 
there is extraluminal gas in the pancreatic and/or peripancreatic tissues on CECT (figure 6) 
or when percutaneous, image-guided, fine-needle aspiration (FNA) is positive for bacteria 
and/or fungi on Gram stain and culture.26 There may be a varying amount of suppuration 
(pus) associated with the infected pancreatic necrosis, and this suppuration tends to increase 
with time with liquefaction. The original Atlanta Classification proposed the term ‘pancreatic 
abscess’ to define a ‘localised collection of purulent material without significant necrotic material’.1 
This finding is extremely uncommon, and because the term is confusing and has not been 
adopted widely,27 the term ‘pancreatic abscess’ is not used in the current classification. The 
development of secondary infection in pancreatic necrosis is associated with increased 
morbidity and mortality.28
A B
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FIGURE 4. Three different patients (A, B, C) with acute necrotising pancreatitis and acute necrotic 
collections (ANC) involving the pancreatic parenchyma and the peripancreatic tissues. In all three 
patients, there is extensive parenchymal necrosis (white stars) of the body and tail of the pancreas. 
Heterogeneous collections are seen in the pancreatic and peripancreatic tissues (white arrows pointing 
at the borders of the ANC) of the left anterior pararenal space (A, B, C) and in the lesser sac (A, C). 
These latter collections represent peripancreatic necrosis.
FIGURE 5. Acute necrotic collection (ANC) in 
a 47-year-old woman with acute necrotising 
pancreatitis involving the pancreatic 
parenchyma alone. Thin white arrows denote 
a newly developed, slightly heterogeneous 
collection in the region of the neck and body 
of the pancreas, without extension in the 
peripancreatic tissues.
A B
C
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FIGURE 6. A 47-year-old man with acute 
necrotising pancreatitis complicated by 
infected pancreatic necrosis. There is a 
heterogeneous, acute necrotic collection 
(ANC) in the pancreatic and peripancreatic 
area (white arrows pointing at the borders of 
the ANC) with presence of gas bubbles (white 
arrowheads), usually a pathognomonic sign of 
infection of the necrosis (infected necrosis).
Complications of acute pancreatitis
Definition of organ failure
Three organ systems should be assessed to define organ failure: respiratory, cardiovascular 
and renal. Organ failure is defined as a score of 2 or more for one of these three organ systems 
using the modified Marshall scoring system29 (table 1). The modified Marshall scoring system 
has the merit of simplicity, universal applicability across international centres, and the ability 
to stratify disease severity easily and objectively.10 The modified Marshall scoring system is 
preferred to the SOFA scoring system,30 which is for patients managed in a critical care unit and 
which takes into account the use of inotropic and respiratory support. Both scoring methods 
have the advantage of being able to be used on presentation and repeated daily.30 31 They also 
allow stratification of the severity of organ failure, although that is not part of the current 
classification.
Definition of local complications
The original Atlanta Classification1 distinguished between uncomplicated interstitial 
pancreatitis and acute pancreatitis associated with ‘local complications’. This distinction (local 
complications being absent or present) is useful. The natural history and clinical consequences 
of different local complications are now better understood and described. Local complications 
are acute peripancreatic fluid collection, pancreatic pseudocyst, acute necrotic collection and 
walled-off necrosis. The morphologic features of these local complications are described in 
detail later in this document (see below, Definition of pancreatic and peripancreatic collections). 
Other local complications of acute pancreatitis include gastric outlet dysfunction, splenic and 
portal vein thrombosis, and colonic necrosis.
Local complications should be suspected when there is persistence or recurrence of abdominal 
pain, secondary increases in serum pancreatic enzyme activity, increasing organ dysfunction, 
and/or the development of clinical signs of sepsis, such as fever and leucocytosis. These 
developments usually prompt imaging to detect local complications. The morphologic features 
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of acute pancreatitis are well delineated by high resolution, multi-detector CECT and form the 
basis of the new, more objective definitions for the local complications of acute pancreatitis 
(box 1).
Pancreatic and peripancreatic collections should be described on the basis of location (pancreatic, 
peripancreatic, other), the nature of the content (liquid, solid, gas), and the thickness of any wall 
(thin, thick). The pattern and extent of impaired pancreatic parenchymal perfusion, if present, 
should also be described.27 The morphologic description of local complications is necessary 
for accurate diagnosis. Local complications alone, however, do not define the severity of acute 
pancreatitis (see below, Definition of severity of acute pancreatitis).32 33
Definition of systemic complications
Exacerbation of pre-existing co-morbidity, such as coronary artery disease or chronic lung 
disease, precipitated by the acute pancreatitis is defined as a systemic complication. In this 
document, we distinguish between persistent organ failure (the defining feature of severe acute 
pancreatitis) and other systemic complications, which are an exacerbation of pre-existing co-
morbid disease.
TABLE 1. Modified Marshall scoring system for organ dysfunction
Organ system
Score
0 1 2 3 4
Respiratory (PaO2/FiO2) >400 301–400 201–300 101–200 ≤101
Renal*
(serum creatinine, µmol/l) ≤134 134–169 170–310 311–439 >439
(serum creatinine, mg/dl) <1.4 1.4–1.8 1.9–3.6 3.6–4.9 >4.9
Cardiovascular (systolic blood 
pressure, mm Hg)†
>90 <90, fluid 
responsive
<90, not fluid 
responsive
<90, pH<7.3 <90, pH<7.2
For non-ventilated patients, the FiO2 can be estimated from below:
Supplemental oxygen (l/min) FiO2 (%)
Room air 21
2 25
4 30
6–8 40
9–10 50
A score of 2 or more in any system defines the presence of organ failure.
*A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. 
No formal correction exists for a baseline serum creatinine ≥134 μmol/l or ≥1.4 mg/dl.
†Off inotropic support.
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Box 1 Revised definitions of morphological features of acute pancreatitis
1. Interstitial oedematous pancreatitis
 Acute inflammation of the pancreatic parenchyma and peripancreatic tissues, but without recognisable tissue necrosis 
CECT criteria
• Pancreatic parenchyma enhancement by intravenous contrast agent
• No findings of peripancreatic necrosis (see below)
• See figures 1 and 2
2. Necrotising pancreatitis
 Inflammation associated with pancreatic parenchymal necrosis and/or peripancreatic necrosis
 CECT criteria
• Lack of pancreatic parenchymal enhancement by intravenous contrast agent and/or
• Presence of findings of peripancreatic necrosis (see below—ANC and WON)
• See figures 3, 4, 5 and 8
3. APFC (acute peripancreatic fluid collection)
 Peripancreatic fluid associated with interstitial oedematous pancreatitis with no associated peripancreatic necrosis. This 
term applies only to areas of peripancreatic fluid seen within the first 4 weeks after onset of interstitial oedematous pan- 
creatitis and without the features of a pseudocyst.
 CECT criteria
• Occurs in the setting of interstitial oedematous pancreatitis
• Homogeneous collection with fluid density
• Confined by normal peripancreatic fascial planes
• No definable wall encapsulating the collection
• Adjacent to pancreas (no intrapancreatic extension)
• See figure 2
4. Pancreatic pseudocyst
 An encapsulated collection of fluid with a well defined inflammatory wall usually outside the pancreas with minimal or no 
necrosis. This entity usually occurs more than 4 weeks after onset of interstitial oedematous pancreatitis to mature.
 CECT criteria
• Well circumscribed, usually round or oval
• Homogeneous fluid density
• No non-liquid component
• Well defined wall; that is, completely encapsulated
• Maturation usually requires >4 weeks after onset of acute pancreatitis; occurs after interstitial oedematous 
pancreatitis
• See figure 7
5. ANC (acute necrotic collection)
 A collection containing variable amounts of both fluid and necrosis associated with necrotising pancreatitis; the necrosis 
can involve the pancreatic parenchyma and/or the peripancreatic tissues
 CECT criteria
• Occurs only in the setting of acute necrotising pancreatitis
• Heterogeneous and non-liquid density of varying degrees in different locations (some appear homogeneous early in 
their course)
• No definable wall encapsulating the collection
• Location—intrapancreatic and/or extrapancreatic
• See figures 3–5
6. WON (walled-off necrosis)
 A mature, encapsulated collection of pancreatic and/or peripancreatic necrosis that has developed a well defined inflam- 
matory wall. WON usually occurs >4 weeks after onset of necrotising pancreatitis.
 CECT criteria
• Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear 
homogeneous)
• Well defined wall, that is, completely encapsulated
• Location—intrapancreatic and/or extrapancreatic
• Maturation usually requires 4 weeks after onset of acute necrotising pancreatitis
• See figure 8
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Phases of acute pancreatitis
There are two overlapping phases in this dynamic disease process with two peaks of mortality: 
early and late.34–37 The early phase, which usually lasts for the first week, is followed by a second 
later phase which can run a protracted course from weeks to months. It is helpful to consider 
these two phases separately.
Early phase
During the early phase, systemic disturbances result from the host response to local pancreatic 
injury. This early phase is usually over by the end of the first week but may extend into the 
second week. Cytokine cascades are activated by the pancreatic inflammation which manifest 
clinically as the systemic inflammatory response syndrome (SIRS)38–40 (box 2). When SIRS is 
persistent,41 42 there is an increased risk of developing organ failure (table 1). The determinant 
of the severity of acute pancreatitis during the early phase is primarily the presence and duration 
of organ failure. This is described as ‘transient organ failure’ if the organ failure resolves within 
48h or as ‘persistent organ failure’ if organ failure persists for >48h.39 41 43 If organ failure affects 
more than one organ system, it is termed multiple organ failure (MOF).
Box 2 Signs of systemic inflammatory response syndrome (SIRS)
SIRS—defined by presence of two or more criteria:
• Heart rate >90 beats/min
• Core temperature <36°C or >38°C
• White blood count <4000 or >12000/mm3
• Respirations >20/min or PCO2 <32 mm Hg
13
Although local complications may be identified during the early phase, they are not the 
predominant determinants of severity,32 and it may be unreliable to determine the extent of 
necrosis during the first few days of disease. In addition, the extent of morphologic changes is 
not directly proportional to the severity of organ failure.24 Therefore, the definition of severe 
or moderately severe acute pancreatitis in the early phase depends on the presence and duration 
of organ failure (see below, Definition of severity of acute pancreatitis).
Late phase
The late phase is characterised by persistence of systemic signs of inflammation or by the 
presence of local complications, and so by definition (see below), the late phase occurs only 
in patients with moderately severe or severe acute pancreatitis. Local complications evolve 
during the late phase. It is important to distinguish the different morphologic characteristics 
of the local complications by radiologic imaging, because these local complications may have 
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direct implications for management. Persistent organ failure, however, remains the main 
determinant of severity, so characterisation of acute pancreatitis in the late phase requires both 
clinical and morphologic criteria.
The SIRS of the early phase may be followed by a compensatory, anti-inflammatory response 
syndrome (CARS) that may contribute to an increased risk of infection; however, these events 
are complex and poorly understood.44
Definition of severity of acute pancreatitis
There are important reasons to define and stratify the severity of acute pancreatitis. First, on 
admission, it is important to identify patients with potentially severe acute pancreatitis who 
require aggressive early treatment. Second, in a secondary care setting, clinicians need to 
identify such patients for possible transfer to specialist care. Third, for specialists who receive 
such referrals, there are advantages to stratifying these patients into subgroups based on the 
presence of persistent organ failure and local or systemic complications.
This classification defines three degrees of severity: mild acute pancreatitis, moderately severe 
acute pancreatitis, and severe acute pancreatitis.32 33 Terminology that is important in this 
classification includes transient organ failure, persistent organ failure, and local or systemic 
complications (boxes 1 and 3). Transient organ failure is organ failure that is present for <48h. 
Persistent organ failure is defined as organ failure that persists for >48h. Local complications 
include peripancreatic fluid collections and acute necrotic collections13 14 39 41 (box 1), while 
systemic complications can be related to exacerbations of underlying co-morbidities related to 
the acute pancreatitis.
Mild acute pancreatitis
Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local 
or systemic complications. Patients with mild acute pancreatitis will usually be discharged 
during the early phase. Patients with mild acute pancreatitis usually do not require pancreatic 
imaging, and mortality is very rare.15
Box 3 Grades of severity
• Mild acute pancreatitis
• No organ failure
• No local or systemic complications
• Moderately severe acute pancreatitis
• Organ failure that resolves within 48h (transient organ failure) and/or
• Local or systemic complications without persistent organ failure
• Severe acute pancreatitis
• Persistent organ failure (>48h)
– Single organ failure
– Multiple organ failure
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Moderately severe acute pancreatitis
Moderately severe acute pancreatitis is characterised by the presence of transient organ failure 
or local or systemic complications in the absence of persistent organ failure. An example 
of a symptomatic local complication is a peripancreatic collection resulting in prolonged 
abdominal pain, leucocytosis and fever, or that prevents the ability to maintain nutrition 
orally. An example of a symptomatic systemic complication is exacerbation of coronary artery 
disease or chronic lung disease precipitated by the acute pancreatitis. Moderately severe acute 
pancreatitis may resolve without intervention (as in transient organ failure or acute fluid 
collection) or it may require prolonged specialist care (as in extensive sterile necrosis without 
organ failure). Mortality of moderately severe acute pancreatitis is far less than that of severe 
acute pancreatitis.32
Severe acute pancreatitis
Severe acute pancreatitis is characterised by persistent organ failure.39 41 Organ failure that 
develops during the early phase is set in motion by the activation of cytokine cascades resulting 
in SIRS38 39 40 (box 2). When SIRS is present and persistent,39 41 42 there is an increased risk 
that the pancreatitis will be complicated by persistent organ failure, and the patient should be 
treated as if they have severe acute pancreatitis.
Persistent organ failure may be single or multiple organ failure. Patients with persistent organ 
failure usually have one or more local complications. Patients who develop persistent organ 
failure within the first few days of the disease are at increased risk of death, with a mortality 
reported to be as great as 36–50%.38 39 41 The development of infected necrosis among patients 
with persistent organ failure is associated with an extremely high mortality.22 28
Evolution of severity of acute pancreatitis
At admission, mild pancreatitis is identified by the absence of organ failure. When organ 
failure is present within the first 24h (and organ failure that occurs during the first week of 
acute pancreatitis is usually present on admission to hospital), it may be difficult to determine 
the final grade of severity, because it is not known whether the patient will prove to have 
transient or persistent organ failure; the patient does not have mild pancreatitis and should be 
classified and treated initially as potentially having severe acute pancreatitis. If the organ failure 
resolves within 48h (indicating only transient organ failure), the patient should be classified as 
having moderately severe acute pancreatitis. If the patient develops persistent organ failure, 
they should be classified as having severe acute pancreatitis.39 45 During the early phase, the 
severity of acute pancreatitis can be reassessed on a daily basis while the pancreatitis is still 
evolving. Convenient time points to re-evaluate are 24h, 48h and 7 days after admission to 
hospital.
While local complications may be identified during the early phase, it is generally not necessary 
to document local complications by imaging during the first week. The reasons for this are as 
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follows. First, the presence and extent of pancreatic and peripancreatic necrosis may not be 
defined clearly on imaging during the first few days of disease.16 When necessary, a CECT 
5–7 days after admission is more reliable in establishing the presence and extent of pancreatic 
necrosis. Second, the extent of morphologic changes and necrosis is not directly proportional 
to the severity of organ failure.24 46 Third, even if imaging during the first week identifies the 
presence of peripancreatic fluid collections or pancreatic necrosis, in general no treatments are 
required for these conditions at that time.
In the late phase of moderately severe or severe acute pancreatitis, local complications evolve 
more fully, although some patients with persistent organ failure may recover without local 
complications.39 The presence of infection within areas of necrosis is a marker of increased 
risk of death. Infected necrosis without persistent organ failure, however, has a lesser mortality 
rate than infected necrosis with persistent organ failure. A systematic review33 found 11 deaths 
(11%) in 93 patients with infected necrosis without organ failure and led to the suggestion of a 
four-tier grading of severity.47 Analysis of two large national studies from the Netherlands25 48 
shows five deaths (6%) in 84 patients with infected necrosis without organ failure.
It is important to distinguish the different morphologic characteristics of the local complications, 
because these local complications may require a variety of interventions to avoid a fatal outcome.
Patients with moderately severe and severe acute pancreatitis can be described more precisely 
and stratified for the purpose of clinical studies by the nature and number of morphologic 
and clinical features (box 1 and 3). The descriptors are local complications (absent, sterile or 
infected) and persistent organ failure (single or multiple).28 33 Use of these terms will aid clear 
communication and will focus attention towards the problems that require management in 
each case.
Definition of pancreatic and peripancreatic collections
In the present classification, an important distinction is made between collections that are 
composed of fluid alone versus those that arise from necrosis and contain a solid component 
(and which may also contain varying amounts of fluid). Below, we define the following terms: 
acute peripancreatic fluid collection (APFC) occurring in interstitial oedematous pancreatitis; 
pancreatic pseudocyst as a delayed (usually >4 weeks) complication of interstitial oedematous 
pancreatitis; and necrosis, which may be an acute necrotic collection (ANC, in the early phase 
and before demarcation) or walled-off necrosis (WON), which is surrounded by a radiologically 
identifiable capsule (which rarely develops before 4 weeks have elapsed from onset of 
pancreatitis). 
Acute peripancreatic fluid collection
Fluid collections usually develop in the early phase of pancreatitis.49 On CECT, APFCs do 
not have a well defined wall, are homogeneous, are confined by normal fascial planes in the 
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retroperitoneum, and may be multiple (figure 2). Most acute fluid collections remain sterile 
and usually resolve spontaneously without intervention.19 49 When a localised APFC persists 
beyond 4 weeks, it is likely to develop into a pancreatic pseudocyst (see below), although this is 
a rare event in acute pancreatitis. APFCs which resolve or remain asymptomatic do not require 
treatment and do not by themselves constitute severe acute pancreatitis.
Pancreatic pseudocyst
The term pancreatic pseudocyst refers specifically to a fluid collection in the peripancreatic 
tissues (occasionally it may be partly or wholly intra-pancreatic). A pancreatic pseudocyst is 
surrounded by a well defined wall and contains essentially no solid material (figure 7). Diagnosis 
can be made usually on these morphologic criteria. If aspiration of cyst content is performed, 
there is usually a markedly increased amylase activity. A pancreatic pseudocyst is thought to 
arise from disruption of the main pancreatic duct or its intra-pancreatic branches without any 
recognisable pancreatic parenchymal necrosis; this theory suggests that consequent leakage 
of pancreatic juice results in a persistent, localised fluid collection, usually after more than 4 
weeks. When there is evident solid necrotic material within a largely fluid-filled cavity, the 
term pseudocyst should not be used. The development of a pancreatic pseudocyst is extremely 
rare in acute pancreatitis, and thus the term pancreatic pseudocyst in the setting of acute 
pancreatitis may fall into disuse. In this classification, pseudocyst does not result from an ANC 
(defined below). Although CECT is the imaging modality used most commonly to describe 
pseudocysts, MRI or ultrasonography may be required to confirm the absence of solid content 
in the collection.
FIGURE 7 A 40-year-old man with two pseudocysts in the lesser sac 6 weeks after an episode of acute 
interstitial pancreatitis on CT (A, B). Note the round to oval, low-attenuated, homogeneous fluid 
collections with a well defined enhancing rim (white arrows pointing at the borders of the pseudocysts), 
but absence of areas of greater attenuation indicative of non-liquid components. White stars denote 
normal enhancing pancreas.
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A pseudocyst may also arise in the setting of acute necrotising pancreatitis as a result of a 
‘disconnected duct syndrome’, whereby pancreatic parenchymal necrosis of the neck or body 
of the gland isolates a still viable distal pancreatic remnant.50 A pseudocyst may be evident 
many weeks after operative necrosectomy due to localised leakage of the disconnected duct 
into the necrosectomy cavity. Necrosis is absent because it has been removed by the earlier 
necrosectomy.
Acute necrotic collection
During the first 4 weeks, a collection containing variable amounts of fluid and necrotic tissue 
is termed an ANC (figures 3, 4, 5) to distinguish it from an APFC. The necrosis can involve 
the pancreatic parenchyma and/or the peripancreatic tissues. On CECT, acute pancreatic or 
peripancreatic necrotic collections contain varying amounts of solid necrotic material and fluid, 
may be multiple, and may appear loculated. An ANC is not an APFC, because an ANC arises 
from necrotising pancreatitis (necrosis of the pancreatic parenchyma and/or peripancreatic 
tissues) and contains necrotic tissue. An ANC may be associated with disruption of the main 
pancreatic duct within the zone of parenchymal necrosis and can become infected.
Sequential imaging may be useful to characterise acute collections. Within the first week 
of the disease, it may be difficult to differentiate an APFC from an ANC. At this stage, both 
types of collections may appear as areas with fluid density (figure 3). After the first week, the 
distinction between these two important types of collections becomes clear, such that at this 
stage of necrosis, a peripancreatic collection associated with pancreatic parenchymal necrosis 
can be properly termed an ANC and not an APFC. MRI, transcutaneous ultrasonography or 
endoscopic ultrasonography may be helpful to confirm the presence of solid content in the 
collection.
Walled-off necrosis
WON consists of necrotic tissue contained within an enhancing wall of reactive tissue. It is 
a mature, encapsulated collection of pancreatic and/or peripancreatic necrosis and has a well 
defined inflammatory wall (figure 8); usually this maturation occurs ≥4 weeks after onset 
of necrotising pancreatitis. Previous suggested nomenclature had designated this entity as 
organised pancreatic necrosis,51 necroma,52 pancreatic sequestration,53 pseudocyst associated 
with necrosis,54 and subacute pancreatic necrosis.55
WON derives from necrotic pancreatic parenchyma and/or necrotic peripancreatic tissues 
and may be infected, may be multiple, and may be present at sites distant from the pancreas. 
CECT may not readily distinguish solid from liquid content, and, for this reason, pancreatic 
and peripancreatic necrosis may be misdiagnosed as a pancreatic pseudocyst. For this purpose, 
MRI, transabdominal ultrasonography or endoscopic ultrasonography may be required for this 
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distinction. Demonstration of the presence or absence of pancreatic ductal communication is 
not necessary in this classification, although determination of such ductal communication is of 
potential importance, because it may affect management.
FIGURE 8 (A–C) Three different patients with walled-off necrosis (WON) after an acute attack of 
necrotising pancreatitis. In all three patients, a heterogeneous, fully encapsulated collection is noted 
in the pancreatic and peripancreatic area. (A) Non-liquid components of high attenuation (black 
arrowheads) in the collection are noted. The collection has a thin, well defined, and enhancing wall 
(thick white arrows). (B, C) A largely liquefied collection in the bed of the pancreas is observed with 
non-liquid components representing areas of trapped fat (black arrowheads). (D) represents the 
corresponding T2-weighted MRI to (C), showing the true heterogeneity of the collection. Black 
arrowheads denote areas of necrotic debris surrounded by fluid (white on T2-weighted image).
Infected necrosis
The diagnosis of infection (infected necrosis) of an ANC or of WON can be suspected by the 
patient’s clinical course or by the presence of gas within the collection seen on CECT (figure 
6). This extraluminal gas is present in areas of necrosis and may or may not form a gas/fluid 
level depending on the amount of liquid content present at that stage of the disease. In cases of 
A B
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doubt, fine needle aspiration for culture may be performed, but some series have shown that 
the large majority of patients can be managed without FNA, especially if percutaneous drainage 
is part of the management algorithm.25
CONCLUSION
This classification revises and updates the definitions from the Atlanta Classification of acute 
pancreatitis. An important feature is the recognition that acute pancreatitis is an evolving, 
dynamic condition and that the severity may change during the course of the disease. 
Early in the disease, SIRS or organ failure indicate potentially severe disease. If the patient 
improves rapidly during the early phase without organ failure and without local or systemic 
complications, the disease is defined as mild acute pancreatitis. If the patient develops local or 
systemic complications and has no persistent organ failure, the disease is defined as moderately 
severe acute pancreatitis. If the patient develops persistent organ failure, the disease is defined 
as severe acute pancreatitis and is associated with very high morbidity and mortality rates.
The accurate description of local complications, including the presence of fluid or necrosis 
in or around the pancreas, the time course of progression, and the presence or absence of 
infection, will improve the stratification of patients both for clinical care in specialised centres 
and for reporting of clinical research.
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A B S T R A C T
Background: For consistent reporting and better comparison of data in research the revised 
Atlanta Classification (RAC) proposes new computed tomography (CT) criteria to describe the 
morphology of acute pancreatitis (AP). The aim of this study was to analyse the interobserver 
agreement among radiologists in evaluating CT morphology by using the new RAC criteria in 
patients with AP.
Methods: Patients with a first episode of AP who obtained a CT were identified and 
consecutively enrolled at six European centres backwards from January 2013 to January 2012. 
A local radiologist at each center and a central expert radiologist scored the CTs separately 
using the RAC criteria. Center dependent and independent interobserver agreement was 
determined using Kappa statistics.
Results: In total, 285 patients with 388 CTs were included. For most CT criteria, interobserver 
agreement was moderate to substantial. In four categories, the center independent kappa values 
were fair: extrapancreatic necrosis (EXPN) (0.326), type of pancreatitis (0.370), characteristics 
of collections (0.408), and appropriate term of collections (0.356). The fair kappa values relate 
to discrepancies in the identification of extrapancreatic necrotic material. The local radiologists 
diagnosed EXPN (33% versus 59% P < 0.0001) and non-homogeneous collections (35% versus 
66%, P < 0.0001) significantly less frequent than the central expert. Cases read by the central 
expert showed superior correlation with clinical outcome.
Conclusion: Diagnosis of EXPN and recognition of non-homogeneous collections show only 
fair agreement potentially resulting in inconsistent reporting of morphologic findings.
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INTRODUCTION
Acute pancreatitis (AP) is a complex disease with potentially severe and fatal outcome 
[1,2]. Simple but clear definitions of the disease are crucial in interdisciplinary consultation, 
communication, and in reporting of clinical research. Such were the incentives to update the 
1992 Atlanta Classification on AP [1]. Besides redefining the disease into three levels of clinical 
severity, the 2012 revised Atlanta Classification (RAC) has put substantial efforts into clarifying 
the terminology on the morphologic subtypes of AP and associated peripancreatic collections 
based on computed tomography (CT)-based criteria [1]. Two morphologic types of AP are 
discriminated: acute interstitial oedematous pancreatitis and acute necrotising pancreatitis. 
Acute necrotising pancreatitis is subdivided into three forms: pancreatic parenchymal necrosis, 
extrapancreatic necrosis (EXPN), and combined necrosis. Peripancreatic collections are 
classified into four types depending on content and maturation. Acute peripancreatic fluid 
collections and pancreatic pseudocysts are composed of fluid only and occur in interstitial 
oedematous pancreatitis. On CT, these collections show a homogeneous fluid density with 
no or incomplete well-defined wall (acute peripancreatic fluid collection) or a complete wall 
(pseudocyst). Acute necrotic collections and walled-off necrosis are associated with acute 
necrotising pancreatitis and contain varying amounts of fluid and necrotic material. On CT, 
these collections have various densities (fat, fluid, solid material) with no or incomplete well-
defined wall (acute necrotic collection) or a complete wall (walled-off necrosis) [1,3-5]. The 
RAC provides approximate time frames for these pancreatic collections. Acute peripancreatic 
fluid collection and acute necrotic collection pertain to the first four weeks of disease after 
which they usually turn into a completely encapsulated pseudocyst and walled-off necrosis, 
respectively.
It is well established that the morphologic types of AP differ in outcomes, therapies, and 
prognosis. For prognostication, stratification, and comparing of interinstitutional data, accurate 
assessment of AP morphology in the different stages of disease is imperative [1]. The extent of 
variation in interpretation of the new CT criteria is, however, unknown [6-8]. The aim of this 
study was to assess the interobserver agreement among radiologists in the evaluation of CT 
morphology using the RAC criteria.
METHODS
Patients and study design
Patients >18 years with a first episode of AP were consecutively identified at six European 
study centres, going backwards from January 2013 to January 2012. Each center included 50 
patients in whom at least one contrast-enhanced CT (CECT) was performed. The cases were 
anonymously enrolled and each patient obtained a code blinded for all investigators except 
for the referring center. CECTs performed within 3 months from date of admission were 
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recorded and subsequently reviewed and scored by a local radiologist at each center. The 
time frame of 3 months was chosen because most CTs are performed within this period and 
controversies in nomenclature and management of pancreatic collections are most evident 
during this phase. Exclusion criteria were insufficient quality of the CECT, signs of chronic 
pancreatitis (i.e. pancreatic calcifications) or patients with prior pancreatitis-related invasive 
intervention, except from endoscopic retrograde cholangiography. Each CECT was performed 
in the pancreatic and/or in the portal venous phase (see Supplementary file 1 for CT specifi- 
cations). Severity and CT morphology of AP were defined according to the RAC (see Box 1 for 
definitions) [1].
Box 1 Morphological features and CECT criteria in AP according to the RAC.
Morphology groups CECT criteria Time
Interstitial oedematous 
pancreatitis (IEP)
Homogenous enhancement of the pancreatic parenchyma, normal or minor 
inflammatory changes of the peripancreatic tissue (see below - APFC or 
pancreatic pseudocyst)
-
Necrotising pancreatitis Heterogeneous enhancement of the pancreatic parenchyma and/or 
peripancreatic tissue necrosis (see below - ANC or WON)
-
Acute peripancreatic fluid 
collection (APFC)
Homogeneous fluid density. No complete wall. No necrosis. Associated with 
IEP. Solely extrapancreatic location.
≤4 weeks
Pancreatic pseudocyst Homogeneous fluid density. Fully encapsulated. No necrosis. Associated with 
IEP. Solely extrapancreatic location.
>4 weeks
Acute necrotic collection 
(ANC)
Heterogeneous and non-liquid density. No complete wall. Associated with 
necrotising pancreatitis. Intra- or extrapancreatic location
≤4 weeks
Walled-off necrosis 
(WON)
Heterogeneous and non-liquid density. Fully encapsulated. Associated with 
necrotising pancreatitis. Intra- or extrapancreatic location
>4 weeks
CECT = contrast enhanced computed tomography.
The following clinical data was collected from review of medical notes: systemic inflammatory 
response syndrome (SIRS) upon admission, highest level of C-reactive protein (CRP) during 
hospitalisation, need for invasive intervention, organ failure (persistent and transient, in line 
with the RAC), and in-hospital mortality. The six participating local radiologists had expertise 
in the field of abdominal radiology, each with more than five years' experience. A short 
instruction sheet was provided to local radiologists to assist in interpretation (Supplementary 
file 2). All individual CECTs were scored according to a protocol based on the parameters 
stated in the RAC (Supplementary file 3). Subsequently, all CECTs were reviewed and scored 
(using the same scoring sheet) by a central expert radiologist (T.L.B) using open source 
DICOM viewer software (32-bit OsiriX version 3.3, Geneva, Switzerland). Local and central 
reviewers were blinded to any clinical data except for the timing (number of days after onset 
of symptoms) of each CECT. Formal approval of the local medical ethical committee was 
requested and obtained at each study center.
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Statistical analysis
Sample size calculations for variables with 2, 3, and 4 categories were performed because most 
of the variables of the revised Atlanta criteria are based on 2, 3, or 4 categories. Κappa values of 
> 0.40 and > 0.60 were used since they represent at least moderate and substantial agreement 
[9]. Based on such a calculation, in a test for agreement between two raters, a sample size of 
360 CECTs would provide a 95% confidence interval for the κ statistic with a width not greater 
than 0.20. Assuming that several patients would have more than one CECT performed, a total 
of 50 patients were included per center. Interobserver agreement was calculated between the 
local and the central radiologist, using Cohen's kappa test, for each of the categories scored 
on the radiology sheet. Agreement levels were defined as: κ level 0.00-0.20 slight; 0.21-0.40 
fair; 0.41-0.60 moderate; 0.61-0.80 substantial; and 0.81-1.00 almost perfect. Continuous data 
analysis was conducted using Mann-Whitney U test. Wilcoxon Signed Rank test was used 
for paired sample analysis. P < 0.05 was considered statistically significant. All analysis was 
performed using IBM SPSS Statistics for Windows, version 21 and 22, Armonk, NY:IBM corp.
RESULTS
Patients
In total, 301 patients were included at six European centres of whom 159 (56%) were male 
with a median age of 58 years (range 18-92). Sixteen patients were excluded due to reasons 
stated in the CECT section below. Baseline characteristics of the remaining 285 patients are 
summarised in Table 1. Etiology of AP differed substantially between the centres. According to 
the RAC, 37.5% of the patients had mild AP, 51.5% moderately severe AP and 11.0% severe AP 
[1]. Overall fourteen patients died (4.9%, range 0-14%), whereas mortality within the severe 
group was 32.3% (range 0-78%). Each center admits 175-250 patients with AP annually, except 
for center F where the number is approximately 470.
Contrast-enhanced computed tomography
A total of 405 CECTs derived from 301 patients were collected. Seventeen CECT studies were 
excluded due to insufficient quality of the CECT or signs of chronic pancreatitis, leaving a 
study cohort of 285 patients with 388 CECTs. Data on CECTs for the separate centres are 
presented in Table 2. Median time from onset of disease to CECT for all centres was 7 days 
(range 0-90, interquartile range 3-13).
Interobserver agreement
For specific information concerning all categories evaluated we refer to Supplementary file 
2. The kappa values representing the interobserver agreement are shown in Table 3. There 
was substantial agreement in seven categories: 'Necrosis - Neck' (0.618); 'Necrosis - Body' 
(0.628); 'Necrosis - Tail' (0.617); presence of 'Collections' (0.756); 'Location of Collections' 
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(0.633); presence of 'Wall' (0.675); and presence of 'Intraluminal Gas and/or Fluid level' 
(0.764). Moderate agreement was reached on 'Parenchymal Necrosis' (0.539) and 'Necrosis - 
Head' (0.516). Finally, there was fair agreement on the categories 'Type of Pancreatitis' (0.370), 
'Extrapancreatic Necrosis' (0.326), 'Characteristics of Collection' (0.408), and 'Collection - most 
appropriate term' (0.356). The center dependent kappa values differed considerably between 
centres.
TABLE 3. Center independent and dependent kappa values for all categories scored.
Category
All 
centres
Center 
B
Center 
C
Center 
D
Center 
E
Center 
F
Center 
G
Type of pancreatitis 0.370 0.317 0.342 0.309 0.098b 0.838a 0.360
Parenchymal Necrosis 0.539 0.380 0.319b 0.609 0.731a 0.663 0.465
Necrosis - Head 0.516 0.669 0.345 0.323b 1.00a 0.660 0.646
Necrosis - Neck 0.618 0.922a 0.577 0.822 0.660 0.364 0.236b
Necrosis - Body 0.628 0.766 0.611 0.687 0.873 0.392b 0.570
Necrosis - Tail 0.617 0.451 0.626 0.687 0.409b 0.806a 0.532
Extrapancreatic Necrosis 0.326 0.321 0.504 0.293 0.120 0.877a 0.024b
Collections 0.756 0.780 0.750 0.624b 0.864a 0.827 0.625
Location of Collections 0.633 0.728 0.761a 0.508 0.694 0.604 0.439b
Characteristics of collections 0.408 0.397 0.485 0.293 0.305 0.744a 0.251b
Wall 0.675 0.638 0.638 0.588b 0.777a 0.726 0.632
Intraluminal gas/fluid level 0.764 0.774 0.671b 0.764 0.887a 0.837 0.675
Collection - most appropriate term 0.356 0.385 0.480 0.136b 0.218 0.673a 0.261
a Highest kappa value for center B to G for each category.
b Lowest kappa value for center B to G for each category.
Discrepancies in the identification of EXPN are shown in Table 4. For image samples see Fig. 
1a,b and 2a-c. The expert radiologist diagnosed EXPN significantly more often than the local 
radiologists (59% vs. 33%, P < 0.0001). Table 4 shows that this difference in total number of 
EXPN stems from the subgroup of isolated EXPN. Since the RAC acknowledges that EXPN 
might be difficult to diagnose within the first week, interobserver agreement was recalculated 
for the categories with low kappa values excluding CECTs performed within 72h, seven days 
and two weeks after onset of disease (see Supplementary file 4). In this subanalysis, kappa 
values did improve only for CECTs performed after two weeks.
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TABLE 4. Number of extrapancreatic necrosis (EXPN) scored by the local radiologists and central 
expert.
Total number of EXPN Combined necrosis Isolated EXPN
Local rad Central exp Local rad Central exp Local rad Central exp
Yes 126 (33%) 230 (59%) 85 (22%) 92 (24%) 41 (11%) 138 (36%)
No 245 (63%) 110 (28%) 303 (78%) 296 (76%) 347 (89%) 250 (64%)
Indet 17 (4%) 48 (12%)
Total number of EXPN = diagnosis of EXPN (yes/no) and indeterminate by local radiologists and central expert, respectively.
Combined necrosis = Extrapancreatic necrosis with Parenchymal necrosis in cases where presence of EXPN (yes/no) was determined.
Isolated EXPN = Extrapancreatic necrosis without Parenchymal Necrosis in cases where presence of EXPN (yes/no) was determined.
Local rad = Local radiologists.
Central exp = Central expert radiologist.
Indet = Indeterminate (radiologist was not able to determine the presence of EXPN, yes/no).
FIG. 1. 70-year-old male with acute pancreatitis (A, B). The pancreas enhances heterogeneously 
(asterisks) but no apparent necrosis was observed by both reviewers. Peripancreatic collections are 
present in the retroperitoneal pancreatic compartment and transverse mesocolon (arrowheads pointing 
at the borders). The local reviewer scored this as interstitial pancreatitis with acute peripancreatic 
fluid collections; the central reviewer as necrotising pancreatitis, subtype EXPN, with acute necrotic 
collections.
Morphological findings scored by the central and local radiologists were correlated with 
clinical outcome parameters (see Table 5). Cases read as interstitial oedematous pancreatitis 
and isolated EXPN by the central expert correlate significantly better with clinical outcome 
than scoring by local radiologists. Given the good interobserver agreement for pancreatic 
parenchymal necrosis, results did not differ significantly between central and local radiologists 
for this subgroup (Supplementary file 5).
A B
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TABLE 5. Correlation of morphologic findings with clinical outcome by central and local radiologists.
Total (N)
IEP Isolated EXPN
Local Central P-value Local Central P-value
All cases (388) 199 107 0.0001 41 138 0.0001
Organ Failure
Persistent (50) 20 (10.0%) 5 (4.7%) 0.0001 4 (9.7%) 24 (17.4%) 0.0001
Transient (51) 15 (7.5%) 5 (4.7%) 0.002 4 (9.7%) 20 (14.5%) 0.0001
Mortality (20) 9 (4.5%) 4 (3.7%) 0.025 1 (2.4%) 7 (5.1%) 0.025
Intervention (79) 11 (5.5%) 6 (5.6%) ns 12 (29.3%) 26 (18.8%) 0.001
CRP (mg/l) 271 165 0.0001 298 318 ns
SIRS (104) 41 (20.6%) 12 (11.2%) 0.0001 9 (22.0%) 38 (27.5%) 0.0001
Cases scored as ‘indeterminate’ are not accounted for. IEP = Interstitial Edematous Pancreatitis.
Isolated EXPN = Extrapancreatic Necrosis without Parenchymal Necrosis. Local = Local radiologists.
Central = Central Expert.
CRP = C-reactive protein, highest value.
SIRS = Systemic Inflammatory Response Syndrome.
DISCUSSION
The RAC proposed a new set of morphologic CT-based criteria to account for alleged 
shortcomings of the 1992 Atlanta Classification [1,2]. One of the major aims of the RAC was 
to ease and ensure consistency in the investigation and reporting of data in clinical research 
[1]. However, the degree of interobserver agreement in the interpretation of CT findings using 
these new RAC criteria has been questioned [6-8].
Main findings of our study are twofold: on the one hand, the morphologic assessment of the 
RAC generates overall moderate to good interobserver agreement (range 0.516-0.764) among 
European radiologists in 9 out of 13 items evaluated. Importantly, agreement among raters was 
good in evaluating clinically important CT findings in patients with AP, such as the presence 
of parenchymal necrosis and gas bubbles. On the other hand, only fair agreement (range 0.326-
0.408) was obtained for items pertaining to necrosis of extrapancreatic tissues. The central 
expert diagnosed EXPN significantly more frequent than the local radiologists (59% versus 
33%, P < 0.0001) with better correlation with patient outcome. Our findings suggest that 
radiologists are largely unfamiliar with the newly defined entity of EXPN.
Several explanations exist for the fair agreement in diagnosing EXPN and for characterisation 
of pancreatic collections on CT. The RAC regards CT as the first-line imaging modality in 
AP, albeit acknowledging the fact that necrotic material within pancreatic collections is often 
overlooked [1]. It is well-established that ultrasound and magnetic resonance imaging are 
better capable of delineating the exact composition of pancreatic collections, especially for 
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depicting necrotic material [10,11]. Furthermore, the CT diagnosis of EXPN and associated 
necrotic collections relies primarily on subjective secondary findings, such as ‘heterogeneity’ or 
the detection of various densities (liquid and non-liquid) within collections, rather than using 
the more objective and reproducible criteria of perfusion characteristics, which is used for 
detecting pancreatic parenchymal necrosis. Perfusion characteristics, however, cannot be used 
to diagnose EXPN because normal extrapancreatic fat does not enhance. In addition, the RAC 
acknowledges that EXPN is difficult to diagnose initially but becomes easier when the disease 
process evolves over time [1]. This is in line with our results with improved kappa values for 
EXPN diagnosis two weeks after symptom onset. Finally, reader expertise and familiarity seem 
equally important for diagnosing EXPN exemplified by the excellent interobserver agreement 
between the central expert and the local radiologist affiliated with center F that admits the 
highest number of patients with AP annually.
FIG. 2. 55-year-old female with acute pancreatitis (A-C). Normal enhancement of pancreatic 
parenchyma was noted by both reviewers (asterisks). Extensive peripancreatic collections are present 
in the retroperitoneum bilaterally and transverse mesocolon (arrowheads pointing at the borders). 
These represented ‘acute peripancreatic fluid collections’ and ‘acute necrotic collections’ according to 
the local and central reviewer, respectively. Coronal reformatted image (C) depicts the magnitude of 
collections.
A B
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In a previous study on CT assessment of morphologic features of AP, good to excellent 
interobserver agreement was found in 55 cases of AP [12]. However, this study used selected 
cases biased towards severe disease (likely associated with more established peripancreatic 
collections) reviewed by tertiary experts. Although imaging is rarely required for mild AP, 
most patients who undergo CT for evaluation of AP turn out to have interstitial pancreatitis. 
Our study more closely resembles clinical practice in different European countries by enrolling 
patients with AP consecutively and evaluating unselected CECTs encompassing the full 
spectrum of morphologic abnormalities in AP, including mild and equivocal cases.
Previous studies show considerable differences in clinical outcome, treatment strategies, 
and prognoses between the various morphological types of AP [13-17]. Clinical outcome 
of EXPN is worse compared with acute interstitial pancreatitis, but better than pancreatic 
necrosis [13,15,17]. Patients with EXPN stay in hospital considerable longer, develop more 
often organ failure, and undergo interventional therapy significantly more frequent than those 
with interstitial pancreatitis. Moreover, when infection ensues of necrotic collections in EXPN 
patients, outcome, therapy, and prognosis are similar to those with infected pancreatic necrosis 
[15]. In our study, the interpretation by the central expert more closely corroborated with 
actual clinical outcome. As such, accurate differentiation between the types of AP is important 
both from a clinical perspective as for consistent reporting of research and reliable comparison 
of inter-institutional data.
This study has some limitations. First, a single central expert radiologist served as standard 
of reference, potentially introducing bias. We considered this a limited risk because of his 
extensive experience in pancreatic imaging, his involvement in the development of the RAC, 
the superior correlation with patient outcome, and the excellent agreement with a local 
radiologist with similar expertise. Second, given the retrospective design of this study, we did 
not investigate to what extent the inconsistencies observed eventually affected clinical decision-
making. Future studies should focus on this interesting topic. Finally, we merely studied the 
interobserver agreement of morphological abnormalities in AP and did not correlate imaging 
findings with histopathology.
Results of this study have revealed areas of controversy when using the RAC criteria for CT 
assessment, especially pertaining to distinguishing interstitial pancreatitis from EXPN only. 
There are several options for improving consistent reporting in AP. Both radiologists and 
clinicians need to become better familiar with imaging features of EXPN (i.e. by education or 
training). Second, the definition of EXPN should preferably be redefined such that stronger 
interrater agreement will be achieved, even among readers with varying expertise. For 
example, by adding a time interval of 2 weeks before its diagnosis or by using an alternative 
imaging (MRI or US) modality as these are better capable of detecting necrotic material within 
collections [10]. Third, a greater role should be attributed to MRI for overall evaluation of AP. 
Finally, as has been alluded to in previous reports, a three-degree morphologic classification 
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system (‘interstitial pancreatitis’ refers to normal enhancing parenchyma without collections, 
‘EXPN’ refers to normal perfused pancreatic parenchyma with pancreatic collections, and 
‘necrotising pancreatitis’ refers to parenchymal necrosis with or without associated collections) 
could potentially lead to less interobserver variability as the differentiation between the various 
types of pancreatic collections becomes less of an issue [18,19]. Additionally, Such a system 
would likely be more in concordance with clinical grades of severity [13-17,20].
In conclusion, this study found only moderate interrater agreement for identification of 
EXPN. For correctly identifying EXPN and necrotic collections on CT, a diligent search for 
heterogeneity within pancreatic collections is crucial for accurate and consistent reporting of 
imaging findings (see Figs. 1 and 2).
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ABSTRACT
Objective: The purpose of this study was to compare the modified CT severity index (MCTSI) 
with the CT severity index (CTSI) regarding assessment of severity parameters in acute 
pancreatitis (AP). Both CT indexes were also compared with the Acute Physiology, Age, and 
Chronic Health Evaluation (APACHE II) index.
Materials and methods: Of 397 consecutive cases of AP, 196 (49%) patients underwent 
contrast-enhanced CT (n = 175) or MRI (n = 21) within 1 week of onset of symptoms. Two 
radiologists independently scored both CT indexes. Severity parameters included mortality, 
organ failure, pancreatic infection, admission to and length of ICU stay, length of hospital stay, 
need for intervention, and clinical severity of pancreatitis. Discrimination analysis and kappa 
statistics were performed.
Results: Although for both CT indexes a significant relationship was observed between the 
score and each severity parameter (p < 0.0001), no significant differences were seen between 
the CT indexes. Compared with the APACHE II index, both CT indexes more accurately 
correlated with the need for intervention (CTSI, p = 0.006; MCTSI, p = 0.01) and pancreatic 
infection (CTSI, p = 0.04; MCTSI, p = 0.06) and more accurately diagnosed clinically severe 
disease (area under the curve, 0.87; 95% CI, 0.82–0.92). Interobserver agreement was excellent 
for both indexes: for CTSI, 0.85 (95% CI, 0.80–0.90) and for MCTSI, 0.90 (95% CI, 0.85–0.95).
Conclusion: No significant differences were noted between the CTSI and the MCTSI in 
evaluating the severity of AP. Compared with APACHE II, both CT indexes more accurately 
diagnose clinically severe disease and better correlate with the need for intervention and 
pancreatic infection.
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INTRODUCTION
Acute pancreatitis (AP) is a common and typically mild, self-limiting disease with only 
minimal or transient systemic manifestations. However, approximately 15–20% of patients 
develop clinically severe AP with local and systemic complications [1]. A number of clinical 
and laboratory prognostic scoring systems have been designed for the early identification of 
patients at greatest risk of developing clinically severe AP. Overall, these scoring systems have 
an accuracy varying between 70% and 80% [2]. Imaging by CT or MRI in the assessment of AP 
is useful not only for diagnosis but also for detecting local pancreatic complications and guiding 
interventional procedures.
Moreover, in the past two decades, several radiologic prognostic scoring systems have been 
developed. Among them, the CT severity index (CTSI), designed by Balthazar et al. [3] in 1990, 
is the most widely adopted for clinical and research settings. The CTSI is a numeric scoring 
system that combines a quantification of pancreatic and extrapancreatic inflammation with the 
extent of pancreatic necrosis. In 2004, a modified CTSI (MCTSI) was designed to account for 
several potential limitations of the CTSI [4]. In contrast to the CTSI, the MCTSI incorporates 
extrapancreatic complications in the assessment and simplifies the evaluation of the extent of 
pancreatic parenchymal necrosis (none, ≤ 30%, or > 30%) and peripancreatic inflammation 
(presence or absence of peripancreatic fluid). In the initial study of 66 patients, the MCTSI, 
when compared with the CTSI, better correlated with patient outcome, in particular, with 
regard to the length of hospital stay and, more important, the development of organ failure [4], 
which has been shown to be the primary determinant of outcome in the early phase of AP [5]. 
To our knowledge, no validation of the MCTSI in a larger cohort has been performed. 
Furthermore, in the initial study of the MCTSI, no detailed evaluation was provided with regard 
to the specific prevalence of each of the extrapancreatic complications. Finally, no comparison 
has been performed between both radiologic scoring systems and the existing clinical 
prognostic scoring system that is commonly used for research purposes (Acute Physiology, 
Age, and Chronic Health Evaluation, [APACHE II] score) [6]. Therefore, the primary aim of 
our study was to compare the MCTSI with the CTSI with regard to the ability to assess clinical 
severity among a consecutive cohort of patients with AP. The secondary aim was to compare 
both radiologic scoring systems with APACHE II with regard to clinical severity parameters.
MATERIALS AND METHODS
Subjects
A retrospective analysis of a prospectively collected database was performed. The demographic, 
clinical, and laboratory data of 397 consecutive cases of AP in patients admitted or transferred 
to our institution between June 2005 and December 2007 were reviewed for this study. 
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Institutional review board approval and written informed consent of each patient were 
obtained. AP was defined as two or more of the following: characteristic abdominal pain (i.e., 
severe upper abdominal pain), serum amylase or lipase levels three or more times the upper 
limit of normal (i.e., > 210 U/L and > 180 U/L, respectively), and changes consistent with 
AP on cross-sectional imaging [7]. Of the 397 cases of AP, there were 196 (49%) cases in 179 
patients (107 men, 89 women; mean age, 53 years; age range, 21–94 years) who underwent 
contrast-enhanced CT (n = 175) or MRI (n = 21) that was performed within 1 week of onset 
of symptoms. Median interval between onset of symptoms and CT or MRI was 2 days (range, 
0–7 days). Of the remainder of cases, 167 were excluded because no contrast-enhanced imaging 
study was done, 20 cases were excluded because they were admitted with acute or chronic 
pancreatitis, nine cases were excluded because imaging was done more than 1 week after onset 
of symptoms, and five cases were excluded because they had undergone previous pancreatic 
surgery or surgery for pancreatitis.
In our final study cohort of 196 cases, the causes of AP were biliary stones in 66 (34%) cases, 
alcohol abuse in 43 (22%) cases, miscellaneous (e.g., hypertriglyceridemia, hereditary) in 31 
(16%) cases, idiopathic in 26 (13%) cases, postendoscopic retrograde pancreatography in 16 
(8%) cases, and drug-induced in 14 (7%) cases. Appropriate clinical and laboratory data were 
recorded prospectively by two of the authors (who were unaware of the radiologic data) to 
permit calculation of APACHE II scores at the day of CT or MRI [6].
Imaging Technique
In 140 cases, CT examinations were performed on a 4-MDCT scanner (Volume Zoom, 
Siemens Healthcare). Contrast-enhanced CT scans (collimation, 4 × 2.5 mm; reconstruction 
section thickness, 5 mm; reconstruction intervals, 5 mm) were obtained 40–50 seconds after 
IV injection of 100 mL of iopromide (Ultravist 300, Bayer HealthCare), injected at a rate of 3.0 
mL/s, using a mechanical power injector. In 35 cases, contrast-enhanced CT studies using a 
variety of parameters were retrieved from the referring hospitals; these studies were deemed 
of good quality (i.e., at least one contrast-enhanced CT scan in the pancreatic or portal venous 
phase).
In 21 cases, contrast-enhanced MRI was performed within 1 week of onset of symptoms. 
MRI was performed with a 1.5-T magnet (Signa EchoSpeed Plus, GE Healthcare) using a 
phased-array torso coil. Axial T2-weighted fast recovery fast spin-echo, axial and coronal 
heavily T2-weighted single-shot fast spin-echo, axial T1-weighted dual-echo gradient-recalled 
echo images, and axial fat-suppressed T1-weighted 3D gradient-echo images were obtained. 
Contrast-enhanced T1-weighted gradient-recalled echo images were obtained 25, 60, and 180 
seconds after IV administration of 20 mL of gadopentetate dimeglumine (Magnevist, Bayer 
HealthCare).
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Image Analysis
The first available contrast-enhanced imaging study was used for this study. All 35 digital CT 
studies from outside hospitals were retrieved and retrospectively reviewed using DICOM 
viewer software (DicomWorks, version 1.3.5, freeware). The remainder of in-house CT and 
MRI studies were retrospectively reviewed on a PACS workstation (Centricity, GE Healthcare). 
Two experienced radiologists separately and independently reviewed all imaging studies and 
recorded all pancreatic, peripancreatic, and extrapancreatic findings and complications, each 
blinded to patient outcome. Pancreatic findings included pancreatic enlargement and presence 
and extent of areas lacking enhancement. Peripancreatic findings included peripancreatic fat 
stranding and number of fluid collections. Extrapancreatic complications included ascites, 
pleural effusion, pericardial effusion, vascular complications (venous thrombosis, hemorrhage, 
and arterial pseudoaneurysm formation), gastrointestinal complications (ileus [adynamic ileus 
or mechanical obstruction], signs of ischemia, marked bowel-wall thickening, perforation, 
and intramural fluid collection), and extrapancreatic parenchymal complications (infarction, 
hemorrhage, and subcapsular fluid collection). In all cases, the morphologic severity of 
pancreatitis was assessed using the CTSI, developed by Balthazar et al. [3], and the MCTSI, 
more recently developed by Mortele et al. [4] (Table 1). For the CTSI, the morphologic severity 
of pancreatitis was categorized as mild (0–3 points), moderate (4–6 points), or severe (7–10 
points). For the MCTSI, the morphologic severity of disease was categorized as mild (0–2 
points), moderate (4–6 points), or severe (8–10 points) (Fig. 1). Both indexes were scored 
during the same interpretation session.
TABLE 1: CT Severity Index (CTSI) and Modified CTSI (MCTSI)
Characteristics CTSI (0–10) MCTSI (0–10)
Pancreatic inflammation
Normal pancreas 0 0
Focal or diffuse enlargement of pancreas 1 2
Peripancreatic inflammation 2 2
Single acute fluid collection 3 4
Two or more acute fluid collections 4 4
Pancreatic parenchymal necrosis
None 0 0
Less than 30% 2 2
Between 30% and 50% 4 4
More than 50% 6 4
Extrapancreatic complicationsa 0 2
a One or more of pleural effusion, ascites, vascular complications, parenchymal complications, or gastrointestinal tract involvement.
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FIG. 1. 46-year-old woman with acute pancreatitis. A, Axial contrast-enhanced CT scan shows 
presence of bilateral pleural effusions with atelectasis of lower lobes. B, Axial contrast-enhanced 
CT scan shows one peripancreatic fluid collection and slightly heterogeneous enhancing pancreatic 
parenchyma without apparent areas of nonenhancement. Score was 3 (morphologic mild pancreatitis) 
on CT severity index and 6 (morphologic moderate severe acute pancreatitis) on modified CT severity 
index. Patient survived but experienced persistent organ failure and, thus, was diagnosed with clinically 
severe acute pancreatitis.
Definitions and Severity Parameters
Severity parameters for all patients were collected during the course of each patient’s 
hospitalization, including in-hospital mortality, length of hospital stay, admission to and length 
of ICU stay, presence and duration of organ failure (transient, ≤ 48 hours; persistent, > 48 
hours), pancreatic infection (infection of pancreatic or peripancreatic necrosis or collections 
documented on the basis of percutaneous aspiration), need for intervention (endoscopic or 
percutaneous drainage or surgical necrosectomy), and clinical severity of pancreatitis. AP was 
defined as clinically severe if the patient died, had organ failure persisting more than 48 hours, 
had local pancreatic complications that required intervention (endoscopic or radiologic drainage 
or surgical necrosectomy), or had prolonged hospitalization (such as need for enteral feeding 
or parenteral antibiotics). This new definition of clinically severe AP is in accordance with the 
most updated version of the revised Atlanta Classification [8]. Organ failure was defined as a 
score of 2 or more in one or more of the three (respiratory, renal, and cardiovascular) organ 
systems of the modified Marshall score [8, 9].
Data Analysis
The interobserver agreement for correlating the morphologic severity of AP (mild, moderate, 
or severe) determined by both the CTSI and the MCTSI was assessed using the kappa statistic. 
An independent radiologist reviewed interobserver discrepancies and agreement was obtained 
by consensus. Descriptive statistics were used for baseline characteristics, outcomes of 
interest, and extrapancreatic findings. Chi-square or Fisher’s exact tests were used to assess 
A B
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relationships between categoric outcomes and morphologic severity of CTSI and MCTSI. 
Analysis of variance or Kruskal-Wallis tests were used to assess relationships between numeric 
outcome variables and morphologic severity of CTSI and MCTSI. The area under curve (AUC) 
with standard error and 95% CI was calculated for each scoring system. The receiver-operating 
characteristic (ROC) curve was examined for an optimal cutoff value for both CT scoring 
systems that most closely correlated with clinical severity of disease. To rule out potential bias 
introduced by incorporating transferred patients, discriminative analysis was also performed 
in the nontransferred group. A reduced p value of < 0.01 was considered statistically significant 
because of multiple testing. All statistical analyses were performed using SAS version 9.1 (SAS 
Institute), SPSS version 15.0 (SPSS), and MedCalc version 10.4.3.0 (MedCalc).
RESULTS
Morphologic Severity of Pancreatitis
For the CTSI, the observers graded the morphologic severity of pancreatitis as mild in 136 
(69%), moderate in 41 (21%), and severe in 19 (10%) cases. Interobserver agreement between 
the two observers was 0.85 (95% CI, 0.80–0.90), indicating excellent agreement. For the 
MCTSI, the morphologic severity of pancreatitis was graded as mild in 86 (44%), moderate in 
75 (38%), and severe in 35 (18%) cases, with interobserver agreement of 0.90 (95% CI, 0.85–
0.95), also indicating excellent agreement.
Patient Outcome
Among the 196 cases, 162 (83%) cases involved clinically mild AP and 34 (17%) were diagnosed 
clinically as severe AP (Table 2). On imaging, 35 patients had acute necrotizing pancreatitis, of 
whom 24 (69%) developed clinically severe AP. Nineteen patients (10%) needed intervention for 
local complications: 12 underwent surgical débridement (5 after prior percutaneous drainage) 
and 7 underwent percutaneous drainage only. Organ failure occurred in 38 (19%) patients, of 
whom 20 (53%) experienced persistent organ failure. Infection of pancreatic or extrapancreatic 
necrosis occurred in seven (4%) cases. Eleven (6%) patients died.
Extrapancreatic Findings
Table 3 outlines the descriptive statistics for the extrapancreatic findings that were observed on 
imaging studies. In 110 (56%) cases, 2 points were credited for extrapancreatic complications 
using the MCTSI. Of these, 85 (77%) cases had either a pleural effusion or ascites without 
vascular, gastrointestinal, or extrapancreatic parenchymal complications. Pleural effusion 
or ascites with the presence of vascular, gastrointestinal, or extrapancreatic parenchymal 
complications were found in 23 (21%) cases. Therefore, only two (2%) cases had vascular, 
gastrointestinal, or extrapancreatic parenchymal complications without the presence of pleural 
effusion or ascites.
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TABLE 2: Severity Outcomes for Full Case Cohort (n = 196)
Outcome Frequency (%) Median (Q1, Q3)
Length of hospital stay (d) 6, range 0–113 3, 12
ICU stay 42 (21)
Length of ICU stay (d) 8.5, range 0–113 3, 12
Need for intervention 19 (10)
Percutaneous catheter drainage 12a
Surgical necrosectomy (débridement) 12
Organ failure
Transient 18 (9.2)
Persistent 20 (10.2)
None 158 (80.6)
Pancreatic infection 7 (4)
Clinically severe acute pancreatitis 34 (17)
Death 11 (6)
a Seven cases were treated with percutaneous drainage only, and five cases needed subsequent surgical necrosectomy.
TABLE 3: Descriptive Statistics for Extrapancreatic Findings in Modified CT Severity Index
Extrapancreatic Findings Present (%)
Ascites 80 (41)
Pleural effusion 69 (35)
Gastrointestinal tract involvement 10 (5)
Vascular complications 16 (8)
Parenchymal complications 3 (2)
Correlation of CT Scoring Indexes With Severity Parameters
Table 4 outlines the relationship between severity parameters and both CTSIs. Table 5 shows 
the comparisons of ROC curves for all severity parameters. For both CT indexes, a significant 
relationship was observed between the score obtained and the severity parameters studied (p 
< 0.0001). The MCTSI had the higher AUC for the severity parameters of death and ICU stay, 
whereas the CTSI had higher AUCs for persistent organ failure, need for intervention, and 
pancreatic infection. However, for all severity parameters studied, no statistically significant 
difference was observed between the CTSI and MCTSI. The optimal cutoff score for assessing 
clinically severe disease from the ROC curves was > 4 for CTSI and > 6 for MCTSI. By using 
these cutoff scores, both MCTSI and CTSI showed similar diagnostic accuracy with regard to 
clinical severity of disease (sensitivity, 71% [95% CI, 53–85%]; specificity, 93% [95% CI, 88–
97%]; negative predictive value, 94% [95% CI, 89–97%]; and positive predictive value, 69% 
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[95% CI, 51–83%]). In addition, post hoc analysis showed that when points for extrapancreatic 
complications were restricted to only the presence of a pleural effusion or ascites, the 
discriminative power of the simplified MCTSI was similar to the MCTSI incorporating all 
extrapancreatic complications (data not shown).
TABLE 5: Area Under Curve for CT Severity Index (CTSI), Modified CT Severity Index (MCTSI), 
and Acute Physiology, Age, and Chronic Health Evaluation II (APACHE II) for Severity Parameters
Severity Parameter CTSI MCTSI APACHE II
ICU stay 0.81 (0.75–0.87) 0.84 (0.79–0.89) 0.84 (0.78–0.88)
Need for intervention 0.94 (0.90–0.97) 0.92 (0.88–0.96) 0.74 (0.67–0.80)
Persistent organ failure 0.85 (0.79–0.90) 0.85 (0.79–0.90) 0.90 (0.85–0.94)
Pancreatic infection 0.92 (0.87–0.95) 0.91 (0.86–0.95) 0.67 (0.59–0.73)
Clinically severe acute pancreatitis 0.87 (0.82–0.92) 0.87 (0.82–0.92) 0.82 (0.76–0.87)
Death 0.78 (0.72–0.84) 0.79 (0.73–0.84) 0.89 (0.84–0.93)
Note—Data are presented with 95% CI in parentheses.
Correlation of All Scoring Indexes With Severity Parameters
When comparing the CT scoring indexes and APACHE II, no statistically significant differences 
were found for mortality, ICU stay, persistent organ failure, and clinical severity of AP. Both 
CT scoring indexes more accurately correlated with pancreatic infection compared with 
APACHE II, albeit without reaching statistical significance (for CTSI: p = 0.04, for MCTSI: p 
= 0.06) (Fig. 2).
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showed excellent interobserver agreement. 
Furthermore, compared with APACHE II, 
both CT scoring systems more accurately cor-
related with pancreatic infection and the need 
for intervention and showed higher accuracy 
for diagnosing clinically severe disease.
In the initial study by Mortele et al. [4], a 
better correlation was observed between the 
MCTSI and the development of organ fail-
ure and length of hospital stay in comparison 
with the CTSI. Our present study did not re-
produce these prior results. The differences 
observed may be due to differences in cri-
teria for organ failure and clinically severe 
AP (the current study used criteria in accor-
dance with the most updated revised Atlanta 
classification). Also, the current study evalu-
ated a larger number of patients, including a 
larger proportion of patients with clinically 
severe AP, and used discrimination analysis, 
which is regarded as more accurate for com-
paring and assessing the diagnostic accuracy 
of prognostic scoring systems [10].
Both CT scoring systems yielded excellent 
interobserver agreement among two experi-
enced readers. The MCTSI could potential-
ly be further improved by using a simplified 
MCTSI in which extrapancreatic complica-
tions can be restricted to only the presence of 
pleural effusion or scites ith similar prog-
nostic value in our post hoc analysis. This is 
supported by the fact that only two cases re-
ceived points for extrapancreatic complica-
tions in the absence of pleural effusion or as-
cites. However, further prospective studies are 
needed to validate this observation. In light of 
the results of this study, there is no obvious 
reason to use one CT scoring system over the 
other. However, the MCTSI (especially by us-
ing the simplified MCTSI) may have better 
interobserver agreement among less-experi-
enced readers. Future studies should be per-
formed to elucidate this hypothesis.
In 1990, Balthazar et al. [3] introduced the 
CT severity index for assessment of AP, which 
correlated well with morbidity, mortality, and 
length of hospital stay. Although several stud-
ies reported a strong correlation between the 
CTSI and the clinical severity of AP [11–15], 
other studies have not corroborated these find-
ings [16–19]. A few studies have noted a signif-
icant relationship between CTSI and mortality 
[11, 14, 20], whereas De Waele and colleagues 
[16] did not observe a similar relationship. 
Leung et al. [11] and Chatzicostas et al. [13] 
noted a strong association between CTSI and 
development of systemic complications, in-
cluding organ failure; however, other inves-
tigators did not reach the same conclusions 
[19, 21, 22]. The strong relationship between 
the development of local complications and the 
CTSI score has been c nfirmed in many stud-
ies [11–14, 19–21], except for one study [22]. 
The current study again corroborates this as-
sociation. In fact, compared with APACHE 
II, the two CT scoring systems correlated bet-
ter with pancreatic infection and the need for 
intervention. Previous studies compared the 
TABLE 5: Area Under Curve for CT Severity Index (CTSI), Modified CT 
Severity Index (MCTSI), and Acute Physiology, Age, and Chronic 
Health Evaluation II (APACHE II) for Severity Parameters
Severity Parameter CTSI MCTSI APACHE II
ICU stay 0.81 (0.75–0.87) 0.84 (0.79–0.89) 0.84 (0.78–0.88)
Need for intervention 0.94 (0.90–0.97) 0.92 (0.88–0.96) 0.74 (0.67–0.80)
Persistent organ failure 0.85 (0.79–0.90) 0.85 (0.79–0.90) 0.90 (0.85–0.94)
Pancreatic infection 0.92 (0.87–0.95) 0.91 (0.86–0.95) 0.67 (0.59–0.73)
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Fig. 2—Graph shows receiver operating characteristic curve for pancreatic infec-
tion. Solid line indicates CT severity index (CTSI), dotted line indicates modified 
CTSI, and dashed line indicates Acute Physiology, Age, and Chronic Health Evalu-
ation II (APACHE II) index.
Fig. 3—Graph shows receiver operating characteristic curve for need for inter-
vention. Solid line indicates CT severity index (CTSI), dotted line indicates modi-
fied CTSI, and dashed line indicates Acute Physiology, Age, and Chronic Health 
Evaluation II (APACHE II) index.
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FIG. 2. Graph shows receiver operating characteristic curve for pancreatic infection. Solid line indicates 
CT severity index (CTSI), dotted line indicates modified CTSI, a d dashed line indicates Acute 
Physiology, Age, and Chronic Health Evaluation II (APACHE II) index.
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Compared with APACHE II, the CTSI significantly better correlated with the need for 
intervention (p = 0.006), whereas the MCTSI did not reach statistical significance (p = 0.01) 
(Fig. 3). No major changes in results were observed when excluding the transferred patients, 
except that statistical significance was reached for both CT scoring systems compared with 
APACHE II for the need for intervention (data not shown).
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showed excellent interobserver agreement. 
Furthermore, compared with APACHE II, 
both CT scoring systems more accurately cor-
related with pancreatic infection and the need 
for intervention and showed higher accuracy 
for diagnosing clinically severe disease.
In the initial study by Mortele et al. [4], a 
better correlation was observed between the 
MCTSI and the development of organ fail-
ure and length of hospital stay in comparison 
with the CTSI. Our present study did not re-
produce these prior results. The differences 
observed may be due to differences in cri-
teria for organ failure and clinically severe 
AP (the current study used criteria in accor-
dance with the most updated revised Atlanta 
classification). Also, the current study evalu-
ated a larger number of patients, including a 
larger proportion of patients with clinically 
severe AP, and used discrimination analysis, 
which is regarded as more accurate for com-
paring and assessing the diagnostic accuracy 
of prognostic scoring systems [10].
Both CT scoring systems yielded excellent 
interobserver agreement among two experi-
enced readers. The MCTSI could potential-
ly be further improved by using a simplified 
MCTSI in which extrapancreatic complica-
tions can be restricted to only the presence of 
pleural effusion or ascites with similar prog-
nostic value in our post hoc analysis. This is 
supported by the fact that only two cases re-
ceived points for extrapancreatic complica-
tions in the absence of pleural effusion or as-
cites. However, further prospective studies are 
needed to validate this observation. In light of 
the results of this study, there is no obvious 
reason to use one CT scoring system over the 
other. However, the MCTSI (especially by us-
ing the simplified MCTSI) may have better 
interobserver agreement among less-experi-
enced readers. Future studies should be per-
formed to elucidate this hypothesis.
In 1990, Balthazar et al. [3] introduced the 
CT severity index for assessment of AP, which 
correlated well with morbidity, mortality, and 
length of hospital stay. Although several stud-
ies reported a strong correlation between the 
CTSI and the clinical severity of AP [11–15], 
other studies have not corroborated these find-
ings [16–19]. A few studies have noted a signif-
icant relationship between CTSI and mortality 
[11, 14, 20], whereas De Waele and colleagues 
[16] did not observe a similar relationship. 
Leung et al. [11] and Chatzicostas et al. [13] 
noted a strong association between CTSI and 
development of systemic complications, in-
cluding organ failure; however, other inves-
tigators did not reach the same conclusions 
[19, 21, 22]. The strong relationship between 
the development of local complications and the 
CTSI score has been confirmed in many stud-
ies [11–14, 19–21], except for one study [22]. 
The current study again corroborates this as-
sociation. In fact, compared with APACHE 
II, the two CT scoring systems correlated bet-
ter with pancreatic infection and the need for 
intervention. Previous studies compared the 
TABLE 5: Area Under Curve for CT Severity Index (CTSI), Modified CT 
Severity Index (MCTSI), and Acute Physiology, Age, and Chronic 
Health Evaluation II (APACHE II) for Severity Parameters
Severity Parameter CTSI MCTSI APACHE II
ICU stay 0.81 (0.75–0.87) 0.84 (0.79–0.89) 0.84 (0.78–0.88)
Need for intervention 0.94 (0.90–0.97) 0.92 (0.88–0.96) 0.74 (0.67–0.80)
Persistent organ failure 0.85 (0.79–0.90) 0.85 (0.79–0.90) 0.90 (0.85–0.94)
Pancreatic infection 0.92 (0.87–0.95) 0.91 (0.86–0.95) 0.67 (0.59–0.73)
Clinically severe acute pancreatitis 0.87 (0.82–0.92) 0.87 (0.82–0.92) 0.82 (0.76–0.87)
Death 0.78 (0.72–0.84) 0.79 (0.73–0.84) 0.89 (0.84–0.93)
Note—Data are presented with 95% CI in parentheses.
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ation II (APACHE II) index.
Fig. 3—Graph shows receiver operating characteristic curve for need for inter-
vention. Solid line indicates CT severity index (CTSI), dotted line indicates modi-
fied CTSI, and dashed line indicates Acute Physiology, Age, and Chronic Health 
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FIG. 3. Graph shows receiver operating characteristic curve for need for intervention. Solid line 
indicates CT sev rity index (CTSI), dotted line indicates modified CTSI, and dashed line indicates 
Acute Physiology, Age, and Chronic Health Evaluation II (APACHE II) index.
DISCUSSION
In this study on the comparative evaluation of MCTSI versus CTSI, we did not detect any 
statistically significant differences between the two CT scoring systems with regard to all the 
studied severity parameters. Both the MCTSI and CTSI were significantly associated with all 
severity parameters evaluated and showed excellent interobserver agreement. Furthermore, 
compared with APACHE II, both CT scoring systems more accurately correlated with 
pancreatic infection and the need for intervention and showed higher accuracy for diagnosing 
clinically severe disease.
In the initial study by Mortele et al. [4], a better correlation was observed between the MCTSI 
and the development of organ failure and length of hospital stay in comparison with the CTSI. 
Our present study did not reproduce these prior results. The differences observed may be due to 
differences in criteria for organ failure and clinically severe AP (the current study used criteria 
in accordance with the most updated revised Atlanta Classification). Also, the current study 
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evaluated a larger number of patients, including larger proportion of patients with clinically 
severe AP, and used discrimination analysis, which is regarded as more accurate for comparing 
and assessing the diagnostic accuracy of prognostic scoring systems [10].
Both CT scoring systems yielded excellent interobserver agreement among two experienced 
readers. The MCTSI could potentially be further improved by using a simplified MCTSI in 
which extrapancreatic complications can be restricted to only the presence of pleural effusion 
or ascites with similar prognostic value in our post hoc analysis. This is supported by the fact 
that only two cases received points for extrapancreatic complications in the absence of pleural 
effusion or ascites. However, further prospective studies are needed to validate this observation. 
In light of the results of this study, there is no obvious reason to use one CT scoring system over 
the other. However, the MCTSI (especially by using the simplified MCTSI) may have better 
interobserver agreement among less-experienced readers. Future studies should be performed 
to elucidate this hypothesis.
In 1990, Balthazar et al. [3] introduced the CT severity index for assessment of AP, which 
correlated well with morbidity, mortality, and length of hospital stay. Although several studies 
reported a strong correlation between the CTSI and the clinical severity of AP [11–15], other 
studies have not corroborated these findings [16–19]. A few studies have noted a significant 
relationship between CTSI and mortality [11, 14, 20], whereas De Waele and colleagues [16] 
did not observe a similar relationship. Leung et al. [11] and Chatzicostas et al. [13] noted a 
strong association between CTSI and development of systemic complications, including organ 
failure; however, other investigators did not reach the same conclusions [19, 21, 22]. The 
strong relationship between the development of local complications and the CTSI score has 
been confirmed in many studies [11–14, 19–21], except for one study [22]. The current study 
again corroborates this association. In fact, compared with APACHE II, the two CT scoring 
systems correlated better with pancreatic infection and the need for intervention. Previous 
studies compared the CTSI and APACHE II in assessing the clinical severity of AP [11–13, 19, 
21]. In line with the results of the current study, prior studies also reported a better performance 
of the APACHE II for assessing systemic complications and organ failure [13, 19, 21]. This is 
to be expected because the APACHE II scoring system gauges the physiologic response of the 
patient to the inflammatory cascade in AP, which drives systemic complications, whereas CT 
assesses the morphologic changes that can result in local complications. However, the APACHE 
II score contains many variables, limiting its use in clinical practice. The observed discrepancies 
between prior studies may relate to the absence of an accurate distinction between predicted 
severe disease (i.e., predictive scoring systems) and actual clinical severity of pancreatitis (i.e., 
clinical endpoints, such as mortality or persistent organ failure) as well as variation in the 
definitions of severe AP, systemic complications, and organ failure. Furthermore, differences in 
treatment regimes and health care practices among institutions could account for the difference 
in length of hospitalization and ICU stay. Uniformity in definitions in a complex disease, such 
as AP, is essential for comparing interinstitutional data [1, 23]. Therefore, the current study 
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used definitions from the recently revised Atlanta Classification [8]. By using these updated 
definitions, the current study confirmed the earlier observations by Balthazar et al. [3] and 
Mortele et al. [4] and showed a significant association between the CT scoring systems and 
clinical severity of disease and all severity parameters.
Similar to the original studies from Balthazar et al. [3] and Mortele et al. [4], who designed 
the scoring systems studied, we used a 7-day interval for correlating imaging scores to clinical 
severity parameters. This study was not designed to predict clinical outcome parameters because 
some outcome parameters are often present at the time of examination (i.e., organ failure, which 
is the most important determinant of outcome in AP and is often present in the first few days 
of hospitalization in patients with clinically severe AP). We included contrast-enhanced MRI 
in our study because recent studies have shown that MRI has comparable diagnostic accuracy 
in assessing morphologic severity of AP [24, 25]. Patients who underwent unenhanced MRI, 
however, were not included because pancreatic parenchymal necrosis, which is part of both 
the CTSI and MCTSI, cannot reliably be assessed without the administration of gadolinium.
This study has one important limitation that is shared by many radiologic studies of AP. 
Although the data of all patients were prospectively gathered, not all patients who were 
diagnosed with AP underwent contrast-enhanced CT or MRI within 1 week of the onset of 
symptoms. Apparently, a proportion of patients with AP have either mild symptoms, obviating 
imaging, or are unable to undergo imaging studies because of their condition. For this reason, 
our study may appear biased toward more severe AP. However, all studies will contend with 
this topic because patients with very mild symptoms do not require cross-sectional imaging for 
diagnosis or management of their condition.
In conclusion, our study did not detect any significant differences between the CTSI and 
MCTSI in evaluating the severity of AP. Furthermore, this study showed that clinical scoring 
systems do not obviate cross-sectional imaging in the evaluation of AP. Clinical scoring systems 
accurately correlate with systemic complications and mortality, but radiologic scoring systems 
more accurately diagnose clinically severe disease and better correlate with pancreatic infection 
and the need for intervention.
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A comparative evaluation of radiologic 
and clinical scoring systems in the early 
prediction of severity in acute pancreatitis
Bollen TL, Singh VK, Maurer R, Repas K, van Es HW, Banks PA, Mortele KJ
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ABSTRACT
Objectives: The early identification of clinically severe acute pancreatitis (AP) is critical for 
the triage and treatment of patients. The aim of this study was to compare the accuracy of 
computed tomography (CT) and clinical scoring systems for predicting the severity of AP on 
admission.
Methods: Demographic, clinical, and laboratory data of all consecutive patients with a primary 
diagnosis of AP during a two-and-half-year period was prospectively collected for this study. 
A retrospective analysis of the abdominal CT data was performed. Seven CT scoring systems 
(CT severity index (CTSI), modified CT severity index (MCTSI), pancreatic size index (PSI), 
extrapancreatic score (EP), 'extrapancreatic inflammation on CT' score (EPIC), 'mesenteric 
oedema and peritoneal fluid' score (MOP), and Balthazar grade) as well as two clinical scoring 
systems: Acute Physiology, Age, and Chronic Health Evaluation (APACHE)-II and Bedside 
Index for Severity in AP (BISAP) were comparatively evaluated with regard to their ability to 
predict the severity of AP on admission (first 24h of hospitalization).
Clinically severe AP was defined as one or more of the following: mortality, persistent organ 
failure and/or the presence of local pancreatic complications that require intervention. All CT 
scans were reviewed in consensus by two radiologists, each blinded to patient outcome. The 
accuracy of each imaging and clinical scoring system for predicting the severity of AP was 
assessed using receiver operating curve analysis.
Results: Of 346 consecutive episodes of AP, there were 159 (46%) episodes in 150 patients 
(84 men, 66 women; mean age, 54 years; age range, 21–91 years) who were evaluated with a 
contrast-enhanced CT scan (n = 131 episodes) or an unenhanced CT scan (n = 28 episodes) on 
the first day of admission. Clinically severe AP was diagnosed in 29/159 (18%) episodes; 9 (6%) 
patients died. Overall, the Balthazar grading system (any CT technique) and CTSI (contrast-
enhanced CT only) demonstrated the highest accuracy among the CT scoring systems for 
predicting severity, but this was not statistically significant. There were no statistically 
significant differences between the predictive accuracies of CT and clinical scoring systems.
Conclusions: The predictive accuracy of CT scoring systems for severity of AP is similar to 
clinical scoring systems. Hence, a CT on admission solely for severity assessment in AP is not 
recommended.
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INTRODUCTION
Acute pancreatitis (AP) is a complex disease characterized by a variable clinical course. AP can 
vary from a mild self-limited disease with only minimal or transient systemic manifestations in 
approximately 80–90% of patients, to a clinically severe form in 10–20% with local and systemic 
complications (1). The identification of patients with clinically severe AP is important for 
several reasons: first, these patients may benefit from transfer to an intermediate or intensive 
care unit, where they can receive aggressive fluid resuscitation and be closely monitored for 
the development of organ failure. Second, these patients may benefit from targeted therapy, 
i.e., enteral feeding, endoscopic sphincterotomy, or antibiotics (1,2). Finally, severity 
stratification is important when reporting and evaluating the results of clinical trials in AP. 
The characterization of high-risk groups of patients is critical for the appropriate comparison 
of management strategies between institutions (1,3).
There are several clinical and laboratory prognostic systems currently used to assess and 
predict the severity of AP with variable accuracy (3,4). Besides assessment of relevant clinical 
and biochemical parameters in AP, in many centers, it is standard practice to obtain a computed 
tomography (CT) scan on admission (i.e., within 24h of hospitalization), not only for diagnostic 
purposes but also for assessing the severity of disease. The severity of AP by CT imaging can 
be evaluated using unenhanced or contrast-enhanced CT studies. Unenhanced CT scoring 
systems evaluate the extent of pancreatic and peripancreatic inflammatory changes (Balthazar 
grade (5) and 'pancreatic size index' or PSI (6)) or evaluate both peripancreatic inflammatory 
changes and extrapancreatic complications ('mesenteric oedema and peritoneal fluid' or MOP 
score (7), 'extrapancreatic' or EP score (8), and the more recently developed 'extrapancreatic 
inflammation on CT' or EPIC score (9)). In addition, there are two CT scoring systems 
that require the use of intravenous contrast agents to determine the presence and extent of 
pancreatic parenchymal necrosis. The 'CT severity index' or CTSI is a numerical scoring system 
combining the quantification of extrapancreatic inflammation with the extent of pancreatic 
necrosis (10). Mortele et al. (11) proposed a 'modified CTSI' or MCTSI, which, in addition 
to the CTSI, assigns points for extrapancreatic complications (vascular, gastrointestinal and 
extrapancreatic parenchymal complications as well as the presence of pleural effusion and/ or 
ascites).
Although many studies have demonstrated a correlation between morphologic severity 
according to CT scoring systems and clinical disease severity, only five utilized data from 
“early” CT scans, defined as those obtained within 24h of admission to the hospital (8,9,12–
14). In addition to methodological shortcomings, limitations of these prior studies are that no 
comparison of the accuracy of the existing CT scoring systems was performed and no com- 
parative assessment was done between the CT scoring systems and clinical scoring systems 
such as the Acute Physiology, Age, and Chronic Health Evaluation (APACHE)-II (15) and the 
recently developed and validated Bedside Index for Severity in AP (BISAP) (16–18).
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The aim of this study is to compare the accuracy of seven different existing CT scoring systems 
in predicting the severity of AP on the first day of admission. The secondary aim is to assess 
whether these CT scoring systems are superior to two commonly employed clinical scoring 
systems.
METHODS
The demographic, clinical, and laboratory data of all consecutive patients with a primary 
diagnosis of AP admitted or transferred to our institution during a 2.5-year period was 
prospectively collected for this study. A retrospective analysis of this prospectively collected 
clinical database was performed. Institutional review board approval was obtained for this 
study, and written informed consent for collecting data during hospitalization was obtained 
from all patients. AP was defined as two or more of the following: characteristic abdominal 
pain; serum amylase and/or lipase levels three or more times the upper limit of normal (i.e., 
>210 and 180 U/l, respectively); and/or an imaging study (CT or magnetic resonance imaging) 
demonstrating changes consistent with AP (19). The day of admission was defined as the first 
24h of hospitalization in our institution or in the referring hospital.
For all episodes, appropriate clinical data were recorded prospectively by two authors (V.K.S. 
and K.R.), who were unaware of the CT scores, to permit calculation of the APACHE-II, BISAP, 
and Charlson Comorbidity Index scores. The decision to obtain a CT scan was based on the 
clinical discretion of the evaluating physician (Figure 1). All CT scans from outside hospitals 
were retrieved and reviewed soft copy using DICOM viewer software (DicomWorks, version 
1.3.5, Lyon, France). The remainder of CT scans, performed at our institution, was reviewed 
on PACS workstations (Centricity GE, Milwaukee, WI). Two radiologists retrospectively 
reviewed all CT studies and were unaware of patient outcomes. Table 1 details the CT 
parameters that were evaluated for the study cohort.
The following parameters were collected for each episode of AP: in-hospital mortality, length 
of hospital stay, admission to and length of intensive care unit stay, presence and duration 
of organ failure (transient; < 48h and persistent; > 48h), pancreatic infection (infection 
of pancreatic and/or peripancreatic necrosis), and need for intervention (endoscopic, 
percutaneous drainage, and/or surgical necrosectomy). Clinically severe AP was defined 
as one or more of the following: mortality, persistent organ failure and/or the presence of 
local pancreatic complications that require intervention (endoscopic or radiologic drainage 
or surgical necrosectomy). This definition is in accordance with the most updated revised 
Atlanta Classification (20). The principle distinction between the new and former definition 
of clinical severity is that the mere presence of pancreatic parenchymal necrosis, peripancreatic 
collections, or organ failure is not regarded as clinically severe disease, unless organ failure 
exceeds 48h in duration or complications of pancreatic necrosis or peripancreatic collections 
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occur, which require active intervention. Organ failure was defined as a score of ≥2 in one 
or more of the three (respiratory, renal, and cardiovascular) organ systems of the modified 
Marshall score (20,21).
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of patients with clinically severe AP is important for several rea-
sons: fi rst, these patients may benefi t from transfer to an inter-
mediate or intensive care unit, where they can receive aggressive 
fl uid resuscitation and be closely monitored for the development 
of organ failure. Second, these patients may benefi t from targeted 
therapy, i.e., enteral feeding, endoscopic sphincterotomy, or anti-
biotics ( 1,2 ). Finally, severity stratifi cation is important when 
reporting and evaluating the results of clinical trials in AP. Th e 
characterization of high-risk groups of patients is critical for the 
appropriate comparison of management strategies between insti-
tutions ( 1,3 ). 
 There are several clinical and laboratory prognostic systems 
currently used to assess and predict the severity of AP with 
variable accuracy ( 3,4 ). Besides assessment of relevant clini-
cal and biochemical parameters in AP, in many centers, it is 
standard practice to obtain a computed tomography (CT) scan 
on admission (i.e., within 24  h of hospitalization), not only for 
diagnostic purposes but also for assessing the severity of dis-
ease. The severity of AP by CT imaging can be evaluated using 
unenhanced or contrast-enhanced CT studies. Unenhanced 
CT scoring systems evaluate the extent of pancreatic and peri-
pancreatic inflammatory changes (Balthazar grade ( 5 ) and 
 ‘ ‘ pancreatic size index ’ ’ or PSI ( 6 )) or evaluate both peripan-
creatic inflammatory changes and extrapancreatic complica-
tions ( ‘ ‘ mesenteric oedema and peritoneal fluid ’ ’ or MOP score 
( 7 ),  ‘ ‘ extrapancreatic ’ ’ or EP score ( 8 ), and the more recently 
developed  ‘ ‘ extrapancreatic inflammation on CT ’ ’ or EPIC 
score ( 9 )). In addition, there are two CT scoring systems that 
require the use of intravenous contrast agents to determine 
the presence and extent of pancreatic parenchymal necrosis. 
The  ‘ ‘ CT severity index ’ ’ or CTSI is a numerical scoring system 
combining the quantification of extrapancreatic inflammation 
with the extent of pancreatic necrosis ( 10 ). Mortele  et al. ( 11 ) 
proposed a  ‘ ‘ modified CTSI ’ ’ or MCTSI, which, in addition 
to the CTSI, assigns points for extrapancreatic complications 
(vascular, gastrointestinal and extrapancreatic parenchymal 
complications as well as the presence of pleural effusion and /
 or ascites). 
 Although many studies have demonstrated a correlation between 
morphologic severity according to CT scoring systems and clini-
cal disease severity, only fi ve utilized data from  “ early ” CT scans, 
defi ned as those obtained within 24  h of admission to the hospital 
( 8,9,12 – 14 ). In addition to methodological shortcomings, limita-
tions of these prior studies are that no comparison of the accuracy 
of the existing CT scoring systems was performed and no com-
parative assessment was done between the CT scoring systems and 
clinical scoring systems such as the Acute Physiology, Age, and 
Chronic Health Evaluation (APACHE)-II ( 15 ) and the recently 
developed and validated Bedside Index for Severity in AP (BISAP) 
( 16 – 18 ). 
 Th e aim of this study is to compare the accuracy of seven dif-
ferent existing CT scoring systems in predicting the severity of 
AP on the fi rst day of admission. Th e secondary aim is to assess 
whether these CT scoring systems are superior to two commonly 
employed clinical scoring systems. 
 METHODS 
 Th e demographic, clinical, and laboratory data of all consecutive 
patients with a primary diagnosis of AP admitted or transferred 
to our institution during a 2.5-year period was prospectively 
collected for this study. A retrospective analysis of this prospec-
tively collected clinical database was performed. Institutional 
review board approval was obtained for this study, and written 
informed consent for collecting data during hospitalization was 
obtained from all patients. AP was defi ned as two or more of the 
following: characteristic abdominal pain; serum amylase and / or 
lipase levels three or more times the upper limit of normal (i.e., 
>210 and 180  U / l, respectively); and / or an imaging study (CT or
magnetic resonance imaging) demonstrating changes consist-
ent with AP ( 19 ). Th e day of admission was defi ned as the fi rst
24  h of hospitalization in our institution or in the referring
hospital.
 For all episodes, appropriate clinical data were recorded pro-
spectively by two authors (V.K.S. and K.R.), who were unaware of 
the CT scores, to permit calculation of the APACHE-II, BISAP, 
and Charlson Comorbidity Index scores. Th e decision to obtain 
a CT scan was based on the clinical discretion of the evaluating 
physician ( Figure 1 ). All CT scans from outside hospitals were 
retrieved and reviewed soft  copy using DICOM viewer soft ware 
(DicomWorks, version 1.3.5, Lyon, France ). Th e remainder of 
CT scans, performed at our institution, was reviewed on PACS 
workstations (Centricity GE, Milwaukee, WI ). Two radiologists 
retrospectively reviewed all CT studies and were unaware of 
patient outcomes.  Table 1 details the CT parameters that were 
evaluated for the study cohort. 
 Th e following parameters were collected for each episode of 
AP: in-hospital mortality, length of hospital stay, admission to 
and length of intensive care unit stay, presence and duration of 
organ failure (transient;  ≤ 48  h and persistent; >48  h), pancreatic 
infection (infection of pancreatic and / or peripancreatic necrosis), 
and need for intervention (endoscopic, percutaneous drainage, 
and / or surgical necrosectomy). Clinically severe AP was defi ned 
as one or more of the following: mortality, persistent organ fail-
ure and / or the presence of local pancreatic complications that 
require intervention (endoscopic or radiologic drainage or 
Episodes admitted with
pancreatitis (n = 397) 
Final study sample (n = 159)
Excluded episodes (n = 238)
• No CT study performed (n = 139)
• CT performed more than 24h 
after admission (n = 48)
• Acute on chronic pancreatitis
(n = 51)
 Figure 1 .  Flowchart outlines the selection of episodes with pancreatitis. 
Data in parentheses are numbers of episodes. 
FIGURE 1 . Flowchart outlines the selection of episodes with pancreatitis. Data in parentheses are 
numbers of episodes. 
TABLE 1. Computed tomography parameters evaluated 
Pancreatic features
Subjective pancreatic enlargement (no, yes)
Pancreatic size indexa
Pancr atic parenchymal necrosis (no, < 30%, 30–50%, > 50%, not applic ble)
Peripancreatic features
Peripancreatic fat stranding (no, partial, entire)
Peripancreatic fluid collection (no, one location, two or more locations)
Perirenal edema (no, yes)
Mesenteric inflammation (no, yes)
Extrapanc atic features
Pleural effusion (no, unilateral, bilateral)
Ascites (no, one location, two or more locations)b
Vascular complications (no, yes, not applicable)
(Venous thrombosis, hemorrhage, arterial pseudoaneurysm)
Extrapancreatic parenchymal complications (no, yes, not applicable)
(Infarctio , hemorrhage, subcapsular fluid collection)
Gastrointestinal complications (no, yes)
(Ileus, signs of ischemia, perforation, marked bowel wall thickening, intramural fluid collection)
a Pancreatic size index defined as multiplication of maximum anteroposterior measurement of the pancreatic head and body. A score of 
< 10 cm2 is regarded as predicted mild pancreatitis and ≥10 cm2 is regarded as predicted severe pancreatitis (6).
b Ascites in either one of these locations: perihepat c, perisplenic, interloop, or i  pelvis (9).
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Statistical analysis
Descriptive statistics were used for baseline characteristics, outcomes, and CT parameters. 
Sensitivity, specificity, positive predictive value, and negative predictive value were calculated 
for individual scoring systems. Also, for APACHE-II we analyzed these values using an 
accepted and standard cutoff value of 8 or more. The diagnostic accuracy of each scoring system 
for mortality and clinical severity were assessed using the area under the receiver operating 
characteristic curve (AUC) with standard error and 95% confidence intervals (CIs). Pairwise 
comparisons of AUCs were assessed using difference between areas, 95% CI and P values. The 
comparisons of the AUCs were performed using an approach described by Hanley and McNeil 
(22). To rule out potential bias introduced by the inclusion of transferred patients, receiver 
operating characteristic curve (ROC) analysis was also performed in the non-transferred 
group. All statistical analysis was performed using SAS v.9.1 (SAS, Cary, NC), SPSS v15.0 
(SPSS, Chicago, IL), and MedCalc v.10.4.3.0 (MedCalc, Mariakerke, Belgium).
RESULTS
Patient characteristics
During the study period there were 346 episodes of AP in 307 patients and 51 episodes of 
acute on chronic pancreatitis (the latter were excluded from analysis). Among 346 episodes 
of AP, there were 159 (46%) episodes in 150 patients in whom a CT (contrast-enhanced CT 
in 131 episodes, unenhanced CT in 28 episodes) was performed on admission; in 30 (19%) 
episodes, the CT scan was performed for confirmation of the diagnosis, while in 129 (81%) 
episodes for assessing severity of AP. The 159 episodes of AP in which an early CT scan was 
performed constitute our study cohort. The additional 187 episodes in which no (n = 139) or 
delayed (n = 48) CT imaging was performed, were excluded from the study. In 131 episodes, 
a contrast-enhanced CT was performed permitting the assessment of all seven CT scoring 
systems; Balthazar grade, CTSI, MCTSI, EP score, EPIC score, MOP score, and PSI. In 28 
episodes, only an unenhanced CT scan was performed, allowing the assessment of only five of 
the seven CT scoring systems.
The median age of patients was 54 years (range 21–91) with 84 men and 66 women. Etiologies 
of AP included gallstones in 48 (30%) episodes, miscellaneous (e.g., hypertriglyceridemia, 
hereditary, and post-endoscopic retrograde cholangiopancreatography) in 38 (24%) episodes, 
alcohol in 34 (21%) episodes, idiopathic in 27 (17%) episodes, and drug-induced in 12 (8%) 
episodes. One hundred and thirty episodes (82%) were labeled as mild AP and 29 episodes 
(18%) as clinically severe AP (Table 2). In 16 episodes, the lack of enhancement of pancreatic 
parenchyma was noted on contrast-enhanced CT on the day of admission, indicating acute 
necrotizing pancreatitis (four of whom were categorized as having clinically mild disease). On 
follow-up imaging, 13 more episodes were identified, in whom necrotizing pancreatitis was 
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detected (three of them had an unenhanced CT on admission). The lack of enhancement on 
follow-up imaging was not used for data analysis. In all episodes, early CT did not reveal an 
alternative diagnosis or local complication that changed clinical management. A total of 14 
(9%) episodes required intervention for local complications: 8 underwent surgical debridement 
(three with prior percutaneous catheter drainage), and percutaneous catheter drainage was 
performed as the only treatment in 6. Persistent organ failure occurred in 21 (13%) episodes. 
Infection of pancreatic and/or extrapancreatic necrosis occurred in five (3%) episodes. A total 
of 9 out of 150 patients (6%) died during hospitalization. One patient with predicted mild CT 
scores died due to the presence of significant co-morbid diseases (history of lymphoma and 
graft versus host disease).
TABLE 2. Severity outcomes for the study cohort (n = 159 episodes) 
Outcome N = 159
Death 9 (6)
Length of hospital stay 5 [3, 11] range 0 –74
ICU admission 37 (23)
Length of ICU stay (in days) 6 [2, 16] range 0 –32
Need for intervention 14 (9)
PCD 9
Surgical necrosectomy 8
Organ failure
Transient 23 (14.5)
Persistent 21 (13.2)
No 115 (72.3)
Pancreatic infection 5 (3)
Clinically severe acute pancreatitis 29 (18)
Charlson Comorbidity Indexa 2 [0, 4] range 0 – 11
APACHE-II 8 [5, 13] range 0 – 33
APACHE-II, Acute Physiology, Age, and Chronic Health Evaluation-II; ICU, intensive care unit; PCD, percutaneous catheter drainage.
a Age adjusted.
Frequency (%), median [Q1, Q3].
Comparison of scoring indices in predicting clinical severity
On the basis of highest sensitivity and specificity values generated from the ROC curves, the 
following cutoffs were selected for predicting clinically severe disease: CTSI ≥4, MCTSI ≥6, 
Balthazar grade ≥5, EPIC score ≥3, EP score ≥3, MOP score ≥2, PSI ≥1, APACHE-II ≥10, and 
BISAP ≥3.
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Figure 2 and Table 3 show the comparisons of ROC curves for clinically severe AP among 
all scoring systems in all episodes who underwent a CT scan (n = 159) and in episodes who 
underwent only a contrast-enhanced CT scan (n = 131). Although the CTSI demonstrated 
the highest accuracy for predicting clinically severe AP among the 131 cases who underwent 
contrast-enhanced CT (AUC 0.88; 95% CI: 0.82–0.93), no statistically significant pairwise 
differences were observed between the CTSI and the other CT scoring systems, except for PSI 
(P = 0.014). Balthazar grade demonstrated the highest accuracy for clinically severe AP for all 
159 episodes (AUC 0.79; 95% CI: 0.72–0.85). However, no statistically significant differences 
were observed between the Balthazar grade and the other CT scoring systems. Also, no 
statistically significant differences were found between the CT and clinical scoring systems 
with highest AUC for clinical severity. No significant changes in results were observed when 
excluding the transferred patients (data not shown).
Comparison of scoring indices in predicting mortality
On the basis of highest sensitivity and specificity values generated from the ROC curves, the 
following cutoffs were selected for predicting mortality: CTSI ≥4, MCTSI ≥4, Balthazar grade 
≥5, EPIC score ≥3, EP score ≥3, MOP score ≥1, PSI ≥1, APACHE-II ≥17, and BISAP ≥3. Table 4 
shows the comparisons of ROC curves for mortality among all scoring systems in all episodes 
in which a CT scan was performed and in those episodes that only a contrast-enhanced CT was 
performed. Among the CT indices, Balthazar grade had the highest AUC for mortality in both 
groups (AUC 0.81; 95% CI: 0.74–0.88 and AUC 0.79; 95% CI: 0.72–0.85, respectively). In the 
study cohort, the APACHE-II score performed best among all studied indices in both groups 
of patients (AUC 0.91; 95% CI: 0.85–0.95 and AUC 0.91; 95% CI: 0.86–0.95, respectively). No 
statistically significant differences were observed between Balthazar grade and the other CT 
scoring systems and between Balthazar grade and the clinical scoring system with the highest 
accuracy for predicting mortality (APACHE-II). Again, no significant changes in results 
were observed when excluding the transferred patients (data not shown). The sensitivity, 
specificity, positive predictive value, and negative predictive value of different scoring systems 
in predicting clinical severity and mortality are shown in Table 5. When using a fixed cutoff 
value for APACHE-II for predicting clinically severe disease and mortality (i.e., the universally 
accepted value of 8 or more) there was an increase of the sensitivity and negative predictive 
value and concomitant decrease in specificity and positive predictive value compared with the 
optimal cutoffs derived from the ROC curves (Table 5). The AUC value of APACHE-II for 
both cutoff values was the same and, again, no significant changes were seen between CT 
scoring system and APACHE-II.
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predicted mild CT scores died due to the presence of signifi cant 
co-morbid diseases (history of lymphoma and graft  versus host 
disease). 
 Comparison of scoring indices in predicting clinical severity 
 On the basis of highest sensitivity and specifi city values generated 
from the ROC curves, the following cutoff s were selected for pre-
dicting clinically severe disease: CTSI  ≥ 4, MCTSI  ≥ 6, Balthazar 
grade  ≥ 5, EPIC score  ≥ 3, EP score  ≥ 3, MOP score  ≥ 2, PSI  ≥ 1, 
APACHE-II  ≥ 10, and BISAP  ≥ 3. 
 Figure 2 and  Table 3 show the comparisons of ROC curves for 
clinically severe AP among all scoring systems in all episodes who 
underwent a CT scan ( n  =  159) and in episodes who underwent 
only a contrast-enhanced CT scan ( n  =  131). Although the CTSI 
demonstrated the highest accuracy for predicting clinically severe 
AP among the 131 cases who underwent contrast-enhanced CT 
(AUC 0.88; 95 % CI: 0.82 – 0.93), no statistically signifi cant pairwise 
diff erences were observed between the CTSI and the other CT 
scoring systems, except for PSI ( P  =  0.014). Balthazar grade dem-
onstrated the highest accuracy for clinically severe AP for all 159 
episodes (AUC 0.79; 95 % CI: 0.72 – 0.85). However, no statistically 
signifi cant diff erences were observed between the Balthazar grade 
and the other CT scoring systems. Also, no statistically signifi cant 
diff erences were found between the CT and clinical scoring sys-
tems with highest AUC for clinical severity. No signifi cant changes 
in results were observed when excluding the transferred patients 
(data not shown). 
 Table 2 .  Severity outcomes for the study cohort ( n =159 episodes) 
 Outcome  N =159 
 Death  9 (6) 
 Length of hospital stay  5 [3, 11] range 0  – 74 
 ICU admission  37 (23) 
 Length of ICU stay (in days)  6 [2, 16] range 0  – 32 
 Need for intervention  14 (9) 
  PCD  9 
  Surgical necrosectomy  8 
 Organ failure  
  Transient  23 (14.5) 
  Persistent  21 (13.2) 
  No  115 (72.3) 
 Pancreatic infection  5 (3) 
 Clinically severe acute pancreatitis  29 (18) 
 Charlson Comorbidity Index a  2 [0, 4] range 0  – 11 
 APACHE-II  8 [5, 13] range 0  – 33 
 APACHE-II, Acute Physiology, Age, and Chronic Health Evaluation-II; 
ICU, intensive care unit; PCD, percutaneous catheter drainage. 
 a Age adjusted. 
 Frequency ( % ), median [Q1, Q3]. 
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 Figure 2 .  AUC comparison of computed tomography (CT) and clini-
cal scoring systems for predicting clinical severity. ( a ) Area under the 
receiver operating curve (AUC) comparison of all scoring systems in 
159 episodes with either contrast-enhanced CT (CECT) or unenhanced 
CT (UECT) in predicting severe acute pancreatitis (SAP). No signifi cant 
differences between the CT and clinical scoring systems are noted. 
( b ) AUC comparison of all scoring systems in 131 episodes with only 
CECT in predicting SAP. No signifi cant differences between the CT and 
clinical scoring systems are noted. APACHE-II, Acute Physiology, Age, 
and Chronic Health Evaluation-II; BISAP, Bedside Index for Severity in 
Acute Pancreatitis; CTSI, CT severity index; EP, extrapancreatic score; 
EPIC, extrapancreatic infl ammation on CT score; MCTSI, modifi ed 
CT severity index; MOP, mesenteric oedema and peritoneal fl uid score; 
PSI, pancreatic size index. 
FIGURE 2 . AUC comparison of computed tomography (CT) and clinical scoring systems for predicting 
clinical severity. ( A ) Area under the receiver operating curve (AUC) comparison of all scoring systems 
in 159 episodes with either contrast-enhanced CT (CECT) or unenhanced CT (UECT) in predicting 
severe acute pancreatitis (SAP). No significant differences between the CT and clinical scoring systems 
ar  not d. ( B ) AUC comparison of all scoring systems in 131 episodes with only CECT in predicting 
SAP. N  significant differe ces b tween the CT and clinical scoring systems are noted. APACHE-II, 
Acute Physiology, Age, and Chronic Health Evaluation-II; BISAP, Bedside Index for Severity in Acute 
Pancreatitis; CTSI, CT severity index; EP, extrapancreatic score; EPIC, extrapancreatic inflammation 
on CT score; MCTSI, modified CT severity index; MOP, mesenteric oedema and peritoneal fluid score; 
PSI, pancreatic size index.
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TABLE 3. AUC of different scoring systems in predicting clinical severity 
Scoring system CECT (n = 131) CECT and UECT (n = 159)
Clinically severe AP N = 23 AUC (95% CI) N = 29 AUC (95% CI)
MCTSI 0.85 (0.77 – 0.90)
CTSI 0.88 (0.82 – 0.93)
Balthazar 0.84 (0.76 – 0.90) 0.79 (0.72 – 0.85)
EPIC score 0.83 (0.75 – 0.89) 0.79 (0.71 – 0.84)
EP score 0.81 (0.74 – 0.88) 0.78 (0.71 – 0.85)
MOP score 0.79 (0.71 – 0.86) 0.75 (0.67 – 0.81)
PSI 0.72 (0.63 – 0.79) 0.68 (0.60 – 0.75)
APACHE-II 0.77 (0.69 – 0.84) 0.77 (0.70 – 0.83)
BISAP 0.68 (0.60 – 0.76) 0.71 (0.63 – 0.78)
AP, acute pancreatitis; APACHE–II, Acute Physiology, Age, and Chronic Health Evaluation-II; AUC, area under curve; BISAP, 
Bedside Index for Severity in Acute Pancreatitis; CECT, contrast-enhanced CT; CI, confidence interval; CTSI, CT severity index; EP, 
extrapancreatic score; EPIC, extrapancreatic inflammation on CT score; MCTSI, modified CT severity index; MOP, mesenteric oedema 
and peritoneal fluid score; PSI, pancreatic size index; UECT, unenhanced CT.
TABLE 4. AUC of different scoring systems in predicting mortality 
Scoring system CECT (n = 131) CECT and UECT (n = 159)
Mortality N = 7 AUC (95% CI) N = 9 AUC (95% CI)
MCTSI 0.72 (0.64 – 0.80)
CTSI 0.80 (0.72 – 0.86)
Balthazar 0.81 (0.74 – 0.88) 0.79 (0.72 – 0.85)
EPIC score 0.79 (0.71 – 0.86) 0.77 (0.70 – 0.83)
EP score 0.75 (0.66 – 0.82) 0.73 (0.65 – 0.80)
MOP score 0.72 (0.63 – 0.79) 0.68 (0.60 – 0.76)
PSI 0.70 (0.61 – 0.78) 0.74 (0.66 – 0.81)
APACHE-II 0.91 (0.85 – 0.95) 0.91 (0.86 – 0.95)
BISAP 0.88 (0.81 – 0.93) 0.88 (0.81 – 0.92)
APACHE –II, Acute Physiology, Age, and Chronic Health Evaluation-II; AUC, area under curve; BISAP, Bedside Index for Severity in 
Acute Pancreatitis; CECT, contrast-enhanced CT; CI, confidence interval; CTSI, CT severity index; EP, extrapancreatic score; EPIC, 
extrapancreatic inflammation on CT score; MCTSI, modified CT severity index; MOP, mesenteric oedema and peritoneal fluid score; 
PSI, pancreatic size index; UECT, unenhanced CT.
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TABLE 5. Sensitivity, specificity, PPV, NPV of different scoring systems in predicting clinical severity 
and mortality 
%
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Clinical severity
CTSI 87 (66 – 97) 83 (75 – 90) 53 (36 – 69) 97 (91 – 99)
MCTSI 78 (56 – 93) 81 (72 – 88) 46 (30 – 63) 95 (88 – 98)
Balthazar 66 (46 – 82) 85 (78 – 91) 50 (33 – 67) 92 (85 – 96)
EPIC score 86 (68 – 91) 62 (53 – 71) 34 (23 – 46) 95 (88 – 99)
EP score 86 (68 – 96) 58 (49 – 67) 32 (22 – 43) 95 (88 – 99)
MOP score 59 (39 – 76) 81 (73 – 87) 40 (26 – 57) 90 (83 – 95)
PSI 62 (42 – 79) 74 (65 – 81) 35 (22 – 49) 90 (82 – 95)
APACHE-II 72 (53 – 87) 65 (57 – 74) 32 (21 – 44) 91 (84 – 96)
APACHE-IIa 83 (64 – 94) 52 (43 – 60) 28 (19 – 38) 93 (85 – 98)
BISAP 48 (29 – 67) 82 (75 – 88) 38 (22 – 55) 88 (81 – 93)
Mortality
CTSI 86 (42 – 100) 74 (66 – 82) 16 (6 – 31) 99 (94 – 100)
MCTSI 86 (42 – 100) 50 (41 – 59) 9 (3 – 18) 98 (91 – 100)
Balthazar 78 (40 – 97) 79 (72 – 86) 18 (8 – 34) 98 (94 – 100)
EPIC score 89 (52 – 100) 56 (48 – 64) 11 (5 – 20) 99 (94 – 100)
EP score 89 (52 – 100) 53 (44 – 61) 10 (4 – 19) 99 (93 – 100)
MOP score 89 (52 – 100) 47 (38 – 55) 9 (4 – 17) 99 (92 – 100)
PSI 78 (40 – 97) 70 (62 – 77) 13 (6 – 26) 98 (93 – 100)
APACHE-II 78 (40 – 97) 94 (89 – 97) 44 (20 – 70) 99 (95 – 100)
APACHE-IIa 100 (66 – 100) 48 (40 – 56) 10 (5 – 19) 100 (95 – 100)
BISAP 89 (52 – 100) 81 (73 – 87) 22 (10 – 38) 99 (96 – 100)
APACHE –II, Acute Physiology, Age, and Chronic Health Evaluation-II; AUC, area under curve; BISAP, Bedside Index for Severity in 
Acute Pancreatitis; CECT, contrast- enhanced CT; CI, confidence interval; CTSI, CT severity index; EP, extrapancreatic score; EPIC, 
extrapancreatic inflammation on CT score; MCTSI, modified CT severity index; MOP, mesenteric oedema and peritoneal fluid score; 
NPV, negative predictive value; PPV, positive predictive value; PSI, pancreatic size index; UECT, unenhanced CT.
a Sensitivity, specificity, PPV, and NPV when using a universal accepted cutoff value of APACHE-II 8 or more.
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DISCUSSION
Since the 1970s, a continuous effort has been made to develop a simple, accurate, and widely 
available prognostic scoring system in AP to predict which patients are at highest risk of 
developing clinically severe AP and may require intensive therapy (3). Balthazar et al. (5) were 
among the first who devised a radiologic scoring system for AP in 1985. Since then, several 
other groups of investigators have also developed CT scoring systems. Although all these 
scoring systems have been shown to correlate with morbidity and mortality, it remains difficult 
to accurately identify individual patients who develop clinically severe disease on admission 
or early in the course of their hospitalization (3,4). Results from this study corroborate this 
observation. This study did not detect any significant differences between the studied CT 
scoring systems. There was no advantage of performing a CT on admission as an independent 
predictor over the more easily obtainable clinical scoring systems in terms of accuracy in 
predicting clinically severe AP and mortality.
There are several potential explanations for the observed moderate accuracy for clinical 
severity and mortality using CT scoring systems. First, the anatomic extent of pancreatic 
inflammation and the size and volume of peripancreatic fluid collections are not included in 
any of the studied scoring systems; both peripancreatic fat stranding and fluid collections can 
range from discrete to extensive in magnitude, but are accorded equal points in the studied 
scoring systems. Second, some patients initially predicted to have mild AP may, nonetheless, 
progress to clinically severe AP over the initial 48h of hospitalization along with worsening 
morphologic changes on imaging. Third, pancreatic parenchymal necrosis may be unrecognized 
on an early CT performed within 24h of admission (38% in the present study). Pancreatic 
parenchymal necrosis has been shown to correlate with the development of organ failure and 
local complications (primarily infection of necrosis) that require intervention (23–25). Finally, 
CT depicts morphologic changes, which are not always clinically relevant and do not always 
correlate with clinical severity of disease. Predicted mild AP on early CT (i.e., low CT scores) 
does not imply that the patient will not develop clinically severe AP, especially when significant 
baseline co-morbidity is present. This limitation is demonstrated in our study as one patient 
died with predicted mild scores who had significant co-morbid disease that was not accounted 
for in any CT scoring system. In this patient, it is conceivable that the mild local pancreatic 
inflammation acted as a trigger for further dysfunction of already impaired organ systems 
culminating in an adverse outcome. Conversely, patients with severe morphologic findings on 
CT may run a clinically mild course. A substantial number of patients with pancreatic necrosis 
established on admission CT (25% in the present study and 38% in a study by Casas et al. (12)) 
did not develop clinically severe disease. It remains poorly understood why different clinical 
courses are observed in patients with significant pancreatic parenchymal necrosis. In both 
groups of patients, CT scoring systems will either under- or overestimate the clinical severity 
of pancreatitis. The overall limitation of CT and clinical prognostic scoring systems is the fact 
that they were devised to identify groups of high-risk patients and not individual patients (3). 
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In addition, scoring systems work best at the extremes of the spectrum (i.e., high negative or 
positive predictive value in patients with very low or high scores), whereas the performance 
of these scoring systems is only moderate in intermediate scores. This explains the overall 
moderate accuracy for predictive scoring systems, limiting their use in predicting a severe 
attack in any single patient.
In five previous studies, the predictive value of early CT was evaluated on admission, all 
showing a moderate positive correlation between CT score and mortality and morbidity 
(8,9,12–14). These studies either evaluated small study populations (8,9,13), focused on 
selective subgroups of patients (e.g., only alcohol-induced pancreatitis) (8), evaluated only one 
CT scoring system (12) or one single CT parameter (i.e., extent of pancreatic necrosis (13) or 
presence of peripancreatic fluid collections (14)), and/ or included a high incidence of clinically 
severe disease (9,13). A comparison of our results with those of previously published studies 
is difficult for several more reasons. First, no clear definition of clinical severity of disease has 
been consistently applied, whereas the present study used the most updated definition of clinical 
severity as proposed in the revised Atlanta Classification. Hitherto, this has been recognized 
as a major limitation for comparison of results between institutions (1,26). Second, different 
threshold values, as opposed to ROC curve analysis, were used to predict clinical severity. It is 
generally acknowledged that the overall performance of a test and comparison of prognostic 
scoring systems is best performed using ROC curve analysis (27), which was only performed 
in the study by De Waele et al. (9). Third, only one of these studies performed comparative 
analysis between the CT scoring systems (9) and no studies compared the radiologic systems 
with clinical scoring systems.
The timing of CT imaging in AP remains an important issue and has engendered significant 
debate. Many groups of investigators advocate that CT should be avoided in mild disease and 
should be reserved for those with a more complicated clinical course (28–30), whereas others 
advocate early CT for prognostication (31,32), or to assist with clinical decision making with 
regard to the initiation of antibiotic prophylaxis or other interventional procedures, such 
as continuous regional arterial infusion (2). In recent reports (33,34), however, the use of 
antibiotic prophylaxis in AP is no longer recommended and there is very limited evidence for 
early intervention by means of regional intra-arterial infusion and, therefore, generally not 
accepted as primary therapy in the initial management of AP (1,19).
Although this study highlights the prognostic accuracy of CT, we feel that a more judicious 
use of CT in AP is warranted for several reasons; AP is a costly disease with annual expenses 
exceeding 2 billion per year in the United States (35). In addition, CT is associated with significant 
radiation exposure (36,37) and several studies have shown the lack of correlation between 
imaging utilization and outcome (38,39). Finally, this study showed that early CT did not reveal 
any other diagnosis, did not reveal any local pancreatic complication, and underestimated the 
presence of parenchymal necrosis in a substantial number of patients. Hence, we recommend 
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that CT studies should be reserved only for those patients with predicted severe AP by clinical 
assessment, for those who fail to improve clinically with conservative management or those in 
whom the diagnosis is unclear or a severe complication is suspected (such as bleeding, bowel 
ischemia, or perforation).
Our study had two limitations. First, not all patients admitted or transferred to our hospital 
underwent a CT on the day of admission. Instead, CT was performed based on the discretion of 
treating physician (primarily for severity assessment) and, therefore, our methodology reflects, 
in some respects, current clinical practice. Moreover, it would be difficult to justify performing 
a CT in all patients hospitalized with AP given the aforementioned high costs and radiation 
issues. Second, there were a relatively small number of severe cases. However, this study was 
the largest so far to compare the use of different CT and clinical prognostic scoring systems 
on the day of admission. In addition, the prevalence of mild and severe cases in our study (82% 
and 18%, respectively) is similar to the prevalence of clinical severity of AP commonly stated 
in the literature (1).
In conclusion, our study did not detect significant differences between any of the seven 
studied CT scoring systems in predicting mortality and clinical severity of AP. Moreover, CT 
scoring systems were not superior to the studied clinical scoring systems. There appears to be 
no advantage of performing a CT on admission for prognostic purposes compared with the 
simpler and more easily obtained clinical scoring systems and, therefore, obtaining a CT for 
assessment of severity on the day of admission is not recommended. Instead, from a resource 
utilization perspective and as a way of reducing radiation exposure in AP, when the diagnosis 
has been made on clinical grounds (abdominal pain and elevated serum amylase and/or lipase), 
severity and prognosis can initially be assessed by clinical scoring systems with imaging 
reserved in cases where the diagnosis is equivocal, in patients who have predicted severe AP 
by clinical assessment or who fail to improve clinically despite conservative therapy or when a 
life-threatening complication is suspected.
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ABSTRACT
Acute pancreatitis is a highly variable disease that varies in severity from mild interstitial or 
edematous pancreatitis to severe forms with considerable local and systemic complications 
that are associated with significant morbidity, mortality, and public health care impact. For 
more than four decades, several multifactorial scoring systems have been used to assess disease 
severity and predict the outcome and prognosis of acute pancreatitis. Early disease stratification 
is deemed important to identify patients at risk for severe acute pancreatitis early in the disease 
process, to guide patient triage and management, and to improve patient outcome. Scoring 
systems related to CT are the most studied imaging tests in acute pancreatitis. Since the 
introduction of CT for diagnosis and severity assessment of acute pancreatitis, many imaging-
based systems have been developed. This chapter will review existing radiologic prognostic 
systems with their respective advantages and limitations and address key findings on cross-
sectional imaging of acute pancreatitis, with an emphasis on the prognostic significance of 
specific findings that impact patient management.
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INTRODUCTION
Acute pancreatitis is a common cause for hospitalization in the Western world. Fortunately, 
most patients with acute pancreatitis follow a mild clinical course without significant compli-
cations [1, 2]. Imaging in these patients is rarely necessary aside from establishing the cause 
of pancreatitis, i.e., an ultrasound on admission is often requested for assessment of biliary 
stones. However, about one-quarter of patients develop clinically severe acute pancreatitis 
accompanied by prolonged hospitalization with high morbidity and mortality rates [1–3]. 
These patients are responsible for most of the healthcare expenses in acute pancreatitis that 
include the need for repeated imaging. Despite increased knowledge of the pathophysiology 
and natural course of acute pancreatitis and notwithstanding the improvements in imaging 
techniques and critical care, mortality rates in severe acute pancreatitis have been unchanged. 
Given these differences in length of hospitalization and intensive care stay, the differences 
in morbidity and mortality and in healthcare costs, a continuous effort for more than four 
decades has been made to develop a prognostic multifactorial scoring system (based on clinical, 
biochemical, and/or imaging parameters) for accurate severity stratification, preferably during 
the first days of admission.
Early severity stratification is deemed important for several reasons. Identification of patients 
with the highest morbidity and mortality is critical because these patients may benefit most 
from timely transfer to the intensive care unit or tertiary referral centers for supportive 
treatment or for targeted therapy (i.e., endoscopic intervention or enteral feeding). In addition, 
stratification is essential for reliable interinstitutional comparison of new methods of therapy 
and for inclusion of patients in randomized trials [2, 4].
This chapter will review existing radiologic prognostic systems with their respective advan-
tages and limitations and addresses imaging features of acute pancreatitis with an emphasis on 
the prognostic significance of specific findings that impacts patient management.
Overview of Imaging Modalities
Multidetector computed tomography (MDCT) is the most widely available imaging modality 
and is the standard for the evaluation of acute pancreatitis [2, 5]. Other imaging modalities 
that are used for evaluation of acute pancreatitis include endoscopic and transabdominal ultra-
sound and magnetic resonance imaging (MRI). Imaging in acute pancreatitis is performed for 
several reasons that include confirmation of the diagnosis, detection of gallstones or biliary 
obstruction, assessment of severity of disease, and evaluation of complications related to acute 
pancreatitis [5–7].
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Ultrasound
Ultrasound has only limited value in the assessment of acute pancreatitis and its severity, 
because overlying bowel gas often obscures portions of the pancreas. However, ultrasound has 
a high sensitivity for detecting gallstones and is useful for follow-up of established pancreatic 
fluid collections [8].
Magnetic Resonance Imaging
The use of MRI in the assessment of acute pancreatitis and its complications is gaining 
increasing acceptance. Indeed, MRI offers similar diagnostic capabilities compared with CT 
with better depiction of stones in gallbladder or common bile duct and better evaluation of 
the pancreatico-biliary ductal system [8, 9]. Additionally, MRI is more accurate than CT in 
characterizing the content of peripancreatic collections that may aid in allowing appropriate 
drainage techniques to be used [10]. Disadvantages of MRI are its limited availability in an 
acute setting and that acquisition times are significantly longer than with MDCT.
Computed Tomography
MDCT is the primary imaging modality used in the evaluation of patients with acute pancreatitis. 
Morphologic changes of the pancreas and peripancreatic region are easily depicted on CT that 
allows for confirmation of the diagnosis, for assessment of disease severity, and for evaluation 
of local pancreatic and extrapancreatic complications [11]. A monophasic CT protocol after 
intravenous contrast administration is usually adequate for assessment of acute pancreatitis 
[12, 13]. Typically, scans are performed during the pancreatic phase (delay of 40–50 s) or portal 
venous phase (delay 60–70 s). Multi-phase studies are recommended in case of hemorrhage, 
ischemia, or suspicion of an arterial pseudoaneurysm [12, 13]. Major disadvantages of CECT 
remain the radiation exposure and the limited capability of differentiating fluid from necrotic 
material in peripancreatic collections [10].
Radiologic Scoring Systems
Scoring systems related to CT are the most studied imaging test in acute pancreatitis [14]. 
Since the introduction of CT for diagnosis and severity assessment of acute pancreatitis in 
the 1980s, many imaging-based systems have been developed. In this section, the most 
relevant scoring systems will be reviewed in order of year of development. Determinants 
of most radiologic scoring systems include pancreatic changes, peripancreatic features, and 
extrapancreatic features (Table 1). Severity assessment of acute pancreatitis by CT can be 
done using unenhanced (Schröder index, Balthazar grade, Pancreatic size index (PSI), MOP 
score, retroperitoneal extension grade, and EPIC score) or contrast-enhanced CT studies (CT 
severity index and Modified CT severity index).
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TABLE 1 CT determinants that constitute radiologic scoring systems
Pancreatic features
Subjective pancreatic enlargement
Pancreatic size index (PSI)a
Pancreatic parenchymal necrosis (presence and extent)
Peripancreatic features
Peripancreatic fat stranding
Peripancreatic fluid collection (presence and number)
Perirenal edema
Mesenteric inflammation
Retroperitoneal extension
Extrapancreatic features
Pleural effusion (presence, uni-, bilateral)
Ascites (presence and number of locations)b
Vascular complications (venous thrombosis, hemorrhage, arterial pseudoaneurysm)
Extrapancreatic parenchymal complications (infarction, hemorrhage, subcapsular fluid collection)
Gastrointestinal complications (ileus, signs of ischemia, perforation, marked bowel wall thickening, 
intramural fluid collection)
a PSI defined as multiplication of maximum anteroposterior measurement of the pancreatic head and body. A score of <10 cm2 is 
regarded as predicted mild pancreatitis and ≥10 cm2 is regarded as predicted severe pancreatitis
b Ascites in either one of these locations: perihepatic, perisplenic, interloop, or in pelvis [41]
Schröder Index
In 1985, Kivisaari and Schröder were among the first to develop a CT scoring system for 
severity stratification in acute pancreatitis based on pancreatic and extrapancreatic findings 
[15]. The pancreatic CT findings include edema in part of the pancreas and edema of the entire 
pancreas. Extrapancreatic findings include peritoneal fluid, perirenal fat edema, mesenteric 
fat edema, pleural effusion, and bowel paralysis. Each of these findings was assigned one 
point with a maximum score of 7. A total score of <4 correlates with predicted mild acute 
pancreatitis, and a score of 4 or more with predicted severe acute pancreatitis. This scoring 
system is relatively easy to apply and practical even among patients with renal failure when no 
intravenous contrast medium agents can be administered. Limitations are that the presence of 
peritoneal fluid (especially in female patients) and perirenal fat edema can be a normal finding 
(especially in the elderly).
Balthazar Grade
In 1985, Balthazar and colleagues developed a CT grading system based on the presence of 
pancreatic and peripancreatic changes into five grades of severity, ranging from Grade A (nor-
mal pancreas) to Grade E (inflamed pancreas with two or more fluid collections) (Fig. 1) [16, 
17]. In their original report, Grade A and B correlated with mild uncomplicated clinical course 
186 | Chapter 10
with no mortality, whereas Grade D and E signified severe disease with 54 % morbidity and 
14 % mortality [16, 17]. These results have been confirmed in subsequent studies by different 
groups of investigators [18–20]. The advantages of the Balthazar grading system are that it can 
be applied at any point during the patient’s hospitalization and requires no iodinated contrast 
medium. Limitations are the subjective assessment of pancreatic enlargement (corresponding 
to Grade B), the arbitrarily chosen distinction between peripancreatic inflammatory changes 
(“fat stranding”) and a peripancreatic collection (Grade C and D, respectively), and the need 
for counting peripancreatic collections (differentiating Grade D from Grade E), all of which 
are associated with moderate interobserver agreement. Some authors maintain that Balthazar 
grading system simplifies the retroperitoneal compartment rather than acknowledging the 
different components that constitute the retroperitoneum [21]. Another shortcoming (put 
forth by Balthazar himself) is that peripancreatic fluid collections (Grade D and E) have a 
variable natural history; in their study 54 % resolved spontaneously, whereas 46 % became 
infected necessitating intervention [16, 22].
FIGURE 1 (A) A 35-year-old man with acute pancreatitis (Balthazar Grade C). Unenhanced CT shows 
a swollen pancreatic tail (white star) with peripancreatic fat stranding (arrowheads). (B) A 56-year-old 
man with acute pancreatitis (Balthazar Grade E). Unenhanced CT shows a heterogeneous pancreas 
(white stars) surrounded by multiple peripancreatic collections (arrowheads)
Pancreatic Size Index
The PSI was first introduced in 1989 by London and colleagues [23]. The PSI (in cm2) is calcu-
lated by multiplying the maximum anteroposterior measurement of the head and body of 
the pancreas resulting in an objective assessment of pancreatic enlargement (as opposed to 
subjective assessment in other CT scoring systems, such as Schröder index, CT severity index 
[CTSI], and modified CT severity index [MCTSI]). By using a cut-off of 10 cm2 the authors 
found a sensitivity of 71 % and specificity of 77 % for clinically severe attacks [23]. In several 
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other studies these results were confirmed [24, 25]. The underlying theory behind the PSI is 
that with increasing degree of pancreatic insult, the resultant swelling of the pancreas releases 
more toxic cytokines and pancreatic enzymes in the systemic circulation and peripancreatic 
area, respectively. Advantage of the PSI is the evaluation of only one parameter. Like other CT 
scoring systems, PSI measurement does not require the administration of intravenous contrast 
medium. Main limitation is that normal values of pancreatic size may vary considerably 
according to age and previous attacks.
CT Severity Index
The advent of incremental dynamic bolus CT technique and faster scanning equipment in the 
early 1990s resulted in considerable improvement of imaging assessment of acute pancreatitis; 
the use of intravenous contrast medium enabled to differentiate interstitial pancreatitis (with 
intact capillary network and homogeneous enhancement) from necrotizing pancreatitis (with 
portions of pancreas failing to enhance) [22]. In 1990, Balthazar made his CT grading system 
more sophisticated by incorporating the presence and extent of parenchymal nonenhancement 
(corresponding to parenchymal necrosis) by using intravenous iodinated contrast medium [22]. 
The resulting CT scoring system (CT severity index or CTSI) combines the Balthazar grade 
(0–4 points) with the extent of pancreatic necrosis (0–6 points) on a 10-point severity scale 
(Table 2). The calculated CTSI can then be subdivided in three categories (CTSI 0–3, 4–6, and 
7–10; corresponding to predicted mild, moderate, and severe disease, respectively) that have 
subsequent increases in morbidity and mortality (Fig. 6.2). In the original study, patients with 
predicted mild disease (CTSI 0–3) had 8 % morbidity and 3 % mortality (of note, no mortality 
occurred in patients with CTSI 0–2), patients with predicted moderate severe pancreatitis had 
35 % morbidity and 6 % mortality, and patients with predicted severe disease (CTSI 7–10) 
had 92 % morbidity and 17 % mortality [22]. CTSI, of all radiologic scoring systems, is the 
most studied system, and many reports from different groups of investigators confirmed the 
utility of using CTSI in assessing patient outcomes [26–29]. However, some have found only a 
modest correlation between presence and extent of pancreatic necrosis and organ failure [30–
32], between pancreatic necrosis and extrapancreatic parenchymal and vascular complications 
[33, 34], and between extent of parenchymal necrosis and clinical outcome (i.e., no significant 
differences in patient outcome are observed in patients with 30–50 % necrosis versus those 
with >50 % necrosis) [35]. Other limitations are the moderate interobserver agreement due to 
the specific categorization of the evaluation of pancreatic inflammation and necrosis and the 
need for intravenous contrast agent.
MOP Score
In 2003, King and co-authors tested a simple CT scoring system based on two CT features 
(mesenteric edema [MO] and peritoneal [P] fluid; resulting in the MOP score) in a cohort of 
patients [36]. MOP score correlated well with disease severity, especially when both features 
were present. This scoring system is appealing because it is simple and easy to evaluate even for 
188 | Chapter 10
non-radiologists, requiring no intravenous contrast medium. However, in the original study, 
patients were included of whom CT was performed up to 10 days after admission, limiting the 
predictive power of this scoring system.
TABLE 2 CT severity index
Characteristics Points
Pancreatic inflammation
Normal pancreas 0
Focal or diffuse enlargement of the pancreas 1
Peripancreatic inflammation 2
Single acute fluid collection 3
Two or more acute fluid collections 4
Pancreatic parenchymal necrosis
None 0
Less than 30 % 2
Between 30 and 50 % 4
More than 50 % 6
FIGURE 2 (A) A 41-year-old man with acute pancreatitis (CTSI 4). Contrast-enhanced CT shows a 
normal enhancing pancreatic parenchyma (white stars) with more than two peripancreatic collections 
(arrows). (B) A 32-year-old man with acute necrotizing pancreatitis (CTSI 10). Contrast-enhanced 
CT shows extensive pancreatic nonenhancement (white stars), representing pancreatic necrosis. More 
than 50 % of the pancreatic volume is involved in the necrotic process. Peripancreatic collections (acute 
necrotic collections) are present (arrowheads).
A B
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Modified CT Severity Index
In 2004, Mortele and colleagues modified the existing CTSI accounting for the presumed 
shortcomings of this scoring system by incorporating extrapancreatic complications in the 
assessment and by simplification of the evaluation of peripancreatic collections and extent of 
parenchymal necrosis (Fig. 3) [26]. In the original study including 66 patients, the MCTSI, 
compared with CTSI, more closely correlated with patient outcome (length of hospital stay, 
need for intervention, and organ failure) with similar interobserver agreement [26]. In a 
larger cohort, these promising results could not be reproduced (no significant differences were 
observed between both CT scoring systems for the clinical parameters evaluated; intensive care 
stay, need for intervention, persistent organ failure, infected necrosis, severity of disease, and 
mortality) [37]. Possibly, because of the simplifications, the MCTSI may be easier to assess by 
less experienced readers.
FIGURE 3 A 65-year-old woman with acute interstitial pancreatitis (MCTSI 4). (a) Contrast-enhanced 
CT of the lung bases shows bilateral pleural effusion. (b) CT at the level of the pancreas shows a normal 
enhancing pancreatic parenchyma with little peripancreatic fat stranding (arrowheads). The CT 
severity index is 2 (predicted mild pancreatitis), while the modified CT severity index credits two extra 
points for pleural effusion (MCTSI 4, representing predicted moderate severe pancreatitis).
Retroperitoneal Extension Grade
Traditionally, it was assumed that the retroperitoneum consisted of three compartments 
(anterior pararenal space, perirenal space, and posterior pararenal space) demarcated by three 
well-defined fascia (anterior renal fascia, posterior renal fascia, and lateroconal fascia). New 
anatomical insights are that each retroperitoneal fascia is composed of multiple layers (i.e., 
fused leaves of embryonic mesentery), creating potential spaces (the retroperitoneal interfascial 
planes) that may serve both as a reservoir for decompression of rapidly accumulating fluid 
collections (as in acute pancreatitis) and as a pathway for spread of an infiltrating neoplasm 
or inflammatory process [38–40]. In 2006, Ishikawa and collaborators used this new anatomic 
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concept to design a CT grading system based on retroperitoneal extension of pancreatic fluid 
along the retroperitoneal interfascial planes on a 5-grade severity scale [21]. In their study, 
patients with Grade I–III (extension of pancreatic fluid from anterior pararenal space to the 
combined interfascial plane at the lower end of the perirenal space) had 22 % morbidity and 0 
% mortality, whereas patients with Grade IV–V (pancreatic fluid extending from the subfascial 
plane, located between the posterior pararenal space and the transverse fascia, into the posterior 
pararenal space) had 92 % morbidity and 39 % mortality (Fig. 4) [21]. This grading system can 
be assessed on unenhanced CT studies, but requires advanced radiologic interpretative skills 
and may not be easy to use for routine clinical practice.
FIGURE 4 A 49-year-old woman with acute 
pancreatitis (retroperitoneal extension grade 
V). Unenhanced CT shows extensive bilateral 
retroperitoneal inflammatory changes 
due to acute pancreatitis (arrows) with 
extension to the left posterior pararenal space 
(arrowheads), representing the highest grade 
of retroperitoneal extension (Grade V).
EPIC Score
The latest CT scoring system is the ExtraPancreatic Inflammation on CT (EPIC score), 
developed in 2007, which measures exclusively extrapancreatic inflammatory changes 
hypothetically regarded as CT signs of systemic inflammation (presence of pleural effusion, 
ascites, and retroperitoneal and mesenteric inflammation on a 7-point severity scale) [41]. The 
EPIC score was validated in a small single-center study composed of 40 patients who received 
an abdominal CT within 24h after admission and proved useful with an area under the receiver 
operating characteristics (AUC) curve for predicting severe disease and mortality of 0.91 (95 
% confidence interval, 0.83–0.99) and 0.85 (95 % confidence interval, 0.71–0.99), respectively 
[41]. However, this study was biased towards inclusion of a high incidence of severe disease 
and high need for surgical intervention.
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VALUE OF RADIOLOGIC SCORING SYSTEMS FOR SEVERITY 
PREDICTION
Since over four decades, an exhaustive search for the ideal scoring system has been undertaken 
to identify patients at risk for severe acute pancreatitis early in the disease process to guide 
patient triage and management, and to improve patient outcome. An ideal prognostic scoring 
system should be simple and easy to use in clinical practice, widely available, objective, 
reproducible, sufficiently accurate in differentiating mild from severe disease and applicable 
early in the disease process, preferably on day of admission, such that patients at risk for severe 
acute pancreatitis are more closely monitored or empirically treated (i.e., with tailored fluid 
resuscitation). Many clinical, biochemical, and imaging-based scoring systems have been 
developed but none fulfills all of the abovementioned criteria. Several shortcomings are shared 
by all staging systems. The available staging systems were devised to identify groups of patients 
at risk of developing organ failure or clinically severe disease rather than identifying individual 
patients. Furthermore, about one fifth of patients with potentially fatal severe pancreatitis are 
inappropriately identified using the traditional scoring systems [42]. Indeed, scoring systems 
perform best at the extremes of the prediction range, while the discriminatory power is 
moderate at best in the middle prediction range (i.e., the range where the clinician needs most 
assistance). Also, the variable timing of patient presentation to the hospital affects the clinical, 
laboratory, and imaging parameters explaining the variability in scores obtained. Finally, 
scoring systems (radiologic and biochemical systems alike) do not correlate with the risk of 
particular extrapancreatic complications (e.g., abdominal compartment syndrome (ACS), 
bowel ischemia, or perforation or arterial pseudoaneurysm) and, therefore, fail to provide 
detailed information that impacts patient management on an individual basis.
Imaging-based systems have their specific shortcomings compared with clinical and bio-
chemical scoring systems. It is commonly known that severe acute pancreatitis may run a 
highly variable clinical course; it may manifest early with SIRS, organ failure, and death in the 
first week or late with local complications demanding intervention [1, 2]. Biochemical scoring 
systems, compared with imaging-based systems, better correlate with early systemic effects of 
pancreatic injury (i.e., organ failure; the main determinant for severity of disease in the revised 
Atlanta Classification) and, thus, are better in predicting clinical severity early in the disease 
course. Conversely, radiologic scoring systems are best in predicting late local complications 
(infected necrosis, need for intervention) [37, 42]. Second, radiologic scoring systems are 
based on visual estimation and, therefore, are subject to variable interpretation, whereas most 
biochemical scoring systems are derived from objective parameters. Third, radiologic scoring 
systems do not account for patients preexisting clinical status; such as age, comorbid disease, 
and obesity which are well-known prognostic factors for morbidity and mortality. Institution 
of preventative measures requires early identification of patients with severe disease before 
the development of a complication. However, the timing of the CT scan in reports on the 
predictive power of radiologic scoring systems has varied from at admission to 10 days after 
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admission [14]. Conversely, clinicobiochemical scoring systems are mostly tested early in the 
clinical course (within the first 24–48h), i.e., in a timeframe where severity stratification is 
most useful. Finally, studies on imaging-based systems are biased toward more severe disease 
because patients with mild or minimal symptoms do not need cross-sectional imaging for 
clinical management while biochemical scoring systems are tested and applicable in all patients 
presenting with acute pancreatitis.
Reports on the discriminatory power of radiologic scoring systems all show a positive cor-
relation between the scoring system studied and patient outcome. However, because of the 
profound lack of homogeneity in study design, differences in methodology used and the wide 
diversity in definitions for severe acute pancreatitis and clinical end points (e.g., variation in 
defining organ failure and systemic complications) comparison of these studies is rendered 
difficult [14]. A recent study comparing seven of the eight abovementioned CT prognostic 
scoring systems on the day of admission accounted for these shortcomings by using definitions 
put forth by the working group on revising the Atlanta Classification [43]. This study did not 
detect significant differences between the studied CT scoring systems in predicting clinical 
severity or mortality (AUC ranging between 0.72–0.88 and 0.70–0.81, respectively). Moreover, 
CT scoring systems did not perform better than commonly used clinical scoring systems [43].
The use of early imaging for prognostication is limited by several factors: (1) In most imaging- 
based systems, the rating of peripancreatic inflammation and fluid is determined based on 
their presence rather than extent; the latter may vary considerably among patients appreciated 
with similar grades (Fig. 5). (2) Morphologic signs of severe disease are a time-dependent 
phenomenon. CT only takes a snapshot of a moment in time, while acute pancreatitis is a 
continuously evolving disease process. Consequently, patients may progress from mild to 
severe grades of CT severity. (3) Parenchymal necrosis may not be evident until after 24–48 
h and, thus, may be underrated on early imaging (Fig. 6). (4) On the other hand, the presence 
and extent of parenchymal necrosis do not invariably correlate with organ failure and clinical 
severity, and (5) the evolution of CT findings does not always parallel the clinical course; CT 
may show little morphologic signs of severe disease early in the disease process (i.e., on day of 
admission) in patients who already have organ failure as sign of a severe attack. Conversely, 
imaging studies late in the disease process may show major morphologic changes (like extensive 
parenchymal necrosis and retroperitoneal collections) in patients who have only mild clinical 
discomfort (Fig. 7).
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FIGURE 5 Two different patients (A, B) with similar grades of severity but marked difference in 
magnitude of peripancreatic collections. (A) A 44-year-old man with limited peripancreatic collections 
(arrowheads). (B) A 37-year-old man with extensive peripancreatic collections (arrowheads). Both 
patients are appreciated with similar grades according to all radiologic scoring systems. White stars 
denote a normal enhancing pancreas in both patients.
FIGURE 6 A 47-year-old woman with false negative parenchymal necrosis on early CT. (A) Contrast-
enhanced CT on day 1 shows a heterogeneous enhancing pancreatic parenchyma, but no apparent 
areas of nonenhancement. (B) Repeat CT was performed on day 4 showing clear nonenhancement 
of pancreatic head, neck and part of body (black stars), while the tail shows preserved enhancement 
(white star).
A B
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FIGURE 7 A 50-year-old man with extensive 
necrosis and mild clinical symptoms. MRI was 
performed for continuing mild discomfort 
6 weeks after an episode of acute pan-
creatitis. T2-weighted sequence shows a fully 
encapsulated collection (walled-off necrosis) 
in the pancreatic area (arrows) with dark 
material (arrowheads), representing necrotic 
pancreatic and peripancreatic tissue.
In summary, current evidence suggests that there is no role for radiologic scoring systems 
for prediction purposes. Additionally, given the high costs associated with acute pancreatitis 
[44], the radiation burden of (serial) CT [45, 46], and the lack of correlation between imaging 
utilization and patient outcome [46, 47], initial evaluation of a patient presenting with acute 
pancreatitis is best performed based on clinical assessment and biochemical scoring systems 
that better correlate with organ failure and systemic complications dominating the clinical 
picture in the first weeks after the initial attack. Performing a CT on admission (or within the 
first days after admission) is unlikely to affect patient management, unless a severe complica-
tion (like hemorrhage or bowel ischemia) is suspected or in case of a diagnostic dilemma. The 
decision about when to perform MDCT depends, therefore, on the overall clinical presentation. 
Unquestionably, the impact of CT is greater in the later phase of the disease process in patients 
who have predicted severe acute pancreatitis by clinical assessment or who fail to improve 
clinically despite conservative therapy when local complications (most commonly infection of 
parenchymal and peripancreatic tissues) predominantly dictate clinical management.
Prognostic Value of Specific Computed Tomography Findings
Morphologic findings of acute pancreatitis include necrosis of pancreatic parenchyma, 
peripancreatic inflammation with or without fluid and extrapancreatic retroperitoneal or 
subperitoneal fatty tissue necrosis, subsequent infection of pancreatic or extrapancreatic 
necrosis, vascular compromise of adjacent veins and arteries, extrapancreatic parenchyma 
complications, biliary complications, and gastrointestinal complications. Some of these 
findings or complications are detected on cross-sectional imaging only but nonetheless may 
harbor significant prognostic importance (Table 3). Given the aforementioned limitations of 
radiologic scoring systems, this section will review the key findings on cross-sectional imaging 
associated with prognostic significance, which may directly influence patient management.
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TABLE 3 CT findings of complications in acute pancreatitis with clinical implications
CT findings Clinical implications
Necrosis of pancreatic parenchyma:
• Extended necrosis (>30 %)
• Central gland necrosis
Increased risk for developing organ failure, infected 
necrosis, and higher need for intervention
Infected necrosis (gas bubbles in necrotic collections) Institution of (empiric) antibiotics and/or intervention
Peripancreatic collections exerting mass effect on 
surrounding structures:
• Biliary dilation
• Obstructive hydronephrosis
If symptomatic, stent placement
Deep vein thrombosis of iliofemoral veins or 
pulmonary emboli/infarction
Initiation of anticoagulant therapy
Hemorrhage/arterial pseudoaneurysm Angiographic coiling/embolization or surgical clipping
Cholecystitis or gallbladder perforation Percutaneous drainage or surgical cholecystectomy
Bowel ischemia or perforation Surgical resection
CT signs of abdominal compartment syndrome (ACS) Percutaneous drainage of ascites (if present) or surgical 
decompression
Pulmonary complications: 
• Pleural empyema
• Pulmonary infiltrate(s)
• Pneumothorax
Initiation of antibiotics (empyema, pneumonia) or 
drain placement (empyema, pneumothorax)
PANCREATIC FINDINGS
Pancreatic Necrosis
Necrosis of pancreatic tissue signifies the most severe morphologic form of acute pancreatitis 
and represents the basis for most of the local complications [48]. Necrosis of pancreatic paren-
chyma results from severe disturbances in the pancreatic microcirculation and occurs early 
in the disease process [5, 22]. Generally, it is fully established by 72–96h and tends to remain 
stable across time [5, 22, 49]. CECT is considered the noninvasive reference standard for 
diagnosing pancreatic necrosis. CECT is highly accurate in assessing parenchymal necrosis 
when performed after 72–96h after symptom onset and when more than 30 % of pancreatic 
parenchyma is involved [5, 22]. Early CECT within 72h of disease may miss the presence and 
extent of necrosis in about 30–40 % of cases [43]. Also, accuracy of pancreatic necrosis detection 
drops to about 50 % when small areas of pancreatic tissues are affected [5, 50]. Mortality rates 
in cases of pancreatic necrosis are about 20 %, as opposed to less than 5 % in patients without 
pancreatic necrosis [3]. Extended pancreatic necrosis (i.e., more than 30 %) is associated with 
SIRS, organ failure, and development of late local complications such as infection of necrosis 
[35]. Furthermore, patients with significant necrosis are prone to develop other infections 
(urinary, respiratory, and systemic infections) during both the early and late phases [51]. These 
infections complicate the clinical course of acute pancreatitis and prolong hospitalization. Some 
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studies have shown that transparenchymal necrosis concerning the central area (pancreatic 
neck and/or body) or central gland necrosis also heralds prognostic significance because of 
the possible involvement of the pancreatic duct, resulting in the pancreatic duct disruption 
syndrome (Fig. 8) [52, 53]. In central gland necrosis, a viable pancreatic tail causes the ongoing 
secretion and extravasation of pancreatic fluid in the necrotic collection and peripancreatic area 
associated with increased need for percutaneous, endoscopic, or surgical intervention [53].
Infection of Necrosis
Necrosis of pancreatic parenchyma and peripancreatic fatty tissue serves as a nidus for bacterial 
superinfection, resulting in the most severe local complication in acute pancreatitis. Mortality 
rate in sterile necrosis is around 5–10 % and increases considerably when the necrosis becomes 
infected [3]. Indeed, infection of necrosis is a major prognostic risk factor in severe acute 
pancreatitis and sepsis-related multiple organ failure is the main life-threatening complication 
with a mortality rate up to 20–50 % [3]. On CECT, the presence of gas bubbles in an area 
of pancreatic and/or peripancreatic fatty tissue necrosis is virtually pathognomonic for the 
diagnosis of infected necrosis, especially in patients with clinical signs of infection (spiking 
fever, leukocytosis, elevated C-reactive protein, and/or (new onset) organ failure) (Fig. 9) [54]. 
In rare instances, gas bubbles can be seen in sterile collections associated with an enteric fistula. 
However, these patients often lack clinical signs of infection. Unfortunately, gas bubbles on 
CECT as sign of infected necrosis is only present in about 40 % of cases [54].
Peripancreatic Collections
In the more severe forms of acute pancreatitis peripancreatic (fluid) collections arise most 
commonly in the lesser sac, the retroperitoneum, and subperitoneal spaces of the mesenteries. 
According to the revised Atlanta Classification 2012, these are termed an acute peripancreatic 
fluid collection or pseudocyst in interstitial pancreatitis (collections contain fluid only) or acute 
necrotic collection or walled-off necrosis in necrotizing pancreatitis (collections contain a 
mixture of necrotic material and variable amounts of fluid) [48]. The natural history of these 
collections is highly unpredictable, ranging from spontaneous resolution in over half of cases, 
to persisting and increasing in size and giving rise to complications like secondary infection 
(in necrotizing pancreatitis, this is termed infected necrosis), mass effect on neighboring 
structures (e.g., biliary system resulting in biliary dilation, urogenital system resulting in 
hydronephrosis, venous system resulting in left-sided portal hypertension, splenomegaly and 
extensive collateral venous network when the portomesenteric and splenic veins are involved, 
and gastric outlet obstruction), or rupture into the peritoneal cavity with development of acute 
peritonitis (Fig. 10) [5, 55, 56].
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FIGURE 8 A 42-year-old woman with central 
gland necrosis. Contrast-enhanced CT depicts 
necrosis of the neck and body of the pancreas 
(black star) among the viable pancreatic head 
and tail (white stars). This patient is at risk 
for having a pancreatic duct disruption with 
increased need for intervention.
FIGURE 9 A 51-year-old woman with 
infected necrosis. Contrast-enhanced CT 
performed on day 26 after symptom onset 
shows a nearly completely encapsulated 
necrotic collection (arrows) with impacted 
gas bubbles (arrowheads), virtually diagnostic 
for infection of necrosis.
EXTRAPANCREATIC FINDINGS
Vascular Complications
Vascular complications are common in patients with moderate severe and severe acute 
pancreatitis and include portomesenteric venous thrombosis, arterial pseudoaneurysm, 
and hemorrhage due to vessel erosion of arteries, veins, or small capillaries either through 
pancreatic enzymes or, iatrogenically, by surgical, endoscopic, or radiological drains.
Recent studies on splanchnic vein thrombosis report an incidence of about 50 % in patients 
with parenchymal necrosis, most frequently in the splenic vein, followed by portal and superior 
mesenteric vein (Fig. 11) [57, 58]. Most are asymptomatic, and spontaneous recanalization 
occurs in about one third of patients irrespective of the use of systemic anticoagulation. 
Reported complications include gastrointestinal bleeding and splenomegaly but are rare [59]. 
Current practice suggests that there is no need for initiation of anticoagulation unless there 
is propagation of thrombosis on serial CT scans [58]. In the literature, there is lack of data 
about the true incidence of deep vein thrombosis or pulmonary embolism on abdominal CT 
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FIGURE 10 A 49-year-old woman with large 
collection compressing the stomach. Coronal 
reformatted contrast-enhanced CT shows a 
large encapsulated necrotic collection (white 
star) exerting mass effect on the stomach 
(arrows), which is displaced medially and 
cranially.
FIGURE 11 A 56-year-old man with thrombus 
in the splenic vein. Contrast-enhanced CT 
depicts an intraluminal filling defect in the 
splenic vein (arrowhead), compatible with a 
thrombus. Usually, this is not an indication 
for initiation of anticoagulant therapy.
FIGURE 12 A 43-year-old woman with 
thrombus in the right iliac vein during the 
course of acute necrotizing pancreatitis. 
Coronal reformatted contrast-enhanced CT 
depicts a large filling defect in the right iliac 
vein (arrowheads), diagnostic for deep vein 
thrombosis in a patient with necrotizing 
pancreatitis and extensive retroperitoneal 
collections (arrows). White star denotes the 
inferior vena cava. To prevent pulmonary 
embolism anticoagulant therapy is mandatory.
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scans in acute pancreatitis. In the author’s experience, this is rare and primarily seen in patients 
with severe necrotizing acute pancreatitis and prolonged hospitalization. However, opposed to 
portomesenteric vein thrombosis, the observation of intraluminal clots in the iliac or femoral 
vein necessitates the initiation of systemic anticoagulation to prevent a fatal outcome (Fig. 
6.12).
Another vascular complication is the occurrence of an arterial pseudoaneurysm, which is 
often a late complication in acute pancreatitis, although rare (estimated incidence of less than 
2 %) (Fig. 13) [60]. In order of frequency, the following arteries are involved: splenic artery, 
gastroduodenal artery, pancreaticoduodenal artery, gastric artery, hepatic artery, and others 
(superior mesenteric artery, jejunal or ileocolic artery) [60]. Generally, there is an indication 
for angiographic embolization or coiling. Uncontrollable bleeding from a ruptured arterial 
pseudoaneurysm requires emergency surgical intervention.
Hemorrhage from erosion of a vascular wall may be a life-threatening complication if an artery 
is involved or may be an incidental finding in case of damage of small capillaries or veins. 
The vast majority of vascular complications are readily detectable on routine abdominal CT 
scans but some (e.g., small arterial pseudoaneurysms or insignificant hemorrhage) require a 
multiphasic scan protocol (including an unenhanced and arterial phase) for accurate detection 
[12].
Extrapancreatic Parenchymal Complications
Acute pancreatitis is capable of inflicting damage to adjacent parenchymal organs, like the 
spleen, liver, and kidneys, due to the central location of the pancreas in the upper abdomen and 
destructive nature of extravasated pancreatic enzymes. Splenic involvement in acute pancreatitis 
include hematoma, infarction, and perisplenic inflammatory fluid collections (sterile or infected) 
attributable to pancreatic secretions that dissect into the splenic hilum as the splenic capsule 
is continuous with the peritoneum covering the anterior surface of the pancreas (Fig. 14) [61, 
62]. Similar complications may occur in the liver [63]. Renal involvement in acute pancreatitis 
includes perirenal fluid collections and parenchymal abnormalities (e.g., renal infarction) [33, 
64]. Renal complications are most often an incidental finding and seem unrelated to the severity 
of pancreatitis. One renal complication with clinical impact is obstructive hydronephrosis as a 
result of eccentric compression of the proximal ureter by retroperitoneal pancreatic collections 
(Fig. 15) [65]. Most of the aforementioned complications lack any specific symptomatology, 
but are easily identifiable on CECT underlining the importance of CT for their diagnosis.
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FIGURE 13 A 40-year-old man with an arterial pseudoaneurysm after an episode of necrotizing 
pancreatitis. (A) Unenhanced CT shows a cotllection (arrowheads) with high density, suggestive of 
hemorrhage. (B) Contrast-enhanced CT in the arterial phase depicts a small arterial pseudoaneurysm 
(arrow) originating from the prepancreatic arcade. Pseudoaneurysm was successfully treated by 
embolization with platinum coils (not shown).
FIGURE 14 A 61-year-old woman with 
splenic infarction and signs of infection 
(abscess) complicating acute pancreatitis. 
Contrast-enhanced CT shows an area of 
splenic infarction (white star) with a gas 
bubble (arrowhead) as a sign of a splenic 
abscess.
FIGURE 15 A 72-year-old man with 
obstructive hydronephrosis of the right 
kidney due to extensive retroperitoneal 
collections. Coronal reformatted contrast-
enhanced CT depicts a newly developed 
dilatation of the pyelocaliceal system of the 
right kidney (arrowhead), compatible with 
hydronephrosis due to obstruction by large 
retroperitoneal necrotic collections (arrows).
A                  B
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Biliary Complications
Concomitant acute cholecystitis and acute pancreatitis is a rare event [66] but development of 
acute cholecystitis during the course of acute biliary pancreatitis is not uncommon and is one 
of the reasons to perform a cholecystectomy shortly after an attack of acute biliary pancreatitis 
[67, 68]. Performing a cholecystectomy may be a surgical challenge, particularly in the presence 
of necrotic collections [69]. In these cases, percutaneous cholecystostomy may be an alternative 
treatment strategy. Assessment of gallbladder pathology can be difficult in the course of acute 
pancreatitis and findings on CECT may be helpful in the diagnosis and, thus, may directly 
influence patient management.
Direct extension of the inflammatory process to the duodenal wall and ampulla of Vater may 
result in transient inflammatory narrowing of the intrapancreatic segment of the common bile 
duct causing jaundice. Persistence of or development of jaundice a few weeks after the acute 
onset of pancreatitis, however, may indicate a more significant complication such as a chronic 
obstruction due to a ductal stricture or compression of the common bile duct by peripancreatic 
collections (i.e., indication for endoscopic stent placement) [70]. CECT easily depicts biliary 
dilatation up to the level of obstruction (Fig. 16). 
Another severe, but extremely rare complication is perforation of the gallbladder leading to 
biliary peritonitis [66]. CECT may diagnose this complication by depicting an interruption 
of the gallbladder wall with adjacent inflammatory fluid. Finally, erosion of the common bile 
duct wall by the inflammatory process may lead to a pancreaticobiliary fistula [71]. On CECT, 
the simultaneous presence of gas bubbles in the biliary tract and intrapancreatic collection is 
highly suggestive of a pancreatic choledochal fistula. Adequate drainage of the pancreatic/
peripancreatic collection and bile duct is generally effective.
Gastrointestinal Complications 
Involvement of gastrointestinal structures in acute pancreatitis is multifactorial and occurs 
primarily in necrotizing pancreatitis. Extravasated pancreatic enzymes may directly damage 
the gastrointestinal tract or may produce vascular thrombosis resulting in ischemic splanchnic 
injury. Also, early in the course of severe acute pancreatitis, hypovolemic shock with a splanchnic 
low flow state may occur because of inadequate fluid therapy and third-space loss responsible 
for further vascular compromise [72–74]. Rare but severe complications are perforation of 
the stomach (mainly the posterior wall of the stomach) and erosion of the medial wall of the 
duodenum in patients with pancreatic necrosis [75, 76]. A small but significant number of 
patients with necrotizing pancreatitis sustain ongoing abdominal pain, nausea, and inability 
to eat owing to centrally located pancreatic collections that displace and compress the stomach 
anteriorly giving rise to gastric outlet obstruction [77]. In these patients, endoscopic drainage 
may be indicated. The most severe small bowel and colonic complication in acute pancreatitis is 
ischemia and subsequent necrosis and perforation because of thrombosis of feeding or draining 
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FIGURE 16 A 76-year-old woman with 
infected necrotizing pancreatitis and biliary 
dilatation. Contrast-enhanced CT shows 
large necrotic collections (white stars) and 
impacted gas bubbles (arrowhead), indicative 
for infected necrosis. Also, dilatation of the 
intrahepatic bile ducts (arrows) is noted due 
to extrinsic compression of the common bile 
duct.
FIGURE 17 A 58-year-old woman with bowel ischemia of descending colon complicating acute 
necrotizing pancreatitis. (A) Contrast-enhanced CT performed on day 2 after symptom onset shows 
extensive necrosis of pancreatic body and tail (white stars). (B) Same CT at a lower level shows normal 
enhancement of the bowel wall of the transverse colon (arrowhead), while the descending colon shows 
absent bowel wall enhancement indicative for ischemia, which was overlooked by the radiologist. 
(C) Repeat contrast-enhanced CT 24h later for continuing severe sepsis depicts the development 
of gas in the bowel wall of the descending colon (pneumatosis intestinalis) and adjacent mesocolon 
(arrowheads) suggestive for bowel necrosis. Emergency laparotomy was performed which confirmed 
the CT findings.
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vessels in the mesentery (Fig. 17) [72, 73]. The usual sites of involvement of the colon are the 
transverse colon and the splenic flexure, because of their proximity to the pancreas, and the 
poor collateral flow [74]. These patients may present with prolonged ileus, gastrointestinal 
bleeding, and peritonitis along with features of necrotizing pancreatitis. Findings on CECT 
that are suggestive for bowel necrosis are the presence of pneumatosis intestinalis, gas in the 
portomesenteric veins, diminished or absent bowel wall enhancement, clots or occlusion of 
feeding arteries, and free intraperitoneal gas (pneumoperitoneum; virtually diagnostic for a 
perforated hollow viscus). Identification of these CT signs is critical because intestinal ischemia 
has a very high mortality if not treated expediently. Other colonic complications with less 
clinical impact are ileus and fistula formation.
Abdominal Compartment Syndrome
ACS is caused by pathological elevation of intra-abdominal pressure in response to various 
diseases (including severe acute pancreatitis) leading to multiple organ dysfunction [78]. ACS 
is increasingly recognized in acute pancreatitis and since the condition is associated with high 
mortality, early diagnosis is imperative [79]. Usually, the diagnosis of ACS is straightforward by 
clinical assessment and intravesical pressure measurements; however, diagnosis may be delayed 
by interfering symptoms from the underlying illness. Abdominal CT scan may reveal subtle 
findings that include narrowing or collapse of the inferior vena cava, direct renal compres-
sion or displacement, bowel wall thickening with increased enhancement, bilateral inguinal 
herniation, elevated hemidiaphragm, and a rounded appearance of the abdomen (so-called 
“round-belly sign”) [80, 81]. The “round-belly sign” is defined as abdominal distension with an 
increased ratio of anteroposterior-to-transverse abdominal diameter (ratio > 0.80). Especially, 
an increasing girth observed on serial CT scans performed at short intervals is worrisome (Fig. 
18) [81]. Individually, these CT findings are neither specific nor sensitive, but when present in 
combination, radiologists should raise the possibility of this life-threatening complication and, 
in the proper clinical setting, should communicate the presence and significance of these CT 
findings to the referring clinician.
Miscellaneous Complications
Routine abdominal CT for acute pancreatitis can reveal some complications that may not 
always be clinically apparent. Among these are abdominal wall extension of infected collections 
(amenable for percutaneous drainage) and pulmonary complications such as pneumothorax, 
focal consolidations indicative for pulmonary infiltrates, pleural empyema, features of the adult 
respiratory distress syndrome, and pulmonary embolus or infarction (Fig. 19) [82].
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FIGURE 18 A 47-year-old woman with development of ACS occurring early in the course of acute 
necrotizing pancreatitis (same patient as Figure 6). (A) Contrast-enhanced CT (day 1) at the level 
of the umbilicus shows mesenterial and retroperitoneal inflammatory changes due to pancreatitis. 
Note, the normal configuration of the abdominal contour. (B) Repeat CT on day 4 shows a rounded 
appearance of the abdomen (round belly-sign). Also note, pneumatosis intestinalis and absent bowel 
wall enhancement of ileal loops (arrowheads), indicative for small bowel ischemia. Patient underwent 
emergency laparotomy.
FIGURE 19 Two different patients (a, b) with pulmonary complications during an episode of acute 
pancreatitis. (A) Coronal reformatted contrast-enhanced CT in a 69-year-old woman shows signs 
of acute necrotizing pancreatitis with necrotic collections in the left retroperitoneum (arrows) and 
perihepatic fluid (white stars). As incidental finding, a thrombus was noted in the right pulmonary 
artery (arrowhead). (B) CT at the lung bases in an 80-year-old man with acute pancreatitis, who 
experienced a sudden onset of dyspnea and fever, demonstrates a left-sided pneumothorax and bilateral 
consolidations in the lower lobes, indicative for pneumonia.
A B
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CONCLUSION
Acute pancreatitis is a common but potentially devastating disease associated with significant 
morbidity, mortality, and public health impact in severe cases. Imaging-based predictive 
systems are useful for identifying groups of patients at risk for local complications or having 
severe disease rather than providing specific information changing clinical management on 
an individual basis. However, there are several individual CT features that may impact patient 
management significantly. Among these are the presence of significant necrosis (more than 30 
%), especially in case of central gland necrosis (associated with increased need for intervention), 
imaging signs of infected necrosis (requiring empirical antibiotics or some kind of radiologic, 
endoscopic, or surgical intervention), massive hemorrhage or detection of an arterial pseudoa-
neurysm (indication for angiographic coiling or surgery), deep vein thrombosis (indication 
for anticoagulation), cholecystitis (amenable for percutaneous drainage), bowel ischemia or 
perforation (indication for surgery), and features of the ACS (requiring percutaneous drainage 
of ascites or surgery). The conveyance of these specific CT findings to clinicians caring for these 
challenging patients will have more clinical impact on patient management than providing any 
radiologic score.
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ABSTRACT
Background. Diagnosing infected necrotizing pancreatitis (INP) may be challenging. The 
aim of this study was to determine the added value of routine fine-needle aspiration (FNA) in 
addition to clinical and imaging signs of infection in patients who underwent intervention for 
suspected INP.
Methods. We conducted a post hoc analysis of 208 consecutive patients from a prospective, 
multicenter database who underwent intervention because of suspected INP. In retrospect, 3 
groups were constructed based on the patients preoperative characteristics: Clinical, imaging, 
and FNA. Patients in the clinical group had clinical signs of infection but no gas on preoperative 
computed tomography (CT) and no FNA performed before intervention. Patients in the 
imaging group had gas bubbles on the preoperative CT but no was FNA performed, whereas 
patients in the FNA group had a positive FNA before intervention. The reference standard 
for infection was the culture taken during the first intervention (either catheter drainage or 
necrosectomy).
Results. The initial intervention for INP was performed a median of 27 days (interquartile 
range, 20–39) after admission without difference between the 3 groups (P = .15). Infection 
was confirmed in 80% of 92 patients of the clinical group, in 94% of 88 patients of the imaging 
group, and in 86% of 28 patients of the FNA group (P = .07). Mortality was 19% and was not 
different between groups (P = .39).
Conclusion. INP can generally be diagnosed based on clinical or imaging signs of infection. 
FNA may be useful in patients with unclear clinical signs and no imaging signs of INP.
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INTRODUCTION
Acute pancreatitis is the most common gastrointestinal condition requiring acute hospitalization 
in the United States.1 Twenty percent of these patients have necrotizing pancreatitis.2 The 
2012 revised Atlanta Classification defines necrotizing pancreatitis by the presence of either 
pancreatic parenchymal or only peripancreatic necrosis.3 In approximately 30% of these 
patients, infection of the necrosis occurs (infected necrotizing pancretitis [INP]), which 
requires radiologic or operative intervention in the vast majority of patients.2,4 Interventions 
in these often critically ill patients carry a morbidity of 50–100% and a mortality of 15–25%.4-9 
Therefore, many studies have focused on prevention of INP. Surprisingly, few studies have 
addressed the topic of diagnosing INP.
Suspicion of infected necrosis can be based on clinical signs only (eg, fever, organ failure), 
on imaging signs of gas bubbles in peripancreatic collections on computed tomography 
(CT), on positive microbiologic culture obtained by fine-needle aspiration (FNA), or on a 
combinations of all these factors.10,11 Since the initial Atlanta Classification12 in 1993, only 1 
retrospective study reported on the incidence of gas in peripancreatic collections (24% of 42 
patients) in relation to patient outcome in patients with necrotizing pancreatitis.10 In contrast, 
several studies reported on the use of FNA in diagnosing infected necrosis.6,11,13-17 As a result 
of these studies, some authors propose routine FNA in patients with necrotizing pancreatitis, 
as reflected by the high use of FNA in the previous literature (40–100%).5,17-19 The accuracy of 
FNA to diagnose infected necrosis may be high (range, 67–98%),19-21 but, for several reasons, 
the added value of routine FNA may be limited.7 First, with the current preferred approach of 
delayed intervention, even in case of infected necrosis, FNA seems to have limited therapeutic 
implications.4,22 Second, false-negative and false-positive (contamination) rates have been 
reported up to be 25% and 15%, respectively.7,18,23 Finally, although FNA is a considered to 
be a safe and minimally invasive procedure, it does carry a small risk of procedure-related 
complications (eg, bleeding, perforation, iatrogenic infection).24
The aim of this study was to determine the individual roles and (added) values of clinical and 
imaging signs and, especially, FNA in diagnosing INP.
PATIENTS AND METHODS
Patients
We performed a post hoc analysis in a prospective database of 639 patients with necrotizing 
pancreatitis, evaluated between March 2004 and November 2008 in all 8 Dutch university 
medical centers and 13 large teaching hospitals of the Dutch Pancreatitis Study Group. This 
cohort has been described previously.4 During the study period, all patients admitted with acute 
pancreatitis were registered in a prospective database.8,25 Patients were selected for the current 
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study if they underwent intervention for suspected infection of peripancreatic or pancreatic 
necrosis. Patients were excluded if the intervention was performed for other indications than 
(suspected) infection (eg, abdominal compartment syndrome, bleeding, bowel ischemia, or 
perforation).
Definitions and groups
A definitive diagnosis of INP was established by a positive microbiologic culture obtained at 
the first intervention (either via percutaneous drainage or surgical necrosectomy). For this post 
hoc analysis, the intervention culture was considered to be the reference standard for infection, 
regardless of other subsequent cultures obtained by drainage or re-interventions. A positive 
FNA culture before intervention or the presence of gas in peripancreatic collections on CT 
was not considered definite proof for infection, being the diagnostic variables under study. In 
clinical practice, however, a positive FNA culture was indicative of infected necrosis. Patients 
without intervention for suspected infected necrosis were excluded from further analysis 
because the reference standard was lacking in these patients. All included patients were divided 
in 3 groups: (1) Clinical signs of infection (clinical group); (2) gas in peripancreatic collections 
on CT and clinical signs (imaging group); and (3) FNA and clinical signs (FNA group).
To facilitate the analysis between the study groups, patients who had both gas in peripancre- 
atic collections on CT and in whom FNA cultures were performed (n = 16) were included in 
the imaging group, because FNA requires an additional intervention, whereas information on 
the presence of gas in peripancreatic collections can be derived from the CT that has already 
been performed routinely. In the clinical situation, however, this positive FNA was not ignored 
and used in the diagnostic workup to establish the diagnosis of infected necrosis; therefore, an 
additional sensitivity analysis was performed to determine the impact of including these 16 
patients in the FNA group.
Treatment protocol
The treatment protocol has been described in detail previously.4 In short, patients received 
broad-spectrum antibiotics in case of (suspected) INP initially. In case of clinical improvement, 
the antibiotic treatment regimen was narrowed based on culture results (if available). The 
majority of patients received broad-spectrum antibiotics for several weeks. Owing to the 
multicenter character of this study, it was not possible to record the exact use of antibiotics 
in all patients. Intervention was postponed if possible for ≥4 weeks after onset of symptoms 
to allow for demarcation and encapsulation of the infected collection, so-called walled-off 
necrosis. The minority of the present cohort (n = 88) was included in the PANTER trial and 
was randomized to open necrosectomy (n = 45) or to the step-up approach (n = 43).8 Since 2006, 
a multidisciplinary expert panel, consisting of 8 gastrointestinal surgeons, 1 gastroenterologist, 
and 3 radiologists guided decisions on intervention. Patients with (suspected) INP were 
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evaluated by the expert panel, and the treating physician was informed about the individual 
recommendations of the members of the panel. Notably, in every case, the ultimate decision for 
treatment and intervention was made by the treating physician.
Clinical group
Patients who had no gas in peripancreatic collections on CT and in whom no FNA was 
performed were classified as patients in whom the suspicion of INP was based on clinical signs. 
Unfortunately, no algorithm exists for establishing the diagnosis of infected necrosis only 
based on clinical signs; therefore, it is not possible to provide clear cutoff points of biochemical 
and mechanical outcome parameters to define infection. Usually, clinical deterioration was an 
important observation in patients with (suspected) infected necrosis. Examples of clinical signs 
were persisting sepsis, (new or prolonged) organ failure, increased need for cardiovascular 
and/or respiratory and/or renal support, leukocytosis, increased levels of C-reactive protein, 
and fever. Moreover, no other infectious focus must be found or held responsible for the 
clinical deterioration. Because experienced clinical judgment is needed in these complex and 
usually critically ill patients, in the majority of patients the decision to intervene was advised 
by the expert panel.
Imaging group
Patients with gas bubbles on CT were included in this group. CTs were performed at the 
discretion of the treating physician. One dedicated abdominal radiologist (T.L.B.) reviewed all 
CTs, and was blinded for the clinical background and treatment.
FNA group
With the policy of postponing intervention regardless the presence of (suspected) infection, 
routine FNA was not used routinely. The indication for performing FNA was left to the 
treating physician; therefore, FNA was only performed in case of unclear clinical and radiologic 
signs of infection. FNA was performed with ultrasound or CT guidance.
Data collection
The following data were extracted from the prospective database: Patient demographics, past 
medical history, American Society of Anesthesiologists class, etiology, day of hospital admission, 
duration of hospital stay, laboratory findings, CT findings from the initial hospitalization and 
second review by an experienced abdominal radiologist, presence of infectious complications, 
presence of (multiple) organ failure, clinical course, type of intervention(s), cultures from FNA 
and first intervention, and mortality.
Statistical analysis
All patients were analyzed in the 3 predefined groups. Per group, all data were pooled and 
baseline characteristics were listed. Percentages were calculated for baseline characteristics 
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and all intervention cultures were compared. Continuous data were presented as mean 
values ± standard deviation (SD), whereas and non-normally distributed data were presented 
as median (interquartile range [IQR]). Differences were compared with the Chi-square or 
Mann- Whitney U tests, as appropriate. All statistical analyses were performed using SPSS for 
Windows version 16.0.2 (SPSS, Chicago, IL).
RESULTS
Baseline characteristics
Of 639 consecutive patients with necrotizing pancreatitis, 208 (32%) underwent either 
percutaneous drainage or operative necrosectomy for suspected INP, and could be evaluated 
for the reference standard of infected necrosis. Median age was 60 years (IQR, 48–69) with a 
male:female ratio of 2:1. The clinical group consisted of 92 of 208 patients (44%); these patients 
had neither gas bubbles on CT nor was FNA performed. Gas in peripancreatic collections on 
CT was seen in 88 of 208 patients (42%; imaging group) and FNA was performed in 28 of 208 
patients (13%; FNA group). Baseline characteristics are shown in Table I.
Timing of intervention
There was no difference in timing of the first intervention between the 3 groups. In the clinical 
group (n = 92), intervention was performed at a median of 27 days (IQR, 21–38) after hospital 
admission, versus 31 days (IQR, 22–46) in the imaging group and 31 days (IQR, 18–38) in the 
FNA group (P = .15).
Gas in collections with necrosis (n = 88) was seen after a median of 22 days (IQR, 13–37) after 
hospital admission and the first intervention was performed a median of 10 days later. The first 
FNA (n = 28) was performed a median of 17 days (IQR, 10–28) after hospital admission and the 
first intervention was performed a median of 14 days later.
Diagnostic accuracy
Infected necrosis was documented by a positive culture of material obtained during the first 
intervention (ie, the reference standard) in 74 of 92 patients (80%) in the clinical group, in 83 
of 88 patients (94%) in the imaging group, and in 24 of 28 patients (86%) of the FNA group (P 
= .07).
In 19 of the 28 patients (68%) in the FNA group, the FNA cultures matched with the 
intervention cultures. In 8 of 28 patients (29%), other (new) micro-organisms were found 
during intervention; in these patients, the FNA culture was considered to be false negative. In 
1 patient (4%), a false-positive culture was found. When all 44 patients who underwent FNA 
before intervention were analyzed (including all 16 patients with both gas bubbles and FNA), 
27% of FNA cultures (12/44 patients) did not match with cultures taken from the intervention, 
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regardless of the presence of gas in peripancreatic collections on CT. In 11 of 44 patients (25%), 
other (new) micro-organisms were found during intervention compared with the FNA culture 
(median time between FNA and intervention 9 days; IQR, 5–20), and in 1 of 44 patients (2%), 
a positive FNA culture was found with subsequently a negative intervention culture. In this 
patient, the time interval between FNA and intervention was five days. These data are shown 
in detail in Table II.
TABLE I. Baseline characteristics
Characteristic
All
patients
(n = 208)
Clinical
group
(n = 92)
Imaging
group
(n = 88)
FNA
group
(n = 28)
Age (y) 60 (48–69) 58 (45–69) 61 (51–72) 57 (43–64)
Male gender 142 (68) 60 (64) 60 (68) 22 (79)
Etiology
Biliary 101 (49) 36 (39) 49 (56) 16 (57)
Alcohol abuse 44 (21) 30 (33) 10 (11) 4 (14)
Other 18 (9) 6 (8) 7 (8) 5 (18)
Unknown 45 (21) 20 (21) 22 (25) 3 (11)
ASA class on admission
I (healthy status) 57 (27) 21 (23) 22 (25) 14 (50)
II (mild systemic disease) 113 (54) 53 (59) 50 (57) 10 (36)
III (severe systemic disease) 38 (18) 18 (18) 16 (18) 4 (14)
Predicted severity of pancreatitis
APACHE-II score on admission 8 (5–11) 9 (5–11) 8 (5–11) 6 (4–10)
APACHE-II score >8 on admission 95 (46) 47 (50) 42 (48) 6 (21)
Imrie-score on admission 4 (3–5) 4 (2–5) 3 (3–5) 4 (2–5)
Imrie-score ≥3 on admission 158 (76) 69 (75) 67 (76) 22 (79)
Highest CRP level in first 48h of 
admission (mg/L)
295 (212–380) 289 (210–372) 289 (205–381) 335 (245–438)
CRP >150 (mg/L) 179 (86) 77 (78) 77 (88) 25 (89)
CT severity index 8 (6–10) 8 (4–10) 6 (6–10) 7 (6–8)
Pancreatic necrosis 156 (75) 66 (72) 70 (80) 20 (71)
Peripancreatic necrosis alone 52 (25) 26 (28) 18 (20) 8 (29)
Extent of pancreatic necrosis (%)
<30 102 (49) 40 (45) 46 (52) 16 (57)
30–50 53 (25) 28 (30) 17 (19) 8 (29)
>50 53 (25) 24 (25) 25 (28) 4 (14)
Continuous variables are presented as median values (interquartile range); percentages are in parenthesis.
APACHE, Acute Physiology And Chronic Health Evaluation; ASA, American Society of Anesthesiologists; CRP, C-reactive protein.
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Mortality
Overall mortality was 19% (40/208 patients) without differences between the groups: 18% 
(17/92 patients) in the clinical group, 17% (15/88 patients) in the imaging group, and 28% 
(8/28 patients) in the FNA group (P = .39). Mortality in all 44 patients who underwent FNA 
before intervention was 27% (12/44 patients).
Microbiology
In 184 of 208 patients (88%), infected necrosis was confirmed by culture taken at the first 
intervention. In 114 of these 184 patients (62%), the infection was monomicrobial, whereas in 
70 patients (38%), ≥ 2 bacteria/fungi were cultured. The mortality between these groups did 
not differ (18%; 21/114 patients) with monomicrobial culture versus 21% (15/70 patients) with 
polymicrobial culture (P = .62). Escherichia coli was cultured most frequently (40%), followed 
by Staphylococcus spp. (28%) and Enterococcus spp. (25%). Yeasts were cultured in 9% of patients, 
predominantly Candida spp. No data were available about the resistance pattern of micro-
organisms cultured from the necrosis.
DISCUSSION
This study suggests that the diagnosis of INP can be based on clinical and imaging signs in the 
majority of patients. FNA can be used selectively in patients in whom the clinical signs are 
unclear and have no imaging signs of infection.
Routine use of FNA has been advocated previously in patients suspected of having INP.26,27 
This recommendation dates from a time period where the diagnosis of infected necrosis was 
believed to require immediate operative treatment or interventional drainage. In current 
series, however, intervention was usually postponed if clinically possible until the necrosis had 
become walled off.4,6,22,28 Thus, even after confirmation of the diagnosis of infected necrosis, 
intervention was postponed whenever possible. This attempt to put off the intervention for 
about 4 weeks is reflected by our data showing that the median timing of intervention was 29 
(IQR, 22–41), without difference between the groups. Apparently, FNA did not necessarily 
prompt earlier intervention, whereas mortality was comparable between groups. Notably, no 
mortality was observed in the 11 patients with gas bubbles and/or positive FNA in whom 
intervention was postponed and ultimately waived because of successful conservative treat- 
ment.4 These findings support the concept that the diagnosis of INP does not mandate 
an emergency intervention and are in line with previous studies.4,7,29 Future studies should 
determine whether earlier intervention after positive FNA without the current 10- to 14-day 
delay can decrease morbidity or mortality.
The presence of gas in peripancreatic collections is considered by many as pathognomonic 
for INP.11 Only 3 studies reported the incidence of gas in peripancreatic collections.10,11,20 Two 
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studies published before 1993 included only a small number of patients (<30).11,20 The third 
study, describing 42 patients with pancreatic necrosis on CT, found gas bubbles in 20 patients 
(48%).10 But, because no consecutive series was described, the actual incidence of gas bubbles 
in patients with necrotizing pancreatitis remained unclear. In the current study, only patients 
in whom an intervention was performed for suspected INP were included (208/639 patients). 
Even though this was a selected subgroup of patients, it enabled us to compare the CT (and 
FNA) findings with the reference standard.
Infection of necrosis can occur at any time after onset of symptoms, but has a peak incidence 
between weeks 3 and 4.30 Therefore, FNA performed early in the disease course often yields 
negative results. Moreover, negative FNA cultures are obviously only reliable for a short period 
of time. Cutoff points varying from 1 to 27 days have been reported,19,21,31 but most studies do 
not actually report on the time between FNA culture and intervention.6,11,13-17
The role of antibiotics in patients with suspected INP remains a topic of debate. In the 
current study, almost all patients with suspicion of infected necrosis received broad-spectrum 
antibiotics as part of the conservative treatment strategy. Consequently, outcome of FNA 
cultures may be influenced and false-negative FNA cultures could occur. This possibility may 
be partly the reason for the high false-negative rate of 29%. Conversely, prolonged antibiotic 
treatment before intervention could result in a negative intervention culture and thus, false-
positive FNA cultures and false-positive gas bubbles in peripancreatic collections. Whether 
antibiotics substantially influenced the intervention cultures remains unclear, although this 
possibility may explain in part the false-positive outcomes of both FNA and CT findings.
Our results show that in almost 40% of patients with INP, multiple micro-organisms were 
found at cultures taken from the first intervention and that in 27% of patients, these findings 
did not (fully) correspond with the micro-organisms found with FNA culture. This finding 
may indicate that translocation of other intestinal micro-organisms occurred in the time 
period between FNA and intervention. These findings do not support the routine narrowing 
of antibiotic treatment based on FNA cultures.
Our study has some limitations. First, because not all patients with necrotizing pancreatitis 
underwent a routine FNA and a subsequent intervention, this study cannot be seen as a purely 
diagnostic study; however, it seems rather unlikely that such a study will be ever performed 
given the clear ethical problems with such an approach. Second, both FNA and CT were 
performed at the discretion of the treating physician. We cannot exclude the possibility that 
only patients without obvious clinical signs and no gas bubbles on CT underwent FNA. This 
approach to treatment could lead to selection bias, but has no further implications for the 
management of the individual patient. The main strength of our report, however, lies in the 
use of a multicenter, prospective database focused specifically on intervention in necrotizing 
pancreatitis in a consecutive series of patients.
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In conclusion, this study showed that in the majority of INP patients can be diagnosed based 
on clinical and imaging signs, and that FNA may be reserved for patients with unclear clinical 
signs without imaging signs of infection. Although FNA may lead to an earlier diagnosis of 
INP, it is unclear whether this is of additional value.
224 | Chapter 11
REFERENCES
1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of 
gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87.
2. Banks PA, Freeman ML. Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006;101:2379-400.
3. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute 
pancreatitis– 2012: revision of the Atlanta classification and definitions by international consensus. 
Gut 2013;62:102-11.
4. van Santvoort HC, Bakker OJ, Bollen TL, Besselink MG, Ahmed Ali U, Schrijver AM, et al. A 
conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. 
Gastroenterology 2011;141:1254-63.
5. Rau B, Bothe A, Beger HG. Surgical treatment of necrotizing pancreatitis by necrosectomy and 
closed lavage: changing patient characteristics and outcome in a 19-year, single-center series. 
Surgery 2005;138:28-39.
6. Buchler MW, Gloor B, Muller CA, Friess H, Seiler CA, Uhl W. Acute necrotizing pancreatitis: 
treatment strategy according to the status of infection. Ann Surg 2000;232:619-26.
7. Rodriguez JR, Razo AO, Targarona J, Thayer SP, Rattner DW, Warshaw AL, et al. Debridement 
and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and 
outcomes in 167 patients. Ann Surg 2008;247:294-9.
8. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH,  et al. A 
step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010;362:1491-
502.
9. Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, et al. 
Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized 
trial. JAMA 2012;307:1053-61.
10. Baril NB, Ralls PW, Wren SM, Selby RR, Radin R, Parekh D, et al. Does an infected peripancreatic 
fluid collection or abscess mandate operation? Ann Surg 2000;231:361-7.
11. Sarr MG, Nagorney DM, Mucha P Jr, Farnell MB, Johnson CD. Acute necrotizing pancreatitis: 
management by planned, staged pancreatic necrosectomy/debridement and delayed primary wound 
closure over drains. Br J Surg 1991;78:576-81.
12. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the 
International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch 
Surg 1993;128:586-90.
13. Bradley EL, Allen K. A prospective longitudinal study of observation versus surgical intervention in 
the management of necrotizing pancreatitis. Am J Surg 1991;161:19-25.
14. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic 
prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol 
Obstet 1993;176:480-3.
15. Banks PA, Gerzof SG, Langevin RE, Silverman SG, Sica GT, Hughes MD. CT-guided aspiration of 
suspected pancreatic infection: bacteriology and clinical outcome. Int J Pancreatol 1995;18:265-70.
The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis | 225
16. Kalfarentzos FE, Kehagias J, Kakkos SK, Petsas T, Kokkinis K, Gogos CA, et al. Treatment of patients 
with severe acute necrotizing pancreatitis based on prospective evaluation. Hepatogastroenterology 
1999;46:3249-56.
17. Olah A, Belagyi T, Issekutz A, Makay R, Zaborszky A. Value of procalcitonin quick test in the 
differentiation between sterile and infected forms of acute pancreatitis. Hepatogastroenterology 
2005;52:243-5.
18. Nordback I, Paajanen H, Sand J. Prospective evaluation of a treatment protocol in patients with 
severe acute necrotising pancreatitis. Eur J Surg 1997;163:357-64.
19. Ashley SW, Perez A, Pierce EA, Brooks DC, Moore FD Jr, Whang EE, et al. Necrotizing pancreatitis: 
contemporary analysis of 99 consecutive cases. Ann Surg 2001;234:572-9.
20. Sostre CF, Flournoy JG, Bova JG, Goldstein HM, Schenker S. Pancreatic phlegmon - clinical features 
and course. Dig Dis Sci 1985;30:918-27.
21. Delattre JF, Chazal NL, Lubrano D, Flament JB. Percutaneous ultrasound-guide drainage in 
complications of acute pancreatitis. Ann Chir 2004;129:497-502.
22. Besselink MG, Verwer TJ, Schoenmaeckers EJ, Buskens E, Ridwan BU, Visser MR, et al. Timing of 
surgical intervention in necrotizing pancreatitis. Arch Surg 2007;142:1194-201.
23. Paye F, Rotman N, Radier C, Nouira R, Fagniez PL. Percutaneous aspiration for bacteriological 
studies in patients with necrotizing pancreatitis. Br J Surg 1998;85:755-9.
24. Banks PA, Pappas TN. Is computerized tomographic fine needle aspiration helpful in the 
management of infected pancreatic necrosis? Am J Gastroenterol 2005;100:2371-4.
25. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, 
et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, 
placebo-controlled trial. Lancet 2008;371:651-9.
26. Uhl W, Warshaw A, Imrie C, Bassi C, McKay CJ, Lankisch PG, et al. IAP Guidelines for the surgical 
management of acute pancreatitis. Pancreatology 2002;2:565-73.
27. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology 
2007;132:2022-44.
28. Horvath K, Freeny P, Escallon J, Heagerty P, Comstock B, Glickerman DJ, et al. Safety and efficacy 
of video-assisted retroperitoneal debridement for infected pancreatic collections: a multicenter, 
prospective, single-arm phase 2 study. Arch Surg 2010;145:817-25.
29. Mouli VP, Sreenivas V, Grag PK. Efficacy of conservative treatment, without necrosectomy, for 
infected pancreatic necrosis: a systematic review and meta-analysis. Gastroenterology 2013;144:333-
40.
30. Besselink MG, van Santvoort HC, Boermeester MA, Nieuwenhuijs VB, van Goor H, Dejong CH, et 
al. Timing and impact of infections in acute pancreatitis. Br J Surg 2009; 96:267-73.
31. Rau B, Pralle U, Mayer JM, Beger HG. Role of ultrasonographically guided fine-needle aspiration 
cytology in the diagnosis of infected pancreatic necrosis. Br J Surg 1998; 85:179-84.

12
An assessment of the severity of 
interstitial pancreatitis
Singh VK, Bollen TL, Wu BU, Repas K, Maurer R, Yu 
S, Mortele KJ, Conwell DL, Banks PA
CLIN GASTROENTEROL HEPATOL. 2011 DEC;9(12):1098-103. IMPACT FACTOR: 7.40 
228 | Chapter 12
ABSTRACT
Background & aims: There is limited information on the incidence of and factors associated 
with severe disease among patients with interstitial pancreatitis (IP). We evaluated a large 
cohort of patients with IP and compared data with those from patients with extrapancreatic 
necrosis (EXPN).
Methods: We evaluated 149 consecutive patients with IP admitted over a 2.5-year period. 
Transferred patients were excluded. We collected data on age, Charlson comorbidity score 
(CCI), measures of severity on admission or within 24 hours (Acute Physiology and Chronic 
Health Evaluation II, bedside index for severity of acute pancreatitis scores), persistent (>48h) 
systemic inflammatory response syndrome, persistent organ failure, need for intensive care 
unit, length of hospital stay (in days), and mortality. We also analyzed levels of severity among 
those with IP and EXPN. Statistical analysis was performed using SAS version 9.1 (Cary, NC).
Results: Among the patients with IP, the median CCI score was 1, the median Acute Physiology 
and Chronic Health Evaluation II score was 7, and the median bedside index for severity of 
acute pancreatitis score was 1. In addition, the median length of hospital stay was only 4 days; 
only 1% had persistent organ failure and only 1% to 2% required intervention. The mortality 
rate of IP was 3%; it was associated significantly with comorbidity (the median CCI scores of 
non-survivors and survivors was 4 and 1, respectively, P .003). Patients with EXPN had greater 
levels of disease severity, compared with patients with IP.
Conclusions: IP is severe in only 1% to 3% of patients; mortality of IP is associated strongly 
with comorbidity. EXPN is more frequently severe than IP; EXPN must be distinguished from 
IP in clinical studies.
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Introduction
Interstitial pancreatitis (IP) has been recognized as a distinct clinicopathologic form of acute 
pancreatitis for nearly 9 decades.1 Although nearly 85% of patients hospitalized for acute 
pancreatitis have IP, most clinical studies over the past 2 decades have evaluated severity of 
necrotizing pancreatitis (NP).2
Early surgical1,3 and autopsy series4–6 of IP were limited by incomplete clinical data and their 
focus on small numbers of patients with the most severe form of disease. More recent surgical 
studies have reported mortality rates of 6.3% to 9.2% in IP.7,8 More recent nonsurgical studies 
have reported mortality rates of 0% to 5.3%.9–19 Several studies reported organ failure rates of 
6.8% to 18%9,18–20 but did not make the important distinction between transient and persistent 
organ failure.21,22 
Key limitations to all prior studies evaluating severity in IP include the inclusion of transferred 
patients23,24 and the likely inclusion of patients with extrapancreatic necrosis (EXPN).17,25 Both 
groups have been shown to have increased severity of disease, and their inclusion in studies of 
IP tends to bias the results. These limitations make it difficult to draw conclusions regarding 
the severity of IP.
The primary aim of our study was to examine the severity of IP among a cohort of nontransferred 
consecutive patients. The secondary aim was to compare severity between patients with IP and 
EXPN.
METHODS
The demographic, clinical, laboratory, and radiologic data for all patients directly admitted to 
our institution with a diagnosis of acute pancreatitis between June 2005 and December 2007 
were collected prospectively. All patients transferred from outside institutions were excluded 
from the study. Patients with radiographic evidence of chronic pancreatitis also were excluded 
from the study. Among patients with prior or multiple episodes of acute pancreatitis, only the 
first admission for acute pancreatitis at our institution was evaluated. Data for all patients were 
collected prospectively for 7 days or until discharge if fewer than 7 days. This Health Insurance 
Portability and Accountability Act–compliant study was approved by our institutional review 
board.
Acute pancreatitis was defined as 2 or more of the following: characteristic abdominal pain; 
serum amylase and/or lipase levels 3 times the upper limit of normal; a contrast-enhanced 
computed tomography (CECT) of the abdomen or magnetic resonance imaging within the first 
7 days of hospitalization showing characteristic changes of acute pancreatitis. IP and NP were 
defined in accordance with the Atlanta Classification of acute pancreatitis.26 EXPN was defined 
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by the presence of normally enhancing pancreatic parenchyma surrounded by a heterogeneous 
collection consisting of liquid and nonliquid densities on at least 2 consecutive CECTs. A prior 
study showed correlation between radiologic and subsequent surgical findings in patients with 
EXPN.25 The CT severity index (CTSI) was used to assess the severity of pancreatitis.14 The 
decision to obtain imaging was at the discretion of the treating clinicians. All imaging studies 
were reviewed separately by 2 radiologists (T.L.B. and K.J.M.) who were blinded to the clinical 
data.
Risk factors for severity of acute pancreatitis on admission included age,27,28 male sex,29 alcohol 
use,30,31 first episode,32 and obesity (body mass index, >30).33,34 Measures of severity at admission 
included increased blood urea nitrogen level (>25 mg/dL)35,36 and hemoconcentration 
(hematocrit, >44).18,37,38 Measures of severity within 24 hours of admission included Acute 
Physiology and Chronic Health Evaluation II26 and bedside index for severity of acute 
pancreatitis scores.39,40
Markers of severity during hospitalization included persistent systemic inflammatory response 
syndrome (SIRS),41–43 persistent organ failure,21,22,41 length of stay, need for intensive care unit 
(ICU), development of hospital-acquired extrapancreatic infection,44,45 and mortality.
Organ failure was defined as a score of 2 or greater in 1 or more of the 3 organ systems 
(cardiovascular, respiratory, and renal).46 Organ failure was assessed for all patients during 
the first 7 days of hospitalization based on the most extreme laboratory value or clinical 
measurement in each 24-hour period. Duration of organ failure was defined as transient if 
lasting 48 hours or fewer, or persistent if lasting more than 48 hours.
SIRS was defined as 2 or more of the following: temperature lower than 36° or greater than 
38°C; PaCO2 less than 32 mm Hg or respiratory rate greater than 20 breaths/min; pulse greater 
than 90 beats/min; white blood count less than 4000 or greater than 12,000 cells/mm3 or 
greater than 10% immature bands. SIRS scores were calculated on all patients during the first 7 
days of hospitalization based on the most extreme laboratory value or clinical measurement in 
each 24-hour period. SIRS was defined as transient if lasting 48 hours or fewer or persistent if 
lasting more than 48 hours during the first 7 days of hospitalization.
Extrapancreatic infection (EI) was defined by the presence of a positive blood, sputum, and/
or urine culture, and/or imaging showing a pulmonary infiltrate within the first 7 days of 
hospitalization.45
Mortality was defined as death occurring during hospitalization or within 30 days of hospital 
discharge.
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The Charlson comorbidity index (CCI) score was used to quantify the burden of comorbid 
disease.47 CCI as well as age-adjusted CCI (ACCI) scores were calculated for all patients in the 
study cohort.
Statistical Analysis
Statistical comparisons were performed using the chi-square or the Fisher exact tests for 
categoric variables, analysis of variance for normally distributed numeric variables, and 
the Wilcoxon rank sum test for non-normally distributed numeric variables. All statistical 
calculations were performed using SAS version 9.1 (Cary, NC).
RESULTS
Figure 1 shows the selection criteria of the study cohort. A total of 306 patients with acute 
pancreatitis were evaluated. We excluded 54 patients transferred from outside institutions. 
Among these 54 patients, 23 had NP, 25 had IP, and 6 had EXPN. Of the remaining 252 patients 
who were admitted directly to our institution, we excluded the 17 patients with an unenhanced 
computed tomography, 11 patients with NP, and 8 patients with EXPN. Among the 216 
imaging studies were reviewed separately by 2 radiologists
(T.L.B. and K.J.M.) who were blinded to the clinical data.
Risk factors for severity of acute pancreatitis on admission
included age,27,28 male sex,29 alcohol use,30,31 first episode,32 and
obesity (body mass index, 30).33,34 Measures of severity at
admission included increased blood urea nitrogen level (25
mg/dL)35,36 and hemoconcentration (hematocrit, 44).18,37,38
Measures of severity within 24 hours of admission included
Acute Physiology and Chronic Health Evaluation II26 and bed-
side index for severity of acute pancreatitis scores.39,40
Markers of severity during hospitalization included persis-
tent systemic inflammatory response syndrome (SIRS),41–43 per-
sistent organ failure,21,22,41 length of stay, need for intensive care
unit (ICU), development of hospital-acquired extrapancreatic
infection,44,45 and mortality.
Organ failure was defined as a score of 2 or greater in 1 or
more of the 3 organ systems (cardiovascular, respiratory, and
renal).46 Organ failure was assessed for all patients during the
first 7 days of hospitalization based on the most extreme lab-
oratory value or clinical measurement in each 24-hour period.
Duration of organ failure was defined as transient if lasting 48
hours or fewer, or persistent if lasting more than 48 hours.
SIRS was defined as 2 or more of the following: temperature
lower than 36° or greater than 38°C; PaCO2 less than 32 mmHg
or respiratory rate greater than 20 breaths/min; pulse greater
than 90 beats/min; white blood count less than 4000 or greater
than 12,000 cells/mm3 or greater than 10% immature bands.
SIRS scores were calculated on all patients during the first 7 days
of hospitalization based on the most extreme laboratory value or
clinical measurement in each 24-hour period. SIRS was defined as
transient if lasting 48 hours or fewer or persistent if lasting more
than 48 hours during the first 7 days of hospitalization.
Extrapancreatic infection (EI) was defined by the presence of
a positive blood, sputum, and/or urine culture, and/or imaging
showing a pulmonary infiltrate within the first 7 days of hos-
pitalization.45
Mortality was defined as death occurring during hospitaliza-
tion or within 30 days of hospital discharge.
The Charlson comorbidity index (CCI) score was used to
quantify the burden of comorbid disease.47 CCI as well as
age-adjusted CCI (ACCI) scores were calculated for all patients
in the study cohort.
Statistical Analysis
Statistical comparisons were performed using the chi-
square or the Fishe exact tests for categoric vari bl s, analysis
of variance for normally distributed numeric variables, and the
Wilcoxon rank sum test for non-normally distributed numeric
variables. All statistical calculations were performed using SAS
version 9.1 (Cary, NC).
Results
Figure 1 shows the selection criteria of the study
cohort. A total of 306 patients with acute pancreatitis were
evaluated. We excluded 54 patients transferred from outside
institutions. Among these 54 patients, 23 had NP, 25 had IP,
and 6 had EXPN. Of the remaining 252 patients who were
admitted directly to our institution, we excluded the 17
patients with an unenhanced computed tomography, 11
patients with NP, and 8 patients with EXPN. Among the 216
remaining patients, 115 underwent a CECT (n  94) or
magnetic resonance imaging (n  21) showing IP, whereas
101 had no imaging while hospitalized. Among the 101
patients without imaging while hospitalized, 34 patients had
a CECT after discharge from the ho pital showing a nor-
mally enhancing pancreas. Therefore, a total of 149 patients
had imaging consistent with interstitial pancreatitis.
Figure 1. Selection criteria for
study cohort. NEP, normally
enhancing pancreas; UECT,
unenhanced CT.
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FIGURE 1. Selection criteria for study cohort. NEP, normally enhancing pancreas; UECT, unenhanced 
CT.
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remaining patients, 115 underwent a CECT (n = 94) or magnetic resonance imaging (n = 21) 
showing IP, whereas 101 had no imaging while hospitalized. Among the 101 patients without 
imaging while hospitalized, 34 patients had a CECT after discharge from the hospital showing 
a normally enhancing pancreas. Therefore, a total of 149 patients had imaging consistent with 
interstitial pancreatitis.
TABLE 1. Severity and Interventions Among Total Patient Cohort and Among Patients With IP 
Confirmed by CT and Those With No CT
Total (n = 216) IP (n = 149) No CT (n = 67) P valuea
Risk factors for severity on admission
Age, y 52 ± 17 54 ± 17 48 ± 16 .35
Male sex 92 (43) 64 (43) 28 (42) .88
BMI≥30 73 (35) 49 (33) 24 (39) .53
Alcohol etiology 38 (18) 23 (15) 15 (22) .25
First episode 155 (72) 107 (72) 48 (72) 1.00
CCI 0 [0, 2] 1 [0, 2] 0 [0, 1] .001
ACCI 1 [0, 4] 2 [0, 4] 1 [0, 3] .007
Measures of severity at admission or ≤ 24h
BUN>25 23 (11) 16 (11) 7 (10) 1.00
HCT≥44 39 (18) 26 (17) 13 (19) .71
APACHE II, ≤ 24h 7 [4, 10] 7 [5, 10] 6 [4, 9] .03
BISAP, ≤ 24h 1 [1, 2] 1 [1, 2] 1 [1, 1] .03
Markers of severity during hospitalization
Persistent SIRS 48 (22) 42 (28) 6 (9) .001
Persistent organ failure 4 (2) 2 (1) 2 (3) .59
Length of stay, d 3 [2, 6] 4 [2, 7] 3 [2, 4] .001
Need for ICU 15 (7) 10 (7) 5 (7) .78
EI 34 (16) 27 (18) 7 (10) .22
Death 6 (3) 5 (3) 1 (1.5) .67
Interventions
Need for intubation 3 (1) 3 (2) 0 (0) .55
Need for dialysis 0 (0) 0 (0) 0 (0) NA
Need for pressors 1 (0.5) 1 (1) 0 (0) 1.00
Received antibiotics 77 (36) 62 (42) 15 (22) .009
NOTE. Values are expressed as mean ± standard deviation, median [Q1, Q3], and number (%).
APACHE, Acute Physiology and Chronic Health Evaluation; BISAP, bedside index for severity of acute pancreatitis; BMI, body mass 
index; BUN, blood urea nitrogen; EI, extrapancreatic infection; HCT, hematocrit.
aP values reflect comparison between IP versus no CT.
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Table 1 displays the severity and interventions of the full cohort of 216 patients and 
compares the severity of the 149 patients with imaging-confirmed IP with the 67 patients 
who did not have any imaging. The 149 patients with IP had significantly higher CCI, ACCI, 
Acute Physiology and Chronic Health Evaluation II, and bedside index for severity of acute 
pancreatitis scores, and had significantly higher rates of persistent SIRS and longer length of 
stay. Given the increased severity among patients with imaging compared with those who did 
not undergo imaging, patients without imaging most likely also had IP. However, we limited 
our evaluation to the 149 patients with imaging-proven IP. These data indicate that nearly all 
TABLE 2. Comparisons Between IP Nonsurvivors and Survivors With Regard to Severity and 
Interventions
IP (n = 149)
Nonsurvivors (n = 5) Survivors (n = 144) P value
Risk factors for severity on admission
Age, y 58 ± 5 54 ± 17 .62
Male sex 3 (60) 61 (42) .65
BMI ≥ 30 1 (20) 48 (33) .67
Alcohol etiology 1 (20) 22 (15) .57
First episode 4 (80) 103 (72) 1.00
CCI 4 [3, 6] 1 [0, 2] .003
ACCI 5 [4, 7] 2 [0, 4] .01
Measures of severity at admission or ≤ 24h
BUN ≥ 25 1 (20) 15 (10) .44
HCT ≥ 44 0 (0) 26 (18) .59
APACHE II, ≤ 24h 11 [9, 14] 7 [5, 10] .07
BISAP, ≤ 24h 1 [1, 1] 1 [1, 2] .59
Markers of severity during hospitalization
Persistent SIRS 5 (100) 37 (26) .002
Persistent organ failure 2 (40) 0 (0) .0001
Length of stay, d 10 [9, 19] 4 [2, 7] .002
Need for ICU 3 (60) 7 (5) .002
EI 1 (20) 26 (18) 1.00
Interventions
Need for intubation 2 (40) 1 (0.7) .003
Need for dialysis NA NA NA
Need for pressors 1 (20) 0 (0) .03
Received antibiotics 4 (80) 58 (40) .16
NOTE. Values are expressed as mean ± standard deviation, median [Q1, Q3], and number (%).
APACHE, Acute Physiology and Chronic Health Evaluation; BISAP, bedside index for severity of acute pancreatitis; BMI, body mass 
index; BUN, blood urea nitrogen; EI, extrapancreatic infection; HCT, hematocrit.
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patients with interstitial pancreatitis have mild disease, with only 1% having persistent organ 
failure, a median length of stay of only 4 days, need for ICU in only 7%, mortality rate of only 
3%, and minimal need for intervention (intubation, dialysis, or pressors).
Table 2 compares severity and interventions between nonsurvivors and survivors with IP. 
Nonsurvivors had a significantly higher median CCI and ACCI and significantly higher rates 
of persistent SIRS and persistent organ failure. They also had an increased need for ICU, longer 
length of stay, and increased need for intubation and pressor support. If the patients who did 
not undergo imaging while hospitalized (n = 67) are included in this comparison, the results do 
not change (P > .05) (data not shown).
Table 3 shows the clinical details of the 5 nonsurvivors with IP. The highest CTSI was only 2 
within the first 7 days of hospitalization for all 5 nonsurvivors. Malignancy and severe liver 
disease were the comorbid conditions associated with death among the nonsurvivors. Among 
the 67 patients who did not undergo imaging, there was a single death as a result of severe liver 
disease.
Table 4 compares severity and interventions among the 149 patients with IP and the 8 patients 
with EXPN. The patients with EXPN were more likely to be male and have acute alcoholic 
pancreatitis compared with those with IP. There were no significant differences in measures 
of severity at admission or within 24 hours. Patients with EXPN had higher rates of persistent 
organ failure, increased need for ICU, a longer median length of stay, and increased need for 
intubation and pressor administration. The mortality rates were similar between both groups 
of patients.
TABLE 3. Clinical Characteristics of IP Nonsurvivors
Patient
Number of days 
from admission 
to death
Highest CTSI in 
first 7 days of 
hospitalization Comorbid diseases Cause of death
1 10 2 Severe liver disease Fulminant liver failure
2 9 2 Metastatic solid malignancy, 
peptic ulcer disease
Metastatic esophageal 
cancer
3 18 2 Metastatic solid malignancy Metastatic duodenal cancer
4 8 2 Diabetes Sepsis
5 30 2 Lymphoma Graft-vs-host disease
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TABLE 4. Comparison of Severity and Interventions Among Patients With IP and EXPN
IP (n = 149) EXPN (n = 8) P value
Risk factors for severity on admission
Age, y 54 ± 17 46 ± 11  .18
Male sex  64 (43) 7 (88) .01
BMI ≥ 30  49 (33)  4 (50)  .45
Alcohol etiology 23 (15)  4 (50) .01
First episode 107 (72) 6 (75) 1.00
CCI 1 [0, 2] 1 [0, 3] .58
ACCI 2 [0, 4] 2 [0, 4]  .80
Measures of severity at admission or ≤ 24h
BUN ≥ 25 16 (11) 1 (13)  1.0
HCT 44 26 (17) 3 (38)  .17
APACHE II, ≤ 24h 7 [5, 10] 8 [5, 13.5]  .38
BISAP, ≤ 24h 1 [1, 2] 1 [1, 2]  .80
Markers of severity during hospitalization
Persistent SIRS 52 (28) 5 (63) .05
Persistent organ failure 2 (1) 2 (25) .01
Length of stay, d 4 [2, 7] 9.5 [5.5, 13] .004
Need for ICU 10 (7) 3 (38)  .02
EI 27 (18) 2 (25) .64
Death  5 (3) 1 (13)  .27
Interventions
Need for intubation 3 (2) 2 (25) .02
Need for dialysis 0 (0) 1 (13)  .05
Need for pressors  1 (0.7)  2 (25)  .007
Received antibiotics 62 (42) 6 (75)  .08
NOTE. Values are expressed as number (%), median [Q1, Q3], or mean ±standard deviation.
APACHE, Acute Physiology and Chronic Health Evaluation; BISAP, bedside index for severity of acute pancreatitis; BMI, body mass 
index; BUN, blood urea nitrogen; EI, extrapancreatic infection; HCT, hematocrit.
DISCUSSION
Our study systematically evaluated severity of IP in a cohort of consecutive nontransferred 
patients. We found that IP was a very mild disease in nearly all patients with a median length of 
stay of only 4 days, persistent organ failure in only 1%, and a mortality rate of only 3%.
Mortality in IP was associated significantly with increased comorbidity, persistent SIRS, and 
persistent organ failure. It appears that comorbidity played a more important role in mortality 
than the severity of underlying IP. This is supported by 2 findings. First, measures of severity at 
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admission and within 24 hours were similar between nonsurvivors and survivors. Second, all 
of our nonsurvivors had a CTSI of only 2 during hospitalization. Because a CTSI of 2 represents 
pancreatic gland inflammation associated with only mild peripancreatic inflammation and no 
fluid collections, our nonsurvivors also clearly had very mild pancreatitis by imaging criteria.14
Prior autopsy studies4–6 also have shown an increased prevalence of comorbid diseases in 
patients with IP but have focused on those with severe acute pancreatitis4–6 and did not use 
a validated instrument to measure comorbidity. A few clinical studies of acute pancreatitis 
have used age as a surrogate for comorbidity.27,28 Other clinical studies have used the CCI48,49 
and Elixhauser index50,51 but focused on patients with severe acute pancreatitis48,49 and did not 
differentiate between patients with IP and NP on the basis of imaging studies.48–51
The mortality of patients with EI has been reported to be 28% in 2 prior studies that included 
patients with NP as well as IP.44,45 Our mortality rate of 3.7% among patients with IP who 
developed an EI was not significantly different from the overall IP mortality rate of 3% in our 
study. It would appear that EI has a stronger impact on mortality in NP than IP.
Prior studies evaluating disease severity in IP have had numerous methodologic limitations. 
First, these studies have included transferred patients who, in general, have more severe 
acute pancreatitis than direct admissions.23,24,52,53 Second, there are no prior studies that have 
distinguished between transient and persistent organ failure among patients with IP.9,18–20 
Several studies have reported that persistent organ failure has a mortality rate of 35% to 55% 
compared with 0% to 1% with transient organ failure,21,22,41 but failed to indicate how many 
patients had IP in their study cohorts. Third, prior studies have focused only on those patients 
who underwent radiologic imaging. The severity of those who did not undergo imaging was 
not determined. In the present study, we found that the severity of acute pancreatitis in patients 
without imaging was less than in those with imaging, suggesting that those without imaging 
likely had IP. Fourth, aside from a single study from Bruennler et al,17 no other studies have 
distinguished between IP and EXPN.
Extrapancreatic necrosis is defined as necrosis of the peripancreatic fat and tissue with a 
normally enhancing pancreatic gland on contrast-enhanced imaging studies.25 Although the 
accuracy of CT for diagnosing EXPN has not been studied in depth, a prior study showed 
correlation between CECT and surgical findings in patients with EXPN.25 Patients with an 
alcohol etiology were more likely to present with EXPN than with IP. Alcohol use has been 
shown previously to be a risk factor for pancreatic necrosis,54 and it also may be a risk factor 
for EXPN. There were no measures of severity at admission or within 24 hours of admission, 
which differentiated patients with EXPN from IP. However, patients with EXPN had increased 
severity of disease during hospitalization when compared with patients with IP. The likely 
inclusion of patients with EXPN in prior studies of IP is a potential explanation for the wide 
variation in rates of organ failure and mortality.
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In 2 prior clinical studies that have evaluated EXPN, the mortality rate was 8% in one study25 and 
100% in the other study.17 However, the results of these studies were limited by the inclusion 
of transferred patients.
The strengths of our study were as follows: (1) prospective data collection, (2) evaluation of 
a large number of consecutive direct admissions with exclusion of patients transferred from 
outside institutions, and (3) assessment of comorbidity using a prospectively validated scoring 
system that has been used previously in several other disease states.
The primary limitation of our study was that some patients did not undergo a CT scan to 
determine whether they had IP. However, if patients without imaging are combined with 
patients who underwent imaging, the rates of mortality and persistent organ failure were 
essentially the same as for patients who underwent imaging (Table 1).
In summary, almost all patients with IP experienced very mild disease. Comorbidity was a very 
important factor for mortality in IP. Because the severity of EXPN was greater than that of IP, 
EXPN must be distinguished from IP in clinical studies.
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ABSTRACT
Objective: In the revised Atlanta Classification of acute pancreatitis, the term necrotising 
pancreatitis also refers to patients with only extrapancreatic fat necrosis without pancreatic 
parenchymal necrosis (EXPN), as determined on contrast-enhanced CT (CECT). Patients with 
EXPN are thought to have a better clinical outcome, although robust data are lacking.
Methods: A post hoc analysis was performed of a prospective multicentre database including 
639 patients with necrotising pancreatitis on contrast-enhanced CT. All CECT scans were 
reviewed by a single radiologist blinded to the clinical outcome. Patients with EXPN were 
compared with patients with pancreatic parenchymal necrosis (with or without extrapancreatic 
necrosis). Outcomes were persistent organ failure, need for intervention and mortality. A 
predefined subgroup analysis was performed on patients who developed infected necrosis.
Results: 315 patients with EXPN were compared with 324 patients with pancreatic 
parenchymal necrosis. Patients with EXPN less often suffered from complications: persistent 
organ failure (21% vs 45%, p<0.001), persistent multiple organ failure (15% vs 36%, p<0.001), 
infected necrosis (16% vs 47%, p<0.001), intervention (18% vs 57%, p<0.001) and mortality (9% 
vs 20%, p<0.001). When infection of extrapancreatic necrosis developed, outcomes between 
groups were equal (mortality with infected necrosis: EXPN 28% vs pancreatic necrosis 18%, 
p=0.16).
Conclusion: EXPN causes fewer complications than pancreatic parenchymal necrosis. It 
should therefore be considered a separate entity in acute pancreatitis. Outcome in cases of 
infected necrosis is similar.
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INTRODUCTION
In a disease as complex as acute pancreatitis, correct terminology and clear definitions are 
essential in interdisciplinary communication among treating physicians as well as in reports of 
clinical research. In the 1992 Atlanta Classification, necrotising pancreatitis was defined as diffuse 
or focal area(s) of non-viable pancreatic parenchyma typically associated with extrapancreatic 
fat necrosis or non-enhanced pancreatic parenchyma >3 cm in length or involving >30% of 
the area of the pancreas.1 This definition did not include patients with extrapancreatic necrosis 
only (EXPN). Over the years a few small case series have described patients undergoing surgical 
removal of extensive extrapancreatic necrosis while the pancreatic parenchyma appeared to be 
viable.2–5 Since these first reports, no prospective study has compared the outcome of patients 
with EXPN with patients with pancreatic parenchymal necrosis (or, in short, pancreatic 
necrosis) in a large consecutive cohort.
The primary aim of this study was to investigate whether the rate of complications and mortality 
of patients with EXPN differs from that of patients with pancreatic necrosis with or without 
extrapancreatic necrosis. The second aim was to determine whether the rates of complications 
differ between patients with EXPN or pancreatic necrosis who develop infected necrosis.
METHODS
Patients
This was a post hoc analysis of a database of a prospective multicentre cohort study.6 Patients 
with acute pancreatitis were included between March 2004 and November 2008 in all eight 
Dutch university medical centres and 13 large teaching hospitals of the Dutch Pancreatitis Study 
Group. During the study period, all patients admitted with acute pancreatitis were screened for 
eligibility for the Dutch PROPATRIA and PANTER trials.7 8 Regardless of eligibility for the 
randomised trials, patients were asked for informed consent for registration in the prospective 
database on admission.
Details on the general treatment protocol, data collection and definitions of outcomes (eg, 
definition of primary infected necrosis or organ failure) of this cohort have been described 
previously.6 Infected necrosis was defined as a positive culture of pancreatic or extrapancreatic 
necrosis obtained by means of fine needle aspiration or from the first drainage procedure or 
first necrosectomy, or the presence of gas in the peripancreatic collection on contrast-enhanced 
CT. In the current study, new analyses were performed specifically to compare patients with 
pancreatic necrosis (with or without extrapancreatic necrosis) with patients with EXPN as 
determined on CECT. Patients with interstitial pancreatitis were excluded. The following 
baseline parameters were assessed: age, aetiology, American Society of Anaesthesiologists 
(ASA) classification on admission, Acute Physiology, Age, and Chronic Health Evaluation 
246 | Chapter 13
(APACHE)-II score on admission, Imrie or Modified Glasgow score, C reactive protein (CRP) 
during the first 48h of admission and number of transferred patients from other hospitals to 
one of the hospitals of the Dutch Pancreatitis Study Group. The following outcome parameters 
were assessed: organ failure, multiple organ failure, development of sterile or infected necrosis, 
conservative treatment or intervention and mortality.
FIGURE 1 Extrapancreatic necrosis. (A, B) Axial and coronal reconstructed contrast-enhanced CT scans 
in a 37-year-old man with alcohol-induced pancreatitis 6 days after onset of symptoms. There is normal 
enhancement of the pancreatic parenchyma (white asterisks) with a poorly marginated peripancreatic 
collection (arrows) extending into the left anterior pararenal compartment. (C, D) Axial and coronal 
reconstructed contrast-enhanced CT scans 2 months later, again showing a normal enhancement of 
the pancreas surrounded by a well encapsulated heterogeneous peripancreatic collection (arrows) with 
areas of non-liquid (fat) densities (arrowheads) in the left anterior pararenal compartment. During 
surgery a large amountof necrotic material was debrided and pus was drained. The patient recovered 
uneventfully with preservation of normal pancreatic function.
A B
C D
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The study was conducted in accordance with the principles of the Declaration of Helsinki 
and was investigator-initiated and investigator-driven. The ethics review board of each 
participating hospital approved the study. Patients or their legal representatives gave written 
informed consent. We adhered to the STROBE statement guidelines for reporting on 
observational cohort studies.9
Definitions of extrapancreatic necrosis and pancreatic necrosis
Pancreatic necrosis was defined as focal or diffuse non-enhancement of the pancreatic gland 
as determined on CECT. Extrapancreatic necrosis only without pancreatic necrosis (ie, EXPN; 
figure 1) was defined as extrapancreatic morphological changes exceeding fat stranding 
with complete enhancement of the pancreatic parenchyma without signs of focal or diffuse 
non-enhancement able to be determined on the final CECT of hospitalisation or before any 
intervention. Patients with both pancreatic and extrapancreatic necrosis were included in the 
pancreatic necrosis group (figure 2). Patients with pancreatic necrosis without extrapancreatic 
necrosis, which is very rare, were also included in the group of patients with pancreatic necrosis.
FIGURE 2 Acute necrotising pancreatitis. 
Axial contrast-enhanced CT scan in a 45-year-
old woman with acute biliary pancreatitis. 
There is non-enhancement of the neck 
and part of the body of the pancreas (white 
asterisk) indicative of parenchymal necrosis 
with normal enhancement of the tail of the 
pancreas (black asterisk).
Evaluation of imaging
CECT generally was performed approximately 7 days after admission. In patients with clinical 
deterioration or without clinical improvement, additional CECTs were performed. In patients 
participating in the PROPATRIA trial, a CECT after 7–10 days was part of the protocol. 
Radiologists in the participating centres assessed the CECT for the presence or absence of 
necrotising pancreatitis. Based on their evaluation, patients were included in the prospective 
database. After closure of the database following completion of the PANTER trial, all CECTs 
performed during and after hospitalisation were reviewed by a single experienced abdominal 
radiologist (TLB) who was unaware of the patients’ clinical background, possible interventions 
and the initial radiology report. Because extrapancreatic or parenchymal necrosis can be missed 
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on CECTs performed early in the disease course, all CECTs performed in each patient were 
reviewed. The final decision on the presence or absence of EXPN or pancreatic necrosis was 
based on the final CECT of hospitalisation or before any intervention.
Statistical analysis
Continuous data are presented as median with interquartile range (IQR). Differences were 
tested with the Mann–Whitney U test. Proportions were compared by the χ2 test, the Fisher 
exact or the linear-by-linear association test, as appropriate. To assess whether EXPN is an 
independent predictor of clinical outcome, multivariable regression analysis was performed 
adjusting for potential confounders (eg, prognostic variables on admission such as age). The 
following clinical outcomes were analysed: persistent organ failure, persistent multiple organ 
failure, infected necrosis, the need for intervention and mortality. EXPN was entered into the 
model as the main factor. As co-variables, all prognostic variables that were potentially different 
between patients with EXPN and those with pancreatic necrosis on admission in univariable 
analysis (p<0.2) were included. The results are reported as adjusted odd ratios (ORs) with 95% 
confidence intervals (CIs). A two-sided p<0.05 was considered statistically significant. Analyses 
were performed with SPSS V.15.0 (SPSS).
RESULTS
Patients
Of the 639 patients included in the prospective database, 315 patients (49%) had EXPN 
(determined on CECT) and 324 patients (51%) had signs of pancreatic necrosis (with or without 
extrapancreatic necrosis) (figure 3). Only four of the 639 patients (0.6%) had pancreatic necrosis 
without any signs of peripancreatic necrosis and these patients were included in the pancreatic 
necrosis group. Patients with interstitial pancreatitis were excluded. Baseline characteristics 
are shown in table 1. No differences were seen in age, sex, aetiology, ASA classification and 
predicted severity based on APACHE-II scores and CRP levels. The median Imrie score at 
48h after admission was higher in patients with pancreatic necrosis (4 vs 3, p<0.001). The 
percentage of transferred patients was also higher in patients with pancreatic necrosis (36% vs 
13%, p<0.001).
Use of CECT
A median number of 2 (IQR 4–7) CECTs were performed in each patient (table 1). Patients 
with EXPN were scanned less frequently than those with pancreatic necrosis (median 2 (IQR 
1–4) vs 6 (IQR 3–10), p<0.001). The overall median time between onset of symptoms and the 
final CECT of hospitalisation or before any intervention was 14 days (IQR 7–46). Patients with 
EXPN had their final CECT earlier than patients with pancreatic necrosis (median 9 days (IQR 
5–21) after admission vs 34 days (IQR 9–71), p<0.001).
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non-enhancement able to be determined on the ﬁnal CECT of
hospitalisation or before any intervention. Patients with both
pancreatic and extrapancreatic necrosis were included in the
pancreatic necrosis group (ﬁgure 2). Patients with pancreatic
necrosis without extrapancreatic necrosis, which is very rare,
were also included in the group of patients with pancreatic
necrosis.
Evaluation of imaging
CECT generally was performed approximately 7 days after
admission. In patients with clinical deterioration or without
clinical improvement, additional CECTs were performed. In
patients participating in the PROPATRIA trial, a CECT after 7–
10 days was part of the protocol. Radiologists in the participat-
ing centres assessed the CECT for the presence or absence of
necrotising pancreatitis. Based on their evaluation, patients were
included in the prospective database. After closure of the data-
base following completion of the PANTER trial, all CECTs per-
formed during and after hospitalisation were reviewed by a
single experienced abdominal radiologist (TLB) who was
unaware of the patients’ clinical background, possible interven-
tions and the initial radiology report. Because extrapancreatic or
parenchymal necrosis can be missed on CECTs performed early
in the disease course, all CECTs performed in each patient were
reviewed. The ﬁnal decision on the presence or absence of
EXPN or pancreatic necrosis was based on the ﬁnal CECT of
hospitalisation or before any intervention.
Statistical analysis
Continuous data are presented as median with interquartile
range (IQR). Differences were tested with the Mann–Whitney U
test. Proportions were compared by the χ2 test, the Fisher exact
or the linear-by-linear association test, as appropriate. To assess
whether EXPN is an independent predictor of clinical outcome,
multivariable regression analysis was performed adjusting for
potential confounders (eg, prognostic variables on admission
such as age). The following clinical outcomes were analysed:
persistent organ failure, persistent multiple organ failure,
infected necrosis, the need for intervention and mortality.
EXPN was entered into the model as the main factor. As
co-variables, all prognostic variables that were potentially
different between patients with EXPN and those with pancreatic
necrosis on admission in univariable analysis (p<0.2) were
included. The results are reported as adjusted odd ratios (ORs)
with 95% conﬁdence intervals (CIs). A two-sided p<0.05 was
considered statistically signiﬁcant. Analyses were performed
with SPSS V.15.0 (SPSS).
RESULTS
Patients
Of the 639 patients included in the prospective database, 315
patients (49%) had EXPN (determined on CECT) and 324
patients (51%) had signs of pancreatic necrosis (with or without
extrapancreatic necrosis) (ﬁgure 3). Only four of the 639
patients (0.6%) had pancreatic necrosis without any signs of
peripancreatic necrosis and these patients were included in the
pancreatic necrosis group. Patients with interstitial pancreatitis
were excluded. Baseline characteristics are shown in table 1. No
differences were seen in age, sex, aetiology, ASA classiﬁcation
and predicted severity based on APACHE-II scores and CRP
levels. The median Imrie score at 48 h after admission was
higher in patients with pancreatic necrosis (4 vs 3, p<0.001).
The percentage of transferred patients was also higher in
patients with pancreatic necrosis (36% vs 13%, p<0.001).
Use of CECT
A median number of 2 (IQR 4–7) CECTs were performed in
each patient (table 1). Patients with EXPN were scanned less
frequently than those with pancreatic necrosis (median 2 (IQR
1–4) vs 6 (IQR 3–10), p<0.001). The overall median time
between onset of symptoms and the ﬁnal CECT of hospitalisa-
tion or before any intervention was 14 days (IQR 7–46).
Patients with EXPN had their ﬁnal CECT earlier than patients
with pancreatic necrosis (median 9 days (IQR 5–21) after admis-
sion vs 34 days (IQR 9–71), p<0.001).
Outcomes
The different outcomes of patients with pancreatic necrosis and
EXPN are presented in table 2. All outcomes occurred less
often in patients with EXPN. More speciﬁcally, patients with
EXPN had a signiﬁcantly lower risk of developing single or mul-
tiple organ failure. Twice as many patients with pancreatic
necrosis developed persistent organ f ilure duri g admission
(21% vs 45%, p<0.001). Persistent multiple organ failure was
Figure 2 Acute necrotising pancreatitis. Axial contrast-enhanced CT
scan in a 45-year-old woman with acute biliary pancreatitis. There is
non-enhancement of the neck and part of the body of the pancreas
(white asterisk) indicative of parenchymal necrosis with normal
enhancement of the tail of the pancreas (black asterisk). Figure 3 Study population.
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FIGURE 3. Study population.
TABLE 1. Admission characteristics of patients with extrapancreatic necrosis only (EXPN) compared 
with patients with pancreatic parenchymal necrosis 
Characteristic
All patients
(N=639)
EXPN
(N=315)
Pancreatic necrosis
(N=324) p Value
Age (years) 58 (45–70) 58 (44–72) 58 (45–69) 0.24†
Male sex 398 (62%) 184 (58%) 214 (66%) 0.05‡
Aetiology 0.26§
Gallstones 304 (48%) 149 (47%) 155 (48%)
Alcohol abuse 150 (24%) 76 (24%) 74 (23%)
Other 63 (10%) 37 (12%) 26 (8%)
Unknown 122 (19%) 53 (17%) 69 (21%)
ASA class on admission 0.79¶
I (healthy status) 202 (32%) 97 (31%) 105 (32%)
II (mild systemic disease) 347 (54%) 174 (55%) 173 (53%)
III (severe systemic disease) 90 (14%) 44 (14%) 46 (14%)
Predicted severity of pancreatitis
APACHE-II score on admission 8 (5–11) 7 (5–10) 8 (5–11) 0.98†
Imrie/modified Glasgow score after 48h 3 (2–5) 3 (2–4) 4 (2–5) <0.001†
Highest CRP level in first 48h 291 (216–382) 293 (216–278) 290 (215–388) 0.60†
Transferred from other hospital 156 (24%) 40 (13%) 116 (36%) <0.001‡
No. of CECTs performed per patient* 2 (4–7) 2 (1–4) 6 (3–10) <0.001†
Timing of final CECT* (days after 
admission)
14 (7–46) 9 (5–21) 34 (9–71) <0.001†
Continuous variables are median (IQR). *Before discharge or any intervention. †Mann–Whitney U test. ‡Fisher exact test. §Pearson 
χ2 test. ¶Linear-by-linear association. APACHE, Acute Physiology Age and Chronic Health Evaluation; ASA, American Society of 
Anaesthesiologists; CECT, contrast-enhanced CT; CRP, C-reactive protein.
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Outcomes
The different outcomes of patients with pancreatic necrosis and EXPN are presented in table 2. 
All outcomes occurred less often in patients with EXPN. More specifically, patients with EXPN 
had a significantly lower risk of developing single or multiple organ failure. Twice as many 
patients with pancreatic necrosis developed persistent organ failure during admission (21% vs 
45%, p<0.001). Persistent multiple organ failure was also seen in twice as many patients with 
pancreatic necrosis (15% vs 36%, p<0.001). Patients with EXPN had a lower risk of developing 
infected necrosis (16% vs 47%, p<0.001). The need for intervention was lower in patients with 
EXPN (18% vs 57%, p<0.001). Finally, the death rate in patients with EXPN was significantly 
lower (9% vs 20%, p<0.001).
TABLE 2. Outcome of patients with extrapancreatic necrosis only (EXPN) compared with patients 
with pancreatic parenchymal necrosis
Characteristic
EXPN
(N=315)
Pancreatic necrosis
(N=324) p Value†
Organ failure
At any time during admission 77 (24%) 163 (50%) <0.001
At any time during admission, persistent 66 (21%) 147 (45%) <0.001
In the first week of admission 47 (15%)   93 (29%) <0.001
Multiple organ failure
At any time during admission 56 (18%) 138 (43%) <0.001
At any time during admission, persistent 46 (15%) 115 (36%) <0.001
In the first week of admission 30 (10%)   64 (20%) <0.001
Sterile or infected necrosis
Sterile necrosis 264 (84%) 173 (54%) <0.001
Primary infected necrosis 51 (16%) 151 (47%) <0.001
Conservative treatment or intervention
Conservative treatment 258 (82%) 139 (43%) <0.001
Any intervention* 57 (18%) 185 (57%) <0.001
Emergency laparotomy 3 (1%) 29 (9%) <0.001
PCD (as first intervention) 37 (12%)   94 (29%) <0.001
Necrosectomy‡ 40 (13%) 129 (40%) <0.001
Mortality 29 (9%) 64 (20%) <0.001
*Emergency laparotomy, PCD or necrosectomy.
†Fisher exact test.
‡With or without previous PCD or emergency laparotomy. PCD, percutaneous catheter drainage.
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After adjustment for potential confounding factors with multi-variable regression, patients 
with EXPN still had better clinical outcomes. After adjusting for male sex, Imrie score and 
transferred patients, EXPN was independently associated with a lower risk of organ failure 
(adjusted OR 0.53, CI 0.37 to 0.78, p<0.001), multiple organ failure (adjusted OR 0.48, CI 
0.32 to 0.72, p<0.001), infected necrosis (adjusted OR 0.30, CI 0.20 to 0.45, p<0.001), any 
intervention (adjusted OR 0.25, CI 0.17 to 0.38, p<0.001) and mortality (adjusted OR 0.59, CI 
0.35 to 0.97, p=0.04).
TABLE 3. Outcome in subgroup of patients with primary infected extrapancreatic necrosis only 
(EXPN) or pancreatic parenchymal necrosis
Characteristic
Infected
EXPN (N=51)
Infected pancreatic
necrosis  (N=151) p Value‡
Organ failure
At any time during admission 31 (61%) 101 (67%) 0.50
At any time during admission, persistent 28 (55%) 90 (60%) 0.62
Multiple organ failure
At any time during admission 26 (51%) 86 (57%) 0.52
At any time during admission, persistent 21 (41%) 70 (46%) 0.63
Conservative treatment or intervention
Conservative treatment 4 (8%) 9 (6%) 0.74
Any intervention* 47 (92%) 142 (94%) 0.74
Emergency laparotomy 0 (0%) 4 (3%) 0.58
PCD (as first intervention) 32 (63%) 84 (56%) 0.42
PCD only† 14 (28%) 34 (23%) 0.57
Necrosectomy§ 33 (65%) 108 (72%) 0.23
Mortality 14 (28%) 27 (18%) 0.16
*Emergency laparotomy, PCD or necrosectomy.
†In subgroup of patients with PCD as first intervention.
‡Fisher exact test.
§With or without previous PCD or emergency laparotomy. PCD, percutaneous catheter drainage.
Subgroup analysis of primary infected necrosis
The subgroup of 202 patients who developed infected necrosis was separately analysed. 
There were no significant differences between patients with infected EXPN and patients with 
infected pancreatic necrosis regarding all the aforementioned clinical outcomes (table 3). The 
incidence of persistent organ failure (55% of EXPN vs 60% of pancreatic necrosis, p=0.62) 
and persistent multiple organ failure (41% of EXPN vs 46% of pancreatic necrosis, p=0.63) 
was similar. Almost all patients with infected necrosis required an intervention (92% vs 94%, 
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p=0.74). The likelihood of recovery following percutaneous catheter drainage without the need 
for additional necrosectomy was 28% versus 23% (p=0.57). Mortality did not differ significantly 
between the two groups (28% vs 18%, p=0.16).
DISCUSSION
This study, evaluating the clinical outcome of a large prospective cohort of patients with 
necrotising pancreatitis, shows that patients with EXPN (as determined on CECT) have a better 
prognosis than patients with pancreatic necrosis. However, in case of infected necrosis, rates 
of complication and mortality are similar. To our knowledge, this is the first report on clinical 
outcomes of EXPN in a large unselected cohort of patients with acute necrotising pancreatitis.
The presence of extrapancreatic necrosis as a separate entity in the absence of pancreatic 
necrosis was first recognised by Howard and Wagner in 1989.2 In a group of 13 patients, 
pancreatography after debridement of necrosis showed an intact pancreatic duct in most 
patients. Subsequently, Madry and Fromm reported the results of 40 patients operated for 
infected necrosis.4 Patients were described as having necrotic retroperitoneal fat without 
overt pancreatic necrosis. Sakorafas and colleagues were the first to report a better outcome in 
patients with EXPN who underwent surgical debridement.5 Operative and CT findings of 12 
patients operated for necrotising pancreatitis between 1983 and 1997 suggested that necrotising 
pancreatitis did not always involve the pancreatic parenchyma. In contrast to the current 
study, this retrospective study only reported the outcome of patients who underwent surgical 
debridement for necrotising pancreatitis and did not provide the clinical outcome of the total 
group of patients (with or without organ failure, sterile or infected, conservative treatment or 
after intervention). In their study, including 12 patients with EXPN, mortality was 8% which is 
comparable to the 9% death rate found in 315 patients with EXPN in this study. In both studies 
the death rate in patients with pancreatic necrosis was 20%. Accurate comparison of death rates 
between the two studies, however, is hampered by differences in patient characteristics, CECT 
assessment of EXPN, and study design (ie, experienced single-centre study vs multicentre study 
with academic and non-academic hospitals).
In the present study EXPN was diagnosed if CECT showed extrapancreatic fat with 
morphological changes that exceeded fat stranding and if the pancreatic parenchyma did not 
show any signs of necrosis as determined on the last CECT of hospitalisation or before any 
intervention. We cannot exclude, however, that small focal areas of parenchymal necrosis were 
overlooked on CT in patients with EXPN. Inversely, extrapancreatic morphological changes 
could also consist of fluid only instead of fat necrosis. Previous studies have indeed questioned 
the accuracy of CECT for diagnosing EXPN.10 11 Small extrapancreatic collections (eg, <2 cm 
in diameter) most likely contain fluid which can easily be absorbed while large extrapancreatic 
effusions (eg, >5 cm in diameter) are less easily absorbed.12 Collections that do not dissolve 
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early in the course of the disease will most likely contain some degree of peripancreatic tissue 
necrosis and, hence, have a greater chance of being detected. If extrapancreatic changes 
have been overestimated and incorrectly scored as EXPN (while those patients actually had 
interstitial pancreatitis without necrosis), this could potentially question the validity of the 
differences found in this study. It is known that patients with interstitial pancreatitis have a 
better prognosis than patients with EXPN. A recent study from Boston compared the outcome 
of patients with interstitial pancreatitis with that of eight patients with EXPN.13 Patients with 
interstitial pancreatitis had a better outcome in terms of organ failure, length of hospital stay, 
need for interventions and mortality, but this study did not include patients with pancreatic 
necrosis.
However, we have several reasons to believe that the presence of EXPN has not been 
overestimated in this study. First, several studies have actually demonstrated a good accuracy 
of CECT for EXPN when CECT findings were compared with the presence of fat necrosis at 
operation or autopsy.14–16 Second, in patients with EXPN the median time between onset of 
symptoms and the last CECT before discharge was 9 days. Extrapancreatic collections that 
persist throughout the second week after onset of symptoms will, in the majority of cases, 
contain some amount of fat necrosis.17 18 Third, the APACHE-II scores on admission and CRP 
levels after 48h did not differ between patients with EXPN and those with pancreatic necrosis. 
If patients with interstitial disease (with extrapancreatic fluid instead of extrapancreatic 
necrosis) had been incorrectly scored as EXPN and included in the study, one could speculate 
that the median severity scores on admission in the EXPN group would have been lower than 
the median severity scores of patients with pancreatic necrosis. However, as patients with 
interstitial disease (based on CECT) were not included in the study, we did not investigate 
whether the severity scores in this group of patients is actually lower than in patients with 
EXPN. In a previous multicentre study we found a death rate of 0.8% in patients with interstitial 
pancreatitis (the death rate in patients with EXPN in this study was 9%).19 Although the Imrie 
scores did differ significantly after 48h, these scores reflect the ongoing inflammatory response 
and are likely to be more severe in patients with parenchymal necrosis. The same difference in 
ongoing inflammatory response between groups was seen in patients with organ failure during 
the first week.
The pathophysiological explanation for the better outcome of patients with EXPN remains 
speculative. It is generally believed that trypsin activation within pancreatic acinar cells leads 
to autodigestion and local inflammation.20 21 Following a cascade of intracellular events, the 
pancreatic acinar cells may become necrotic. In some patients, extensive local inflammation 
causes a severe systemic inflammatory response syndrome that may lead to organ failure.22 23 
In EXPN, necrosis of the acinar cells does not seem to occur and the pancreatic parenchyma 
is preserved  (at least on CECT). This might be indicative of a less severe local inflammatory 
response. Subsequently, a less severe local inflammatory response could explain the less severe 
systemic inflammatory response in patients with EXPN. Another potential explanation may 
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be that the amount of released inflammatory mediators or cytokines in EXPN is lower. The 
concentration of inflammatory mediators might be higher in the pancreatic acinar cells than in 
the extrapancreatic fatty tissue. Parenchymal necrosis causes these mediators to be released into 
the systemic circulation. Conceivably, the higher the amount of mediators released, the more 
severe the systemic inflammatory response will be.24 Lastly, it might be possible that ductal 
disruption, which may occur with parenchymal necrosis, causes more complications. Ductal 
disruption could facilitate bacterial invasion of pancreatic tissue. In this study we found that 
patients with pancreatic necrosis developed infection significantly more often (47% vs 16%).
In patients with necrotising pancreatitis, pancreatic exocrine and endocrine insufficiencies 
and pancreatic fistulas following interventions are common long-term complications.8 25 26 In 
theory, EXPN will not cause these complications. None of the patients with EXPN in the study 
by Sakorafas developed endocrine or exocrine insufficiency during long-term follow-up. In 
a previous study, pancreatic fistulas were shown to cause considerable morbidity.27 For this 
cohort, however, our prospective database did not include data on exocrine and endocrine 
insufficiency or pancreatic fistulas.
This clinical study does not necessarily prove, in terms of biology, that EXPN is a separate 
entity. Based on the results of this study, however, EXPN should be recognised as a different 
clinical entity within necrotising pancreatitis (compared with parenchymal necrosis) because it 
heralds several significant clinical implications. First, in cases of EXPN determined on CECT, 
surgeons should refrain from debridement of the pancreas during necrosectomy (eg, in case of 
infected necrosis) to prevent iatrogenic pancreatic injury. This knowledge is crucial as during 
surgery the differentiation between necrotic pancreatic parenchyma and peripancreatic fat 
necrosis can be difficult. Second, to compare reports of clinical studies on new interventions 
in necrotising pancreatitis accurately, future studies should report the number of patients with 
EXPN. Third, the presence of EXPN is a favourable prognosticator compared with pancreatic 
necrosis. The presence of EXPN should not change overall management but does provide 
the clinician with information for risk stratification. Fourth, our finding that infected EXPN 
has a similar poor outcome to that of infected pancreatic necrosis underlines the importance 
of adequate monitoring and timely recognition and treatment of sepsis in all patients with 
necrotising pancreatitis.
In summary, this study provides necessary data on the outcome of patients with EXPN. The 
prognosis of patients with non-infected EXPN has been shown to be significantly better than 
that of patients with non-infected pancreatic necrosis and could be considered a different 
clinical entity in acute pancreatitis. In case of infection, however, the prognosis is similar 
among patients with EXPN and those with parenchymal necrosis.
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ABSTRACT
Introduction: In acute pancreatitis, the extent of pancreatic parenchymal necrosis is deemed 
an important determinant of clinical outcome. Data on the impact of location of pancreatic 
necrosis is lacking. We investigated the clinical impact of both extent and location of pancreatic 
necrosis in a large cohort.
Material and Methods: This was a prospective observational cohort study. During a 4.5-year 
study period, all consecutive patients with pancreatic necrosis on contrast-enhanced computed 
tomography (CT) were included in 21 Dutch hospitals. Two radiologists, blinded to clinical 
outcome, independently reviewed all CTs and classified pancreatic necrosis with respect to its 
extent and location (i.e. the pattern of involvement) according to predefined criteria. Clinical 
severity parameters were available from a prospective database and included persistent organ 
failure, infected pancreatic necrosis, invasive intervention, and death.
Results: A total of 324 patients with pancreatic necrosis were included. Extent of pancreatic 
necrosis was less than 30% in 132 patients (40%), between 30-50% in 83 patients (26%), and 
over 50% in 109 patients (34%). All severity parameters, except mortality, differed significantly 
(p<0.001) between patients with less than 30% compared with over 30% pancreatic necrosis, 
but not between patients with 30 to 50% versus those with over 50% pancreatic necrosis. 
Central gland necrosis was the most frequent pattern of necrosis encountered. All outcomes 
studied were significantly associated with location of pancreatic necrosis (p<0.001). Outcomes 
were poorer in patients with right-sided, central gland, and subtotal necrosis. In most 
multivariable analyses, the location of pancreatic necrosis was independently and most strongly 
associated with clinical outcomes.
Conclusion: Clinical severity of necrotizing pancreatitis is most strongly associated with 
location of pancreatic necrosis. Patients with right-sided, central gland, and subtotal necrosis 
have the poorest outcomes.
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INTRODUCTION
Around one in five patients with acute pancreatitis develops pancreatic parenchymal necrosis 
(in short, pancreatic necrosis). These patients suffer frequently from local and systemic 
complications with an overall mortality of 5-10% (1,2). Computed tomography (CT) is regarded 
the standard technique for imaging patients with severe acute pancreatitis (3,4). CT is used for 
diagnosis and severity classification of the disease and its complications. Local complications 
depicted on CT that influence clinical outcome are the presence of pancreatic necrosis and 
associated peripancreatic collections (4-6). Several studies have evaluated the association between 
extent of pancreatic necrosis and clinical outcomes, with varying results. Some have found 
a strong linear correlation between extent of pancreatic necrosis and clinical outcome (7-18), 
others did not (19-28). Particularly, varying associations have been reported for patients with 30-
50% versus those with more than 50% pancreatic necrosis. Several reports have also studied the 
clinical significance of location of pancreatic necrosis (7-9,20,29-33), again, with conflicting results. 
Previous studies on extent and location of pancreatic necrosis are limited due to smaller study 
populations (median 82, range 32-161 patients), retrospective acquisition of clinical data, 
selected study populations (e.g. alcoholic etiology or cohorts undergoing invasive therapy or 
managed non-operatively), heterogeneity of study outcomes and severity parameters (varying 
from differing criteria for organ failure, admission to intensive care unit or length of hospital 
stay to need for intervention), use of outdated imaging techniques (before the era of multisclice 
CT technique), performed in an era of different invasive intervention criteria (for example, 
early surgical intervention), or spanning longer time periods (median 7 years, range 2-12 
years). Hence, we performed this study with the following aims; (a) to analyze and classify the 
extent and location of pancreatic necrosis and (b) to study the association between extent and 
location of pancreatic necrosis (based on the pattern of involvement) and clinical outcome.
MATERIALS AND METHODS
Study Design 
This was an observational cohort study using a prospectively collected database of patients with 
a primary episode of necrotizing pancreatitis enrolled between March 2004 and November 
2008 at 21 centers of the Dutch Pancreatitis Study Group. The ethics review board of all 
participating hospitals approved the study protocol. Written informed consent was obtained 
from all patients or their legal representatives. The original cohort consisted of 639 patients 
with necrotizing pancreatitis, including those with extrapancreatic necrosis alone. The clinical 
outcomes of these patients have been described previously (34). For the current study, the subset 
of patients who had pancreatic necrosis was selected from this cohort. 
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Pancreatic Necrosis
Pancreatic necrosis was defined as areas of nonenhancement of pancreatic parenchyma on 
contrast-enhanced CT (CECT) (4-6). The extent and anatomic location of pancreatic necrosis 
were recorded on all CECTs before any kind of intervention or death. 
Extent of necrosis: The full extent of pancreatic necrosis was estimated visually as <30%, between 
30-50%, and >50% (5,6). 
Anatomic location of necrosis: Per pancreatic region (head, neck, body, and tail) the extent of 
involvement of necrosis was estimated visually as <50%, between 50% and 100%, and 100%. 
The porto-mesenteric confluence was used as an anatomic landmark for subdividing the 
pancreas into four regions (35,36). The pancreatic head (including the uncinate process) was 
defined as the portion of the pancreas right of the porto-mesenteric confluence. The pancreatic 
neck was defined as the portion of pancreas ventral to the porto-mesenteric confluence. The 
pancreatic body and tail was defined as the portion of the pancreas left to the pancreatic neck. 
The border between the body and tail was defined as halfway between the pancreatic neck and 
the left margin of the pancreas (35). 
Pattern of necrosis: Subsequently, pancreatic necrosis was classified in the following five 
categories based on the dominant location of involvement, modified from Kemppainen et al (8); 
right-sided necrosis, central gland necrosis, left-sided necrosis, subtotal necrosis, and scattered 
necrosis (Fig. 1). Right-sided necrosis was defined as lack of enhancement primarily in the 
pancreatic head (at least 50% of area involved) with or without little necrosis of other parts of 
the pancreas (Fig. 2). Central gland necrosis was defined as transparenchymal (necrosis of the 
entire anteroposterior width and craniocaudal length of the pancreas) lack of enhancement 
of pancreatic neck and/or body with normal enhancement of pancreatic head and viable 
upstream tail of at least 3 cm (Fig. 3). Left-sided necrosis was defined as lack of enhancement 
of pancreatic tail with or without involvement of the body and normal enhancement of head 
and neck of the pancreas (Fig. 4). Subtotal necrosis was defined as lack of enhancement of 
pancreatic neck, body and greater part of pancreatic head and tail (with or without sparing 
of small part of pancreatic head and tail) (Fig. 5). Scattered necrosis was defined as uni- or 
multifocal area(s) of lack of enhancement throughout the pancreas, without complete thickness 
or transparenchymal necrosis (i.e. partial thickness necrosis) (Fig. 6).
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Pattern 1 – Right-sided necrosis Pattern 2 – Central gland necrosis
Pattern 3 – Left-sided necrosis Pattern 4 – Subtotal necrosis
Pattern 5 – Scattered necrosis
FIGURE 1. Patterns of pancreatic necrosis
FIGURE 2A and B. Right sided necrosis – pattern 1. (A) CT showing normal enhancement of 
pancreatic body and tail, whereas the greater part of the pancreatic head (B) shows non-enhancement 
(small arrows).
A B
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FIGURE 3A and B. Central gland necrosis – pattern 2. (A) CT depicts an area of non-enhancement 
at the body of the pancreas (arrowhead) representing <30% extent of necrosis with viable upstream 
pancreatic tissue. (B) Follow-up CT at day 17 shows a significant enlargement of the associated necrotic 
collection (arrows) abutting the stomach, likely related to a disrupted pancreatic duct. 
FIGURE 4A and B. Left sided necrosis – pattern 3. (A) CT shows an area of necrosis at the pancreatic 
tail with associated necrotic collection in the left retroperitoneal space (arrows). (B) Follow-up CT 
at day 24 shows stable non-enhancement of pancreatic tail with associated heterogeneous necrotic 
collection (arrows) which has diminished in size.
A B
A B
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FIGURE 5A and B. Subtotal necrosis – pattern 4. (A) CT on the day of admission shows a large area of 
hypo-perfusion of the pancreatic body and tail and part of the head, likely representing >90% necrosis 
(arrows). (B) Follow-up CT on day 14 confirms necrosis of the pancreatic parenchyma for more than 
90% with small area of remaining vital pancreatic parenchyma in the pancreatic head (arrowhead). 
There is an associated heterogeneous partially encapsulated acute necrotic collection (arrows).
FIGURE 6. Scattered necrosis – pattern 5. 
CT depicts multifocal small areas of non-
enhancement in pancreatic body and tail 
(small arrows) with associated peripancreatic 
necrotic collections.
CT Acquisition and Analysis
CECTs from all registered patients (including imaging performed at referring centers) 
performed during hospitalization was retrieved and reviewed soft copy using open source 
DICOM viewer software (32-bit OsiriX version 3.3, Geneva, Switzerland). Because this was 
a multicenter study, a variety of CT scanners (all performed on multidetector CT; 16-slice 
or higher) with varying CT parameters had been used. In all patients, at least one CECT 
in the pancreatic or portal venous phase was performed and available for review during 
hospitalization. The decision to perform the index CECT and all consecutive CECTs was made 
A B
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by discretion of the attending physicians, in general because of deteriorating clinical condition 
of the patient. In the PROPATRIA trial, CECT was performed per protocol 7-10 days after 
admission and on demand therefore and thereafter (37). The first CECT performed after 72 
hours after symptom onset was used for assessment of pancreatic necrosis, since early CT may 
miss the presence and extent of pancreatic necrosis (3-6). All subsequent CTs were reviewed 
for progressive or late onset of pancreatic necrosis. All digitalized CECTs were reviewed 
retrospectively and independently by two radiologists (T.L.B. and I.G.S., with 10 and 5 years 
experience in abdominal imaging, respectively), blinded to clinical outcome, for assessment of 
extent, location, and pattern of pancreatic necrosis. Consensus between the two observers was 
reached when discrepant results were obtained. 
Clinical Data and Outcome
The demographic, laboratory, and clinical data until discharge or death were recorded 
prospectively. The following predefined clinical outcome parameters were collected: in-
hospital mortality, persistent organ failure (lasting more than 48 hours), infection of pancreatic 
or extrapancreatic necrosis (infected necrosis), need for invasive intervention (endoscopic 
or percutaneous drainage, surgical, or endoscopic necrosectomy), and the composite of 
major morbidity and death (presence of at least one of the aforementioned clinical outcome 
parameters). Severe acute pancreatitis was defined as persistent organ failure adopted from the 
2012 Revised Atlanta Classification (38).
Data Analysis
Analyses were performed with SPSS version 22.0 (Chicago, IL). The Kolmogorov–Smirnov 
test was used to assess whether continuous data were distributed normally (p<0.05). Kappa 
statistics were used to calculate the interobserver agreement between the two radiologists. 
Continuous data are presented as mean ± SD and in case of non-normal distributions as median 
with interquartile range (IQR). A kappa of less than 0.00 represents no agreement, 0.0-0.20, 
slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; and 0.81-1.00, excellent 
agreement (39). In the entire study population, the following variables were compared with 
clinical outcomes: extent and pattern (based on dominant location) of pancreatic necrosis. 
Differences were tested by the Student’s T-test or Mann–Whitney U test. Proportions were 
compared by the Chi-square test. Various multivariable logistic regression analyses were 
performed with the clinical outcomes as dependent outcomes and extent of pancreatic necrosis 
and pattern of pancreatic necrosis as co-variates, to determine whether pattern and extent 
were independently associated with severity parameters. A p-value of <0.05 was considered 
statistically significant.  
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RESULTS 
Patients
Among 639 patients with necrotizing pancreatitis, some 324 patients had pancreatic necrosis 
on CECT and, hence, constitute the final study cohort of whom 214 patients (66%) were 
male (median age 58 years, IQR 45 - 69). The etiology of pancreatitis was biliary in 155 (48%) 
patients, alcohol in 74 (23%) patients, other causes (including hyperlipidaemia, hypercalcemia, 
post-ERCP) in 26 (8%) patients, and idiopathic in 69 (21%) patients. A total of 1164 CECTs in 
324 patients were available for review (median of 6, IQR 3 - 10). Data on patient outcome of 
the study cohort are summarized in Table 1.
TABLE 1. Patient characteristics
Characteristic
Pancreatic necrosis
N = 324
Age – yr 58 (45 – 69)
Male sex 214 (66%)
Etiology
Gallstones 155 (48%)
Alcohol abuse 74 (23%)
Other 26 (8%)
Unknown 69 (21%)
ASA# class on admission
I (healthy status) 105 (32%)
II (mild systemic disease) 173 (53%)
III (severe systemic disease) 46 (14%)
Predicted severity of pancreatitis
APACHE-II† score on admission 8 (5 – 11)
Imrie / modified Glasgow score after 48 hours 4 (2 – 5)
Highest CRP‡ level in first 48h 290 (215 – 388)
Transferred from another hospital 116 (36%)
No. of CECTs performed per patient* 6 (3 – 10)
Continuous variables are median (interquartile range). #ASA, American Society of Anaesthesiologists; †APACHE, Acute Physiology 
Age and Chronic Health Evaluation; ‡CRP, C-reactive protein; CECT, contrast-enhanced CT; *After 72h of symptom onset and before 
discharge or any intervention.
Extent of Pancreatic Necrosis and Clinical Outcome
Interobserver agreement for assessing the extent of pancreatic necrosis was 0.79 (95% CI: 0.71-
0.84), indicating substantial correlation. The extent of pancreatic necrosis in the 324 patients 
was as follows: <30% necrosis; 132 patients (40%), 30-50%; 83 patients (26%), and >50% 
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TABLE 2. Anatomic region of pancreatic necrosis 
Anatomic region
N = 324 Involvement (%)
Extent of involvement per region
<50% 50-100% 100%
Head 184 (57%) 142 (77%) 42 (23%) 0
Neck 240 (74%) 65 (27%) 21 (9%) 154 (64%)
Body 229 (71%) 96 (42%) 39 (17%) 94 (41%)
Tail 159 (49%) 78 (49%) 39 (25%) 42 (26%)
 TABLE 3. Pattern in relation to extent of pancreatic necrosis
Pattern
N = 324
Extent of involvement of total parenchyma
Number (%) <30% n = 132 >30-50% n = 83 >50% n = 109
Right 17 (5%) 15 (88%) 2 (12%) 0
Central 128 (40%) 25 (20%) 55 (43%) 48 (37%)
Left 35 (11%) 17 (49%) 6 (17%) 12 (34%)
Subtotal 47 (14%) 0 0 47 (100%)
Scattered 97 (30%) 75 (77%) 20 (21%) 2 (2%)
TABLE 4. Association of extent of pancreatic necrosis with clinical outcome
Clinical Outcome
N = 324
Extent of involvement of total parenchyma
<30% n = 132 >30-50% n = 83 >50% n = 109
Persistent organ failure  42 (32%)*¶ 42 (51%)*† 63 (58%)†¶
Infected necrosis 52 (39%)*¶ 46 (55%)*† 53 (49%)†¶
Invasive intervention 61 (46%)*¶ 58 (70%)*† 66 (61%)†¶
Mortality 23 (17%)† 15 (18%)† 26 (24%)†
Composite endpoint# 76 (58%)*¶ 62 (75%)*†  83 (76%)†¶
*,¶, significant differences between groups (p<0.05)
†, no significant differences between groups     
#, presence of any of the following severity parameters: persistent organ failure, infected necrosis, invasive intervention, or mortality
TABLE 5. Association of pattern of pancreatic necrosis with clinical outcome
Clinical Outcome
N = 324
Pattern of pancreatic necrosis
Right
n = 17
Central
n = 128
Left
n = 35
Subtotal
n = 47
Scattered
n = 97
Persistent organ failure 9 (53%) 77 (60%) 8 (23%) 29 (62%) 24 (25%)
Infected necrosis 8 (47%) 76 (59%) 10 (29%) 20 (43%) 37 (38%)
Invasive intervention 11 (65%) 99 (77%) 12 (34%) 25 (53%) 38 (39%)
Mortality 7 (41%) 34 (27%) 3 (9%) 13 (28%) 7 (7%)
Composite endpoint# 14 (82%) 108 (84%) 14 (40%) 38 (81%) 47 (49%)
P<0.001
#, presence of any of the following severity parameters: persistent organ failure, infected necrosis, invasive intervention, or mortality
Location of Pancreatic Parenchymal Necrosis determines Clinical Outcome in Necrotizing Pancreatitis | 269
necrosis; 109 patients (34%). Once pancreatic necrosis was established on a CECT at a median 
of 6 days (IQR 4 - 12 days) after symptom onset, no late onset or increase in extent of pancreatic 
necrosis was observed on follow-up CECTs. The association between clinical outcome and 
extent of pancreatic necrosis is shown in Table 4. For all severity parameters studied there was 
a significant relationship between extent of pancreatic necrosis and clinical outcome, except 
for mortality. Patients with <30% pancreatic necrosis had a significantly better outcome than 
those with >30% pancreatic necrosis (p<0.001). No significant differences in clinical outcome, 
however, was seen in patients with 30-50% versus those with >50% pancreatic necrosis 
(p=0.37). Moreover, for infected necrosis and need for invasive intervention a stronger 
association was seen in patients with 30-50% versus those with >50% pancreatic necrosis, albeit 
without reaching statistical significance.
Location and Pattern of Pancreatic Necrosis and Clinical Outcome
Interobserver agreement for assessing location and pattern of pancreatic necrosis was 0.81 
(95% CI: 0.73-0.86), indicating excellent correlation. The location of pancreatic necrosis, 
including the percentage of involvement per region is depicted in Table 2. Pancreatic necrosis 
occurred most often in the pancreatic body and neck in 71% and 74% of patients, respectively. 
Accordingly, central gland necrosis was the most frequent pattern observed (128 patients, 
40%), followed by scattered necrosis (97 patients, 30%), and subtotal necrosis (47 patients, 
14%) (Table 3). The extent of pancreatic necrosis involved per pattern of pancreatic necrosis is 
shown in Table 4. In Table 5, clinical outcome according to the pattern of pancreatic necrosis is 
depicted. A significant association was observed between all outcomes studied with pattern of 
pancreatic necrosis (p<0.001). The highest association of all severity parameters, including the 
composite endpoint, occurred in patients with right-sided, central gland, and subtotal necrosis. 
Patients with right-sided necrosis had the highest mortality rates (41%). Patients with left-sided 
and scattered necrosis had significantly lower rates of persistent organ failure, infected necrosis, 
need for intervention, mortality, including the composite of major morbidity and death. The 
multivariable analyses generally demonstrated that the pattern of pancreatic necrosis was 
independently and most strongly associated with severity parameters (data not shown).
DISCUSSION
This is the largest cohort study focusing on extent and location of pancreatic necrosis and 
their association with clinical outcome. Major findings are that: a) a significant correlation 
exists between extent of pancreatic necrosis and clinical outcome (mortality, infected necrosis, 
persistent organ failure, and need for intervention), albeit no significant differences were 
observed when comparing outcomes in patients with 30-50% and >50% pancreatic necrosis; 
b) central gland necrosis is the dominant pattern of pancreatic necrosis (occurring in 40% of 
patients) with significant association with infected necrosis and need for invasive intervention; 
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c) patients with right-sided, central gland, and subtotal necrosis have the poorest clinical 
outcome compared with patients with left-sided and scattered necrosis; and d) in multivariable 
analysis, the pattern of pancreatic necrosis was most strongly associated with clinical outcome.
The pathophysiology of parenchymal necrosis is thought of as an ischemic event caused by 
vascular changes of intrapancreatic vessels following acinar cell injury. After cytolysis, the 
activated pancreatic enzymes incite an inflammatory reaction leading to vasospasm, vascular 
stasis and thrombosis (7,40-42). Although it has been reported that the pancreatic head is often 
spared in necrotizing pancreatitis (7,8,21,43), we found that this part is involved in over half 
the cases. However, complete necrosis of the pancreatic head does not occur as areas of the 
pancreatic head were spared in all patients studied. Conversely, other pancreatic regions 
frequently showed complete necrosis (Table 2). It is believed that the large number of collaterals 
in the pancreatic head (i.e. an anatomically and functionally important area) is protective for 
complete necrosis (21,44,45). In our study, the pancreatic neck and body were the most vulnerable 
areas to undergo necrosis (with complete necrosis in 66% and 40%, respectively), most likely 
attributed to a lack of a satisfactory collateral network. Indeed, these regions are regarded as the 
‘watershed areas’ between the proximal and distal pancreas and, therefore, are more susceptible 
to perfusion alterations (45-49). This clarifies the high prevalence of central gland necrosis and the 
relatively low prevalence of isolated right- or left-sided necrosis. Opposed to what is reported 
by some (7,8,21,48), we found that even in case of extensive necrosis, areas of the pancreatic gland 
remained viable (primarily in the pancreatic head and tail) and, hence, ‘complete necrosis’ 
of the whole pancreatic gland was not seen. Presumably, advances of CT technique have 
contributed to improved assessment of the pancreas; i.e. all patients in our study underwent 
multislice CT examinations with probably better detection of remaining viable pancreatic 
tissue. Furthermore, different from several groups of investigators (6,7,8,10,50), we did not observe 
an increase or late onset of pancreatic necrosis once necrosis was definitively established on 
the index CECT. This is in keeping with the assumption that pancreatic necrosis develops 
within the first 72 hours after symptom onset (51). In some patients, close analysis of successive 
CTs revealed a decrease in pancreatic volume in the later phase of disease due to subsidence of 
initial pancreatic swelling (43). Also, during follow-up enlarging peripancreatic collections may 
compress remaining viable pancreatic tissue with restoration after resolution of collections by 
drainage or necrosectomy (52). Both latter manifestations may simulate an ‘increase’ in extent 
of pancreatic necrosis. Alternatively, the differing findings can be ascribed to differences in 
timing of CECT on which pancreatic necrosis is assessed (i.e. an early CT within 48-72 hours 
following symptom onset may underrate the degree and extent of pancreatic necrosis) or in the 
event of repeated pancreatic insults during the same hospitalization.
Most studies have shown a clear correlation between presence of pancreatic necrosis and 
increased morbidity and mortality (7-18). But, some have questioned the linear relationship 
between extent of pancreatic necrosis and clinical outcome (19-28). Balthazar and colleagues 
classified the extent of pancreatic necrosis into 3 categories (i.e. <30%, 30-50%, and >50%) and 
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incorporated the presence and extent of parenchymal necrosis in the CT Severity Index (CTSI) 
(6). The CTSI represents a numeric CT-based predictive scoring system on a 10-point scale 
implying that prognosis is directly correlated with extent of pancreatic necrosis (6). Yet, our 
results and other studies do not support this premise (9,19,20,26,27). In their original study, Balthazar 
and colleagues reported minor morbidity in patients with <30% pancreatic necrosis compared 
with 40% morbidity in patients with >30% pancreatic necrosis (6). Differences in morbidity 
and mortality between the groups with 30-50% and >50% pancreatic necrosis, however, were 
not statistically significant. We also found a modest correlation between extent of pancreatic 
necrosis and clinical outcome. Noteworthy, an even stronger association was observed in the 
group with 30-50% pancreatic necrosis for infected necrosis and need for invasive intervention 
compared with those with >50% pancreatic necrosis. In multivariable analysis, the pattern 
of pancreatic necrosis appeared to be more strongly correlated with clinical outcome than 
its extent. We found that patients with right-sided, central gland, and subtotal necrosis had 
significantly higher morbidity and mortality rates than patients with left-sided and scattered 
necrosis. Our results are comparable with previous reports that studied smaller cohorts or were 
biased towards a high prevalence of alcohol-related disease (7,53). From a pathophysiological 
perspective, there is a plausible explanation for the clinical impact of pattern of pancreatic 
necrosis. In recent reports, the integrity of the main pancreatic duct is regarded as a major 
determinant in clinical course and kind of treatment applied in patients with acute pancreatitis 
(46,47,54-56). Patients with right-sided and central gland necrosis (with significant remaining viable 
pancreatic tissue proximal to the blockage, often >50% of parenchyma) are at highest risk of 
disruption of the pancreatic duct resulting in continued leakage of pancreatic enzymes in and 
outside the pancreas (also known as ‘disconnected duct syndrome’) (46,47,49,54-58). Interestingly, 
the incidence of main pancreatic duct disruption in necrotizing pancreatitis is reported to be 
around 40%, which corresponds to the incidence of central gland necrosis observed in our 
study (46,59,60). The diagnosis of a disrupted pancreatic duct depends on clinical and endoscopic 
retrograde cholangiography criteria. This entity can, however, be inferred from CT when right-
sided necrosis or transparenchymal central gland necrosis of the pancreas is seen, especially 
when the segment involved measures more than 2 cm and an increase of necrotic collections is 
observed on sequential CTs (61). Furthermore, in right-sided necrosis vital structures surround 
the pancreatic head in a constrained anatomic compartment that likely provokes increased 
inflammatory stress, locally and systemically, manifested clinically as systemic inflammatory 
response syndrome and prolonged organ dysfunction (8,9). 
Our results might clarify the non-linear relationship between extent of pancreatic necrosis and 
clinical outcome. All patients with right-sided necrosis and 63% of patients with central gland 
necrosis had <50% pancreatic necrosis (Table 4), but a strong association was observed with 
all clinical outcome parameters studied, in particular rate of infected necrosis and the need 
for invasive intervention. Notably, 24% of patients with extensive necrosis (>50% pancreatic 
necrosis) had a relatively clinically mild course; i.e. these patients did not die, did not develop 
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persistent organ failure or infected necrosis, and did not need invasive intervention (Table 
5). The absence of significant vital upstream pancreatic parenchyma (and, hence, the leakage 
of pancreatic enzymes) likely precludes the development of complications in these patients. 
Conversely, it is also important to identify those with left-sided and scattered necrosis as these 
have a significant better outcome regardless of extent of pancreatic necrosis, probably related 
to the absence of pancreatic duct disruption.
The strengths of this study are the large study population on necrotizing pancreatitis with 
CT correlation (previous studies included smaller study populations (7,29-32), the prospective 
acquisition of clinical data, and the recruitment of a large cohort in a relatively small time period 
of 4.5 years receiving similar management (34). Prior studies used outdated CT equipment or 
evaluated long time intervals ranging up to 9-12 years despite major improvement in imaging 
techniques and advanced management of severe acute pancreatitis (7-9,30). However, our study 
has some limitations. First, because this was a multicenter study, CTs were performed with 
a variety of CT scanners with varying protocols. However, all CTs were performed on 
multidetector CT scanners and, in the majority of patients, multiple CECTs were available 
for determining the location and extent of pancreatic necrosis. Hence, we feel that this did not 
influence our findings significantly. Second, most CTs were performed on discretion of the 
clinician with no standardized timing. This reflects common and current practice; given the high 
costs and radiation issues associated with CT, judicious use of this modality is recommended 
(62-64). Third, as with all classification systems, there is clearly some subjectivity in grading the 
pattern of pancreatic necrosis. Although, we found a good interobserver agreement between 
two experienced readers, additional studies are needed in a different cohort and readers with 
varying experience.
In summary, the pancreatic neck and body are the most vulnerable regions to undergo 
necrosis, with central gland necrosis being the dominant pattern of necrosis occurring in 40% 
of patients presenting with pancreatic necrosis. Extent of pancreatic necrosis is associated with 
most severity parameters studied (except mortality) with significant better clinical outcome in 
patients with <30% versus those with >30% pancreatic necrosis. Furthermore, the pattern of 
pancreatic necrosis is associated most strongly with all severity parameters studied, especially 
when involving primarily the head or central part of the pancreas (likely related to a disrupted 
pancreatic duct) with an upstream vital pancreatic parenchyma. 
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This thesis had two main objectives pertaining to the classification and severity prediction 
of acute pancreatitis. We evaluated the previous classification system on acute pancreatitis 
(1992 Atlanta Classification) extensively by means of two literature reviews and interobserver 
agreement studies and studied the morphologic part of the most recent Revised Atlanta 
Classification constructed in 2012. The predictive accuracy of imaging-based scoring systems 
was addressed in two comparative studies and a severity assessment of interstitial edematous 
pancreatitis and necrotizing pancreatitis was performed in two different cohorts.
In Chapter 2, we performed an interobserver agreement study among 5 experienced abdominal 
radiologists for categorizing pancreatic (fluid) collections on CT using the 1992 Atlanta 
Classification. To this end, preoperative contrast-enhanced CTs from 70 consecutive patients 
operated for acute necrotizing pancreatitis were reviewed. Results of this study showed a poor 
interobserver agreement among the five radiologists as in only three out of 70 cases (4%) the 
same Atlanta definition was chosen and in 42 out of 70 cases (42%), three radiologists agreed 
on the same Atlanta definition. We concluded that the 1992 Atlanta definitions should not be 
used for categorizing pancreatic collections on CT.
In a complex disease such as acute pancreatitis, correct terminology and clear definitions are 
important. The clinically based Atlanta Classification was formulated in 1992, but in recent 
years it has been criticized increasingly. In two literature reviews, an extensive evaluation 
was undertaken to assess the use and acceptance of the 1992 Atlanta definitions in medical 
literature. In Chapter 3, a Medline search strategy (during the period 1993-2006) was conducted 
that included terms abandoned by the 1992 Atlanta Classification: ‘phlegmon’, ‘infected 
pseudocyst’, ‘hemorrhagic pancreatitis’, and ‘persistent pancreatitis’. Also, new terms that have 
emerged in literature after the publication of the 1992 Atlanta Classification were categorized. 
In total 239 articles were reviewed, including 10 guidelines and 42 reviews. We found that 
the abandoned terms ‘hemorrhagic pancreatitis’ and ‘persistent pancreatitis’ were discarded 
effectively, whereas ‘infected pseudocyst’ and ‘phlegmon’ were encountered frequently with 
several authors openly questioning their abandonment. New terms identified were ‘organized 
pancreatic necrosis’, ‘necroma’, ‘extrapancreatic necrosis’, and ‘central gland necrosis’. Some of 
these are manifestations of acute pancreatitis that were not addressed adequately by the 1992 
Atlanta Classification. In Chapter 4, a formal evaluation of the use of the 1992 Atlanta definitions 
in the literature was performed. A Medline literature search sought studies published between 
1993 and 2006. In total, 447 articles were identified, including 12 guidelines and 82 review 
articles. Alternative definitions of predicted severity of acute pancreatitis, actual severity, and 
organ failure were used in more than half of the studies. There was a large variation in the 
interpretation of the 1992 Atlanta definitions of local complications, especially relating to the 
content of peripancreatic collections. Both literature reviews revealed that the 1992 Atlanta 
Classification was outdated and was in need for revision. 
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To that purpose, a new set of morphologic terms to describe pancreatic collections in acute 
pancreatitis on CT was developed. The morphologic terms consisted of: presence of a collection, 
relation with the pancreas, content, shape, mass effect, loculated gas bubbles, gas-fluid level, 
encapsulation and presence and extent of concomitant pancreatic non-enhancement. Because 
the terms proposed by the 1992 Atlanta Classification (e.g. pseudocyst, pancreatic abscess) had 
shown a very poor interobserver agreement (Chapter 2), creating the potential for patient 
mismanagement, in Chapter 5 we performed an interobserver agreement study for the above 
mentioned new set of morphologic terms to describe pancreatic collections in acute pancreatitis 
on CT. Among 17 readers (9 clinicians and 8 radiologist from US and Europe), the overall 
interobserver agreement was good to excellent for these individual morphologic terms. Thus, 
we advocate to use these descriptive terms to describe CT morphology of acute pancreatitis 
rather than using the 1992 Atlanta definitions. 
Although the 1992 Atlanta Classification of acute pancreatitis enabled standardized reporting 
of research and aided communication between clinicians, it became increasingly clear over 
the years that a revision was necessary based on improved understanding of acute pancreatitis 
and to overcome the deficiencies identified. An international iterative web-based consultation 
was undertaken in 2007 to ensure wide participation of pancreatologists. After five years of 
discussion, a consensus document (the 2012 Revised Atlanta Classification) was constructed 
and presented in Chapter 6. The 2012 Revised Atlanta Classification defines criteria for the 
diagnosis of acute pancreatitis and identifies two phases of disease: early and late. Acute 
pancreatitis can be either interstitial pancreatitis without tissue necrosis, or necrotizing 
pancreatitis, with necrosis of pancreatic parenchyma, peripancreatic tissue, or both. Severity 
of acute pancreatitis is categorized into three grades: mild, moderate severe, and severe, 
depending upon presence of organ failure and local or systemic complications. For the first 
time, a imaging-based classification has been added based on morphologic CT criteria. The 
nomenclature of pancreatic collections was divided into four subsets: acute peripancreatic 
fluid collection, pseudocyst, acute necrotic collection, and walled-off necrosis, based on their 
composition and morphology on CT. The wide consultation among pancreatologists to reach 
this consensus should encourage widespread adoption.
An important aim of the 2012 Revised Atlanta Classification was to facilitate consistent 
reporting and better comparison of data, obtained in clinical research. Therefore, new CT 
based criteria were proposed to describe the morphology of acute pancreatitis. In Chapter 7, the 
interobserver agreement in evaluating the new CT criteria was assessed among radiologists in 
285 consecutive patients with acute pancreatitis who underwent a CT during their admission. 
For most of the newly introduced CT criteria, the interobserver agreement was moderate 
to substantial. In four categories, the interrater agreement was only fair: extrapancreatic 
necrosis (EXPN) (0.326), type of pancreatitis (0.370), characteristics of collections (0.408), and 
appropriate term of collections (0.356). The fair kappa values were related to discrepancies in 
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the identification of extrapancreatic necrotic material. This is an increasingly acknowledged 
limitation of CT and the 2012 Revised Atlanta Classification. Consequently, further adjustments 
to the new criteria are likely to be expected.  
The severity prediction of acute pancreatitis has engendered as much attention as its 
classification. A decade after the development of the first predictive clinical scoring, the Ranson 
score in 1974 (1),  Balthazar and colleagues proposed a radiologic scoring system in 1985 
based on an unenhanced CT (2). Some 5 years later, the same authors updated this grading 
system by adding presence and extent of parenchymal necrosis on an contrast-enhanced 
CT to the Balthazar score, resulting in the CT Severity Index (CTSI), which is still the most 
frequently used CT scoring system to date (3). In 2004, this scoring system was modified by 
Mortele and colleagues (the Modified CT Severity Index or MCTSI) by incorporating some 
simplifications and subsequently tested in a small cohort of 66 patients (4). In Chapter 8, we 
compared the MCTSI with the original CTSI regarding assessment of severity parameters 
in 196 acute pancreatitis patients who underwent a contrast-enhanced CT or MRI within 1 
week of symptom onset. Both CT indexes were also compared with the Acute Physiology, Age, 
and Chronic Health Evaluation (APACHE)-II index. Two abdominal radiologists scored both 
CT indexes independently. Severity parameters included mortality, organ failure, pancreatic 
infection (infected necrosis), admission to and length of ICU stay, length of hospital stay, need 
for intervention, and clinical severity of acute pancreatitis. Although, for both CT indexes 
a significant relationship was observed between the score and each severity parameter (p < 
0.0001), no significant differences were seen between the CT indexes. Compared with the 
APACHE II index, both CT indexes more accurately correlated with the need for intervention 
(CTSI, p = 0.006; MCTSI, p = 0.01) and pancreatic infection (CTSI, p = 0.04; MCTSI, p = 0.06) 
and more accurately diagnosed clinically severe disease (area under the curve, 0.87; 95% CI, 
0.82-0.92). Interobserver agreement was excellent for both indexes: for CTSI, 0.85 (95% CI, 
0.80-0.90) and for MCTSI, 0.90 (95% CI, 0.85-0.95). Thus, in clinical practice, both indexes can 
be used interchangeably for grading the morphologic severity of disease. 
It is generally acknowledged that early identification of patients with clinically severe acute 
pancreatitis is critical for triage and individualized treatment. In Chapter 9, we compared the 
predictive accuracy of CT and clinical scoring systems in their severity assessment on admission. 
During a two-and-half-year period all consecutive patients with a primary diagnosis of acute 
pancreatitis were enrolled prospectively for this study. Of these, 150 patients (159 episodes 
of pancreatitis) received a (unenhanced or contrast-enhanced) CT on the day of admission. 
A retrospective analysis of the abdominal CT data was performed. Seven CT scoring systems 
(CT severity index (CTSI), modified CT severity index (MCTSI), pancreatic size index (PSI), 
extrapancreatic score (EP), ''extrapancreatic inflammation on CT'' score (EPIC), ''mesenteric 
edema and peritoneal fluid'' score (MOP), and Balthazar grade) as well as two clinical scoring 
systems: Acute Physiology, Age, and Chronic Health Evaluation (APACHE)-II and Bedside 
Index for Severity in AP (BISAP) were compared with regard to their ability to predict disease 
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severity on admission (i.e. first 24h of hospitalization). Clinically severe acute pancreatitis was 
defined as one or more of the following: mortality, persistent organ failure and/or the presence 
of local pancreatic complications that require intervention. At the time of this study, the 
definitive parameters of disease severity were not yet defined, therefore, definitions for disease 
severity differ slightly from the 2012 Revised Atlanta Classification. All CTs were reviewed 
in consensus by 2 abdominal radiologists, each blinded to patient outcome. The accuracy 
of each CT and clinical scoring system for predicting the severity of acute pancreatitis was 
assessed using receiver operating curve analysis. Overall, the Balthazar grading system (any CT 
technique) and CTSI (contrast-enhanced CT only) demonstrated the highest accuracy among 
all 7 CT scoring systems for predicting disease severity, but this was not statistically significant. 
The predictive accuracy of CT scoring systems for severity of AP was, however, similar to 
clinical scoring systems. Hence, a CT on admission solely for disease severity assessment is not 
recommended.
In the radiologic literature, however, it is often acclaimed that CT should be performed early 
in acute pancreatitis to evaluate morphologic severity of acute pancreatitis (5-7), but this is 
not supported by clinical guidelines and most clinicians (6-12). In Chapter 10, an overview of 
existing radiologic scoring systems (mostly based on CT) is presented combined with their 
strengths and limitations in predicting ultimate severity. The primary limitation of imaging 
scoring systems is that they better correlate with local complications than with systemic 
complications (particularly persistent organ failure which is the defining feature of severe acute 
pancreatitis). Besides providing a radiologic score in a CT report, a list of possible complications 
are reviewed that may be encountered on CT for evaluation of acute pancreatitis. These 
include imaging signs of infected necrosis (gas bubbles within necrotic collections), massive 
hemorrhage or detection of an arterial pseudoaneurysm, deep vein thrombosis or pulmonary 
emboli, cholecystitis, bowel ischemia or perforation, and imaging features of abdominal 
compartment syndrome (‘round-belly sign’ or increasing girth on serial CT). Most of these 
complications are not part of any imaging scoring system, but nonetheless have a significant 
and direct impact on patient management. 
One of the most severe local complication of acute pancreatitis is infected necrosis, which 
is associated with significant morbidity and mortality rates of around 20-30% (12, 13). The 
depiction of gas configurations within necrotic collections on CT represents a virtually 
pathognomonic feature of infected necrosis, but is not always present. Diagnosing infected 
necrosis clinically may be challenging as severe SIRS may present with a septic profile as 
well. In Chapter 11, we determined the added value of routine fine-needle aspiration (FNA) 
in addition to clinical and imaging signs of infection in patients who underwent intervention 
for suspected infected necrosis. We conducted a post hoc analysis of 208 consecutive patients 
from a prospective, multicenter database who underwent intervention because of suspected 
infected necrosis. In retrospect, three groups were constructed based on patients’ preoperative 
characteristics: clinical profile, imaging findings, and results of FNA. Patients in the clinical 
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group had clinical signs of infection but no gas on preoperative CT and no FNA performed 
before intervention. Patients in the imaging group had gas bubbles on the preoperative CT 
but no FNA was performed, whereas patients in the FNA group had a positive FNA before 
intervention. The reference standard for infection was the culture taken during the first 
intervention (either catheter drainage or necrosectomy). The initial intervention for infected 
necrosis was performed a median of 27 days (interquartile range, 20-39) after admission without 
difference between the 3 groups (p = .15). Infection was confirmed in 80% of 92 patients of the 
clinical group, in 94% of 88 patients of the imaging group, and in 86% of 28 patients of the 
FNA group (p = .07). Mortality was 19% and was not different between groups (p = .39). We 
conclude that infected necrosis can generally be diagnosed based on clinical or imaging signs 
of infection. FNA is useful in patients with equivocal clinical signs and no imaging signs of 
infected necrosis. 
There is limited information on the incidence of factors associated with clinically severe disease 
among patients with interstitial pancreatitis. In Chapter 12, we evaluated 149 consecutive 
patients with interstitial pancreatitis admitted over a 2.5-year period and compared data 
with those from patients with EXPN. We assessed the Charlson comorbidity score (CCI) 
and some measures of severity on admission or within 24 hours (APACHE II, BISAP scores). 
Furthermore, we assessed the incidence of persistent (>48h) systemic inflammatory response 
syndrome, persistent organ failure, need for intensive care unit, length of hospital stay (in 
days), and mortality among patients with interstitial pancreatitis and those with EXPN. Among 
the patients with interstitial pancreatitis, the median APACHE II score was 7, and the median 
BISAP score was 1. In addition, the median length of hospital stay was only 4 days; only 1% 
had persistent organ failure and only 1% to 2% required intervention. The mortality rate of 
interstitial pancreatitis was 3% and this was associated significantly with comorbidity (the 
median CCI scores of nonsurvivors and survivors was 4 and 1, respectively, p = 0.003). Patients 
with EXPN had greater levels of disease severity, compared with patients with interstitial 
pancreatitis and, therefore, should be distinguished from interstitial pancreatitis in clinical 
studies. 
In the 2012 Revised Atlanta Classification of acute pancreatitis, the term necrotizing 
pancreatitis also refers to patients with only EXPN without pancreatic parenchymal necrosis, 
as determined on CECT. Patients with EXPN are thought to have a better clinical outcome 
compared with those with parenchymal necrosis, although robust data are lacking. In Chapter 
13, we performed a post hoc analysis of a prospective multicenter database including 639 patients 
with necrotizing pancreatitis on CECT. All CTs were reviewed by a single radiologist blinded 
to the clinical outcome. Some 315 patients with EXPN were compared with 324 patients with 
pancreatic parenchymal necrosis (with or without extrapancreatic necrosis). Outcomes were 
persistent organ failure, need for intervention, and mortality. A predefined subgroup analysis 
was performed on patients who developed infected necrosis. Patients with EXPN less often 
suffered from complications: persistent organ failure (21% vs 45%, p < 0.001), persistent 
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multiple organ failure (15% vs 36%, p < 0.001), infected necrosis (16% vs 47%, p < 0.001), 
intervention (18% vs 57%, p < 0.001), and mortality (9% vs 20%, p < 0.001). When infection 
of extrapancreatic necrosis developed, outcomes between groups were similar (mortality with 
infected necrosis: EXPN 28% vs pancreatic necrosis 18%, p = 0.16). Based on these and other 
data we propose that EXPN should be regarded a separate entity within the morphological 
spectrum of acute pancreatitis.
In acute pancreatitis, the extent of pancreatic parenchymal necrosis is deemed an important 
determinant of clinical outcome. Data on the impact of location of pancreatic necrosis 
is lacking. In Chapter 14, we investigated the clinical impact of both extent and location of 
pancreatic necrosis in a large cohort. Clinical severity parameters included persistent organ 
failure, infected pancreatic necrosis, invasive intervention, and death. A total of 324 patients 
had pancreatic necrosis. Extent of pancreatic necrosis was less than 30% in 132 patients 
(40%), between 30-50% in 83 patients (26%), and over 50% in 109 patients (34%). All severity 
parameters, except mortality, differed significantly (p<0.001) between patients with less than 
30% compared with over 30% pancreatic necrosis, but not between patients with 30 to 50% 
versus those with over 50% pancreatic necrosis. Central gland necrosis was the most frequent 
pattern of pancreatic necrosis encountered (40%). All outcomes studied were significantly 
associated with location of pancreatic necrosis (p<0.001). The strongest association was found 
in patients with right-sided, central gland, and subtotal necrosis. After multivariable analysis, 
the pattern of pancreatic necrosis (based on location) was associated most strongly with all 
severity parameters studied, especially when involving primarily the head or central part of 
the pancreas (likely related to a disrupted pancreatic duct) with an upstream vital pancreatic 
parenchyma. We conclude that the location of pancreatic necrosis is an important prognostic 
factor determining the clinical course of patients with acute necrotizing pancreatitis.
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PART I - CLASSIFYING AN UNCLASSIFIABLE DISEASE?!
Classification of acute pancreatitis is important for improvement of individual clinical care and 
for advancement of clinical research. For clinicians from various disciplines it is imperative to 
agree on terminology to apply appropriate therapy in an effective manner, including medical, 
surgical, and radiologic options (1). For example, if acute peripancreatic fluid collections are 
referred to as ‘pseudocysts’ by the reporting radiologist there is a tendency for the clinician 
to think immediately of interventional techniques (2-5). Many of these acute peripancreatic 
fluid collections, however, regress spontaneously without need for specific treatment (6,7). But 
if the collection contains necrotic material and is classified erroneously as a ‘pseudocyst’, the 
clinician is misled, potentially leading to therapeutic misadventures (2,4,8,9). Accurate disease 
classification and broad consensus on terminology is equally important for improvement of 
the quality of clinical research. In the past, communication between clinicians treating and 
studying acute pancreatitis and assessment of various methods of therapy has been hampered 
greatly by the use of varying definitions for disease severity, incomplete data reporting, and 
lack of comparable data (10,11). Moreover, misclassification errors occur in up to a quarter or a 
third of patients enrolled in clinical studies (i.e. patients with predicted severe acute pancreatitis 
experience a mild clinical course and vice versa), which further impedes the assessment of 
efficacy of new therapies (12-14). Classification systems have been constructed and recently 
modified to help in guiding and selecting homogeneous patient populations. For these reasons, 
some 40 pancreatologists from 15 countries involving 6 different disciplines convened at the 
1992 International Symposium on Acute Pancreatitis, held in Atlanta, Georgia, USA. This 
symposium resulted in a clinically based classification system for acute pancreatitis, which more 
precisely defined the diagnosis, the subtypes, and complications of acute pancreatitis (15).
Over the ensuing decades, the shortcomings of the 1992 Atlanta Classification became 
increasingly apparent and were addressed resulting in the Revised Atlanta Classification.
Limitations of 2012 Revised Atlanta Classification and how to proceed
Since its publication several studies have been performed showing that the 2012 Revised Atlanta 
Classification better correlates with clinical outcome than the 1992 Atlanta Classification (16-
24). Although the 2012 Revised Atlanta Classification represents a major advancement in the 
field of pancreatology incorporating the latest understandings of the disease, some studies and 
editorials have identified a number of shortcomings.
Some claim that the 2012 Revised Atlanta Classification failed to acknowledge a subgroup 
of patients with very early severe acute pancreatitis (i.e. those with severe organ failure at 
admission with high mortality and morbidity) within the subgroup of patients with severe 
acute pancreatitis (25-27). They advocate that this subgroup deserves separate grouping 
because the conventional and largely supportive treatment is mostly ineffective due to the lack 
of knowledge of this intense and disproportionate inflammatory response.
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The impact of extrapancreatic infection on the clinical course of acute pancreatitis has been 
subject of several studies, but is not addressed in the 2012 Revised Classification (28,29). Others 
state that the 2012 Revised Atlanta Classification also failed to acknowledge infected necrosis as 
determinant of severe disease and cause of most of late mortality in acute pancreatitis (18,23). 
The Determinant-Based Classification or DBC (published in 2012) postulates that there are 
two fundamental determinants of severity; both local (presence of necrosis and/or infection) 
and systemic (organ failure) and these can both occur in the early and late phases (30). An 
interaction between these determinants exists as it is claimed that the risk of mortality doubles 
if both infected necrosis and organ failure are present together (18,23,31-36).
The dynamic nature of organ failure is addressed only moderately in the 2012 Revised Atlanta 
Classification that merely discriminated transient and persistent organ failure. Some claim that 
a severity classification should incorporate the number of organs failing, the degree and timing 
of organ dysfunction, and the impact of ongoing deterioration (beyond 48h) or improvement 
of organ dysfunction on clinical outcome (37-42).    
Another limitation pertains to the rather ‘simplistic’ approach of the ‘two-phase theory’ (42). In 
the early phase, most of the systemic manifestations of acute pancreatitis are a consequence of 
the host response to pancreatic injury (activation of cytokine cascade manifesting as SIRS and/
or compensatory anti-inflammatory response syndrome (CARS). In the late phase, persistence 
of systemic signs of ongoing inflammation may result from infection of necrosis (43). The 
2012 Revised Atlanta Classification predicates strongly on the notion of these two distinct 
phases in the evolution of acute pancreatitis and states that “these two phases of the disease 
have a distinct pathophysiology, need for different therapies, and different ways of describing 
severity”. In practice, however, there is considerable overlap in the pathophysiological drivers 
early in the disease (e.g. cytokines not associated with infection) and late in the disease (e.g. 
cytokines associated with infection) (42-44). In a distinct proportion of patients, early infection 
of pancreatic and peripancreatic tissue occurs belying in essence the two-phase theory (45-
47). Future large-scale prospective multicenter studies from different centers worldwide 
should investigate the impact of the dynamic nature of organ failure and elucidate whether the 
interaction between organ failure and infected necrosis and the two-phase theory pertaining 
to organ failure truly exists.
In the 2012 Revised Atlanta Classification, the presence of extrapancreatic tissue necrosis 
(EXPN) is headed under necrotizing pancreatitis. Based on this definition, the incidence of 
necrotizing pancreatitis will likely rise considerably by including patients with limited or 
moderate extensive EXPN, many of whom have a mild course clinically. Hence, the disparity 
between the morphologic and clinical severity of acute pancreatitis will become more 
pronounced. Furthermore, the role of EXPN has been studied increasingly over the past 
years with mounting evidence that patients with EXPN have distinct outcomes compared 
with those with interstitial disease and those with pancreatic parenchymal necrosis (48-53). 
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A 3-tier morphological classification system (with EXPN regarded as a separate entity within 
the morphological spectrum of acute pancreatitis) has, therefore, been proposed (54-56). More 
data from large scale studies are awaited.
The final shortcoming reported relates to the moderate severe group, which is composed of 
a heterogeneous group of patients with wide spectrum of severity: patients with varying local 
complications (with varying prognostic significance; e.g. sterile acute peripancreatic fluid 
collections versus infected necrotic collections), patients with transient organ failure, and 
those with deterioration of pre-existing comorbidities (regarded as a consequence rather than a 
cause of acute pancreatitis severity) (57). Also, the number and degree of existing comorbidities 
might influence the clinical course of acute pancreatitis. 
Although the 2012 Revised Atlanta Classification has incorporated current clinical knowledge, 
there remains a lack of complete understanding of the pathophysiology of acute pancreatitis 
and a number of limitations pertaining to this new classification have been raised. To improve 
the 2012 Revised Atlanta Classification, future observational multicenter studies and disease 
registries (preferably from different centers from different countries across the world) should 
record and report data of organ failure (any, transient, persistent, single or multi-organ, 
organ type, and timing) and tissue necrosis (yes or no, pancreatic, peripancreatic and/or 
both, infected or not), as well as information on the details of the frequency of and outcomes 
within subgroups of patients in the moderate severe and severe categories to allow for future 
reliable comparisons. More reliable data is needed on the clinical outcome of the ‘critical’ 
disease category, i.e. patients with combined persistent organ failure and infected necrosis. 
As such new data become available, adjustments to the current classification should be made 
according to the principle: progress mandates change. The Dutch Pancreatitis Study Group has 
had major input in the 2012 Revised Atlanta Classification and has a recognized track record 
in performing randomized controlled clinical trials to elucidate longstanding enigmas, and, 
hence, is the endorsed authority to take the lead in executing this task.
Remaining issues in nomenclature of morphologic definitions
Lack of histopathologic evidence
Much of our current understandings of the dynamic process of acute pancreatitis stems from 
serial cross-sectional imaging, primarily in those with severe disease. In the 2012 Revised 
Atlanta Classification, the pathogenesis of pancreatic collections is based on several assumptions 
with lack of histopathologic proof. It is assumed that in acute pancreatitis pancreatic collections 
develop from rupture of the pancreatic duct or its side-branches or from edema. In the 2012 
Revised Atlanta Classification, a divergent pathogenesis of pseudocyst and WON is presumed. 
But, the reverse may also be true; both may develop from damage of pancreatic tissue with 
leakage of pancreatic juice in damaged areas and formation of a fibrous capsule around such 
collections. Furthermore, the natural evolution and exact composition of pancreatic collections 
296 | Chapter 16
may vary for different patients in different anatomic locations at different stages of disease. 
Unfortunately, there is lack of data on the exact composition of these collections early as 
well as later in the disease course. Also, the process and rate of liquefaction of pancreatic and 
peripancreatic tissues remains an area of enigma. Finally, it is not clearly understood why some 
collections resolve or regress and some persist. 
Differentiating fat stranding from collection
Pancreatic collections may range from rather discrete to extensive in size and extension. The 
distinction between ‘extensive fat stranding’ and a ‘collection’ is subjective and arbitrarily. In 
the 2012 Revised Atlanta Classification, the term ‘collection’ is used for any peripancreatic 
abnormality, which is more than simple fat stranding comparable to conditions like 
uncomplicated appendicitis or diverticulitis, even when no well-defined wall is seen. 
Diagnosis of isolated EXPN
Activated pancreatic enzymes (such as lipase) that intersperse with anatomic areas containing 
fat (primarily in the retroperitoneum and mesenteries) may lead to lipolysis of extrapancreatic 
fat with development of EXPN. It is a difficult diagnosis to make at cross-sectional imaging 
since current imaging techniques are not able to demonstrate fat perfusion or lack thereof. 
Moreover, CT cannot reliably distinguish peripancreatic fat necrosis (EXPN) from other 
causes of peripancreatic fluid (interstitial pancreatitis). At early baseline CT, the diagnosis of 
EXPN is suggested by the presence of collections that show increased attenuation and fluid 
densities interspersed among fat present in the retroperitoneum and mesenteries. At follow-
up CT, EXPN becomes more apparent when pancreatic collections have a more heterogeneous 
appearance with varying densities (i.e. acute necrotic collections). The morphologic type of 
acute pancreatitis, however, may remain indeterminate in those patients who have only one 
early CT available for severity evaluation showing equivocal findings.
Differentiating liquid from necrotic collections
The 2012 Revised Atlanta Classification relies heavily on CT criteria for defining the four 
subsets of pancreatic collections based on content and maturation. Although CT elegantly 
depicts the extent of pancreatic collections and degree of encapsulation, it is limited in the 
accurate assessment of internal contents of pancreatic collections (58,59). Peripancreatic 
collections may display attenuation values approaching water densities on CT; the actual fluid 
content of such collections may be minimal. In particular, collections developing in the first 
week of acute pancreatitis may have an equivocal appearance on CT (i.e. homogeneous fluid 
attenuation) where it is impossible to distinguish an acute peripancreatic fluid collection from 
an acute necrotic collection and thus, in determining the type of pancreatitis (interstitial or 
necrotizing pancreatitis). 
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Some unanswered questions remain specifically pertaining to the local complications in acute 
pancreatitis. What is the prognostic significance of acute peripancreatic fluid collections? 
Should acute peripancreatic fluid collection be regarded as a local complication or as an 
insignificant local event? What is the frequency of infection of such acute peripancreatic fluid 
collections? How many of these acute peripancreatic fluid collections turn into pseudocysts (i.e. 
fluid collections in absence of necrotic material)? Also, there are a number of outstanding issues 
that relate to the relative prognostic significance of presence and extent of both pancreatic 
parenchymal necrosis and EXPN and issues pertaining to the timing, diagnosis, and risk factors 
for infected necrosis. 
Some of these questions demand a different approach of imaging patients with acute pancreatitis 
as CT is not able to elucidate the aforementioned enigmas. Compared with CT, MRI is superior 
for differentiating liquid from necrotic collections due to its superior tissue contrast resolution 
capabilities. With increasing use and availability of MR imaging in acute pancreatitis, some 
of these questions may, therefore, be answered in large prospective longitudinal studies using 
serial MRIs, preferably performed standardized and periodically (e.g. weekly).
PART II - PREDICTING AN UNPREDICTABLE DISEASE?!
Acute pancreatitis is one of the least predictable acute gastrointestinal disorders. The clinical 
course of acute pancreatitis is highly variable, ranging from mild self-limiting symptoms 
to rapidly progressive organ dysfunction, potentially culminating in death if not treated 
appropriately (60,61). Since nearly half a century, an exhaustive search for the ideal scoring 
system has been undertaken to identify those who will develop organ failure in the early 
stages and infected necrosis and sepsis in the later phase. An ideal prognostic scoring system 
should be simple and easy to use in clinical practice, widely available, objective, reproducible, 
sufficiently accurate in differentiating mild from severe disease in individual patients, and 
applicable early in the disease process, preferably on the day of admission (or better within a 
few hours of admission), such that patients at risk for severe acute pancreatitis are more closely 
monitored for supportive treatment (in medium or intensive care units), empirically treated 
(i.e. institution of tailored fluid resuscitation, endoscopic intervention, enteral nutrition, or 
new therapies as they become available), or transferred to specialized centers. These predictive 
tools should assist clinicians in identifying patients who are at risk of developing complications 
to be able to initiate effective therapies before those complications develop. In contrast, patients 
with mild acute pancreatitis have no need of specific treatment, except for a cholecystectomy 
during hospitalization in those with predicted mild biliary pancreatitis (62).
Reports on the discriminatory power of clinical and imaging-based scoring systems all show 
a positive correlation between the scoring system studied and patient outcome. Comparison 
of these studies is, rendered difficult because of the profound lack of homogeneity in study 
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design, differences in methodology used and the wide diversity in definitions for severe acute 
pancreatitis and clinical end points (e.g. variation in defining organ failure and systemic 
complications). Two recent studies accounted for these shortcomings by using the 2012 
Revised Atlanta definitions and compared the accuracy of several imaging-based scoring 
systems (including the CTSI) at admission (63,64). Results of these studies showed comparable 
performance characteristics among the imaging-based scoring systems studied in the prediction 
of disease severity and overall mortality. Also, these studies showed that imaging-based scoring 
systems did not perform better than commonly used clinical scoring systems, such as the BISAP 
and APACHE II score.
Shortcomings of all predictive systems
Despite the plethora of clinical, biochemical, and imaging-based scoring systems, none qualifies 
as the ideal prognostic system. Several shortcomings are shared by all staging systems. The 
available staging systems were devised to identify groups of patients at risk for developing 
organ failure or clinically severe disease rather than identifying individual patients (65). 
Furthermore, one-fifth to one-third of patients with potentially fatal severe acute pancreatitis 
is identified inappropriately using the traditional scoring systems (66-69). Indeed, scoring 
systems perform best at the extremes of the prediction range, while the discriminatory power 
is moderate at best in the middle prediction range; i.e. the range where the clinician needs 
most assistance. Additionally, the variable timing of patient admission to the hospital affects 
the clinical, laboratory, and imaging parameters, which may explain the interinstitutional 
variability in scores obtained. Moreover, all scoring systems identify those with severe disease 
only as it develops and do not predict severe disease with enough lead time for potential 
intervention. Several simple, routinely available clinical measures, such as serum hematocrit, 
elevations in blood urea nitrogen, and presence of systemic inflammatory response syndrome 
(especially lasting more than 48h), may be as accurate as the more complex multiple-factor 
scoring systems in predicting severe acute pancreatitis (67). From an imaging perspective; 
the degree of morphologic abnormalities is influenced largely by the time interval between 
symptom onset and performance of the imaging study with increasing changes seen with 
increasing time interval (with correspondent higher scores or grades). Finally, scoring systems 
(imaging-based and biochemical systems alike) do not correlate with the risk of particular 
extrapancreatic complications (e.g. abdominal compartment syndrome, bowel ischemia or 
perforation or hemorrhage from an arterial pseudoaneurysm) and, therefore, fail to provide 
detailed information that influences patient management on an individual basis.
Shortcomings of imaging-based versus clinical scoring systems
Imaging-based systems have their specific shortcomings compared with clinical and 
biochemical scoring systems. Severe acute pancreatitis may run a highly variable clinical 
course; it may manifest early with SIRS, organ failure, and death in the first week or late 
with local complications demanding intervention. Compared with imaging-based systems, 
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biochemical scoring systems correlate better with early systemic effects of pancreatic injury 
(i.e. organ failure; the main determinant for severity of disease in the 2012 Revised Atlanta 
Classification) and are in general better in predicting clinical severity early in the disease course 
(69). Conversely, imaging-based scoring systems are best in predicting late local complications 
(infected necrosis, need for intervention) (70,71). Second, imaging-based scoring systems are 
largely based on visual assessment and, therefore, are subject to variable interpretation, which 
likely relates to readers’ expertise and familiarity of imaging findings of acute pancreatitis. In 
contrast, most biochemical scoring systems are derived from objective parameters. Third, 
imaging-based scoring systems do not account for patients pre-existing clinical status; such as 
age, co-morbid disease, and obesity which are well-known prognostic risk factors for morbidity 
and mortality (60,61). Fourth, as opposed to clinical scoring systems, imaging-based scoring 
systems are not repeated routinely within a short time period such that an interval change in 
significant morphology may go unnoticed (e.g. interval detection of parenchymal necrosis on 
serial CT not visible on the index CT). Fifth, institution of preventative measures requires early 
identification of patients with severe disease before the development of a complication. The 
timing of the CT scan in studies on the predictive power of imaging-based scoring systems, 
however, has varied from at admission to 10 days after admission. Conversely, clinical and 
biochemical scoring systems are tested mostly early in the clinical course (within the first 24-
48h); i.e. in a timeframe where severity stratification is most useful. Finally, studies on imaging-
based systems are biased toward more severe disease because cross-sectional imaging is usually 
not performed in patients with mild or minimal symptoms as they do not require imaging for 
clinical management, while clinical and biochemical scoring systems are tested and applicable 
in all patients presenting with acute pancreatitis.
Specific shortcomings of imaging-based scoring systems
The use of early imaging for prognostication is limited by several other factors specifically 
related to imaging-based scoring systems. First, in most imaging-based systems the rating 
of peripancreatic inflammation and fluid is determined based on their presence rather than 
extent; the latter may vary considerably among patients appreciated with similar grades. 
Second, morphologic signs of severe disease are a time-dependent phenomenon. CT only takes 
a snapshot at a moment in time whilst acute pancreatitis is a continuously evolving disease 
process, especially in the early phase. Consequently, patients may progress from mild to severe 
grades of CT severity. Third, the extent of parenchymal necrosis may not be evident until after 
48h and, thus, may be underrated on early imaging (72,73). Fourth, in a definite percentage 
of patients with acute pancreatitis, there is a non-linear relationship between morphologic 
findings and clinical severity. CT may demonstrate little morphologic signs of severe disease 
early in disease process (i.e. on day of admission) in patients who already have organ failure 
as sign of a severe attack. Conversely, some 30% of patients with parenchymal necrosis will 
have a relatively benign clinical course (without organ dysfunction or systemic complications) 
(74,75). Finally, the fallacy of linking one imaging feature or a constellation of imaging features 
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to severe clinical outcome falls short simply because of the intrinsic morbidity and mortality, 
albeit low in numbers, in patients with interstitial pancreatitis. In the minority of patients with 
interstitial pancreatitis with dismal outcome, grave CT-imaging features tend to be absent. 
Clinicians need a powerful, simple, and easy to use predictive system early in the disease 
process, preferably within several hours after admission, for triaging patients to different levels 
of care. Cross-sectional imaging studies performed within this timeframe will unlikely surpass 
clinical scoring systems as has been shown in aforementioned reports comparing the various 
imaging-based scoring systems on day of admission (63,64). In view of the abovementioned 
limitations of imaging-based scoring systems, the added costs, efforts, and radiation burden 
associated with CT, and the ease of use of some of the clinical scoring systems, it is, therefore, 
unlikely that imaging-based scoring systems will ever serve as an accurate means of correctly 
identifying all those with severe acute pancreatitis early on in the disease process. The limited 
efficacy of imaging-based scoring systems reflects the complexity, variability, and heterogeneity 
of acute pancreatitis with its myriad possible clinical expressions.
Based on current evidence, the initial severity assessment of patients with acute pancreatitis 
should be based on laboratory and/or clinical scoring systems rather than relying on imaging 
parameters. The decision if and when to perform CT depends, therefore, on the overall clinical 
presentation. Undeniably, CT has its greatest merits in the later phase of the disease in those 
who have predicted moderate severe or severe acute pancreatitis by clinical assessment or those 
who do not improve clinically despite appropriate therapy when local complications, most 
commonly infection of necrotic tissue, largely affect clinical decision-making. 
Future perspectives
Predicting the severity, prognosis, and clinical course of acute pancreatitis in individual patients 
remains important to clinicians. As aforementioned, the disease course of acute pancreatitis is 
highly variable and driven mainly by differences in individual susceptibility, general health, 
physiologic reserve, and by variations in the processes and pathogenicity of acute pancreatitis 
(primarily the occurrence of SIRS, organ dysfunction, tissue necrosis, and infected necrosis). 
Although there are many approaches to severity prediction, the continuing fundamental 
problem is that misclassification error occurs in 20-30% of patients. This limits the usefulness 
of any predictive system in an individual patient. Yet, there is still some value in predicting 
disease severity and this relates to triage, transfer, treatment, and trials.
To date, probably the best predictor of disease severity in clinical practice is not one of the 
multiple-factor systems, but rather an experienced clinician who is informed by patient- and 
disease-related risk factors, such as older age, (morbid) obesity, comorbidities, and who is familiar 
with the predictive value of the simple measures such as, SIRS, blood urea nitrogen, creatinine, 
and hematocrit levels. All of these factors are associated with worse outcomes and help in 
making decisions pertaining to patient triage and care. With reference to scientific research, 
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it is doubtful that new multiple-factor clinical scoring systems (whether or not combined with 
other clinical or imaging systems) will increase the predictive accuracy any further. Future 
studies should, therefore, focus on the translational research to find better biological markers 
(i.e. sophisticated analytical technologies such as serum proteomic pattern analysis, genetic 
polymorphisms, metabolomics, and cytokine profiles, among others) of the primary factors 
determining clinical outcome (organ failure and (infected) pancreatic necrosis), as well as host-
related factors that influence the severity of SIRS. Such an approach might help in understanding 
the mechanisms of severe acute pancreatitis, in identifying patients who are at-risk soon after 
or before pancreatic injury occurs, and in developing new therapies to mitigate the severity of 
acute pancreatitis. Notably, the latter is still not available and, therefore, it remains uncertain 
whether any future accurate prognostic indicator will actually decrease the severity of acute 
pancreatitis during hospitalization. Another approach to predicting severity of disease will 
likely come from analytic methods (e.g. artificial neural networks) and primarily intelligence-
based data (artificial intelligence). Contemporary cross-sectional images (stored as DICOM) 
contain much metadata (e.g., imaging abnormalities, age, compression thickness, radiation 
dose, among others parameters), but very little of the vast amount of information contained in 
an individual imaging study is being used currently (76,77). Future advancements in imaging 
analytic tools, such as computer aided diagnosis, image segmentation, automated analysis tools 
(e.g. automatic assessment of ‘bone density’,  quantification of visceral and subcutaneous fat, 
and measurements of muscle mass and density), and deep learning algorithms, will enable the 
integration of clinical data derived from hospital information systems, including imaging data, 
combined with genomic analysis, and lifestyle information. Furthermore, future advances in 
machine learning (a subfield of artificial intelligence that gives computers the ability to learn 
without being explicitly programmed) and data mining (identifying unanticipated associations 
in unstructured and seemingly unrelated datasets) will likely result in the identification of 
previously unrecognized patterns, risk factors, and relationships in complex diseases such as 
acute pancreatitis (78-80). In view of these advances in the field of medical technology, future 
breakthroughs are foreseen in creating new highly refined models for accurately predicting 
individual acute pancreatitis severity. 
Finally, it is pivotal that future studies on pancreatitis severity prediction use similar definitions 
of severity in line with the 2012 Revised Atlanta Classification, including the presence of 
parenchymal necrosis (representing moderately severe acute pancreatitis) and persistent organ 
failure (representing severe acute pancreatitis). Other surrogate severity parameters, such as 
mortality (the end result of severity) and length of hospital or intensive care stay and need for 
intervention (among other variables) should be regarded as consequences of severity. Lack 
of using uniform definitions in the past has hampered comparison of interinstitutional data. 
It is to be hoped that with increased awareness within the scientific pancreatic community, 
pancreatologists worldwide comply with standardized definitions of disease severity. 
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Acute pancreatitis is een acute ontsteking van het pancreas, welke in de Westerse wereld 
voornamelijk wordt veroorzaakt door galstenen (40-50%) en alcohol (10-40%). Andere 
oorzaken zijn o.a. geneesmiddelen, hypertriglyceridemie, hypercalciëmie en na een ingreep 
(ERCP-procedure en na abdominale of thoracale chirurgie). In 10-20% van de gevallen blijft 
de oorzaak echter onbekend. De incidentie van acute pancreatitis neemt wereldwijd toe, 
waarschijnlijk door de toename van obesitas en incidentie van galstenen. In de Verenigde 
Staten is acute pancreatitis verantwoordelijk voor meer dan 200.000 opnames per jaar. In 
Europa varieert de incidentie van 4 tot 45 per 100.000 patiënten per jaar. In Nederland ziet een 
gemiddeld ziekenhuis jaarlijks 5 tot 10 patiënten met de ernstige vorm van acute pancreatitis. 
Acute pancreatitis gaat gepaard met hoge kosten; in de Verenigde Staten wordt jaarlijks ruim 2 
miljard dollar uitgegeven aan acute pancreatitis, terwijl in Nederland de gemiddelde kosten van 
een ernstige necrotiserende pancreatitis, inclusief interventie, ongeveer 80.000 Euro bedraagt. 
Traditioneel wordt de klinische ernst van acute pancreatitis onderverdeeld in een milde en een 
ernstige vorm, terwijl op beeldvorming de interstitiële (met behoud van vitaal pancreasweefsel 
en omgevend weefsel) en necrotiserende (het afsterven van pancreas en/of omgevend weefsel) 
vorm wordt onderscheiden.
Dit proefschrift heeft 2 doelen betreffende de classificatie en het voorspellen van ernst 
van acute pancreatitis. Het oude classificatie systeem van acute pancreatitis (1992 Atlanta 
Classificatie) werd geëvalueerd door literatuuronderzoek en zogenaamde ‘interobserver-
overeenstemming’ studies. Tevens werd een studie gedaan naar het morfologische deel van 
het nieuwe classificatiesysteem (Gereviseerde Atlanta Classificatie uit 2012). De voorspellende 
waarde voor het inschatten van ernst van ziekte door beeldvormende scoringssystemen werd 
gedaan door 2 studies. Tenslotte, zijn in 2 verschillende cohorten de ernst van de interstitiële 
en necrotiserende vorm van acute pancreatitis in kaart gebracht.
In hoofdstuk 2 beschrijven we de resultaten van een ‘interobserver-overeenstemming’ studie 
tussen 5 abdominale radiologen voor het categoriseren van peripancreatische collecties op 
CT door gebruik te maken van de 1992 Atlanta Classificatie. De preoperatieve CT scans van 
70 patiënten met necrotiserende pancreatitis werden hiervoor gebruikt. De interobserver-
overeenstemming was slecht (kappa van 0.144 met standaarddeviatie van 0.095). In slechts 
3 van de 70 patiënten kozen de 5 radiologen dezelfde definitie, terwijl 3 radiologen dezelfde 
definitie kozen in 42 van de 70 casus (42%). Conclusie van deze studie was dat de Atlanta 
definities uit 1992 niet gebruikt moeten worden voor het categoriseren van peripancreatische 
collecties op CT.
In een complex ziektebeeld zoals acute pancreatitis is het gebruik van correcte terminologie en 
gestandaardiseerde definities erg belangrijk zowel in de klinische praktijk als in wetenschappelijk 
onderzoek. Het 1992 Atlanta Classificatie systeem was een klinisch georiënteerd systeem 
en werd in toenemende mate bekritiseerd. In 2 uitgebreide literatuuronderzoeken werd de 
acceptatie en het gebruik van de 1992 Atlanta definities in de medische literatuur geanalyseerd. 
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In hoofdstuk 3 beschrijven we een uitgebreid literatuuronderzoek gedurende de periode 
1993 – 2006 waarbij gezocht werd naar termen die afgeraden werden te gebruiken door de 
1992 Atlanta Classificatie: de verbannen terminologie betroffen ‘phlegmone’, ‘geïnfecteerde 
pseudocyste’, ‘hemorragische pancreatitis’, en ‘persisterende pancreatitis’. Verder werden 
nieuwe termen gerubriceerd die opdoemden in de medische literatuur sinds de publicatie van 
de 1992 Atlanta Classificatie. In totaal werden 239 artikelen bestudeerd, inclusief 10 richtlijnen 
en 42 overzichtsartikelen. Uit ons onderzoek bleek dat 2 oude termen definitief uitgebannen 
waren (‘hemorragische pancreatitis’ en ‘persisterende pancreatitis’), terwijl de verbanning van 
de termen ‘geïnfecteerde pseudocyste’ en ‘phlegmone’ het minst geaccepteerd is. Tegelijkertijd 
zijn er in dezelfde periode nieuwe termen geïntroduceerd. Dit betreffen de termen: ‘organized 
pancreatic necrosis’, ‘necroma’, extrapancreatic necrosis’, en ‘central gland necrosis’. Deze 
termen zijn geopperd om entiteiten te beschrijven die volgens de auteurs onvoldoende waren 
geadresseerd door de 1992 Atlanta Classificatie.
In hoofdstuk 4 rapporteren we de uitkomsten van een systematisch literatuuronderzoek over 
het gebruik van de 1992 Atlanta definities sinds de publicatie van deze classificatie tot 2006 in 
de medische literatuur. In totaal werden 447 artikelen geanalyseerd, inclusief 12 richtlijnen en 
82 overzichtsartikelen. In meer dan de helft van de gepubliceerde artikelen werden alternatieve 
definities gebruikt voor de voorspelde ernst van ziekte, de daadwerkelijke ernst van ziekte en 
criteria voor orgaanfalen. Ook de 1992 Atlanta definities voor wat betreft de lokale complicaties 
in en rondom het pancreas werden vrij geïnterpreteerd, vooral daar waar het ging om de 
inhoud van peripancreatische collecties. Beide literatuuronderzoeken toonden aan dat de 1992 
Atlanta Classificatie gedateerd was en gereviseerd diende te worden.
Vanwege de gevonden beperkingen van de 1992 Atlanta Classificatie voor de lokale 
complicaties werd een nieuwe set van morfologische termen ontwikkeld om peripancreatische 
collecties op CT te beschrijven. Deze morfologische termen betroffen: de aan- of afwezigheid 
van een collectie, de relatie van de collectie met het pancreas, de inhoud, de vorm, het massa-
effect, de aanwezigheid van geïmpacteerde gasbellen, gas-vocht niveau beeld, de mate van 
afkapseling en aanwezigheid en uitgebreidheid van niet-aankleurend pancreas parenchym. 
Omwille van het feit dat er een slechte interobserver-overeenstemming was bij gebruik van de 
1992 Atlanta definities (zie hoofdstuk 2), beschrijven we in hoofdstuk 5 een vergelijkbare studie 
bij gebruik van deze nieuwe set van morfologische termen om peripancreatische collecties op 
CT te beschrijven. De interobserver-overeenstemming tussen 17 pancreatologen (waaronder 
7 gastro-intestinale chirurgen, 2 gastro-enterologen en 8 radiologen uit 3 Amerikaanse en 5 
Europese gespecialiseerde ziekenhuizen) voor de nieuwe set van morfologische termen voor 
het beschrijven van peripancreatische collecties bij acute pancreatitis was goed tot uitstekend. 
Daarom adviseren wij om bij het beschrijven van morfologische afwijkingen van acute 
pancreatitis op CT de nieuwe descriptieve termen te gebruiken in plaats van de 1992 Atlanta 
definities.
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De 1992 Atlanta Classificatie heeft ervoor gezorgd dat er meer gestandaardiseerd over 
acute pancreatitis werd gerapporteerd dan in de periode voorafgaande aan de introductie 
van dit classificatie systeem en dit zowel in wetenschappelijk onderzoek als in de dagelijkse 
communicatie tussen clinici onderling. Gaandeweg werd echter ook duidelijk dat de 1992 
Atlanta Classificatie gedateerd was en aan revisie toe was door de vastgestelde tekortkomingen 
en door verbeterde ziekte inzichten over acute pancreatitis. Dit was de drijfveer om in 2007 een 
internationale consultatie via het internet op te zetten met medewerking van pancreatologen 
uit alle delen van de wereld, waaronder leden van de Dutch Pancreatitis Study Group. Na 5 jaar 
discussie resulteerde dit in een consensus document (de 2012 Gereviseerde Atlanta Classificatie) 
welke wordt gepresenteerd in hoofdstuk 6. De 2012 Gereviseerde Atlanta Classificatie heeft 
criteria voor de diagnose van acute pancreatitis gedefinieerd en onderscheidt het verloop van 
de ziekte in 2 fasen: de vroege en late fase. Morfologisch wordt acute pancreatitis onderverdeeld 
in de interstitiële vorm en necrotiserende vorm waarbij de necrose kan bestaan uit pancreas 
parenchym, peripancreatisch vetweefsel of beide. De onderverdeling van de aanwezigheid van 
peripancreatische necrose onder de necrotiserende vorm is nieuw ten opzichte van de oude 
definitie van necrotiserende pancreatitis. De ernst van acute pancreatitis wordt, in plaats van 
2 gradaties, nu gecategoriseerd in 3 gradaties: mild, matig ernstig en ernstig, afhankelijk van 
het optreden van orgaanfalen en lokale en systemische complicaties. Tenslotte is voor het eerst 
een beeldvormende classificatie toegevoegd voor de beschrijving van de lokale complicaties 
gebaseerd op morfologische CT criteria. De naamgeving van peripancreatische collecties is 
onderverdeeld in 4 types: acute peripancreatische vocht collectie (APFC), pseudocyste, acute 
necrotische collectie (ANC) en walled-off necrosis (WON) gebaseerd op de samenstelling van 
de collectie en de mate van afkapseling. De wereldwijde consultatie van pancreatologen om tot 
overeenstemming te komen die geleid heeft tot dit consensus document zou moeten leiden tot 
universele aanvaarding en gebruik van het nieuwe classificatie systeem.
Een belangrijk doel van de 2012 Gereviseerde Atlanta Classificatie is om consistente rapportage 
te vergemakkelijken en om onderzoeksgegevens voortvloeiend uit klinisch onderzoek beter 
onderling te kunnen vergelijken. Dit was de reden om morfologische criteria te introduceren 
om de afwijkingen van acute pancreatitis op CT te beschrijven. In hoofdstuk 7 testen we de 
interobserver-overeenstemming tussen radiologen bij gebruik van deze nieuwe CT criteria 
in 285 consecutieve patiënten met acute pancreatitis die gedurende hun ziekenhuisverblijf 
een of meer CT scans hebben ondergaan. Voor de meeste nieuw geïntroduceerde CT criteria 
was de interobserver-overeenstemming matig tot substantieel. Vier criteria toonden beperkte 
interobserver-overeenstemming: extrapancreatische necrose (EXPN) (kappa van 0.326), type 
van pancreatitis (kappa van 0.370), karakteristieken van collecties (kappa van 0.408), en juiste 
term van collecties (kappa van 0.356). De matige kappa waarden kunnen worden toegeschreven 
aan de moeilijkheid om necrotisch materiaal op CT te onderscheiden. Dit is een in toenemende 
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mate gekende beperking van CT en dus van de 2012 Gereviseerde Atlanta Classificatie. Het is 
aannemelijk dat er in de toekomst verdere aanpassingen aan de nieuwe morfologische criteria 
zullen worden doorgevoerd. 
Het voorspellen van de ernst van acute pancreatitis heeft ongeveer evenveel aandacht gekregen 
in de medische literatuur als de classificatie van ziekte. Een decade na de ontwikkeling van 
het eerste klinische scoringssysteem om de ernst van ziekte te voorspellen (de ‘Ranson 
score’ uit 1974) (1), hebben Balthazar en collega’s in 1985 een radiologisch scoringssysteem 
bedacht gebaseerd op basis van een blanco CT (2). Dezelfde radiologen hebben 5 jaar later 
een vernieuwde scoringssysteem ontwikkeld waarbij de aanwezigheid en uitgebreidheid van 
parenchymnecrose geïncorporeerd werd door gebruik te maken van een intraveneus contrast 
versterkte CT. Dit heeft geresulteerd in de ‘CT severity index’ ofwel CTSI wat heden ten dage 
de meest gebruikte CT scoringssysteem wereldwijd is (3).
In 2004 hebben Mortele en collega’s enkele modificaties aangebracht aan de bestaande CTSI 
(de zogenaamde ‘modified CTSI’ ofwel MCTSI) en getest in een klein cohort van 66 patiënten 
waarbij de MCTSI beter correleerde met uitkomstmaten dan de originele CTSI (4). In 
hoofdstuk 8 hebben we de MCTSI vergeleken met de originele CTSI voor wat betreft diverse 
parameters die correleren met de ernst van acute pancreatitis in een groter cohort van 196 
patiënten die gedurende de eerste week van opname een contrast versterkte CT of MRI hebben 
ondergaan. Beide radiologische scoringssystemen werden vergeleken met een vaak gebruikte 
klinisch scoringssysteem (APACHE-II score). Twee radiologen beoordeelden onafhankelijk 
van elkaar beide radiologische scoringssystemen. De scoringssystemen werden gecorreleerd 
met diverse parameters voor de ernst van acute pancreatitis, inclusief mortaliteit, orgaanfalen, 
geïnfecteerde necrose, opname en duur van intensive care periode, nood aan interventie en 
klinische ernst van acute pancreatitis. Voor beide radiologische scoringssystemen werd een 
significante correlatie gevonden tussen de score en elke afzonderlijke parameter (p < 0.001), 
echter zonder significant verschil. Vergeleken met de APACHE-II index, was de correlatie 
tussen beide radiologische scoringssystemen significant beter voor de parameters nood aan 
interventie (CTSI, p = 0.006; MCTSI, p = 0.01), geïnfecteerde necrose (CTSI, p = 0.04; MCTSI, 
p = 0.06), en klinische ernst van acute pancreatitis (receiver operator curve, 0.87; 95%, 0.82-
0.92). De interobserver-overeenstemming voor beide radiologische scoringssystemen was 
uitstekend tussen beide radiologen: voor CTSI, 0.85 (95% CI, 0.80-0.90) en voor MCTSI, 0.90 
(95% CI, 0.85-0.95). Concluderend stellen we dat in de klinische praktijk beide radiologische 
scoringssystemen willekeurig gebruikt kunnen worden voor het inschatten van de ernst van 
ziekte.
Het wordt algemeen onderkend dat vroege herkenning van patiënten met klinisch ernstige 
pancreatitis cruciaal is voor de triage van patiënten en voor geïndividualiseerde behandeling. 
In hoofdstuk 9 vergeleken we de voorspellende accuratesse van verschillende CT en klinische 
scoringssystemen voor het bepalen van ernst van ziekte op de dag van ziekenhuisopname 
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(gedefinieerd als: binnen 24 uur na opname). Gedurende een periode van twee-en-een-half 
jaar werden alle patiënten die opgenomen werden met de diagnose van acute pancreatitis 
prospectief geregistreerd. Van dit cohort ontvingen 150 patiënten (in totaal 159 episodes van 
pancreatitis) een niet-contrast versterkte of contrast-versterkte CT op de dag van opname. 
De CT scans werden retrospectief gescoord door 2 radiologen geblindeerd voor de klinische 
uitkomstmaten. In totaal werden 7 verschillende CT scoringssystemen (CTSI, MCTSI, 
‘pancreatic size index’ (PSI), ‘extrapancreatic score’ (EP), ‘extrapancreatic inflammation on 
CT’ (EPIC), ‘mesenteric edema and peritoneal fluid’ score (MOP), en Balthazar gradering) 
en 2 klinische scoringssystemen (APACHE-II en ‘Bedside Index for Severity in AP’ (BISAP)) 
onderling met elkaar vergeleken in hun voorspellend vermogen om de ernst van acute 
pancreatitis in te schatten op de dag van ziekenhuisopname. Klinisch ernstige pancreatitis 
werd gedefinieerd indien werd voldaan aan 1 van de navolgende criteria: mortaliteit, 
persisterend orgaanfalen (langer dan 48 uur) en/of lokale complicaties waarvoor een invasieve 
interventie noodzakelijk werd geacht. Ten tijde van deze studie was de definitie van ernstige 
pancreatitis nog niet helemaal uitgekristalliseerd, zodoende verschilt deze definitie enigszins 
van de 2012 Gereviseerde Atlanta Classificatie. De accuratesse van alle scoringssystemen voor 
het voorspellen van de ernst van acute pancreatitis werd bepaald door middel van receiver 
operating curve analyse. Van alle 7 CT scoringssystemen toonden de Balthazar gradering 
(voor elke CT techniek) en CTSI (voor enkel contrast-versterkte CT) de hoogste accuratesse 
voor het voorspellen van ernst van ziekte, evenwel zonder significante verschillen. Daarbij 
was de voorspellende accuratesse van CT scoringssystemen en klinische scoringssystemen 
vergelijkbaar. Wij concludeerden dat vanwege kostenbesparende en stralingshygiënische 
overwegingen een CT op de dag van opname voor het inschatten van ernst van ziekte niet is 
geïndiceerd.
In de radiologische literatuur wordt vaak vernoemd dat een CT vroeg in het beloop van de 
ziekte aangeraden is voor het evalueren van de morfologische ernst van acute pancreatitis (5-
7), echter dit wordt niet ondersteund door klinische richtlijnen noch onderschreven door de 
meeste clinici (6-12). Hoofdstuk 10 bevat een overzicht van de meest gebruikte radiologische 
scoringssystemen (voornamelijk gebaseerd op CT), inclusief de voordelen en beperkingen 
voor het voorspellen van de ernst van acute pancreatitis. De voornaamste beperking van 
alle scoringssystemen is dat ze beter met lokale complicaties correleren dan met systemische 
complicaties (vooral persisterend orgaanfalen, welke de voornaamste component vormt 
voor ernstige acute pancreatitis). In een CT verslag bij een patiënt met acute pancreatitis 
is het daarom belangrijker om complicaties als gevolg van acute pancreatitis te beschrijven 
dan het benoemen van een CT score. In hoofdstuk 10 wordt verder een overzicht gegeven 
van dergelijke bevindingen en dit omvat o.a. tekenen van geïnfecteerde necrose (gasbellen 
binnen necrotische collecties), tekenen van hemorragie of het detecteren van een arterieel 
pseudoaneurysma, diepe veneuze trombose of longembolieën, acute cholecystitis, darmischemie 
of perforatie, en CT kenmerken van het abdominaal compartiment syndroom (zoals ‘round-
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belly sign’ ofwel de toenemende ronding van een buik op opeenvolgende CT scans). De meeste 
van deze complicaties maken geen onderdeel uit van een CT scoringssysteem maar hebben wel 
een directe en significante impact op de behandeling van een patiënt met acute pancreatitis. 
Een van de meest ernstige lokale complicatie van acute pancreatitis is geïnfecteerde 
necrose welke gepaard gaat met hoge morbiditeit en een mortaliteit van ongeveer 20-30% 
(12,13). De waarneming van gasbellen binnen een necrotische collectie op CT is nagenoeg 
pathognomonisch voor geïnfecteerde necrose. De diagnose van geïnfecteerde necrose is in de 
klinische praktijk echter niet eenvoudig. In hoofdstuk 11 beschrijven we de toegevoegde waarde 
van het routinematig verrichten van een fijne naald aspiratie (FNA) van peripancreatisch vocht 
in combinatie met klinische en beeldvormende kenmerken van geïnfecteerde necrose bij alle 
patiënten die een interventie hebben ondergaan voor de verdenking van geïnfecteerde necrose. 
Daartoe deden we een post-hoc analyse bij 208 patiënten uit een prospectief bijgehouden 
multicentrische database bij wie een invasieve interventie werd verricht voor geïnfecteerde 
necrose. Retrospectief werden 3 groepen gereconstrueerd gebaseerd op basis van preoperatieve 
patiënt karakteristieken: klinisch beeld, bevindingen op beeldvorming, en resultaten van FNA. 
Patiënten in de klinische groep hadden klinische tekenen van infectie bij wie geen FNA werd 
verricht en bij wie geen gasbellen op een preoperatieve CT aanwezig waren. Patiënten in de 
beeldvormende groep hadden gasbellen op een preoperatieve CT bij wie geen FNA is verricht. 
Patiënten in de FNA groep hadden een positief resultaat voor geïnfecteerde necrose. Als gouden 
standaard voor geïnfecteerde necrose gold een positieve kweek verkregen tijdens de eerste 
invasieve interventie (ofwel via percutane drainage ofwel gedurende een necrosectomie). De 
initiële interventie voor geïnfecteerde necrose werd gemiddeld 27 dagen na opname uitgevoerd 
zonder significante verschillen tussen de 3 groepen (p = 0.15). Infectie werd bevestigd in 80% 
van de 92 patiënten in de klinische groep, in 94% van de 88 patiënten in de CT groep en in 
86% van de 28 patiënten in de FNA groep (p = 0.07). Mortaliteit was 19% en verschilde niet 
tussen de groepen (p = 0.39). De diagnose van geïnfecteerde necrose kan doorgaans gesteld 
worden op basis van de kliniek of CT kenmerken van infectie. FNA is voorbehouden en nuttig 
bij patiënten met een onduidelijke kliniek zonder CT kenmerken van geïnfecteerde necrose.
In de medische literatuur is er veel beschreven over de uitkomsten van patiënten met 
necrotiserende pancreatitis, echter beperkt over factoren die geassocieerd zijn met klinisch 
ernstige pancreatitis bij patiënten met een interstitiële pancreatitis op beeldvorming. In 
hoofdstuk 12 presenteren we de resultaten van een cohort van 149 patiënten die gedurende een 
periode van twee-en-een-half jaar opgenomen werden met de diagnose interstitiële pancreatitis 
op beeldvorming en dit cohort werd vergeleken met patiënten met extrapancreatische necrose 
(EXPN). Daartoe bepaalden we de Charlson co-morbiditeit score (CCI), de APACHE-II en 
BISAP score op de dag van opname (de eerste 24 uur van opname). Bovendien evalueerden we de 
incidentie van persisterend systemische inflammatoire response syndroom (SIRS), persisterend 
orgaanfalen (langer dan 48 uur), nood aan ICU opname, duur van hospitalisatie (in dagen) en 
mortaliteit bij patiënten met interstitiële pancreatitis en bij patiënten met EXPN. De mediane 
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APACHE-II score en BISAP score bij patiënten met interstitiële pancreatitis was respectievelijk 
1 en 7. De mediane ziekenhuisopnameduur bedroeg 4 dagen, 1% had persisterend orgaanfalen 
en 1-2% had nood aan een vorm van interventie. De mortaliteit bij patiënten met interstitiële 
pancreatitis was 3% en dit was geassocieerd met significante co-morbiditeit (mediane CCI score 
voor degenen die overleden en overleefden bedroeg respectievelijk 4 en 1, p = 0.003). Patiënten 
met EXPN verschilden significant ten opzichte van patiënten met interstitiële pancreatitis voor 
alle parameters. In klinische studies dient derhalve een onderscheid gemaakt te worden tussen 
deze 2 groepen patiënten.
In de 2012 Gereviseerde Atlanta Classificatie is de term necrotiserende pancreatitis gedefinieerd 
als necrose van het extrapancreatisch vetweefsel (EXPN), van het pancreas parenchym of beide. 
Het wordt verondersteld dat patiënten met EXPN een betere uitkomst hebben dan patiënten 
met parenchymnecrose, echter betrouwbare data om dit te staven ontbreken. In hoofdstuk 13 
beschrijven we een post-hoc analyse van een prospectief bijgehouden multicentrische database 
van 639 patiënten met necrotiserende pancreatitis op CT. Alle CT scans werden geblindeerd 
voor klinische uitkomsten beoordeeld door 1 radioloog. Van het cohort van 639 patiënten 
waren er 324 met necrose van pancreas parenchym (met of zonder begeleidende EXPN) en 
315 met necrose van alleen EXPN (dus zonder parenchymnecrose). Klinische uitkomstmaten 
omvatte persisterend orgaanfalen, nood aan invasieve interventie en mortaliteit. Een 
vooraf opgestelde subgroep analyse werd verricht bij patiënten die geïnfecteerde necrose 
ontwikkelden. Resultaten lieten zien dat patiënten met EXPN minder complicaties kregen ten 
opzichte van patiënten met parenchymnecrose: persisterend orgaanfalen (21% versus 45%, p 
< 0.001), persisterend multi-orgaanfalen (15% versus 36%, p < 0.001), geïnfecteerde necrose 
(16% versus 47%, p < 0.001), nood aan invasieve interventie (18% versus 57%, p < 0.001) 
en mortaliteit (9% versus 20%, p < 0.001). Echter indien patiënten met EXPN geïnfecteerde 
necrose ontwikkelden waren de klinische uitkomsten gelijkwaardig aan die van patiënten 
met infectie van parenchymnecrose (mortaliteit bij geïnfecteerde necrose: EXPN 28% versus 
parenchymnecrose 18%, p = 0.16). Wij concluderen dat op basis van deze studie patiënten met 
EXPN tot een aparte categorie dienen te horen binnen het morfologische spectrum van acute 
pancreatitis. 
Bij acute pancreatitis wordt de uitgebreidheid van parenchymnecrose als een belangrijk 
uitkomstmaat beschouwd. Echter er is weinig informatie over de locatie (patroon) van 
parenchymnecrose en diens correlatie met diverse uitkomstmaten. In hoofdstuk 14 analyseren 
wij de klinische impact van zowel uitgebreidheid van parenchymnecrose als de locatie 
(patroon) van necrose in een cohort van 324 patiënten. Klinische uitkomstmaten waren 
persisterend orgaanfalen, geïnfecteerde necrose, nood aan invasieve interventie en mortaliteit. 
De uitgebreidheid van parenchymnecrose was minder dan 30% in 132 patiënten (40%), 
tussen de 30 en 50% in 83 patiënten (26%) en meer dan 50% in 109 patiënten (34%). Op alle 
klinische uitkomstmaten, behalve voor mortaliteit, zagen we een significant verschil (p<0.001) 
tussen patiënten met minder dan 30% necrose ten opzichte van patiënten met meer dan 30% 
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necrose, echter niet tussen patiënten met 30-50% necrose en die met meer dan 50% necrose. 
Qua locatie van parenchymnecrose stelden we vast dat het centrale deel van het pancreas 
het vaakst necrose ondergaat (40%). Alle uitkomstmaten waren significant gecorreleerd met 
locatie van parenchymnecrose (p<0.001). De sterkste associatie werd gezien bij patiënten met 
rechtszijdige, centrale deel en subtotale necrose. Na multivariabele analyse bleek dat de patroon 
van parenchymnecrose (gebaseerd op locatie) het sterkst was geassocieerd met klinische 
uitkomsten, vooral wanneer de parenchymnecrose de pancreaskop of het centrale deel 
betrof (gerelateerd aan een disruptie van de ductus pancreaticus) met vitaal pancreasweefsel 
stroomopwaarts. Derhalve concluderen wij dat de locatie van parenchymnecrose een 
belangrijke prognostische factor is die van invloed is op het klinisch beloop van patiënten met 
acute necrotiserende pancreatitis.
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overwinnen van persoonlijke beslommeringen en promotieperikelen. Uiteindelijk doe je het 
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(of in het Engels: Dutch Pancreatitis Study Group, kortweg DPSG) en pancreatoloog van het 
eerste uur. Met gevoel voor eufemisme durf ik te stellen dat ik niet bepaald de meest snelle 
promovendus onder je bezielende leiding ben geweest, maar wellicht wel de meest eigengereide. 
Ik ben je zeer dankbaar voor het grote vertrouwen, de ruimte en vrijheid die je mij hebt gegund 
bij het bedenken, opzetten en uitvoeren van de verschillende studies. Ik waardeer je toegewijde 
begeleiding van een onconventionele promovendus van een ‘perifere’ proefschrift, je nadruk 
op klinische relevantie van diverse onderzoeksprojecten en je rotsvast geloof in een goede 
afloop. Je was er als ik erom vroeg en gaf me wijze raad en advies waar nodig. Ik heb dit als 
bijzonder prettig ervaren en heb dat enorm gewaardeerd. “Lang gewacht, stil gezwegen, nooit 
gedacht, toch gekregen”. Precies deze door jouw gebezigde zinsnede typeert jou als promotor. 
Heel veel dank!
Copromotor Dr. M.S. van Leeuwen, beste Maarten. Ons gezamenlijke interesse in de 
beeldvorming van het pancreas heeft ons inmiddels alweer 15 jaar geleden bij elkaar gebracht. 
Je bent een man van vele ideeën, soms onnavolgbaar en lastig uitvoerbaar maar altijd kritisch en 
beschouwend met oog voor detail. Dank voor je belangrijke wetenschappelijke en inhoudelijke 
toevoegingen en kritische beoordelingen van de manuscripten welke hebben bijgedragen aan 
de kwaliteit van dit proefschrift. Ik waardeer je oprechte sociale betrokkenheid bij mijn wel en 
wee en voel me altijd hartelijk welkom bij de RAKU besprekingen. 
Copromotor Dr. H.C. van Santvoort, beste Hjalmar. Op een herfstavond in het begin 
van deze eeuw kwam jij als jonge arts-onderzoeker bij mij langs om over een onderzoekje te 
praten. Ik kon toen niet bevroeden dat jij mij de erop volgende jaren zou gaan ‘stalken’ over 
alles wat met beeldvorming van acute pancreatitis vandoen heeft. Wees gerust, ik heb het met 
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plezier gedaan! Je was de ideale opvolger van Marc Besselink, de denker versus de doener, 
een groter contrast tussen jullie is nauwelijks denkbaar behalve jullie gedeelde passie voor het 
pancreas. Discussiëren is je 2de natuur en toch knopen doorhakken; een opmerkelijke combi 
voor een chirurg! Je bent een betrokken clinicus en wetenschapper pur sang, toegewijd en 
gepassioneerd met oog voor detail en je bent behept met een scherp analytisch vermogen. 
Je bent uitgebreid betrokken geweest bij het afronden van het laatste hoofdstuk. Je kritische 
vragen en beschouwingen hebben geleid tot verdere diepgang die ten goede zijn gekomen 
aan de kwaliteit van diverse manuscripten. Bijzonder knap hoe je werk en privé weet te 
combineren gezien de bulk werk die je op je neemt. Daarnaast ben je altijd geïnteresseerd, 
sociaal betrokken en kan ik met jou over van alles en nog wat discussiëren. Ik zie uit naar onze 
verdere samenwerking en vriendschap. 
Leden van de manuscriptcommissie en promotiecommissie:
Hartelijke dank aan alle leden van de manuscriptcommissie voor het beoordelen van het 
manuscript (professoren Ploeg, Siersema en Stoker) en overige leden van de commissie 
(professoren Besselink, Bleijs, van Eijck en Prokop). Ik ben jullie zeer erkentelijk voor de expertise 
en tijd die jullie hebben aangewend om dit proefschrift kritisch op zijn wetenschappelijke 
waarde te beoordelen. 
Prof. Dr. M.G.H. Besselink, beste Marc. Het begon allemaal met je vraag of ik voor de chirurgen 
in het St Antonius ziekenhuis een presentatie over beeldvorming van acute pancreatitis kon 
geven. Op voorspraak van jou zat ik dezelfde avond al bij de vergadering van de Pancreatitis 
Werkgroep Nederland, de rest is geschiedenis! Pancreas is op je lijf geschreven – of het nou gaat 
om acute pancreatitis, chronische pancreatitis of pancreaskanker. Je bent mede grondlegger van 
de DPSG en een kei in het aangaan van nationale en internationale samenwerkingsverbanden. 
Als jong broekie (arts-onderzoeker) hield jij je met branie en bravoure staande temidden 
van door-de-wol geverfde internationale pancreatologen die dachten met een belangrijke 
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eigen wijze ingevuld, een zeer knappe prestatie!  Op zijn tijd lekker gezond eigenwijs, maar 
altijd hardwerkend, ambitieus, kordaat en met een recht-door-zee mentaliteit. Ons reisje naar 
de EPC in Polen (met Hjalmar) zal me voor altijd bijblijven en niet eens zozeer vanwege het 
missen van de terugvlucht! Inmiddels bevlogen vaatchirurg in het St Antonius ziekenhuis, zo 
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omstandigheden, je mag trots zijn op jezelf voor deze uitstekende prestatie. 
Drs. N. J. Schepers, beste Nicolien. Gedreven, rasoptimist, altijd vrolijk en energiek zijn 
enkele typeringen die bij jou passen. Inmiddels mama en in opleiding tot MDL-arts. Binnenkort 
kan er hopelijk ook een nietje in jouw boekje. 
Dr. J. van Grinsven, best Janneke. Je had een enorme drive om te promoveren en om in 
opleiding te komen. Beide is je gelukt, een prestatie van formaat. Succes met je opleiding tot 
chirurg. 
Overige arts-onderzoekers van de Pancreatitis Werkgroep Nederland (in willekeurige 
volgorde) - Usama Ahmed Ali, Yama Issa, Rens Kempeneers, Geert Cirkel, Mark van Baal, 
Ingrid van Doesburg, Rian Nijmeijer, Stefan Bouwense, Xavier Smeets, David da Costa, Bob 
Hollemans, Noortje Hallensleben, Sven van Dijk, Lotte Boxhoorn en alle overige aanstormende 
talenten – dank voor de prettige samenwerking en gezelligheid en succes met jullie projecten.
Oud-medewerkers van het datacentrum van de Pancreatitis Werkgroep Nederland 
- Vera Zeguers, Anneke Roeterdink, Hilda Rijnhart. Het was altijd fijn binnenkomen in het 
datacentrum voor een praatje en kop koffie. Dank voor de fijne samenwerking.
Robert Verdonk (de geboren voorzitter) en overige leden van Pancreas 2000 
werkgroep (artikel over EXPN) – dank voor jullie medewerking en significante input aan een 
belangrijk hoofdstuk van dit proefschrift. 
Leden van de Pancreatitis Werkgroep Nederland (in willekeurige volgorde) - Louis 
Akkermans, Marja Boermeester, Marco Bruno, Kees Dejong, Harry van Goor, Bert van 
Ramshorst, Paul Fockens, Casper van Eijck, Sandro Schaapherder, Robin Timmer, Bas 
Weusten, Rutger Ploeg, Vincent Nieuwenhuijs, Sijbrand Hofker, Erwin van der Harst, Erwin 
van Geenen, Ben Witteman, Flip Kruyt, Menno Brink, Han Lameris, en alle overige leden 
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door de Pancreatitis Werkgroep Nederland geroemd. De unieke en nauwe samenwerking 
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is een voedingsbodem gebleken voor een enorme wetenschappelijke output in de afgelopen 
2 decaden waarbij menig vastgeroest dogma in de behandeling van ziekten van het pancreas 
omver is geworpen. Hierover mogen jullie allen enorm trots op zijn. Keep up the good work! 
I want to express my sincerest gratitude to the international colleagues in the field of 
pancreatology, in particular Karen Horvath, Patrick Freeny, Bechien Wu, Mike Sarr, and 
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thereafter. Our close collaboration has resulted in many excellent scientific papers. It was a 
great pleasure to have worked with you. Thank you.
Dear Vikesh Singh and Moona, thank you for your generous hospitality during my time in 
Boston. You regarded me as your “grown-up Dutch son” and I have highly appreciated your 
warm welcome. I hope to welcome you and your ‘real’ kids somewhere in the near future in the 
Netherlands. Thank you both for everything.
Dear Koenraad Mortele, I thought I knew something about the pancreas, but you have clearly 
surpassed me. Thank you for sharing your knowledge with me. I treasure great memories of 
my visit to Boston and your department. It was a great honour to have worked with you and I 
truly hope we will continue to collaborate in the future. Thank you for your friendship.
Oude maatschap radiologie van het St Antonius ziekenhuis Nieuwegein - Tim 
Overtoom (door jou heb ik een brede opleiding genoten over de radiologie en vooral de 
levenslessen erbuiten neem ik graag ter harte), Hans Casparie (mooi om te zien dat je ook 
buiten de radiologie je draai hebt gevonden als Picasso in de dop), Hans van Heesewijk (er 
waren dagen dat je mijn promotie niet noemde, maar die zijn op 1 hand te tellen: ik ‘vrees’ je 
toespraak, maar het is dan “eindelijk tijd voor een feestje”!), Wouter van Es (de beste medisch 
manager van het ziekenhuis, knap hoe snel en doortastend jij niet alleen de radiologie maar ook 
alle andere nevenactiviteiten beheerst), Jiri Zapletal (in veel ben jij me voorgegaan, dat is iets 
wat ik nooit had voorzien!), Marc van Leersum (met speels gemak, humor en ogenschijnlijke 
nonchalance -schijn bedriegt echt!- beheers jij je vak op uitmuntende wijze), Daniël van den 
Heuvel (ooit ook bezig met een promotie, je had de kans gehad om op mijn ‘Fyra trein’ te 
springen, misschien was je dan uitgerangeerd, maar waarschijnlijker is dat je dan sneller dan ik 
gepromoveerd zou zijn), Marco van Strijen (globetrotter, innovator en vader van 4 kinderen 
en toch alom vertegenwoordigd in het ziekenhuis, knap hoe je dat weet te combineren), Jan-
Albert Vos (collega van de lange promotietrajecten, maar ik heb je overtroffen: jij slechts 9 jaar, 
ik 14 jaar!), Erik van der Hoeven (het is me gelukt, nog net eerder gepromoveerd dan jij… 
Succes met jouw promotie!). Beste maten, jullie hebben een optimale werkklimaat gecreëerd 
binnen de maatschap waardoor ik in staat ben gesteld om dit proefschrift af te ronden. Veel 
dank hiervoor.
Hanny Rouwenhorst, Ingrid Bartling, laboranten en overig administratief personeel 
van het St Antonius ziekenhuis - jullie zijn onmisbare krachten in een woelige radiologische 
praktijk. Dank voor jullie inzet en interesse.
Overige collegae in het St Antonius ziekenhuis – dank voor de goede samenwerking, 
belangstelling voor mijn promotie en fijne sfeer.
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Beste collega’s en oud collega’s (arts-assistenten, fellows en nieuwe lichting radiologen 
binnen de maatschap Radiologie Midden Nederland) van het St Antonius ziekenhuis 
– dank voor jullie oprechte en niet aflatende interesse in de vorderingen van het ‘boekje’, dank 
voor de bijdrage (Ivo Schoots) en goede sfeer waardoor werk een inspirerend onderdeel is van 
het leven. 
Vrienden en kennissen - dank voor jullie vriendschap, gezelligheid en plezier de afgelopen 
jaren en jullie support en begrip tijdens drukke periodes. 
Lieve schoonfamilie - dank dat jullie mij hebben opgenomen in jullie familiekring. Ik voel 
me erg gesteund en gewaardeerd en dat is een fijn gevoel.
Lieve familie (broers en zussen) - dank voor jullie oprechte interesse, morele steun, liefde 
en betrokkenheid. Jullie hebben regelmatig voor de hoognodige ontspanning gezorgd. De 
waardevolle adviezen in moeilijke fasen werden erg gewaardeerd. We zijn op onze manier 
een hecht gezin waar eenieder in zijn waarde wordt gelaten en dat is goed. Hoewel we elkaar 
minder zien dan we misschien zouden willen, zijn we er voor elkaar in mindere tijden. Heel 
veel dank!
Lieve ouders - dank voor jullie liefde en vertrouwen gedurende het promotietraject. Dank 
voor jullie adviezen en respect voor keuzevrijheid (ook als ze verkeerd uitpakken…) en de 
onvoorwaardelijke steun om jezelf te ontplooien. Jullie hebben een stevig fundament gelegd 
door al jullie kinderen de normen en waarden bij te brengen die nodig zijn om te functioneren 
in deze maatschappij. Dat eenieder goed terecht is gekomen, is de vrucht van jullie opvoeding 
en kroon van jullie inspanningen. 
Lieve (wijlen) Pa - heel erg spijtig dat je mijn aanstaande promotie niet mag meemaken. Je 
hebt altijd oprechte interesse getoond in de voortgang. In ieder geval heb ik jouw adagium eer 
aan gedaan: “geneeskunde is niet moeilijk, je moet uren, uren en uren maken” en, Pa, ik kan uit 
ervaring spreken dat dit ook geldt voor promoveren. Dit boekje draag ik op aan jou, wat zou 
je trots geweest zijn!
Lieve Ma - je opofferingsgezindheid om je werkzaamheden neer te leggen ten behoeve van 
de opvoeding van je kinderen siert jou en heeft ervoor gezorgd dat thuis altijd een veilig haven 
was. Ik ben erg trots op hoe je in het leven staat na het overlijden van Pa, hoe je invulling en zin 
geeft aan het leven, ook al is dit niet gemakkelijk. Dank voor alles.
Lieve Xafier, Mila en Tobias - jullie aanwezigheid heeft alles doen relativeren en heeft 
meteen duidelijk gemaakt wat echt belangrijk is in mijn leven.
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Allerliefste Elvin - je hebt me de tijd en ruimte gegeven om dit proefschrift succesvol af te 
ronden. Oneindig veel dank voor je geduld en begrip. Sinds dat we elkaar kennen is er altijd wel 
wat geweest en hebben we veel lief en leed gedeeld, veel meegemaakt en doorstaan. Ik heb je 
erg lief. Ik kijk enorm uit naar de toekomst en verheug me op ons verdere leven samen.
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CURRICULUM VITAE
Thomas Bollen was born on March 30th, 1973 in Nijmegen. He spent most of his childhood 
in Pesse in the provence of Drenthe. He graduated from secondary school at the Menso Alting 
College in Hoogeveen in 1992. Due to numerus fixus he was not selected for medical school and, 
therefore, started (and finished) his medical training in Ghent, Belgium, at Ghent University. 
He graduated from medical school in 1999 and started his working career as surgical resident 
(not in training) at the St. Antonius Hospital in Nieuwegein for the following 18 months. In 
July 2001, he started his training in Radiology at the St. Antonius Hospital in Nieuwegein 
(dr. J.C. de Valois and dr. J.P.M. van Heesewijk). As radiology resident, he joined the Dutch 
Pancreatitis Study Group (DPSG) in 2003. For all randomized clinical trials conducted by the 
DPSG (i.e. PROPATRIA, PANTER, PENGUIN, PYTHON, PONCHO, and TENSION trial), 
he reviewed the imaging (primarily CTs) of randomized patients. After finishing his training 
in radiology, he followed a 3-month research fellowship at the Division of Abdominal Imaging 
& Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical 
School, Boston, Massachusetts, USA (Associate Professor K.J. Mortele). After 2 years as junior 
staff member, he became a senior staff radiologist at the St. Antonius Hospital in Nieuwegein. 
As of 2011, he is the Abdominal Imaging Fellowship Program Director at St Antonius Hospital 
and since then he has trained 8 fellows. Thomas Bollen is (co-)author of over 100 peer-reviewed 
articles and 5 book-chapters. Since January 2018, he is chairman-person of the abdominal 
section of the Dutch Society of Radiology (NVvR). Thomas is father of his eldest son Xafier. 
He lives with his girlfriend Elvin and their two children Mila and Tobias.
C L A S S I F I C A T I O N
of   A C U T E
P A N C R E A T I T I S
CLA
SSIFICA
TIO
N
 of  A
CU
TE PA
N
CR
EA
TITIS 
T
H
O
M
A
S
 
B
O
L
L
E
N T H O M A S  B O L L E N
U I T N O D I G I N G
Voor het bijwonen van de openbare 
verdediging van het proefschrift
C L A S S I F I C A T I O N
of  A C U T E
P A N C R E A T I T I S
door
T H O M A S  B O L L E N
Op woensdag 13 maart 2019
Om 14.30 uur precies
In de Aula van de 
Radboud Universiteit Nijmegen, 
Comeniuslaan 2,
6525 HP te Nijmegen
Receptie na afloop van de promotie in 
de Aula van de Radboud Universiteit
Paranimfen
Alexander Bol
06-18498916
abolabol@yajoo.com
Léon Magis
06-28486228
leonmagis@hotmail.com
Thomas Bollen
Engelszstraat 34
2023EV Haarlem
06-40560608
tlbollen@hotmail.com
15468-bollen-cover.indd   1 30/01/2019   12:54
